]> 2019-01-12 A biomedical ontology in the domain of drug adverse events Edison Ong Hong Yu Noemi Garg ODAE is a biomedical ontology in the area of drug adverse events. It is developed by following OBO Foundry principles (e.g., openness, collaboration). ODAE: Ontology of Drug Adverse Events OWL-DL Solomiya Nysak Vision Release: 1.0.08 Yongqun "Oliver" He BFO OWL specification label BFO OWL specification label Really of interest to developers only Relates an entity in the ontology to the name of the variable that is used to represent it in the code that generates the BFO OWL file from the lispy specification. BFO CLIF specification label BFO CLIF specification label Person:Alan Ruttenberg Really of interest to developers only Relates an entity in the ontology to the term that is used to represent it in the the CLIF specification of BFO2 has_RxCUI editor preferred term editor preferred term~editor preferred label editor preferred label editor preferred term editor preferred term~editor preferred label GROUP:OBI:<http://purl.obolibrary.org/obo/obi> PERSON:Daniel Schober The concise, meaningful, and human-friendly name for a class or property preferred by the ontology developers. (US-English) editor preferred term example of usage example of usage A phrase describing how a class name should be used. May also include other kinds of examples that facilitate immediate understanding of a class semantics, such as widely known prototypical subclasses or instances of the class. Although essential for high level terms, examples for low level terms (e.g., Affymetrix HU133 array) are not GROUP:OBI:<http://purl.obolibrary.org/obo/obi> PERSON:Daniel Schober example of usage has curation status has curation status OBI_0000281 PERSON:Alan Ruttenberg PERSON:Bill Bug PERSON:Melanie Courtot has curation status definition textual definition definition definition DEFINITION English language definitions of what NCI means by the concept. These are limited to 1024 characters. They may also include information about the definition's source and attribution in a form that can easily be interpreted by software. definition GROUP:OBI:<http://purl.obolibrary.org/obo/obi> PERSON:Daniel Schober The official OBI definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions. The official definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions. definition editor note editor note editor note 1 IAO:0000116 editor_note editor_note uberon An administrative note intended for its editor. It may not be included in the publication version of the ontology, so it should contain nothing necessary for end users to understand the ontology. GROUP:OBI:<http://purl.obfoundry.org/obo/obi> PERSON:Daniel Schober editor note term editor definition editor term editor 20110707, MC: label update to term editor and definition modified accordingly. See http://code.google.com/p/information-artifact-ontology/issues/detail?id=115. GROUP:OBI:<http://purl.obolibrary.org/obo/obi> Name of editor entering the term in the file. The term editor is a point of contact for information regarding the term. The term editor may be, but is not always, the author of the definition, which may have been worked upon by several people PERSON:Daniel Schober term editor alternative term alternative term An alternative name for a class or property which means the same thing as the preferred name (semantically equivalent) GROUP:OBI:<http://purl.obolibrary.org/obo/obi> PERSON:Daniel Schober alternative term definition source definition source Discussion on obo-discuss mailing-list, see http://bit.ly/hgm99w GROUP:OBI:<http://purl.obolibrary.org/obo/obi> PERSON:Daniel Schober definition source formal citation, e.g. identifier in external database to indicate / attribute source(s) for the definition. Free text indicate / attribute source(s) for the definition. EXAMPLE: Author Name, URI, MeSH Term C04, PUBMED ID, Wiki uri on 31.01.2007 curator notes curator note curator note 1 IAO:0000232 curator_notes curator_notes uberon An administrative note of use for a curator but of no use for a user PERSON:Alan Ruttenberg curator note imported from imported from For external terms/classes, the ontology from which the term was imported GROUP:OBI:<http://purl.obolibrary.org/obo/obi> PERSON:Alan Ruttenberg PERSON:Melanie Courtot imported from expand expression to expand assertion to OBO foundry unique label elucidation elucidation has associated axiom(nl) has associated axiom(nl) has associated axiom(fol) has associated axiom(fol) Has_NICHD_Parent Has_NICHD_Parent A property created to allow the source NICHD to assign a parent to each concept with the intent of creating a hierarchy that includes only terms in which they are the contributing source. A11 Conceptual Entity Has_NICHD_Parent code code code NHC0 true Semantic_Type Conceptual Entity Semantic Type Semantic_Type Semantic_Type P106 In general, applying semantic types aids in allowing users (or computer programs) to draw conclusions about concepts by virtue of the categories to which they have been assigned. We use a set of semantic types developed for the UMLS Metathesaurus. There are currently 134 semantic types in the UMLS. The semantic type describes the sort of thing or category to which a concept belongs in the context of the UMLS semantic network. Display_Name Display Name Display Name Provides an alternative Preferred Name for use in some NCI systems. Display_Name Display_Name Conceptual Entity P107 Preferred_Name Preferred Term Conceptual Entity The word or phrase that NCI uses by preference to refer to the concept. P108 Preferred Name Preferred Name Preferred_Name Preferred_Name UMLS_CUI P207 Concept Unique Identifiers, or CUIs, are concept numbers assigned by the National Library of Medicine (NLM). If a concept in any NCI-maintained knowledgebase exists in the NLM Unified Medical Language System (UMLS), NCI includes the NLM CUI among the information we provide about the concept. UMLS_CUI UMLS_CUI Conceptual Entity UMLS CUI Contributing_Source This property is used to indicate when a non-EVS entity has contributed to, and has a stake in, a concept. This is used where such entities, within or outside NCI, have indicated the need to be able to track their own concepts. A single concept can have multiple instances of this property if multiple entities have such a defined stake. Contributing Source Conceptual Entity Contributing_Source P322 Contributing_Source Legacy_Concept_Name A retired unique concept identifier created and stored as Concept Name by legacy EVS software. Use of these values was long discouraged, but continued as late as 2009 when creation of new values ceased and Concept Name was retired. Legacy values are intended solely to help resolve and update earlier coding. Legacy Concept Name Legacy Concept Name true Conceptual Entity P366 NICHD_Hierarchy_Term P371 NICHD NICHD_Hierarchy_Term NICHD_Hierarchy_Term Conceptual Entity DesignNote Conceptual Entity DesignNote DesignNote P98 Design notes are notations made by NCI vocabulary curators. They are intended to provide supplemental, unstructured information to the user or additional insight about the concept. DesignNote Chinese translation YH, JX a chinese translation represents a chinese translation of the existing term. adverse event outcome The AE 'cough AE' has the 'label of AE outcome' of 'cough'; 'infection AE' has the 'label of AE outcom' of 'infection'. an annotation property that represents the label of an adverse event label of adverse event outcome Yongqun Oliver He, Jiangan Hardy Xie has_meddra_id temporal interpretation https://github.com/oborel/obo-relations/wiki/ROAndTime An assertion that holds between an OWL Object Property and a temporal interpretation that elucidates how OWL Class Axioms that use this property are to be interpreted in a temporal context. never in taxon x never in taxon T if and only if T is a class, and x does not instantiate the class expression "in taxon some T". Note that this is a shortcut relation, and should be used as a hasValue restriction in OWL. ?X DisjointWith RO_0002162 some ?Y Chris Mungall tooth SubClassOf 'never in taxon' value 'Aves' taxonomic class assertion An assertion that holds between an ontology class and an organism taxon class, which is intepreted to yield some relationship between instances of the ontology class and the taxon. dubious_for_taxon 1 1 RO:0002174 S dubious_for_taxon T if it is probably the case that no instances of S can be found in any instance of T. dubious_for_taxon dubious_for_taxon this relation lacks a strong logical interpretation, but can be used in place of never_in_taxon where it is desirable to state that the definition of the class is too strict for the taxon under consideration, but placing a never_in_taxon link would result in a chain of inconsistencies that will take time to resolve. Example: metencephalon in teleost uberon present_in_taxon 1 1 RO:0002175 S present_in_taxon T if some instance of T has some S. This does not means that all instances of T have an S - it may only be certain life stages or sexes that have S applicable for taxon present_in_taxon present_in_taxon uberon logical macro assertion https://github.com/oborel/obo-relations/wiki/ShortcutRelations An assertion that involves at least one OWL object that is intended to be expanded into one or more logical axioms. The logical expansion can yield axioms expressed using any formal logical system, including, but not limited to OWL2-DL. logical macro assertion on a class A logical macro assertion whose domain is an IRI for a class The domain for this class can be considered to be owl:Class, but we cannot assert this in OWL2-DL logical macro assertion on a property A logical macro assertion whose domain is an IRI for a property logical macro assertion on an object property Used to annotate object properties to describe a logical meta-property or characteristic of the object property. logical macro assertion on an annotation property is direct form of Chris Mungall relation p is the direct form of relation q iff p is a subPropertyOf q, p does not have the Transitive characteristic, q does have the Transitive characteristic, and for all x, y: x q y -> exists z1, z2, ..., zn such that x p z1 ... z2n y If we have the annotation P is-direct-form-of Q, and we have inverses P' and Q', then it follows that P' is-direct-form-of Q' external_definition 1 An alternate textual definition for a class taken unmodified from an external source. This definition may have been used to derive a generalized definition for the new class. This annotation property may be replaced with an annotation property from an external ontology such as IAO UBPROP:0000001 external_definition external_definition uberon axiom_lost_from_external_ontology 1 A textual description of an axiom loss in this ontology compared to an external ontology. This annotation property may be replaced with an annotation property from an external ontology such as IAO UBPROP:0000002 axiom_lost_from_external_ontology axiom_lost_from_external_ontology uberon homology_notes 1 Notes on the homology status of this class. This annotation property may be replaced with an annotation property from an external ontology such as IAO UBPROP:0000003 homology_notes homology_notes uberon external_comment 1 An alternate comment for a class taken unmodified from an external source. Note that obo format only allows a single comment for a class, and does not provide a structured means of adding provenance info. This annotation property may be replaced with an annotation property from an external ontology such as IAO UBPROP:0000005 external_comment external_comment uberon implements_design_pattern 1 UBPROP:0000006 implements_design_pattern implements_design_pattern uberon has_relational_adjective 1 UBPROP:0000007 Used to connect a class to an adjectival form of its label. For example, a class with label 'intestine' may have a relational adjective 'intestinal'. has_relational_adjective has_relational_adjective uberon taxon_notes 1 Notes on the how instances of this class vary across species. UBPROP:0000008 taxon_notes taxon_notes uberon function_notes 1 Notes on the evolved function of instances of this class. This annotation property may be replaced with an annotation property from an external ontology such as IAO UBPROP:0000009 function_notes function_notes uberon structure_notes 1 Notes on the structure, composition or histology of instances of this class. This annotation property may be replaced with an annotation property from an external ontology such as IAO UBPROP:0000010 structure_notes structure_notes uberon development_notes 1 Notes on the ontogenic development of instances of this class. This annotation property may be replaced with an annotation property from an external ontology such as IAO UBPROP:0000011 development_notes development_notes uberon external_ontology_notes 1 Notes on how similar or equivalent classes are represented in other ontologies. This annotation property may be replaced with an annotation property from an external ontology such as IAO UBPROP:0000012 external_ontology_notes external_ontology_notes uberon terminology_notes 1 Notes on how lexical conventions regarding this class, in particular any issues that may arise due to homonyny or synonymy. This annotation property may be replaced with an annotation property from an external ontology such as IAO UBPROP:0000013 terminology_notes terminology_notes uberon is count of 1 UBPROP:0000100 is_count_of is_count_of uberon preceding element is 1 A property used in conjunction with repeated_element_number to indicate an axis and directionality along that axis. If P preceding_element_is R, and P is_count_of S, and X P N, and X' P N+1, then it follows that every X R some X', and the class expression [S and R some X' and inv(R) some X] is empty (i.e. X is followed by X', with no intermediates) UBPROP:0000101 preceding_element_is preceding_element_is uberon pharyngeal arch number 1 UBPROP:0000103 gill arch N = PA N-2. the term branchial_arch is ambiguous. pharyngeal_arch_number pharyngeal_arch_number uberon x pharyngeal_arch_number N if and only if (i) x is a pharyngeal arch, and (ii) x is ancestrally pharyngeal arch number N in a series of pharyngeal arches repeated along a antero-posterior axis, with arch_number 1 being the mandibular arch. phalanx number 1 Most land mammals including humans have a 2-3-3-3-3 formula in both the hands (or paws) and feet. Primitive reptiles typically had the formula 2-3-4-4-5, and this pattern, with some modification, remained in many later reptiles and in the mammal-like reptiles. The phalangeal formula in the flippers of cetaceans (marine mammals) is 2-12-8-1 UBPROP:0000105 phalanx_number phalanx_number uberon x phalanx_number N if and only if (i) x is a phalanx, and (ii) x is phalanx number N in a series of phalanges repeated along an prixomo-distal axis, with phalanx_number 1 being the proximalmost phalanx. Note that in humans, the distalmost phalanx has phlanax_number 3, except in ray_number 1, where the distalmost has phalanx_number 2 fma_set_term 1 FMA has terms like 'set of X'. In general we do not include set-of terms in uberon, but provide a mapping between the singular form and the FMA set term UBPROP:0000202 fma_set_term fma_set_term uberon has_rank A metadata relation between a class and its taxonomic rank (eg species, family) ncbi_taxonomy contributor 1 dc-contributor dc-contributor uberon Source Source has_alternative_id has_alternative_id has_broad_synonym database_cross_reference database_cross_reference has exact synonym has_exact_synonym has_exact_synonym Fully qualified synonym, contains the string, term type, source, and an optional source code if appropriate. Each subfield is deliniated to facilitate interpretation by software. Synonym with Source Data FULL_SYN has_narrow_synonym has_narrow_synonym has_obo_namespace has_related_synonym has_related_synonym in subset in_subset in_subset Concept_In_Subset Used to associate the concept defining a particular terminology subset with concepts that belong to this subset. shorthand is defined by label depicted_by 1 foaf-depicted_by foaf-depicted_by uberon CI_ChemClass C26 CI_MoA C30 CI_PE C22 CI_with C36 effect_may_be_inhibited_by C52 has_Ingredient C24 has_MoA C28 has_PE C20 has_PK C32 induces C40 may_diagnose C42 may_prevent C38 may_treat C34 site_of_metabolism C50 part of part of BFO:0000050 part_of part_of uberon Everything is part of itself. Any part of any part of a thing is itself part of that thing. Two distinct things cannot be part of each other. Occurrents are not subject to change and so parthood between occurrents holds for all the times that the part exists. Many continuants are subject to change, so parthood between continuants will only hold at certain times, but this is difficult to specify in OWL. See https://code.google.com/p/obo-relations/wiki/ROAndTime a core relation that holds between a part and its whole http://www.obofoundry.org/ro/#OBO_REL:part_of is part of my brain is part of my body (continuant parthood, two material entities) my stomach cavity is part of my stomach (continuant parthood, immaterial entity is part of material entity) part_of this day is part of this year (occurrent parthood) has part has part BFO:0000051 has_part has_part uberon Everything has itself as a part. Any part of any part of a thing is itself part of that thing. Two distinct things cannot have each other as a part. Occurrents are not subject to change and so parthood between occurrents holds for all the times that the part exists. Many continuants are subject to change, so parthood between continuants will only hold at certain times, but this is difficult to specify in OWL. See https://code.google.com/p/obo-relations/wiki/ROAndTime a core relation that holds between a whole and its part has part has_part my body has part my brain (continuant parthood, two material entities) my stomach has part my stomach cavity (continuant parthood, material entity has part immaterial entity) this year has part this day (occurrent parthood) realized in Paraphrase of elucidation: a relation between a realizable entity and a process, where there is some material entity that is bearer of the realizable entity and participates in the process, and the realizable entity comes to be realized in the course of the process [copied from inverse property 'realizes'] to say that b realizes c at t is to assert that there is some material entity d & b is a process which has participant d at t & c is a disposition or role of which d is bearer_of at t& the type instantiated by b is correlated with the type instantiated by c. (axiom label in BFO2 Reference: [059-003]) is realized by realized in realized_in this disease is realized in this disease course this fragility is realized in this shattering this investigator role is realized in this investigation realizes Paraphrase of elucidation: a relation between a process and a realizable entity, where there is some material entity that is bearer of the realizable entity and participates in the process, and the realizable entity comes to be realized in the course of the process realizes this disease course realizes this disease this investigation realizes this investigator role this shattering realizes this fragility to say that b realizes c at t is to assert that there is some material entity d & b is a process which has participant d at t & c is a disposition or role of which d is bearer_of at t& the type instantiated by b is correlated with the type instantiated by c. (axiom label in BFO2 Reference: [059-003]) preceded_by preceded by BFO:0000062 X preceded_by Y iff: end(Y) before_or_simultaneous_with start(X) is preceded by preceded_by preceded_by takes place after uberon An example is: translation preceded_by transcription; aging preceded_by development (not however death preceded_by aging). Where derives_from links classes of continuants, preceded_by links classes of processes. Clearly, however, these two relations are not independent of each other. Thus if cells of type C1 derive_from cells of type C, then any cell division involving an instance of C1 in a given lineage is preceded_by cellular processes involving an instance of C. The assertion P preceded_by P1 tells us something about Ps in general: that is, it tells us something about what happened earlier, given what we know about what happened later. Thus it does not provide information pointing in the opposite direction, concerning instances of P1 in general; that is, that each is such as to be succeeded by some instance of P. Note that an assertion to the effect that P preceded_by P1 is rather weak; it tells us little about the relations between the underlying instances in virtue of which the preceded_by relation obtains. Typically we will be interested in stronger relations, for example in the relation immediately_preceded_by, or in relations which combine preceded_by with a condition to the effect that the corresponding instances of P and P1 share participants, or that their participants are connected by relations of derivation, or (as a first step along the road to a treatment of causality) that the one process in some way affects (for example, initiates or regulates) the other. http://www.obofoundry.org/ro/#OBO_REL:preceded_by is preceded by preceded by preceded_by x is preceded by y if and only if the time point at which y ends is before or equivalent to the time point at which x starts. Formally: x preceded by y iff ω(y) <= α(x), where α is a function that maps a process to a start point, and ω is a function that maps a process to an end point. precedes precedes BFO:0000063 precedes precedes uberon precedes x precedes y if and only if the time point at which x ends is before or equivalent to the time point at which y starts. Formally: x precedes y iff ω(x) <= α(y), where α is a function that maps a process to a start point, and ω is a function that maps a process to an end point. occurs in Paraphrase of definition: a relation between a process and an independent continuant, in which the process takes place entirely within the independent continuant b occurs_in c =def b is a process and c is a material entity or immaterial entity& there exists a spatiotemporal region r and b occupies_spatiotemporal_region r.& forall(t) if b exists_at t then c exists_at t & there exist spatial regions s and s’ where & b spatially_projects_onto s at t& c is occupies_spatial_region s’ at t& s is a proper_continuant_part_of s’ at t occurs in occurs_in unfolds in unfolds_in contains process Paraphrase of definition: a relation between an independent continuant and a process, in which the process takes place entirely within the independent continuant [copied from inverse property 'occurs in'] b occurs_in c =def b is a process and c is a material entity or immaterial entity& there exists a spatiotemporal region r and b occupies_spatiotemporal_region r.& forall(t) if b exists_at t then c exists_at t & there exist spatial regions s and s’ where & b spatially_projects_onto s at t& c is occupies_spatial_region s’ at t& s is a proper_continuant_part_of s’ at t site of anterior_to 2009-07-31T02:15:46Z BSPO:0000096 anterior_to anterior_to cjm uberon x anterior_to y iff x is further along the antero-posterior axis than y, towards the head. An antero-posterior axis is an axis that bisects an organism from head end to opposite end of body or tail: bearer distal_to BSPO:0000097 distal_to distal_to uberon x distal_to y iff x is further along the proximo-distal axis than y, towards the appendage tip. A proximo-distal axis extends from tip of an appendage (distal) to where it joins the body (proximal). dorsal_to BSPO:0000098 dorsal_to dorsal_to uberon x dorsal_to y iff x is further along the dorso-ventral axis than y, towards the back. A dorso-ventral axis is an axis that bisects an organism from back (e.g. spinal column) to front (e.g. belly). posterior_to BSPO:0000099 caudal_to posterior_to posterior_to uberon x posterior_to y iff x is further along the antero-posterior axis than y, towards the body/tail. An antero-posterior axis is an axis that bisects an organism from head end to opposite end of body or tail. proximal_to BSPO:0000100 proximal_to proximal_to uberon x proximal_to y iff x is closer to the point of attachment with the body than y. ventral_to BSPO:0000102 uberon ventral_to ventral_to x ventral_to y iff x is further along the dorso-ventral axis than y, towards the front. A dorso-ventral axis is an axis that bisects an organism from back (e.g. spinal column) to front (e.g. belly). deep_to BSPO:0000107 Further away from the surface of the organism. Thus, the muscular layer is deep to the skin, but superficial to the intestines. deep_to deep_to uberon superficial_to BSPO:0000108 Near the outer surface of the organism. Thus, skin is superficial to the muscle layer. superficial_to superficial_to uberon in_left_side_of BSPO:0000120 X in_left_side_of Y <=> if Y is subdivided into left and right portions, X is part_of the left portion. https://github.com/obophenotype/uberon/wiki/Modeling-paired-structures-Design-Pattern in_left_side_of in_left_side_of uberon in_right_side_of BSPO:0000121 X in_right_side_of Y <=> if Y is subdivided into left and right portions, X is part_of the right portion. https://github.com/obophenotype/uberon/wiki/Modeling-paired-structures-Design-Pattern in_right_side_of in_right_side_of uberon in_anterior_side_of BSPO:0000123 X anterior_side_of Y <=> if Y is subdivided into two anterior and posterior portions, X is part_of the anterior portion. in_anterior_side_of in_anterior_side_of uberon in_proximal_side_of BSPO:0000124 X proximal_side_of Y <=> if Y is subdivided into distal and proximal portions, X is part_of the proximal portion. in_proximal_side_of in_proximal_side_of uberon in_distal_side_of BSPO:0000125 X distal_side_of Y <=> if Y is subdivided into distal and proximal portions, X is part_of the distal portion. in_distal_side_of in_distal_side_of uberon in_lateral_side_of BSPO:0000126 X in_lateral_side_of Y <=> if X is in_left_side_of Y or X is in_right_side_of Y. X is often, but not always a paired structure https://github.com/obophenotype/uberon/wiki/Modeling-paired-structures-Design-Pattern in_lateral_side_of in_lateral_side_of uberon proximalmost_part_of BSPO:0001106 X proximalmost_part_of Y <=> X is part_of Y and X is adjacent_to the proximal boundary of Y proximalmost_part_of proximalmost_part_of uberon distalmost_part_of BSPO:0001108 X distalmost_part_of Y <=> X is part_of Y and X is adjacent_to the distal boundary of Y distalmost_part_of distalmost_part_of uberon induced_by Yongqun He induced by a preceded_by relation that indicates that one process (e.g., an adverse event) is causally preceded by (induced by) another process (e.g., a medical intervention) and there is a causal relation between these two processes. This relation indicates the existence of a causal chain, meaning many processes may occur in between these two processes. is evidence of This represents a relation between two adverse events AE1 and AE2. However, AE1 may be an evidence of another adverse event AE3, and a dfferent adverse event AE4 may also be an evidence of the same AE2. SS, YH, YL AE1 is_evidence_of AE2 if and only if: given an adverse event instance ae1 that instantiates class AE1 (e.g., electrocardiogram qt prolonged AE) and another adverse event instance ae2 that instantiates class AE2 (e.g., arrhythmia AE), both ae1 and ae2 are adverse events that are clinically observed after a medical intervention (at time t0) on the same patient. The presence of ae1 is supported by priori knowledge of medicine to imply the presence of ae2 with some probability P (P is NOT always 1, thus transitivity does not apply to is_evidence_of relation. AE1 is_evidence_of AE2 and AE2 is_evidence_of AE3 DOES NOT imply AE1 is_evidence_of AE3). The instance ae1 and ae2 are observed or detected at time t1 and t2, respectively. The biological onset time for ae1 or ae2 may occur before t1 or t2. The t1 and t2 can be the same time point or different time points. An electrocardiogram qt prolonged AE is_evidence_of arrhythmia AE; arrhythmia AE is_evidence_of cardiomyopathy AE; fever AE is_evidence_of inflammation AE; fever AE is_evidence_of viral infection AE; plural effusion AE is_evidence_of cardiac disorder AE. has participant quality an object property that represents a relation between a process and a quality, in which the process has a participant that has the quality. An adverse event has a participant quality, such as a hyperkalemia AE has a participatn quality blood potassium increased. Yongqun He This is a shortcut relation of the following full version: 'has participant' some (participant 'has quality' ) in: process 'has participant' some (participant 'has quality' some quality) adverse event occurs in a 'occurs in' relation that is applied at the adverse event setting and indicates where an adverse event occurs in. Yongqun He drug associated with AE OH, SN An object property that represents a relation between a drug and its associated AE. has disease An object property that represents a relation between a human and a disease. OH, SN treated with drug OH, SN An object property that represents a relation between a patient and a drug that is used to treat the patient. drug associated with AE in adult An object property that represents a relation between a drug and its associated AE where the AE occurs in an adult patient. Oliver He drug associated with AE in senior Oliver He An object property that represents a relation between a drug and its associated AE where the AE occurs in a senior patient. drug associated with AE in pediatric Oliver He An object property that represents a relation between a drug and its associated AE where the AE occurs in a pediatric patient. drug associated with AE in newborn Oliver He An object property that represents a relation between a drug and its associated AE where the AE occurs in a newborn patient. drug associated with AE in adolescent Oliver He An object property that represents a relation between a drug and its associated AE where the AE occurs in an adolescent patient. used to treat disease An object property that represents a relation between a material entity (e.g., drug) and a disease that is treated by the material entity. OH, SN occurs in adult having disease Oliver He A shortcut object property that represents an adverse event and a disease in an adult patient where the adult patient with the disease has an adverse event after a medical intervention. occurs in patient having disease A shortcut object property that represents an adverse event and a disease in a patient where the patient with the disease has an adverse event after a medical intervention. Oliver He occurs in patient treated with drug Oliver He A shortcut object property that represents a process (e.g., adverse event) and a drug where the process occurs in a patient treated with the drug. drug AE occurs in A shortcut object property that represents a drug and human where the drug associated adverse event (AE) occurs in the human patient. Oliver He inheres in bearer of A bearer can have many dependents, and its dependents can exist for different periods of time, but none of its dependents can exist when the bearer does not exist. a relation between an independent continuant (the bearer) and a specifically dependent continuant (the dependent), in which the dependent specifically depends on the bearer for its existence bearer of bearer_of is bearer of this apple is bearer of this red color this vase is bearer of this fragility has participant Has_participant is a primitive instance-level relation between a process, a continuant, and a time at which the continuant participates in some way in the process. The relation obtains, for example, when this particular process of oxygen exchange across this particular alveolar membrane has_participant this particular sample of hemoglobin at this particular time. a relation between a process and a continuant, in which the continuant is somehow involved in the process has participant http://www.obofoundry.org/ro/#OBO_REL:has_participant has_participant this blood coagulation has participant this blood clot this investigation has participant this investigator this process has participant this input material (or this output material) has role A bearer can have many roles, and its roles can exist for different periods of time, but none of its roles can exist when the bearer does not exist. A role need not be realized at all the times that the role exists. a relation between an independent continuant (the bearer) and a role, in which the role specifically depends on the bearer for its existence has_role this person has role this investigator role (more colloquially: this person has this role of investigator) location_of RO:0001015 location_of location_of uberon located_in RO:0001025 located_in located_in uberon has boundary RO:0002002 has_boundary has_boundary uberon bounding layer of A relationship that applies between a continuant and its outer, bounding layer. Examples include the relationship between a multicellular organism and its integument, between an animal cell and its plasma membrane, and between a membrane bound organelle and its outer/bounding membrane. RO:0002007 bounding_layer_of bounding_layer_of uberon before or simultaneous with <= David Osumi-Sutherland Primitive instance level timing relation between events simultaneous_with simultaneous with RO:0002082 Relation between occurrents, shares start and end boundaries. coincides_with is_equal_to simultaneous_with simultaneous_with uberon David Osumi-Sutherland t1 simultaneous_with t2 iff:= t1 before_or_simultaneous_with t2 and not (t1 before t2) ends after David Osumi-Sutherland X ends_after Y iff: end(Y) before_or_simultaneous_with end(X) immediately_preceded_by immediately preceded by A non-transitive temporal relation in which one process immediately precedes another process, such that there is no interval of time between the two processes[SIO:000251]. RO:0002087 X immediately_preceded_by Y iff: end(X) simultaneous_with start(Y) directly preceded by immediately_preceded_by immediately_preceded_by is directly preceded by is immediately preceded by starts_at_end_of uberon starts_at_end_of David Osumi-Sutherland X immediately_preceded_by Y iff: end(X) simultaneous_with start(Y) immediately precedes X immediately_precedes_Y iff: end(X) simultaneous_with start(Y) ends_at_start_of meets David Osumi-Sutherland starts during David Osumi-Sutherland X starts_during Y iff: (start(Y) before_or_simultaneous_with start(X)) AND (start(X) before_or_simultaneous_with end(Y)) io happens during X happens_during Y iff: (start(Y) before_or_simultaneous_with start(X)) AND (end(X) before_or_simultaneous_with end(Y)) d during David Osumi-Sutherland ends during David Osumi-Sutherland o overlaps X ends_during Y iff: ((start(Y) before_or_simultaneous_with end(X)) AND end(X) before_or_simultaneous_with end(Y). overlaps http://purl.obolibrary.org/obo/BFO_0000051 some (http://purl.obolibrary.org/obo/BFO_0000050 some ?Y) x overlaps y if and only if there exists some z such that x has part z and z part of y continuous_with RO:0002150 continuous_with continuous_with uberon homologous_to RO:0002158 homologous_to homologous_to uberon connected to Binary relationship: x connected_to y if and only if there exists some z such that z connects x and y in a ternary connected_to(x,y,z) relationship. Connection does not imply overlaps. RO:0002170 connected_to connected_to uberon connects Binary relationship: z connects x if and only if there exists some y such that z connects x and y in a ternary connected_to(x,y,z) relationship. RO:0002176 connects connects this is currently used for both structural relationships (such as between a valve and the chamber it connects) and abstract relationships (anatomical lines and the entities they connect) uberon supplies FMA:86003 RO:0002178 arterial supply of relation between an artery and the structure is supplies with blood. source: FMA supplies supplies uberon develops_from RO:0002202 develops_from develops_from uberon develops_into RO:0002203 develops_into develops_into uberon surrounded_by RO:0002219 surrounded_by surrounded_by uberon x surrounded_by y iff: x is adjacent to y and for every region r adjacent to x, r overlaps y adjacent_to RO:0002220 adjacent_to adjacent_to uberon x adjacent_to y iff: x and y share a boundary surrounds RO:0002221 inverse of surrounded_by surrounds surrounds uberon temporally related to https://docs.google.com/document/d/1kBv1ep_9g3sTR-SD3jqzFqhuwo9TPNF-l-9fUDbO6rM/edit?pli=1 Chris Mungall Do not use this relation directly. It is ended as a grouping for relations between occurrents involving the relative timing of their starts and ends. A relation that holds between two occurrents. This is a grouping relation that collects together all the Allen relations. starts RO:0002223 Relation between occurrents, shares a start boundary with. starts starts uberon starts with starts with RO:0002224 starts_with starts_with uberon started by x starts with y if and only if x has part y and the time point at which x starts is equivalent to the time point at which y starts. Formally: α(y) = α(x) ∧ ω(y) < ω(x), where α is a function that maps a process to a start point, and ω is a function that maps a process to an end point. Every insulin receptor signaling pathway starts with the binding of a ligand to the insulin receptor Chris Mungall ends RO:0002229 Relation between occurrents, shares an end boundary with. ends ends finishes uberon ends with ends with RO:0002230 ends_with ends_with uberon Chris Mungall finished by x ends with y if and only if x has part y and the time point at which x ends is equivalent to the time point at which y ends. Formally: α(y) > α(x) ∧ ω(y) = ω(x), where α is a function that maps a process to a start point, and ω is a function that maps a process to an end point. has developmental contribution from RO:0002254 has_developmental_contribution_from has_developmental_contribution_from uberon developmentally_induced_by RO:0002256 developmentally_induced_by developmentally_induced_by sources for developmentally_induced_by relationships in Uberon: Developmental Biology, Gilbert, 8th edition, figure 6.5(F) t1 developmentally_induced_by t2 if there is a process of organ induction (GO:0001759) with t1 and t2 as interacting participants. t2 causes t1 to change its fate from a precursor tissue type T to T', where T' develops_from T. uberon developmentally preceded by RO:0002258 developmentally_preceded_by developmentally_preceded_by uberon developmentally_replaces RO:0002285 developmentally_replaces developmentally_replaces uberon mereotopologically related to A mereological relationship or a topological relationship Chris Mungall Do not use this relation directly. It is ended as a grouping for a diverse set of relations, all involving parthood or connectivity relationships has member RO:0002351 has_member has_member uberon has potential to developmentally contribute to RO:0002385 has_potential_to_developmentally_contribute_to has_potential_to_developmentally_contribute_to uberon x has potential to developmentrally contribute to y iff x developmentally contributes to y or x is capable of developmentally contributing to y has potential to develop into RO:0002387 has_potential_to_develop_into has_potential_to_develop_into uberon x has the potential to develop into y iff x develops into y or if x is capable of developing into y contributes to morphology of RO:0002433 contributes_to_morphology_of contributes_to_morphology_of uberon composed primarily of RO:0002473 UBREL:0000002 composed_primarily_of composed_primarily_of uberon x composed_primarily_of y iff: more than half of the mass of x is made from parts of y existence starts during BFO:0000068 RO:0002488 Relation between continuant c and occurrent s, such that every instance of c comes into existing during some s. begins_to_exist_during existence_starts_during existence_starts_during uberon existence starts with RO:0002489 Relation between continuant and occurrent, such that c comes into existence at the start of p. existence_starts_with existence_starts_with uberon existence ends during BFO:0000069 RO:0002492 Relation between continuant c and occurrent s, such that every instance of c ceases to exist during some s, if it does not die prematurely. ceases_to_exist_during existence_ends_during existence_ends_during uberon existence ends with RO:0002493 Relation between continuant and occurrent, such that c ceases to exist at the end of p. existence_ends_with existence_ends_with uberon transformation of RO:0002494 transformation_of transformation_of transforms from uberon immediate transformation of RO:0002495 direct_transformation_of immediate_transformation_of immediate_transformation_of immediately transforms from uberon existence starts during or after RO:0002496 existence_starts_during_or_after existence_starts_during_or_after uberon existence ends during or before RO:0002497 existence_ends_during_or_before existence_ends_during_or_before uberon has material contribution from RO:0002507 has_material_contribution_from has_material_contribution_from uberon has skeleton A relation between a subdivision of an organism and the single subdivision of skeleton that provides structural support for that subdivision. RO:0002551 has sekeletal support has supporting framework has_skeleton has_skeleton uberon luminal space of RO:0002572 luminal_space_of luminal_space_of uberon skeleton of RO:0002576 skeleton_of skeleton_of uberon produces RO:0003000 produces produces uberon produced_by RO:0003001 produced_by produced_by uberon anteriorly connected to anteriorly_connected_to uberon x anteriorly_connected_to y iff the anterior part of x is connected to y. i.e. x connected_to y and x posterior_to y. channel for carries channel_for uberon channels_from channels_from uberon channels_into channels_into uberon conduit for conduit_for uberon x is a conduit for y iff y passes through the lumen of x. distally connected to distally_connected_to uberon x distally_connected_to y iff the distal part of x is connected to y. i.e. x connected_to y and x proximal_to y. evolved_from Status: experimental evolved_from uberon existence starts and ends during existence_starts_and_ends_during uberon extends_fibers_into extends_fibers_into uberon in_central_side_of X in_central_side Y <=> if Y is subdivided into left and right portions around some median divisor, all parts of X are closer to the median divisor than the outermost lateral sides. https://github.com/obophenotype/uberon/wiki/Modeling-paired-structures-Design-Pattern in_central_side_of uberon posteriorly connected to posteriorly_connected_to uberon x posteriorly_connected_to y iff the posterior part of x is connected to y. i.e. x connected_to y and x anterior_to y. protects protects uberon proximally connected to proximally_connected_to uberon x proximally_connected_to y iff the proximal part of x is connected to y. i.e. x connected_to y and x distal_to y. subdivision of placeholder relation. X = 'subdivision of A' and subdivision_of some B means that X is the mereological sum of A and B subdivision_of uberon transitively anteriorly connected to . transitively_anteriorly_connected_to uberon transitively_connected to transitively_connected_to uberon transitively distally connected to . transitively_distally_connected_to uberon transitively proximally connected to . transitively_proximally_connected_to uberon Ingredient Ingredient Strength Packaged Product VA Class VA Product Active Inactive has age in year Pharmaceutical Preparations C0013227 N0000000001 3683 Pharmaceutical Preparations C176 Chemical Ingredients [Chemical/Ingredient] C178 N0000000002 991181 Chemical Ingredients Clinical Kinetics [PK] Clinical Kinetics C180 1030853 C1373163 N0000000003 Diseases, Manifestations or Physiologic States [Disease/Finding] N0000000004 Diseases, Manifestations or Physiologic States 989348 C182 C1373233 Mental Disorders and Manifestations [Disease/Finding] N0000000006 Mental Disorders and Manifestations 984721 C2916796 C190 Infectious Diseases [Disease/Finding] 40733004 N0000000007 C192 190563008 189822004 Infectious Diseases 191415002 C0009450 1023583 Elimination [PK] C222 Elimination [PK] Elimination 986944 C0221102 N0000000022 Metabolism [PK] N0000000023 C0025519 1023904 Metabolism C224 Site of Metabolism [PK] C1373176 988808 C226 N0000000024 Site of Metabolism Hepatic Metabolism [PK] C230 984512 N0000000026 Hepatic Metabolism C1373178 Route of Excretion [PK] C260 Route of Excretion Route of Excretion [PK] N0000000041 C1373186 987962 Renal Excretion [PK] Renal Excretion N0000000042 C1373187 986666 C262 Hepatic Excretion [PK] Hepatic Excretion N0000000043 989209 C264 C1373188 Physiochemical Activity [MoA] Physiochemical Activity N0000000065 989958 C308 C1372991 Small Ion Transport Pump Interactions [MoA] 986087 N0000000066 C310 Small Ion Transport Pump Interactions C1373107 HER Receptor Family Interactions [MoA] EGFR Family Interactions C312 Human Epidermal Growth Factor Receptor Family Interactions N0000000067 HER Receptor Family Interactions 986672 Epidermal Growth Factor Receptor Family Interactions C2916814 HER Family Interactions Calcium Channel Antagonists [MoA] 986242 D002121 Calcium Channel Blockers C2757014 N0000000069 Calcium Channel Antagonists C316 Calcium Channel Blocker Angiotensin 2 Receptor Antagonists [MoA] 984935 C318 N0000000070 Angiotensin II Receptor Blockers C2757003 Angiotensin II Receptor Antagonists Angiotensin 2 Receptor Antagonists Active Transporter Interactions [MoA] Active Transporter Interactions 1031287 C322 N0000000072 C1373104 Protease Inhibitors [MoA] Protease Inhibitors N0000000076 992709 Protease Inhibitors C330 C2756997 D011480 Immunologic Factors [MoA] C342 Immunologic Factors Immunologic Factors C2757006 993127 D007155 N0000000082 Leukotriene Receptor Antagonists [MoA] C2757015 992724 C344 N0000000083 Leukotriene Receptor Antagonists Sex Hormone Receptor Antagonists [MoA] C1373000 N0000000084 Sex Hormone Receptor Antagonists 985639 C346 Receptor Interactions [MoA] C1372999 C348 Receptor Interactions 988560 N0000000085 Chelating Activity [MoA] N0000000087 Chelating Activity Chelating Activity C352 1025213 D002614 C1527256 Excitatory Amino Acid Antagonists [MoA] Excitatory Amino Acid Antagonists D018691 Excitatory Amino Acid Antagonists C2757055 N0000000088 1036066 C354 Adrenergic Antagonists [MoA] C2757018 993129 Adrenergic Antagonists Adrenergic Antagonists N0000000092 D018674 C362 Cholinergic Muscarinic Receptor Interactions [MoA] C372 986244 N0000000097 C1373009 Cholinergic Muscarinic Receptor Interactions Thymidylate Synthetase Inhibitors [MoA] N0000000098 993154 C374 Thymidylate Synthetase Inhibitors C2756988 Adrenergic alpha-Antagonists [MoA] Adrenergic alpha-Antagonists 1023426 C2756989 Adrenergic alpha-Antagonists D000317 Alpha-adrenergic Blocker N0000000099 C376 Estrogen Receptor Agonists [MoA] C378 988811 N0000000100 C1373007 Estrogen Receptor Agonists Norepinephrine Uptake Inhibitors [MoA] 989028 Norepinephrine Uptake Inhibitors C2757023 C382 D018759 Adrenergic Uptake Inhibitors N0000000102 Reverse Transcriptase Inhibitors [MoA] N0000000103 C2757067 993157 Reverse Transcriptase Inhibitors C384 D018894 Reverse Transcriptase Inhibitors Cholinergic Muscarinic Agonists [MoA] C386 Cholinergic Muscarinic Agonists 990721 N0000000104 C2757026 Neurotransmitter Transporter Interactions [MoA] Neurotransmitter Transporter Interactions C1373006 N0000000105 C388 985066 Serotonin Uptake Inhibitors [MoA] C2757053 Serotonin Uptake Inhibitors Serotonin Uptake Inhibitors C396 D017367 N0000000109 992711 Folic Acid Metabolism Inhibitors [MoA] C2916820 Folic Acid Antagonists 1029786 C400 Folic Acid Metabolic Inhibitors N0000000111 Folic Acid Metabolism Inhibitors Folic Acid Antagonists D005493 Dopamine Uptake Inhibitors [MoA] C406 N0000000114 C2757017 Dopamine Uptake Inhibitors 1028789 D018765 Dopamine Uptake Inhibitors Dopamine Agonists [MoA] D018491 N0000000117 C2757007 992714 C412 Dopaminergic Agonist Dopamine Agonists Dopamine Agonists GABA A Modulators [MoA] C1373017 C414 N0000000118 GABA A Modulators 990722 Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA] D019161 993150 C2756999 Hydroxymethylglutaryl-CoA Reductase Inhibitors C420 HMG-CoA Reductase Inhibitor HMG-CoA Reductase Inhibitors N0000000121 Hydroxymethylglutaryl-CoA Reductase Inhibitors Adrenergic Agonists [MoA] 1029285 C422 Adrenergic Agonists C2757025 N0000000122 Adrenergic Agonists D000322 Leukotriene Receptor Interactions [MoA] C1373014 N0000000124 Leukotriene Receptor Interactions C426 987670 Phosphodiesterase Inhibitors [MoA] N0000000128 D010726 C1656262 Phosphodiesterase Inhibitors 993167 C434 Phosphodiesterase Inhibitors Serotonin Antagonists [MoA] D012702 N0000000130 C2757052 C438 993156 Serotonin Antagonists Serotonin Antagonists Organic Anion Transporter Interactions [MoA] C1373100 987411 N0000000132 Organic Anion Transporter Interactions C442 Enzyme Inhibitors [MoA] C444 D004791 N0000000133 Enzyme Inhibitors C2756995 Enzyme Inhibitors 1032544 Lipoxygenase Inhibitors [MoA] D016859 C446 1031400 C2757064 Lipoxygenase Inhibitors Lipoxygenase Inhibitors N0000000134 Immunologic Adjuvants [MoA] Adjuvants, Immunologic Immunologic Adjuvants 989878 N0000000135 Adjuvants, Immunologic D000276 C448 C1383096 GABA A Receptor Interactions [MoA] C454 N0000000138 GABA A Receptor Interactions C1373022 988922 Calcium Channel Interactions [MoA] C458 C1373020 990245 N0000000140 Calcium Channel Interactions Iron Chelating Activity [MoA] C466 985781 N0000000144 Iron Chelating Activity Iron Chelating Activity D007502 C2757050 Estrogen Receptor Antagonists [MoA] 984514 N0000000145 C1373098 C468 Estrogen Receptor Antagonists Estrogen Receptor Inhibitor Proton Pump Inhibitors [MoA] 986356 Proton Pump Inhibitors C1384478 N0000000147 C472 Hormone Receptor Agonists [MoA] 985200 Hormone Receptor Agonists C476 C1373095 N0000000149 Protein Synthesis Inhibitors [MoA] C2757051 993158 Protein Synthesis Inhibitors C478 N0000000150 Protein Synthesis Inhibitors D011500 G-Protein-linked Receptor Interactions [MoA] 984725 C482 G-Protein-linked Receptor Interactions C2916797 G-Protein-linked Receptor-Effector Interactions N0000000152 Adrenergic Receptor Interactions [MoA] 987972 Adrenergic Receptor Interactions C1373072 C484 N0000000153 Uncouplers [MoA] Uncouplers C488 C1373071 N0000000155 986674 Chloride Channel Interactions [MoA] C1373070 N0000000156 C490 987326 Chloride Channel Interactions Glucocorticoid Receptor Agonists [MoA] Glucocorticoid Receptor Agonists C496 N0000000159 989879 C1373068 Cyclooxygenase Inhibitors [MoA] C2756982 D016861 992710 Cyclooxygenase Inhibitors N0000000160 Cyclooxygenase Inhibitors C498 Adrenergic beta-Antagonists [MoA] D000319 993131 Adrenergic beta-Antagonists Beta-adrenergic Receptor Inhibitor C500 N0000000161 C2757061 beta-Adrenergic Receptor Inhibitor beta-Adrenergic Blocker Beta-adrenergic Blocker Adrenergic beta-Antagonists Steroid Receptor Antagonists [MoA] N0000000162 987973 C1373067 C502 Steroid Receptor Antagonists Enzyme Interactions [MoA] Enzyme Interactions N0000000163 C504 C1373066 988200 Serotonin Transporter Interactions [MoA] N0000000167 987204 C512 Serotonin Transporter Interactions C1373063 Selective Estrogen Receptor Modulators [MoA] D020845 993164 Selective Estrogen Receptor Modulators N0000000168 C2757056 C514 Selective Estrogen Receptor Modulators Excitatory Amino Acid Receptor Interactions [MoA] N0000000171 Excitatory Amino Acid Receptor Interactions C520 C1373062 988925 Steroid Receptor Modulators [MoA] C1373061 C522 Steroid Receptor Modulators N0000000172 987671 Opioid Agonists [MoA] 985466 C1373059 N0000000174 Opioid Agonists C526 Cytokine Receptor Superfamily Interactions [MoA] Cytokine Receptor Superfamily Interactions C1373058 984937 C528 N0000000175 Topoisomerase Inhibitors [MoA] DNA Gyrase Inhibitors 989757 Topoisomerase Inhibitors N0000000176 C1384454 Topoisomerase Inhibitor C530 Cholinesterase Inhibitors [MoA] 992680 Cholinesterase Inhibitors D002800 C532 Cholinesterase Inhibitors N0000000177 C2757012 Sodium Channel Interactions [MoA] Sodium Channel Interactions C538 987802 C1373055 N0000000180 Angiotensin-converting Enzyme Inhibitors [MoA] C540 N0000000181 Angiotensin Converting Enzyme Inhibitor 992731 D000806 C2757044 Angiotensin-Converting Enzyme Inhibitors Angiotensin-converting Enzyme Inhibitors Steroid Hormone Receptor Agonists [MoA] N0000000182 C1373054 C542 Steroid Hormone Receptor Agonists 990907 Monoamine Oxidase Inhibitors [MoA] N0000000184 992698 D008996 Monoamine Oxidase Inhibitors C2756978 C546 Monoamine Oxidase Inhibitors MAOI Progestational Hormone Receptor Agonists [MoA] Progestational Hormone Receptor Agonists C1373052 N0000000185 C548 986818 Histamine H1 Receptor Antagonists [MoA] C2757048 C558 992695 H1 Receptor Blockers Histamine H1 Antagonists Histamine H1 Blockers N0000000190 Histamine H1 Receptor Antagonists Histamine H1 Antagonists H1 Receptor Antagonists D006634 Dihydrofolate Reductase Inhibitors [MoA] C1373048 N0000000191 C560 441741 Dihydrofolate Reductase Inhibitors Ion Channel Interactions [MoA] N0000000193 C1373047 988382 Ion Channel Interactions C564 Serotonin Receptor Interactions [MoA] Serotonin Receptor Interactions N0000000198 988082 C574 C1373043 Opioid Receptor Interactions [MoA] N0000000200 989758 C578 Opioid Receptor Interactions C1373041 Dopamine Receptor Interactions [MoA] N0000000203 C584 C1373039 985948 Dopamine Receptor Interactions Radiopharmaceutical Activity [MoA] Radiopharmaceutical Activity C2757000 987975 Radiopharmaceuticals N0000000205 D019275 C588 Histamine Receptor Antagonists [MoA] D006633 Histamine Receptor Antagonists Histamine Antagonists C592 989667 N0000000207 C1383092 Histamine Antagonists Adrenergic alpha-Agonists [MoA] Adrenergic alpha-Agonists Adrenergic alpha-Agonists C2757042 1029039 N0000000209 D000316 Alpha-adrenergic Agonist C596 Potassium Channel Interactions [MoA] C600 N0000000211 C1373036 989960 Potassium Channel Interactions Ribonucleotide Reductase Inhibitors [MoA] Ribonucleotide Reductase Inhibitors N0000000212 C602 441728 C1373035 Receptor Protein Kinase Interactions [MoA] C604 Receptor Protein Kinase Interactions C1373034 986538 N0000000213 Sex Hormone Receptor Agonists [MoA] 990080 N0000000214 C606 Sex Hormone Receptor Agonists C1373033 Histamine Receptor Interactions [MoA] Histamine Receptor Interactions 989394 N0000000216 C610 C1373031 Dopamine Transporter Interactions [MoA] N0000000219 984515 C1373028 Dopamine Transporter Interactions C616 Hormone Receptor Antagonists [MoA] 990790 C620 Hormone Receptor Antagonists N0000000221 C1373026 Cellular or Molecular Interactions [MoA] 986459 N0000000223 C1373094 Cellular or Molecular Interactions C624 Insulin Receptor Agonists [MoA] N0000000225 C628 C1373092 Insulin Receptor Agonists 986676 Dopamine Antagonists [MoA] Dopamine Antagonists Dopamine Antagonists D018492 C2757008 C638 N0000000230 1032050 Nucleic Acid Synthesis Inhibitors [MoA] C644 N0000000233 993166 Nucleic Acid Synthesis Inhibitors C2757009 Nucleic Acid Synthesis Inhibitors D019384 Norepinephrine Transporter Interactions [MoA] N0000000234 988817 C2267223 C646 Norepinephrine Transporter Interactions Alkylating Activity [MoA] D000477 N0000000236 C650 Alkylating Activity 1031878 C2756975 Alkylating Activity Insulin Receptor Interactions [MoA] C1373083 987414 N0000000240 C658 Insulin Receptor Interactions Transcription Factor Activity [MoA] Transcription Factor Activity N0000000242 C1148759 1028825 C662 Androgen Receptor Antagonists [MoA] Androgen Receptor Antagonists C664 989356 C1373082 Androgen Receptor Inhibitor N0000000243 HIV Protease Inhibitors [MoA] D017320 HIV Protease Inhibitors Human Immunodeficiency Virus Protease Inhibitors N0000000246 C670 HIV Protease Inhibitors C2756991 993149 Biological Response Modifiers [MoA] Biological Response Modifiers C672 D015545 N0000000247 993132 Biological Response Modifiers C2757019 Polycationic Channel Interactions [MoA] N0000000253 Polycationic Channel Interactions C1373076 990209 C684 Immunologic and Biological Factors [MoA] Immunologic and Biological Factors 1032698 D007151 C686 C0021048 Immunologic and Biological Factors N0000000254 Hormone Receptor Modulators [MoA] 989214 C688 N0000000255 C1373075 Hormone Receptor Modulators Serotonin Agonists [MoA] 1022850 C690 C2756998 N0000000256 Serotonin Agonists Serotonin Agonists D017366 Hormone Receptor Interactions [MoA] N0000000257 C692 986361 C1373074 Hormone Receptor Interactions Congenital Abnormalities [Disease/Finding] 276654001 Defects, Congenital 276655000 1021840 Congenital Defects Deformities Malformations of organs or body parts during development in utero. N0000000264 D000013 Birth Defects M0000013 Congenital Abnormalities Congenital Abnormalities C0000768 C706 276720006 Abnormalities, Congenital Abscess [Disease/Finding] Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection. C730 128477000 M0000059 Abscess C0000833 D000038 984804 Abscess N0000000276 Acinetobacter Infections [Disease/Finding] Infections, Acinetobacter M0000230 D000151 C752 Acinetobacter Infections 984730 Infections with bacteria of the genus ACINETOBACTER. C0001139 Acinetobacter Infections Mimae Infections N0000000287 Infections, Mimae Acquired Immunodeficiency Syndrome [Disease/Finding] An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. Immunologic Deficiency Syndrome, Acquired Acquired Immunodeficiency Syndrome Acquired Immune Deficiency Syndrome Immunodeficiency Syndrome, Acquired Acquired Immunodeficiency Syndrome AIDS Acquired Immuno-Deficiency Syndrome 1022762 N0000000291 62479008 C0001175 D000163 C760 M0000245 Actinomycetales Infections [Disease/Finding] D000193 Infections with bacteria of the order ACTINOMYCETALES. Infections, Actinomycete C0001255 1024017 N0000000299 M0000289 C776 Actinomycete Infections Actinomycetales Infections Actinomycetales Infections Infections, Actinomycetales Addison Disease [Disease/Finding] 363732003 Primary Adrenal Insufficiency 1023821 Primary Hypoadrenalism Primary Adrenocortical Insufficiency C788 Addison Disease An adrenal disease characterized by the progressive destruction of the ADRENAL CORTEX, resulting in insufficient production of ALDOSTERONE and HYDROCORTISONE. Clinical symptoms include ANOREXIA; NAUSEA; WEIGHT LOSS; MUSCLE WEAKNESS; and HYPERPIGMENTATION of the SKIN due to increase in circulating levels of ACTH precursor hormone which stimulates MELANOCYTES. M0000346 N0000000305 D000224 C0001403 Addison Disease Addison's Disease 373662000 Adenocarcinoma [Disease/Finding] 35917007 M0000355 D000230 Adenocarcinoma Adenoma, Malignant A malignant epithelial tumor with a glandular organization. C0001418 Adenocarcinoma C790 N0000000306 1023834 Adenoma [Disease/Finding] Adenoma Adenoma A benign epithelial tumor with a glandular organization. M0000367 C0001430 1026445 N0000000310 D000236 C798 32048006 Adenoviridae Infections [Disease/Finding] C806 Adenovirus Infections Virus diseases caused by the ADENOVIRIDAE. Infections, Adenovirus N0000000314 Adenoviridae Infections 1025703 25225006 M0000404 C0001486 Adenoviridae Infections D000257 Infections, Adenoviridae Adenovirus Infections, Human [Disease/Finding] Adenovirus Infections, Human 1022278 N0000000315 C0001487 M0000405 Infections, Human Adenovirus Respiratory and conjunctival infections caused by 33 identified serotypes of human adenoviruses. C808 D000258 Adenovirus Infections, Human Human Adenovirus Infections Tissue Adhesions [Disease/Finding] Pathological processes consisting of the union of the opposing surfaces of a wound. C810 Tissue Adhesions 1028050 C0001511 D000267 N0000000316 M0000418 Tissue Adhesions Adhesions, Tissue 42685002 Adnexal Diseases [Disease/Finding] N0000000320 C818 Adnexal Diseases D000291 M0000457 Diseases of the uterine appendages (ADNEXA UTERI) including diseases involving the OVARY, the FALLOPIAN TUBES, and ligaments of the uterus (BROAD LIGAMENT; ROUND LIGAMENT). Adnexal Diseases 988928 C0001576 Adrenal Gland Diseases [Disease/Finding] C0001621 N0000000324 D000307 1025795 Adrenal Gland Diseases C826 30171000 Pathological processes of the ADRENAL GLANDS. M0000482 Adrenal Gland Diseases Adrenocortical Hyperfunction [Disease/Finding] Excess production of ADRENAL CORTEX HORMONES such as ALDOSTERONE; HYDROCORTISONE; DEHYDROEPIANDROSTERONE; and/or ANDROSTENEDIONE. Hyperadrenal syndromes include CUSHING SYNDROME; HYPERALDOSTERONISM; and VIRILISM. C828 275437005 D000308 Adrenocortical Hyperfunction Hyperadrenocorticism Adrenal Gland Hyperfunction N0000000325 1022833 M0000483 Hyperadrenalism Adrenocortical Hyperfunction C0001622 47270006 Hypercorticism Adrenal Insufficiency [Disease/Finding] Adrenal Gland Hypofunction M0000484 N0000000326 237785004 Conditions in which the production of adrenal CORTICOSTEROIDS falls below the requirement of the body. Adrenal insufficiency can be caused by defects in the ADRENAL GLANDS, the PITUITARY GLAND, or the HYPOTHALAMUS. C830 Adrenal Insufficiency C0001623 Adrenal Insufficiency 111563005 D000309 1025230 Hypoadrenalism Adrenal Hyperplasia, Congenital [Disease/Finding] Adrenal Hyperplasia, Congenital M0000487 D000312 C0001627 C834 Hyperplasia, Congenital Adrenal Congenital Adrenal Hyperplasia 237751000 A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders. Adrenal Hyperplasia, Congenital N0000000328 1023878 Affective Disorders, Psychotic [Disease/Finding] Psychoses, Affective Psychotic Affective Disorders Affective Disorders, Psychotic 191663008 M0000522 N0000000332 D000341 Disorders in which the essential feature is a severe disturbance in mood (depression, anxiety, elation, and excitement) accompanied by psychotic symptoms such as delusions, hallucinations, gross impairment in reality testing, etc. 1024660 Affective Disorders, Psychotic C0001723 C842 Agranulocytosis [Disease/Finding] A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS). Granulocytopenia Agranulocytosis C860 1023345 C0001824 N0000000341 17182001 Agranulocytosis M0000580 417672002 D000380 Alzheimer Disease [Disease/Finding] Dementia, Senile C0002395 Alzheimer Type Senile Dementia M0000842 1022264 N0000000363 Dementia, Alzheimer Type A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) C904 26929004 Senile Dementia, Alzheimer Type Alzheimer's Disease Alzheimer Disease D000544 Alzheimer Disease Primary Senile Degenerative Dementia Dementia, Primary Senile Degenerative Amebiasis [Disease/Finding] C908 C0002438 Infection with any of various amebae. It is an asymptomatic carrier state in most individuals, but diseases ranging from chronic, mild diarrhea to fulminant dysentery may occur. 105637008 D000562 Amebiasis 111910009 388759003 1023982 N0000000365 M0000878 Amebiasis Amoebiasis Renal Aminoacidurias [Disease/Finding] Renal Aminoacidurias M0000934 N0000000370 Aminoaciduria, Renal Renal Aminoacidurias C918 D000608 C0002534 985952 A group of inherited kidney disorders characterized by the abnormally elevated levels of AMINO ACIDS in URINE. Genetic mutations of transport proteins result in the defective reabsorption of free amino acids at the PROXIMAL RENAL TUBULES. Renal aminoaciduria are classified by the specific amino acid or acids involved. Amyloidosis [Disease/Finding] N0000000375 A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits. C928 Amyloidosis M0001053 1024175 Amyloidosis 17602002 C0002726 D000686 Anaphylaxis [Disease/Finding] 1023517 C0002792 39579001 N0000000379 Anaphylactic Reaction An acute hypersensitivity reaction due to exposure to a previously encountered ANTIGEN. The reaction may include rapidly progressing URTICARIA, respiratory distress, vascular collapse, systemic SHOCK, and death. C936 Anaphylaxis Shock, Anaphylactic D000707 Anaphylaxis M0001076 Anemia [Disease/Finding] Anemia A reduction in the number of circulating erythrocytes or in the quantity of hemoglobin. 1024481 M0001119 271737000 267531008 C946 D000740 C0002871 N0000000384 Anemia Anemia, Aplastic [Disease/Finding] 1023343 C948 N0000000385 Anemia, Aplastic 304132006 A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements. Anemia, Aplastic D000741 C0002874 306058006 M0001120 Angina Pectoris [Disease/Finding] M0001180 194828000 C990 D000787 Stenocardia C0002962 Angina Pectoris Angina Pectoris Angor Pectoris N0000000406 1022730 The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION. Angina Pectoris, Variant [Disease/Finding] 87343002 C992 Angina Pectoris, Variant Prinzmetal's Angina D000788 C0002963 M0001181 Angina Pectoris, Variant N0000000407 Prinzmetal Angina 1026917 A clinical syndrome characterized by the development of CHEST PAIN at rest with concomitant transient ST segment elevation in the ELECTROCARDIOGRAM, but with preserved exercise capacity. Angina, Unstable [Disease/Finding] C994 Angina, Unstable 1021853 Angina at Rest Angina, Unstable 25106000 Unstable Angina N0000000408 Angina, Preinfarction M0001182 D000789 64333001 Precordial pain at rest, which may precede a MYOCARDIAL INFARCTION. C0002965 Angioedema [Disease/Finding] C0002994 Quincke's Edema Swelling involving the deep DERMIS, subcutaneous, or submucosal tissues, representing localized EDEMA. Angioedema often occurs in the face, lips, tongue, and larynx. Urticaria, Giant 1022344 C1008 N0000000415 Angioedema M0001197 Angioedema 400075008 41291007 D000799 Angioneurotic Edema Anorexia [Disease/Finding] C0003123 79890006 249471002 N0000000421 Anorexia The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA. 1023296 C1020 D000855 M0001278 Anorexia Anthrax [Disease/Finding] C1036 1021996 M0001315 Anthrax An acute infection caused by the spore-forming bacteria BACILLUS ANTHRACIS. It commonly affects hoofed animals such as sheep and goats. Infection in humans often involves the skin (cutaneous anthrax), the lungs (inhalation anthrax), or the gastrointestinal tract. Anthrax is not contagious and can be treated with antibiotics. D000881 N0000000429 C0003175 Anthrax 409498004 Anuria [Disease/Finding] 1023563 C0003460 Absence of urine formation. It is usually associated with complete bilateral ureteral (URETER) obstruction, complete lower urinary tract obstruction, or unilateral ureteral obstruction when a solitary kidney is present. M0001524 N0000000431 C1040 Anuria Anuria D001002 2472002 Anus Diseases [Disease/Finding] C0003462 N0000000432 1023545 Anus Diseases Anus Diseases C1042 32110003 M0001528 D001004 Anxiety Disorders [Disease/Finding] C1048 D001008 C0003469 N0000000435 Persistent and disabling ANXIETY. M0001533 Anxiety Disorders Anxiety Disorders 197480006 1023219 Eating Disorders [Disease/Finding] 1025187 72366004 Eating Disorders C0013473 C1092 M0001616 D001068 N0000000457 A group of disorders characterized by physiological and psychological disturbances in appetite or food intake. Eating Disorders Arbovirus Infections [Disease/Finding] Arbovirus Infections M0001658 Infections caused by arthropod-borne viruses, general or unspecified. D001102 1023709 C0003723 40610006 N0000000462 Arbovirus Infections C1102 Arrhythmias, Cardiac [Disease/Finding] Arrhythmia Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction. 1023395 C1116 Cardiac Arrhythmias Arrythmia N0000000469 Arrhythmias, Cardiac Arrhythmias, Cardiac M0001715 Cardiac Dysrhythmia C0003811 195107004 Cardiac Arrhythmia D001145 Arrhythmia, Sinus [Disease/Finding] Arrhythmia, Sinus 71792006 1025764 Sinus Arrhythmia Arrhythmia, Sinus N0000000470 Arrhythmia, Sinoatrial Sinoatrial Arrhythmia D001146 M0001716 C1118 C0003813 Irregular HEART RATE caused by abnormal function of the SINOATRIAL NODE. It is characterized by a greater than 10% change between the maximum and the minimum sinus cycle length or 120 milliseconds. Arterial Occlusive Diseases [Disease/Finding] M0001730 C1120 N0000000471 1025357 Arterial Obstructive Diseases Arterial Occlusive Diseases C0003838 Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency. Arterial Occlusive Diseases 2929001 D001157 Arteriosclerosis [Disease/Finding] M0001734 C0003850 Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries. 72092001 1021767 Arteriosclerosis D001161 Arteriosclerosis N0000000473 C1124 Arthritis [Disease/Finding] Arthritis Arthritis D001168 C0003864 C1134 M0001741 1023652 N0000000478 3723001 Arthritis, Juvenile Rheumatoid [Disease/Finding] Arthritis, Juvenile Chronic C1140 239796000 410502007 1022211 Rheumatoid arthritis of children occurring in three major subtypes defined by the symptoms present during the first six months following onset: systemic-onset (Still's Disease, Juvenile-Onset), polyarticular-onset, and pauciarticular-onset. Adult-onset cases of Still's disease (STILL'S DISEASE, ADULT-ONSET) are also known. Only one subtype of juvenile rheumatoid arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent. Arthritis, Juvenile Rheumatoid C0553662 N0000000481 Arthritis, Juvenile Rheumatoid M0001748 410795001 Arthritis, Juvenile Idiopathic 410796000 Juvenile Idiopathic Arthritis D001171 Arthritis, Rheumatoid [Disease/Finding] M0001750 C1142 69896004 D001172 N0000000482 Rheumatoid Arthritis Arthritis, Rheumatoid Arthritis, Rheumatoid 1023050 A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. C0003873 Aspergillosis [Disease/Finding] C1162 Infections with fungi of the genus ASPERGILLUS. D001228 1025666 N0000000492 Aspergillosis Aspergillosis C0004030 M0001850 65553006 Asthma [Disease/Finding] C0004096 A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). 1023235 Bronchial Asthma M0001885 195979001 N0000000498 Asthma 195967001 Asthma, Bronchial C1174 D001249 Asthma Astrocytoma [Disease/Finding] D001254 C0004114 N0000000501 Astroglioma Astrocytoma 1024668 M0001891 Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082) Glioma, Astrocytic C1180 254938000 Astrocytoma Atrial Fibrillation [Disease/Finding] N0000000507 C0004238 M0001926 C1192 Atrial Fibrillation D001281 1023706 Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation. Auricular Fibrillation Atrial Fibrillation 49436004 Atrial Flutter [Disease/Finding] 5370000 C1194 Auricular Flutter M0001927 Atrial Flutter C0004239 985206 Rapid, irregular atrial contractions caused by a block of electrical impulse conduction in the right atrium and a reentrant wave front traveling up the inter-atrial septum and down the right atrial free wall or vice versa. Unlike ATRIAL FIBRILLATION which is caused by abnormal impulse generation, typical atrial flutter is caused by abnormal impulse conduction. As in atrial fibrillation, patients with atrial flutter cannot effectively pump blood into the lower chambers of the heart (HEART VENTRICLES). Atrial Flutter N0000000508 D001282 Attention Deficit Disorder with Hyperactivity [Disease/Finding] Attention Deficit Disorder with Hyperactivity Hyperkinetic Syndrome 1023721 C1263846 Attention Deficit Hyperactivity Disorder 31177006 7461003 C1198 D001289 A behavior disorder originating in childhood in which the essential features are signs of developmentally inappropriate inattention, impulsivity, and hyperactivity. Although most individuals have symptoms of both inattention and hyperactivity-impulsivity, one or the other pattern may be predominant. The disorder is more frequent in males than females. Onset is in childhood. Symptoms often attenuate during late adolescence although a minority experience the full complement of symptoms into mid-adulthood. (From DSM-IV) Attention Deficit Disorders with Hyperactivity N0000000510 406506008 M0001943 Attention Deficit Hyperactivity Disorders Attention Deficit Disorder with Hyperactivity Autistic Disorder [Disease/Finding] N0000000513 Autism, Early Infantile Kanner's Syndrome 408858002 408856003 A disorder beginning in childhood. It is marked by the presence of markedly abnormal or impaired development in social interaction and communication and a markedly restricted repertoire of activity and interest. Manifestations of the disorder vary greatly depending on the developmental level and chronological age of the individual. (DSM-IV) 43614003 Autistic Disorder Autism M0001983 D001321 408857007 Autism, Infantile C0004352 Autistic Disorder 1025154 C1204 Autoimmune Diseases [Disease/Finding] Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides. 1026092 Autoimmune Diseases D001327 M0001989 C1206 Autoimmune Diseases N0000000514 85828009 C0004364 Avitaminosis [Disease/Finding] M0002041 1023168 85670002 C0376286 C1216 Avitaminosis Avitaminosis A condition due to a deficiency of one or more essential vitamins. (Dorland, 27th ed) D001361 N0000000519 Back Pain [Disease/Finding] C1222 M0002115 Acute or chronic pain located in the posterior regions of the THORAX; LUMBOSACRAL REGION; or the adjacent regions. 419258005 1022771 N0000000522 Back Ache 161891005 D001416 Backache Back Pain Back Pain 267984001 C0004604 Bacterial Infections and Mycoses [Disease/Finding] Infections caused by bacteria and fungi, general, specified, or unspecified. Bacterial Infections and Mycoses N0000000523 C0004615 D001423 986958 M0002125 C1224 Bacterial Infections and Mycoses Bacterial Infections [Disease/Finding] N0000000524 D001424 Bacterial Infections 186335000 Infection, Bacterial Bacterial Infections C0004623 M0002126 301811001 Infections by bacteria, general or unspecified. Infections, Bacterial 87628006 1022614 C1226 Bacterial Infection Bacteroides Infections [Disease/Finding] 2918000 1023555 C1230 Bacteroides Infections Bacteroides Infections C0004669 Infections, Bacteroides Infections with bacteria of the genus BACTEROIDES. N0000000526 M0002147 D001442 Bartter Syndrome [Disease/Finding] D001477 N0000000534 Bartter's Disease C0004775 71275003 M0002194 Bartter Disease 1025612 Bartter Syndrome Bartter Syndrome C1246 Bartter's Syndrome A group of disorders caused by defective salt reabsorption in the ascending LOOP OF HENLE. It is characterized by severe salt-wasting, HYPOKALEMIA; HYPERCALCIURIA; metabolic ALKALOSIS, and hyper-reninemic HYPERALDOSTERONISM without HYPERTENSION. There are several subtypes including ones due to mutations in the renal specific SODIUM-POTASSIUM-CHLORIDE SYMPORTERS. Basal Ganglia Diseases [Disease/Finding] 1030459 Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA. Basal Ganglia Disorders C1250 70835005 Basal Ganglia Diseases C0004782 N0000000536 Basal Ganglia Diseases D001480 M0002198 Mental Disorders [Disease/Finding] 1022308 M0002289 C1254 N0000000538 Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function. C0004936 74732009 Mental Disorders D001523 Mental Disorders Behcet Syndrome [Disease/Finding] Behcet's Syndrome 985793 N0000000539 Triple-Symptom Complex Rare chronic inflammatory disease involving the small blood vessels. It is of unknown etiology and characterized by mucocutaneous ulceration in the mouth and genital region and uveitis with hypopyon. The neuro-ocular form may cause blindness and death. SYNOVITIS; THROMBOPHLEBITIS; gastrointestinal ulcerations; RETINAL VASCULITIS; and OPTIC ATROPHY may occur as well. C0004943 Behcet Syndrome M0002296 310701003 Behcet Syndrome Behcet Disease D001528 C1256 Bile Duct Diseases [Disease/Finding] C1266 Diseases in any part of the ductal system of the BILIARY TRACT from the smallest BILE CANALICULI to the largest COMMON BILE DUCT. M0002478 985587 C0005395 118926004 N0000000544 D001649 Bile Duct Diseases Bile Duct Diseases Biliary Tract Diseases [Disease/Finding] 105997008 C0005424 D001660 M0002491 984740 Diseases in any part of the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER. Biliary Tract Diseases Biliary Tract Diseases N0000000551 C1280 Bipolar Disorder [Disease/Finding] Affective Psychosis, Bipolar N0000000553 Bipolar Disorder 13746004 C1284 Psychosis, Manic-Depressive D001714 Psychoses, Manic-Depressive A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence. 191647000 Bipolar Disorder 1022518 M0002571 191646009 Manic-Depressive Psychosis C0005586 Urinary Bladder Diseases [Disease/Finding] D001745 1022750 Urinary Bladder Diseases Bladder Diseases N0000000560 C1298 42643001 Pathological processes of the URINARY BLADDER. Urinary Bladder Diseases C0005686 M0002630 Urinary Bladder Neck Obstruction [Disease/Finding] N0000000563 1023806 Bladder Neck Obstruction Bladder Outlet Obstruction C0005694 Blocked urine flow through the bladder neck, the narrow internal urethral opening at the base of the URINARY BLADDER. Narrowing or strictures of the URETHRA can be congenital or acquired. It is often observed in males with enlarged PROSTATE glands. 399072004 M0002634 Urinary Bladder Neck Obstruction D001748 C1304 Urinary Bladder Neck Obstruction Urinary Bladder Neoplasms [Disease/Finding] Neoplasms, Bladder N0000000564 Tumors or cancer of the URINARY BLADDER. Bladder Tumors 126885006 Urinary Bladder Neoplasms D001749 M0002635 1022826 C1306 Bladder Neoplasms C0005695 Urinary Bladder Neoplasms Blastomycosis [Disease/Finding] A fungal infection that may appear in two forms: 1, a primary lesion characterized by the formation of a small cutaneous nodule and small nodules along the lymphatics that may heal within several months; and 2, chronic granulomatous lesions characterized by thick crusts, warty growths, and unusual vascularity and infection in the middle or upper lobes of the lung. D001759 C0005716 M0002647 Blastomycosis Blastomycosis C1314 69996000 1025849 N0000000568 Blepharospasm [Disease/Finding] N0000000571 C1320 1022613 Blepharospasm Blepharospasm 59026006 D001764 C0005747 M0002660 Excessive winking; tonic or clonic spasm of the orbicularis oculi muscle. Blood Coagulation Disorders [Disease/Finding] Disorders, Blood Coagulation D001778 64779008 C0005779 N0000000575 Coagulation Disorders, Blood Blood Coagulation Disorders Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions. M0002683 362970003 1022276 Blood Coagulation Disorders C1328 Blood Platelet Disorders [Disease/Finding] Disorders caused by abnormalities in platelet count or function. 1025348 C1332 D001791 Blood Platelet Disorders Blood Platelet Disorders 22716005 Thrombocytopathy N0000000577 M0002703 C0005818 Blood Protein Disorders [Disease/Finding] Blood Protein Disorders M0002708 N0000000578 D001796 C0005830 C1334 Blood Protein Disorders 1027678 Body Temperature Changes [Disease/Finding] 1027280 N0000000581 C0005904 D001832 Body Temperature Changes C1340 M0002753 Body Temperature Changes Significant alterations in temperature of the human body, above or below 98.6 degrees F. or 37 degrees C. when taken orally. Body Weight Changes [Disease/Finding] D001836 N0000000582 C1342 1022599 M0002759 Body Weight Changes Body Weight Changes A clinical manifestation consisting of alterations in an individual's weight from his or her norm. C0005911 248346009 Bone Diseases [Disease/Finding] C1346 M0002776 Diseases of BONES. C0005940 1025929 D001847 Bone Diseases Bone Diseases N0000000584 308147009 76069003 Bone Diseases, Infectious [Disease/Finding] Bone diseases caused by pathogenic microorganisms. 1031879 Bone Diseases, Infectious C1352 N0000000587 M0002779 Bone Diseases, Infectious C0005943 D001850 Bone Diseases, Metabolic [Disease/Finding] M0002780 1026469 C1354 Bone Diseases, Metabolic 50279003 N0000000588 C0005944 D001851 Metabolic Bone Diseases Bone Diseases, Metabolic Bone Marrow Diseases [Disease/Finding] 1023913 M0002788 Bone Marrow Diseases 127035006 C0005956 D001855 Bone Marrow Diseases N0000000589 C1356 Bradycardia [Disease/Finding] C0428977 N0000000600 Bradycardia C1378 D001919 Bradyarrhythmia Cardiac arrhythmias that are characterized by excessively slow HEART RATE, usually below 50 beats per minute in human adults. They can be classified broadly into SINOATRIAL NODE dysfunction and ATRIOVENTRICULAR BLOCK. 1025503 Bradycardia Bradyarrhythmias 48867003 M0002863 Brain Diseases [Disease/Finding] D001927 Central Nervous System Disorders, Intracranial Central Nervous System Intracranial Disorders N0000000605 CNS Disorders, Intracranial Brain Diseases Encephalon Diseases C1388 81308009 Intracranial CNS Disorders 986258 Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM. Brain Disorders C0006111 Brain Diseases M0002874 Intracranial Central Nervous System Disorders Brain Edema [Disease/Finding] M0002876 Brain Edema 2032001 Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6) Brain Edema Brain Swelling Intracranial Edema 1029271 N0000000607 C1392 C1527311 D001929 Brain Injuries [Disease/Finding] Brain Injuries D001930 M0002878 2470005 Injuries, Brain C0270611 C1394 N0000000608 Brain Injuries Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits. 1024106 Brain Neoplasms [Disease/Finding] D001932 Brain Neoplasms Brain Neoplasms Brain Tumors 1025641 189537005 C1396 M0002885 Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Neoplasms, Brain 126952004 N0000000609 C0006118 Breast Diseases [Disease/Finding] Breast Diseases M0002906 N0000000611 79604008 C1400 1025046 C0006145 Pathological processes of the BREAST. D001941 Breast Diseases Breast Neoplasms [Disease/Finding] Tumors, Breast C1402 N0000000612 C1458155 Neoplasms, Breast Breast Tumors Tumors or cancer of the human BREAST. Breast Neoplasms Breast Neoplasms 1023282 126926005 M0002910 D001943 Bronchial Diseases [Disease/Finding] D001982 Bronchial Diseases Bronchial Diseases 41427001 C1406 M0002963 1024394 N0000000614 C0006261 Bronchial Neoplasms [Disease/Finding] Bronchial Neoplasms 126705004 Bronchial Neoplasms N0000000616 C1410 C0006264 Tumors or cancer of the BRONCHI. D001984 Neoplasms, Bronchial 986912 M0002965 Bronchial Spasm [Disease/Finding] 4386001 C1412 Spasmodic contraction of the smooth muscle of the bronchi. C0006266 Bronchial Spasm N0000000617 D001986 Bronchospasm M0002967 1024176 Bronchial Spasm Bronchitis [Disease/Finding] 1025453 N0000000622 C1422 Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI. 266354009 Bronchitis M0002972 C0006277 Bronchitis 32398004 D001991 Brucellosis [Disease/Finding] N0000000627 75702008 C1432 Malta Fever Gibraltar fever Brucellosis 1022508 Cyprus fever Undulant Fever Infection caused by bacteria of the genus BRUCELLA mainly involving the MONONUCLEAR PHAGOCYTE SYSTEM. This condition is characterized by fever, weakness, malaise, and weight loss. Brucellosis C0006309 D002006 M0002989 Bulimia [Disease/Finding] Binge Eating Eating an excess amount of food in a short period of time, as seen in the disorder of BULIMIA NERVOSA. It is caused by an abnormal craving for food, or insatiable hunger also known as "ox hunger". C0006370 Bulimia M0003021 1024255 Bulimia D002032 C1438 N0000000630 78004001 Bundle-Branch Block [Disease/Finding] 1022539 195048003 M0003027 6374002 D002037 A form of heart block in which the electrical stimulation of HEART VENTRICLES is interrupted at either one of the branches of BUNDLE OF HIS thus preventing the simultaneous depolarization of the two ventricles. Bundle-Branch Block Bundle-Branch Block C1440 C0006384 N0000000631 Bursitis [Disease/Finding] 1022311 Bursitis M0003070 C1456 Bursitis 84017003 N0000000639 D002062 C0006444 Inflammation or irritation of a bursa, the fibrous sac that acts as a cushion between moving structures of bones, muscles, tendons or skin. Cachexia [Disease/Finding] D002100 1023603 238108007 M0003126 Cachexia C0006625 N0000000641 General ill health, malnutrition, and weight loss, usually associated with chronic disease. Cachexia C1460 Calcium Metabolism Disorders [Disease/Finding] 71638002 M0003174 Calcium Metabolism Disorders N0000000646 C0006705 D002128 C1470 Calcium Metabolism Disorders Disorders in the processing of calcium in the body: its absorption, transport, storage, and utilization. 1024541 Campylobacter Infections [Disease/Finding] Infections, Campylobacter N0000000649 86500004 Campylobacter Infections C1476 1022934 M0003245 D002169 Infections with bacteria of the genus CAMPYLOBACTER. Campylobacter Infections C0006818 Candidiasis [Disease/Finding] Candidiasis Candidiasis Moniliasis Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed) N0000000650 C1478 C0006840 1022538 M0003258 D002177 78048006 Candidiasis, Chronic Mucocutaneous [Disease/Finding] C1480 A clinical syndrome characterized by development, usually in infancy or childhood, of a chronic, often widespread candidiasis of skin, nails, and mucous membranes. It may be secondary to one of the immunodeficiency syndromes, inherited as an autosomal recessive trait, or associated with defects in cell-mediated immunity, endocrine disorders, dental stomatitis, or malignancy. 1023229 Candidiasis, Chronic Mucocutaneous 234568006 N0000000651 D002178 C0006845 M0003259 Candidiasis, Chronic Mucocutaneous Candidiasis, Oral [Disease/Finding] 79740000 Candidiasis, Oral Candidiasis, Oral Infection of the mucous membranes of the mouth by a fungus of the genus CANDIDA. (Dorland, 27th ed) Moniliasis, Oral C0006849 Thrush N0000000653 C1484 M0003261 D002180 1022622 Candidiasis, Vulvovaginal [Disease/Finding] N0000000654 C0700345 Candidiasis, Vulvovaginal M0003262 Moniliasis, Vulvovaginal C1486 1024776 D002181 72605008 Infection of the VULVA and VAGINA with a fungus of the genus CANDIDA. Candidiasis, Vulvovaginal Carcinoma [Disease/Finding] Epithelial Tumors, Malignant M0003424 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed) D002277 Malignant Epithelial Neoplasms Epithelioma 68453008 Epithelial Neoplasms, Malignant N0000000664 C1506 1024578 C0007097 Neoplasms, Malignant Epithelial Carcinoma Carcinoma, Basal Cell [Disease/Finding] 254701007 275265005 M0003431 D002280 N0000000667 1023628 Ulcer, Rodent C0007117 A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471) Carcinoma, Basal Cell C1512 Epithelioma, Basal Cell Rodent Ulcer Carcinoma, Basal Cell Carcinoma, Bronchogenic [Disease/Finding] 1027239 Carcinoma, Bronchial M0003434 254622008 D002283 363493006 Carcinoma, Bronchogenic Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA. C1518 N0000000670 Carcinoma, Bronchogenic C0007121 Carcinoma, Non-Small-Cell Lung [Disease/Finding] D002289 N0000000676 Carcinoma, Non-Small-Cell Lung Carcinoma, Non-Small-Cell Lung C0007131 C1530 A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. 1022450 Carcinoma, Non-Small Cell Lung Non-Small-Cell Lung Carcinoma Non-Small Cell Lung Cancer M0003440 254637007 Carcinoma, Renal Cell [Disease/Finding] Adenocarcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma. 188251003 M0003442 N0000000678 Nephroid Carcinoma Renal Cell Cancer Carcinoma, Renal Cell D002292 1025619 Carcinoma, Renal Cell C0007134 C1534 Renal Cell Carcinoma Cardiac Tamponade [Disease/Finding] Cardiac Tamponade 1024098 C1546 Compression of the heart by accumulated fluid (PERICARDIAL EFFUSION) or blood (HEMOPERICARDIUM) in the PERICARDIUM surrounding the heart. The affected cardiac functions and CARDIAC OUTPUT can range from minimal to total hemodynamic collapse. C0007177 M0003456 Pericardial Tamponade N0000000684 Cardiac Tamponade 35304003 D002305 Cardiovascular Diseases [Disease/Finding] 49601007 1022075 105980002 Cardiovascular Diseases N0000000689 M0003473 C0007222 Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. C1556 Cardiovascular Diseases D002318 Cartilage Diseases [Disease/Finding] D002357 50927007 367355001 C0007302 N0000000694 1023741 C1566 Cartilage Diseases Pathological processes involving the chondral tissue (CARTILAGE). Cartilage Diseases M0003568 Central Nervous System Diseases [Disease/Finding] D002493 C1596 Central Nervous System Disorders M0003805 23853001 Central Nervous System Diseases N0000000709 Central Nervous System Diseases CNS Diseases 1023588 C0007682 Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord. Central Nervous System Infections [Disease/Finding] C1598 128117002 1026115 D002494 Pathogenic infections of the brain, spinal cord, and meninges. DNA VIRUS INFECTIONS; RNA VIRUS INFECTIONS; BACTERIAL INFECTIONS; MYCOPLASMA INFECTIONS; SPIROCHAETALES INFECTIONS; fungal infections; PROTOZOAN INFECTIONS; HELMINTHIASIS; and PRION DISEASES may involve the central nervous system as a primary or secondary process. M0003806 Infections, Central Nervous System Central Nervous System Infections Central Nervous System Infection Central Nervous System Infections C0007684 N0000000710 Intracranial Embolism and Thrombosis [Disease/Finding] Embolism or thrombosis involving blood vessels which supply intracranial structures. Emboli may originate from extracranial or intracranial sources. Thrombosis may occur in arterial or venous structures. C1618 D002542 N0000000720 M0333623 C0007781 Intracranial Embolism and Thrombosis Intracranial Embolism and Thrombosis 1027996 Cerebral Infarction [Disease/Finding] C0007785 D002544 C1622 266256009 1025113 Cerebral Infarction The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction). N0000000722 Cerebral Infarction Infarction, Cerebral M0003885 Brain Ischemia [Disease/Finding] D002545 N0000000723 Encephalopathy, Ischemic C0007786 C1624 Brain Ischemia 389100007 Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION. 1023203 Brain Ischemia Ischemic Encephalopathy M0003886 Ischemic Attack, Transient [Disease/Finding] Brain TIA Ischemic Attack, Transient TIA (Transient Ischemic Attack) C0007787 N0000000724 Transient Ischemic Attack C1626 1023504 266257000 M0003887 313242003 Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6) Ischemic Attack, Transient D002546 Cerebrovascular Disorders [Disease/Finding] Intracranial Vascular Disorders 1022010 C1638 N0000000730 Cerebrovascular Disorders C0007820 Vascular Diseases, Intracranial Cerebrovascular Disorders D002561 A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES; or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others. M0003914 Brain Vascular Disorders 62914000 Chest Pain [Disease/Finding] D002637 N0000000746 Pressure, burning, or numbness in the chest. M0004035 C0008031 1024345 Chest Pain Chest Pain C1670 29857009 Chickenpox [Disease/Finding] Chickenpox 1025604 38907003 C0008049 Varicella C1676 M0004041 N0000000749 Chicken Pox D002644 A highly contagious infectious disease caused by the varicella-zoster virus (HERPESVIRUS 3, HUMAN). It usually affects children, is spread by direct contact or respiratory route via droplet nuclei, and is characterized by the appearance on the skin and mucous membranes of successive crops of typical pruritic vesicular lesions that are easily broken and become scabbed. Chickenpox is relatively benign in children, but may be complicated by pneumonia and encephalitis in adults. (From Dorland, 27th ed) Chickenpox Child Behavior Disorders [Disease/Finding] C0008066 Child Behavior Disorders Disturbances considered to be pathological based on age and stage appropriateness, e.g., conduct disturbances and anaclitic depression. This concept does not include psychoneuroses, psychoses, or personality disorders with fixed patterns. N0000000751 C1680 M0004052 1029830 Child Behavior Disorders D002653 Child Development Disorders, Pervasive [Disease/Finding] M0004062 D002659 Severe distortions in the development of many basic psychological functions that are not normal for any stage in development. These distortions are manifested in sustained social impairment, speech abnormalities, and peculiar motor movements. Pervasive Child Development Disorders Child Development Disorders, Pervasive Child Development Disorders, Pervasive C0008074 C1684 N0000000753 1028303 Chlamydia Infections [Disease/Finding] C1686 M0004107 105629000 N0000000754 Chlamydia Infections Chlamydia Infections Infections, Chlamydia Infections with bacteria of the genus CHLAMYDIA. C0008149 D002690 1023626 Chlamydiaceae Infections [Disease/Finding] C1688 C0008153 987383 Chlamydiaceae Infections Infections with bacteria of the family CHLAMYDIACEAE. N0000000755 Chlamydiaceae Infections M0004111 D002694 Cholestasis [Disease/Finding] 197446008 Bile Duct Obstruction Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS). 30144000 C1702 1023457 Cholestasis C0008370 N0000000762 Biliary Stasis D002779 M0004258 Cholestasis Cholestasis, Intrahepatic [Disease/Finding] N0000000763 Biliary Stasis, Intrahepatic D002780 4637005 M0004262 C1704 1028249 Cholestasis, Intrahepatic Bile Duct Obstruction, Intrahepatic Cholestasis, Intrahepatic C0008372 Impairment of bile flow due to injury to the HEPATOCYTES; BILE CANALICULI; or the intrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC). Intrahepatic Cholestasis Choriocarcinoma [Disease/Finding] Choriocarcinoma D002822 M0004339 A malignant metastatic form of trophoblastic tumors. Unlike the HYDATIDIFORM MOLE, choriocarcinoma contains no CHORIONIC VILLI but rather sheets of undifferentiated cytotrophoblasts and syncytiotrophoblasts (TROPHOBLASTS). It is characterized by the large amounts of CHORIONIC GONADOTROPIN produced. Tissue origins can be determined by DNA analyses: placental (fetal) origin or non-placental origin (CHORIOCARCINOMA, NON-GESTATIONAL). C0008497 C1728 N0000000775 188188009 Choriocarcinoma 1025772 Chromoblastomycosis [Disease/Finding] M0004392 187079000 238441002 Chromomycosis Chromoblastomycosis Dermatitis Verrucosa N0000000782 D002862 Scaly papule or warty growth, caused by five fungi, that spreads as a result of satellite lesions affecting the foot or leg. The extremity may become swollen and, at its distal portion, covered with various nodular, tumorous, verrucous lesions that resemble cauliflower. In rare instances, the disease may begin on the hand or wrist and involve the entire upper extremity. (Arnold, Odom, and James, Andrew's Diseases of the Skin, 8th ed, p362) C0008582 C1742 1024319 Chromoblastomycosis 252402000 Cicatrix [Disease/Finding] N0000000790 C1758 M0004472 Scar 1024421 D002921 Scars C2004491 Cicatrix Cicatrix 275322007 The fibrous tissue that replaces normal tissue during the process of WOUND HEALING. Clostridium Infections [Disease/Finding] Infections with bacteria of the genus CLOSTRIDIUM. D003015 Clostridium Infections N0000000796 Clostridium Infections M0004637 56688005 989684 C1770 C0009062 Infections, Clostridium Cluster Headache [Disease/Finding] Histamine Cephalgia Cluster Headache Cluster Headache Ciliary Neuralgia 1022422 Horton's Syndrome C1774 C0009088 Cluster Headache Syndrome Headache, Cluster A primary headache disorder that is characterized by severe, strictly unilateral PAIN which is orbital, supraorbital, temporal or in any combination of these sites, lasting 15-180 min. occurring 1 to 8 times a day. The attacks are associated with one or more of the following, all of which are ipsilateral: conjunctival injection, lacrimation, nasal congestion, rhinorrhea, facial SWEATING, eyelid EDEMA, and miosis. (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1) 193947008 193031009 D003027 N0000000798 Horton Syndrome 230473009 Chronic Cluster Headache Neuralgic Migraine M0004652 Coccidioidomycosis [Disease/Finding] San Joaquin Valley Fever Valley Fever M0004676 1023493 Coccidioides immitis Infection Coccidioidomycosis D003047 C0009186 N0000000800 Infection with a fungus of the genus COCCIDIOIDES, endemic to the SOUTHWESTERN UNITED STATES. It is sometimes called valley fever but should not be confused with RIFT VALLEY FEVER. Infection is caused by inhalation of airborne, fungal particles known as arthroconidia, a form of FUNGAL SPORES. A primary form is an acute, benign, self-limited respiratory infection. A secondary form is a virulent, severe, chronic, progressive granulomatous disease with systemic involvement. It can be detected by use of COCCIDIOIDIN. Coccidioidomycosis C1778 60826002 Coccidiosis [Disease/Finding] C0009187 M0004678 1023852 Coccidiosis Coccidiosis C1780 N0000000801 Protozoan infection found in animals and man. It is caused by several different genera of COCCIDIA. D003048 62005008 Colitis [Disease/Finding] D003092 Colitis Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER. C1790 1024342 N0000000806 M0004770 C0009319 64226004 Colitis, Ulcerative [Disease/Finding] Colitis, Ulcerative Colitis, Ulcerative D003093 C0009324 1025158 64766004 M0004771 N0000000807 Ulcerative Colitis C1792 Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN. Collagen Diseases [Disease/Finding] M0004792 C0009326 N0000000808 D003095 Collagen Diseases Collagen Diseases 1022203 Historically, a heterogeneous group of acute and chronic diseases, including rheumatoid arthritis, systemic lupus erythematosus, progressive systemic sclerosis, dermatomyositis, etc. This classification was based on the notion that "collagen" was equivalent to "connective tissue", but with the present recognition of the different types of collagen and the aggregates derived from them as distinct entities, the term "collagen diseases" now pertains exclusively to those inherited conditions in which the primary defect is at the gene level and affects collagen biosynthesis, post-translational modification, or extracellular processing directly. (From Cecil Textbook of Medicine, 19th ed, p1494) C1794 81573002 Colonic Diseases [Disease/Finding] Pathological processes in the COLON region of the large intestine (INTESTINE, LARGE). D003108 M0004814 Colonic Diseases Colonic Diseases C0009373 1025915 C1800 N0000000811 128524007 Colonic Diseases, Functional [Disease/Finding] Colonic Diseases, Functional 1026889 C0009374 Colonic Diseases, Functional Functional Colonic Diseases Chronic or recurrent colonic disorders without an identifiable structural or biochemical explanation. The widely recognized IRRITABLE BOWEL SYNDROME falls into this category. N0000000812 D003109 M0004815 C1802 Colonic Neoplasms [Disease/Finding] Neoplasms, Colonic C1804 D003110 Colonic Neoplasms Colonic Neoplasms N0000000813 1024201 C0009375 Tumors or cancer of the COLON. Colon Neoplasms M0004817 126838000 Coma [Disease/Finding] A profound state of unconsciousness associated with depressed cerebral activity from which the individual cannot be aroused. Coma generally occurs when there is dysfunction or injury involving both cerebral hemispheres or the brain stem RETICULAR FORMATION. D003128 C1816 N0000000819 M0004841 988251 Coma Coma 371632003 C0009421 Comatose Confusion [Disease/Finding] C0009676 D003221 C1838 1021821 N0000000830 M0005001 A mental state characterized by bewilderment, emotional disturbance, lack of clear thinking, and perceptual disorientation. 286933003 Confusion Confusion Confusional State Conjunctival Diseases [Disease/Finding] N0000000831 C0009759 M0005013 59698003 Conjunctival Diseases 1024252 C1840 D003229 Conjunctival Diseases Conjunctivitis [Disease/Finding] Conjunctivitis 9826008 1026151 Conjunctivitis 193875009 D003231 M0005015 C0009763 C1844 N0000000833 Conjunctivitis, Bacterial [Disease/Finding] Conjunctivitis, Purulent 243462001 Purulent infections of the conjunctiva by several species of gram-negative, gram-positive, or acid-fast organisms. Some of the more commonly found genera causing conjunctival infections are Haemophilus, Streptococcus, Neisseria, and Chlamydia. Bacterial Conjunctivitis Conjunctivitis, Mucopurulent D003234 N0000000836 C0009768 Bacterial Conjunctivitides Conjunctivitis, Bacterial 128350005 243321006 Conjunctivitides, Bacterial 1024334 C1850 M0005021 Conjunctivitis, Bacterial Connective Tissue Diseases [Disease/Finding] M0005027 C0009782 C1856 D003240 Connective Tissue Diseases 105969002 N0000000839 A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides. 986518 Connective Tissue Diseases Consciousness Disorders [Disease/Finding] C0009792 M0005031 Organic mental disorders in which there is impairment of the ability to maintain awareness of self and environment and to respond to environmental stimuli. Dysfunction of the cerebral hemispheres or brain stem RETICULAR FORMATION may result in this condition. 1031236 N0000000840 Consciousness Disorders Consciousness Disorders C1858 D003244 Constipation [Disease/Finding] 14760008 Constipation M0005043 1022104 C1860 Constipation Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections. N0000000841 C0009806 D003248 Corneal Diseases [Disease/Finding] M0005177 15250008 1024256 C0010034 Corneal Diseases C1880 N0000000851 D003316 Corneal Diseases Diseases of the cornea. Coronary Artery Disease [Disease/Finding] 53741008 C1890 Coronary Artery Disease 414024009 C1956346 Coronary Artery Disease N0000000856 M0502868 1103697 Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause. D003324 Coronary Disease [Disease/Finding] Coronary Heart Disease 1022922 C1892 53741008 N0000000857 An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Disease M0005191 C0010068 Coronary Disease D003327 Coronary Thrombosis [Disease/Finding] D003328 1025738 Coronary Thrombosis N0000000858 M0005194 398274000 Coagulation of blood in any of the CORONARY VESSELS. The presence of a blood clot (THROMBUS) often leads to MYOCARDIAL INFARCTION. Coronary Thrombosis C0010072 C1894 Thrombosis, Coronary Coronary Vasospasm [Disease/Finding] N0000000859 Spasm of the large- or medium-sized coronary arteries. Coronary Vasospasm Coronary Vasospasm C0010073 D003329 C1896 23687008 1021875 Coronary Artery Vasospasm M0005195 Cranial Nerve Diseases [Disease/Finding] C0010266 Disorders of one or more of the twelve cranial nerves. With the exception of the optic and olfactory nerves, this includes disorders of the brain stem nuclei from which the cranial nerves originate or terminate. 1023353 Cranial Nerve Disorders Neuropathies, Cranial 73013002 Cranial Nerve Diseases Cranial Nerve Diseases C1910 Cranial Neuropathies D003389 N0000000866 Nervus Cranialis Disorders M0005279 Crohn Disease [Disease/Finding] Crohn's Disease D003424 A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients. N0000000875 34000006 C1928 M0005335 C0010346 Crohn Disease Crohn Disease 1024195 Cryoglobulinemia [Disease/Finding] 30911005 C0010403 C1936 M0005376 N0000000879 Cryoglobulinemia Cryoglobulinemia A condition characterized by the presence of abnormal quantities of CRYOGLOBULINS in the blood. Upon cold exposure, these abnormal proteins precipitate into the microvasculature leading to restricted blood flow in the exposed areas. D003449 1027021 Cryptococcosis [Disease/Finding] Cryptococcosis 1021843 C0010414 N0000000880 Cryptococcosis Infection with a fungus of the species CRYPTOCOCCUS NEOFORMANS. 42386007 M0005381 C1938 Torulosis D003453 Cushing Syndrome [Disease/Finding] Hypercortisolism C0010481 190505004 Cushing Syndrome Cushing's Syndrome D003480 Cushing Syndrome M0005427 N0000000883 A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent. C1944 1023535 Cystinuria [Disease/Finding] D003555 Cystinuria 1024925 M0005557 An inherited disorder due to defective reabsorption of CYSTINE and other BASIC AMINO ACIDS by the PROXIMAL RENAL TUBULES. This form of aminoaciduria is characterized by the abnormally high urinary levels of cystine; LYSINE; ARGININE; and ORNITHINE. Mutations involve the amino acid transport protein gene SLC3A1. 85020001 C0010691 Cystinuria C1964 N0000000893 Cystitis [Disease/Finding] 38822007 C0010692 D003556 1024624 Cystitis M0005558 N0000000894 C1966 Cystitis Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain. Cytomegalovirus Infections [Disease/Finding] M0005604 D003586 N0000000897 C0010823 Cytomegalovirus Infections Salivary Gland Virus Disease Inclusion Disease Infections, Cytomegalovirus Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults. Cytomegalovirus Infections C1972 Cytomegalic Inclusion Disease 1023187 28944009 Deficiency Diseases [Disease/Finding] D003677 Deficiency Diseases Deficiency Diseases M0005753 N0000000909 A condition produced by dietary or metabolic deficiency. The term includes all diseases caused by an insufficient supply of essential nutrients, i.e., protein (or amino acids), vitamins, and minerals. It also includes an inadequacy of calories. (From Dorland, 27th ed; Stedman, 25th ed) 1025258 C0011156 C1996 Deglutition Disorders [Disease/Finding] Deglutition Disorders 1023938 M0005756 C1998 Deglutition Disorders Difficulty in SWALLOWING which may result from neuromuscular disorder or mechanical obstruction. Dysphagia is classified into two distinct types: oropharyngeal dysphagia due to malfunction of the PHARYNX and UPPER ESOPHAGEAL SPHINCTER; and esophageal dysphagia due to malfunction of the ESOPHAGUS. 40739000 N0000000910 D003680 Dysphagia C0011168 Swallowing Disorders Delirium [Disease/Finding] 2776000 A disorder characterized by CONFUSION; inattentiveness; disorientation; ILLUSIONS; HALLUCINATIONS; agitation; and in some instances autonomic nervous system overactivity. It may result from toxic/metabolic conditions or structural brain lesions. (From Adams et al., Principles of Neurology, 6th ed, pp411-2) D003693 1024817 C2002 C0011206 Delirium Delirium M0005774 N0000000912 Hepatitis D [Disease/Finding] Infection, Delta 1023265 M0005790 Delta Hepatitis INFLAMMATION of the LIVER in humans caused by HEPATITIS DELTA VIRUS, a defective RNA virus that can only infect HEPATITIS B patients. For its viral coating, hepatitis delta virus requires the HEPATITIS B SURFACE ANTIGENS produced by these patients. Hepatitis D can occur either concomitantly with (coinfection) or subsequent to (superinfection) hepatitis B infection. Similar to hepatitis B, it is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. C0011226 Hepatitis, Delta C2004 Hepatitis D D003699 Delta Infection N0000000913 Hepatitis D Dementia [Disease/Finding] C2006 Dementia C0497327 M0005797 Dementia 1022551 Amentia D003704 N0000000914 52448006 An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness. Demyelinating Diseases [Disease/Finding] Demyelinating Diseases M0005825 D003711 Demyelinating Diseases Demyelinating Disorders C2008 N0000000915 1026682 Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system. C0011303 Depressive Disorder [Disease/Finding] D003866 C0011581 Depressive Disorder Depressive Disorder 35489007 1026289 C2054 N0000000938 An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent. M0006033 Neurosis, Depressive Dermatitis [Disease/Finding] C2056 1023378 182782007 Dermatitis M0006046 C0011603 Any inflammation of the skin. D003872 Dermatitis N0000000939 Dermatitis, Exfoliative [Disease/Finding] N0000000940 Erythroderma 200948000 399992009 396349005 D003873 400005007 Dermatitis, Exfoliative M0006047 C2058 C0011606 Dermatitis Exfoliativa 1022880 396350005 The widespread involvement of the skin by a scaly, erythematous dermatitis occurring either as a secondary or reactive process to an underlying cutaneous disorder (e.g., atopic dermatitis, psoriasis, etc.), or as a primary or idiopathic disease. It is often associated with the loss of hair and nails, hyperkeratosis of the palms and soles, and pruritus. (From Dorland, 27th ed) Dermatitis, Exfoliative Dermatitis Herpetiformis [Disease/Finding] C2060 1026352 Rare, chronic, papulo-vesicular disease characterized by an intensely pruritic eruption consisting of various combinations of symmetrical, erythematous, papular, vesicular, or bullous lesions. The disease is strongly associated with the presence of HLA-B8 and HLA-DR3 antigens. A variety of different autoantibodies has been detected in small numbers in patients with dermatitis herpetiformis. Dermatitis Herpetiformis Dermatitis Herpetiformis N0000000941 Duhring's Disease 111196000 M0006048 Duhring Disease D003874 C0011608 Drug Eruptions [Disease/Finding] 1025301 275447008 M0006049 28926001 Drug Eruptions Dermatitis, Adverse Drug Reaction N0000000942 Adverse cutaneous reactions caused by ingestion, parenteral use, or local application of a drug. These may assume various morphologic patterns and produce various types of lesions. D003875 403675008 Dermatitis Medicamentosa C0011609 Drug Eruptions C2062 Dermatitis, Atopic [Disease/Finding] Eczema, Atopic 200773006 Neurodermatitis, Disseminated 1022124 Neurodermatitis, Atopic C0011615 Dermatitis, Atopic M0006050 N0000000943 Dermatitis, Atopic D003876 24079001 200775004 A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema. C2064 Dermatomycoses [Disease/Finding] N0000000945 Skin Diseases, Fungal C0011630 14560005 276206000 Fungal Skin Diseases C2068 Dermatomycosis Dermatomycoses Dermatomycoses 1021749 D003881 Superficial infections of the skin or its appendages by any of various fungi. M0006059 Diabetes Mellitus [Disease/Finding] M0006148 73211009 C0011849 D003920 Diabetes Mellitus Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE. 990753 C2078 N0000000950 Diabetes Mellitus, Type 2 [Disease/Finding] 44054006 M0006155 Diabetes Mellitus, Stable Maturity-Onset Diabetes Mellitus Diabetes Mellitus, Non-Insulin-Dependent Diabetes Mellitus, Type 2 Diabetes Mellitus, Non Insulin Dependent D003924 N0000000954 C0011860 MODY Diabetes Mellitus, Maturity-Onset NIDDM Diabetes Mellitus, Noninsulin Dependent Diabetes Mellitus, Slow-Onset Type 2 Diabetes Mellitus Diabetes Mellitus, Ketosis-Resistant A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset 1025564 C2086 Diabetes Mellitus, Type II Diabetes Mellitus, Type 2 Diabetic Nephropathies [Disease/Finding] M0006160 C2092 D003928 KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE. Diabetic Kidney Disease N0000000957 197605007 Diabetic Nephropathy 54181000 127013003 C0011881 21858001 Diabetic Nephropathies 1021799 Diabetic Nephropathies Diabetic Neuropathies [Disease/Finding] M0006162 C0011882 230572002 N0000000958 Diabetic Neuropathies Diabetic Neuropathies Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325) C2094 267382005 1027333 D003929 Diarrhea [Disease/Finding] C0011991 Diarrhea D003967 267060006 N0000000963 1022243 C2104 62315008 An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight. M0006212 Diarrhea 398032003 Digestive System Diseases [Disease/Finding] N0000000973 C0012242 Digestive System Diseases Diseases in any part of the GASTROINTESTINAL TRACT or the accessory organs (LIVER; BILIARY TRACT; PANCREAS). M0006374 1023342 C2124 D004066 53619000 Digestive System Diseases Digestive System Neoplasms [Disease/Finding] 128348002 M0006375 Neoplasms, Digestive System N0000000974 1027801 C2126 Digestive System Neoplasms 128415001 C0012243 D004067 189527000 Tumors or cancer of the DIGESTIVE SYSTEM. Digestive System Neoplasms Diverticulitis [Disease/Finding] 197102009 D004238 Diverticulitis 1027287 C2154 307496006 N0000000988 M0006630 C0012813 Inflammation of a DIVERTICULUM or diverticula. Diverticulitis DNA Virus Infections [Disease/Finding] M0006675 C0012922 1027612 D004266 DNA Virus Infections N0000000993 DNA Virus Infections Infections, DNA Virus C2164 Drug Hypersensitivity [Disease/Finding] D004342 Drug Allergy Drug Hypersensitivity 416093006 Drug Hypersensitivity 416098002 C0013182 M0006829 Hypersensitivity, Drug Immunologically mediated adverse reactions to medicinal substances used legally or illegally. Allergy, Drug C2176 1024684 N0000000999 Drug Toxicity [Disease/Finding] 7895008 N0000001000 Drug Toxicity D004362 C0013221 Manifestations of the adverse effects of drugs administered therapeutically or in the course of diagnostic techniques. It does not include accidental or intentional poisoning for which specific headings are available. C2178 1022029 M0006855 Toxicity, Drug Drug Toxicity Ductus Arteriosus, Patent [Disease/Finding] M0006877 Patency of the Ductus Arteriosus N0000001003 Ductus Arteriosus, Patent C2184 83330001 A congenital heart defect characterized by the persistent opening of fetal DUCTUS ARTERIOSUS that connects the PULMONARY ARTERY to the descending aorta (AORTA, DESCENDING) allowing unoxygenated blood to bypass the lung and flow to the PLACENTA. Normally, the ductus is closed shortly after birth. C0013274 1021972 D004374 Ductus Arteriosus, Patent Duodenal Diseases [Disease/Finding] N0000001005 Pathological conditions in the DUODENUM region of the small intestine (INTESTINE, SMALL). C0013289 D004378 M0006881 1022796 C2188 Duodenal Diseases Duodenal Diseases 52182008 Duodenal Ulcer [Disease/Finding] A PEPTIC ULCER located in the DUODENUM. D004381 Duodenal Ulcer C0013295 1025099 C2194 196672001 N0000001008 51868009 367474008 M0006885 Duodenal Ulcer Dysentery [Disease/Finding] 111939009 D004403 Infectious Diarrheal Disease N0000001016 C0013369 1022956 C2210 236076004 M0006913 Dysentery Dysentery 19213003 Acute inflammation of the intestine associated with infectious DIARRHEA of various etiologies, generally acquired by eating contaminated food containing TOXINS, BIOLOGICAL derived from BACTERIA or other microorganisms. Dysentery is characterized initially by watery FECES then by bloody mucoid stools. It is often associated with ABDOMINAL PAIN; FEVER; and DEHYDRATION. Dyskinesia, Drug-Induced [Disease/Finding] N0000001022 C0013386 Dyskinesia, Drug-Induced 1022304 Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199) 102448004 M0006920 C2222 Dyskinesia, Drug-Induced D004409 Dysmenorrhea [Disease/Finding] Dysmenorrhea C2228 M0006924 Menstruation, Painful N0000001025 C0013390 Painful menstruation. 266599000 Pain, Menstrual 986315 D004412 Dysmenorrhea Edema [Disease/Finding] C2292 M0007051 1022374 Edema 79654002 Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE. Dropsy 20741006 N0000001057 D004487 C0013604 Hydrops Emaciation [Disease/Finding] N0000001066 C0013911 Emaciation Emaciation M0007242 Clinical manifestation of excessive LEANNESS usually caused by disease or a lack of nutrition (MALNUTRITION). C2310 371597004 D004614 1027077 Encephalitis [Disease/Finding] M0007337 D004660 N0000001076 C2330 Encephalitis 1022474 C0014038 Brain Inflammation Inflammation, Brain 45170000 Inflammation of the BRAIN due to infection, autoimmune processes, toxins, and other conditions. Viral infections (see ENCEPHALITIS, VIRAL) are a relatively frequent cause of this condition. Encephalitis Encephalitis, Arbovirus [Disease/Finding] C0014055 Infections of the brain caused by arthropod-borne viruses (i.e., arboviruses) primarily from the families TOGAVIRIDAE; FLAVIVIRIDAE; BUNYAVIRIDAE; REOVIRIDAE; and RHABDOVIRIDAE. Life cycles of these viruses are characterized by ZOONOSES, with birds and lower mammals serving as intermediate hosts. The virus is transmitted to humans by the bite of mosquitoes (CULICIDAE) or TICKS. Clinical manifestations include fever, headache, alterations of mentation, focal neurologic deficits, and COMA. (From Clin Microbiol Rev 1994 Jan;7(1):89-116; Walton, Brain's Diseases of the Nervous System, 10th ed, p321) Arthropod-Borne Viral Encephalitis 192687008 285756005 186498004 Epidemic Encephalitis D004671 C2334 Encephalitis, Arbovirus 1021779 Encephalitis, Arthropod-Borne Encephalitis, Arbovirus M0007356 N0000001078 Arthropod-Borne Encephalitis Viral Encephalitis, Arthropod-Borne Encephalitis, Epidemic Encephalomyelitis [Disease/Finding] Encephalomyelitis 62950007 C0014070 Myeloencephalitis D004679 N0000001085 C2348 A general term indicating inflammation of the BRAIN and SPINAL CORD, often used to indicate an infectious process, but also applicable to a variety of autoimmune and toxic-metabolic conditions. There is significant overlap regarding the usage of this term and ENCEPHALITIS in the literature. M0007368 Encephalomyelitis 1025712 Endocarditis [Disease/Finding] Inflammation of the inner lining of the heart (ENDOCARDIUM), the continuous membrane lining the four chambers and HEART VALVES. It is often caused by microorganisms including bacteria, viruses, fungi, and rickettsiae. Left untreated, endocarditis can damage heart valves and become life-threatening. 1027251 M0007392 Endocarditis C2370 56819008 N0000001096 D004696 Endocarditis C0014118 Endocarditis, Bacterial [Disease/Finding] C2372 M0007393 Endocarditis, Bacterial Endocarditides, Bacterial Inflammation of the ENDOCARDIUM caused by BACTERIA that entered the bloodstream. The strains of bacteria vary with predisposing factors, such as CONGENITAL HEART DEFECTS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; or intravenous drug use. Bacterial Endocarditides N0000001097 C0014121 D004697 301183007 Bacterial Endocarditis 1021809 Endocarditis, Bacterial Endocrine System Diseases [Disease/Finding] N0000001099 Pathological processes of the ENDOCRINE GLANDS, and diseases resulting from abnormal level of available HORMONES. 362969004 Endocrine Diseases D004700 Endocrine System Diseases M0007396 Diseases of Endocrine System C2376 Endocrine System Diseases 1022080 C0014130 Endocrine Gland Neoplasms [Disease/Finding] Tumors or cancer of the ENDOCRINE GLANDS. C2378 Endocrine Gland Neoplasms M0007397 Endocrine Gland Neoplasms 1022324 387922007 N0000001100 387927001 C0014132 D004701 Neoplasms, Endocrine Gland Endometriosis [Disease/Finding] D004715 Endometriosis 129103003 M0007413 1024249 C2382 Endometriosis A condition in which functional endometrial tissue is present outside the UTERUS. It is often confined to the PELVIS involving the OVARY, the ligaments, cul-de-sac, and the uterovesical peritoneum. N0000001102 C0014175 Enterobacteriaceae Infections [Disease/Finding] C0014347 C2394 M0007472 Infections, Enterobacterial Enterobacteriaceae Infections Enterobacterial Infections D004756 Infections with bacteria of the family ENTEROBACTERIACEAE. 1024436 Enterobacteriaceae Infections N0000001108 Infections, Enterobacteriaceae Enterocolitis [Disease/Finding] M0007478 1025705 Enterocolitis C0014356 C2396 Inflammation of the MUCOSA of both the SMALL INTESTINE and the LARGE INTESTINE. Etiology includes ISCHEMIA, infections, allergic, and immune responses. N0000001109 D004760 43752006 Enterocolitis Enterocolitis, Pseudomembranous [Disease/Finding] C0014358 C2398 Pseudomembranous Enterocolitis Enterocolitis, Pseudomembranous Enterocolitis, Pseudomembranous 1025680 D004761 N0000001110 M0007479 397683000 An acute inflammation of the INTESTINAL MUCOSA that is characterized by the presence of pseudomembranes or plaques in the SMALL INTESTINE (pseudomembranous enteritis) and the LARGE INTESTINE (pseudomembranous colitis). It is commonly associated with antibiotic therapy and CLOSTRIDIUM DIFFICILE colonization. Enuresis [Disease/Finding] 1023181 C0014394 8009008 D004775 Enuresis C2406 Involuntary discharge of URINE after expected age of completed development of urinary control. This can happen during the daytime (DIURNAL ENURESIS) while one is awake or during sleep (NOCTURNAL ENURESIS). Enuresis can be in children or in adults (as persistent primary enuresis and secondary adult-onset enuresis). M0007497 N0000001114 Enuresis Eosinophilia [Disease/Finding] M0007532 C0014457 Eosinophilia N0000001115 D004802 Abnormal increase of EOSINOPHILS in the blood, tissues or organs. 1021800 C2408 191363000 Eosinophilia Ependymoma [Disease/Finding] Ependymoma N0000001117 1025308 M0007536 Glioma derived from ependymocytes that tend to present as malignant intracranial tumors in children and as benign intraspinal neoplasms in adults. It may arise from any level of the ventricular system or central canal of the spinal cord. Intracranial ependymomas most frequently originate in the FOURTH VENTRICLE and histologically are densely cellular tumors which may contain ependymal tubules and perivascular pseudorosettes. Spinal ependymomas are usually benign papillary or myxopapillary tumors. (From DeVita et al., Principles and Practice of Oncology, 5th ed, p2018; Escourolle et al., Manual of Basic Neuropathology, 2nd ed, pp28-9) C2412 Ependymoma C0014474 57706008 D004806 Epidermolysis Bullosa [Disease/Finding] Epidermolysis Bullosa C2424 D004820 Epidermolysis Bullosa N0000001123 61003004 1025920 M0007557 C0014527 Acantholysis Bullosa Group of genetically determined disorders characterized by the blistering of skin and mucosae. There are four major forms: acquired, simple, junctional, and dystrophic. Each of the latter three has several varieties. Epilepsy [Disease/Finding] Seizure Disorder Epilepsy C0014544 M0007564 Epilepsy 1021750 128613002 D004827 84757009 C2430 N0000001126 Seizures, Epileptic Epileptic Seizures A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Epilepsies, Partial [Disease/Finding] Epilepsy, Localization-Related M0007566 C2432 Partial Epilepsy Focal Seizure Disorder 230381009 C0014547 Seizure Disorder, Focal 1024007 N0000001127 Partial Seizure Disorder Epilepsies, Partial D004828 Seizure Disorder, Partial Epilepsy, Partial Epilepsy, Focal Conditions characterized by recurrent paroxysmal neuronal discharges which arise from a focal region of the brain. Partial seizures are divided into simple and complex, depending on whether consciousness is unaltered (simple partial seizure) or disturbed (complex partial seizure). Both types may feature a wide variety of motor, sensory, and autonomic symptoms. Partial seizures may be classified by associated clinical features or anatomic location of the seizure focus. A secondary generalized seizure refers to a partial seizure that spreads to involve the brain diffusely. (From Adams et al., Principles of Neurology, 6th ed, pp317) Epilepsies, Partial Epilepsy, Generalized [Disease/Finding] Epilepsy, Generalized N0000001128 Epilepsy, Generalized 19598007 1024495 M0007570 C0014548 Seizure Disorder, Generalized Recurrent conditions characterized by epileptic seizures which arise diffusely and simultaneously from both hemispheres of the brain. Classification is generally based upon motor manifestations of the seizure (e.g., convulsive, nonconvulsive, akinetic, atonic, etc.) or etiology (e.g., idiopathic, cryptogenic, and symptomatic). (From Mayo Clin Proc, 1996 Apr;71(4):405-14) C2434 D004829 Epilepsy, Tonic-Clonic [Disease/Finding] Epilepsy, Grand Mal N0000001129 Tonic-Clonic Seizure Disorder Major Motor Seizure Disorder Epilepsy, Tonic-Clonic 1022827 Seizure Disorder, Grand Mal Tonic-Clonic Convulsion Disorder Epilepsy, Major Tonic-Clonic Convulsion Syndrome C0014549 M0007573 A generalized seizure disorder characterized by recurrent major motor seizures. The initial brief tonic phase is marked by trunk flexion followed by diffuse extension of the trunk and extremities. The clonic phase features rhythmic flexor contractions of the trunk and limbs, pupillary dilation, elevations of blood pressure and pulse, urinary incontinence, and tongue biting. This is followed by a profound state of depressed consciousness (post-ictal state) which gradually improves over minutes to hours. The disorder may be cryptogenic, familial, or symptomatic (caused by an identified disease process). (From Adams et al., Principles of Neurology, 6th ed, p329) Tonic-Clonic Seizure Syndrome 352818000 Tonic Clonic Convulsions D004830 Seizure Disorder, Tonic Clonic Convulsions, Grand Mal Grand Mal Seizure Disorder Epilepsy, Tonic-Clonic C2436 Seizure Disorder, Major Motor Epilepsy, Temporal Lobe [Disease/Finding] 1024058 C0014556 C2442 193000002 N0000001132 Epilepsy, Temporal Lobe D004833 Epilepsy, Temporal Lobe M0007578 A localization-related (focal) form of epilepsy characterized by recurrent seizures that arise from foci within the temporal lobe, most commonly from its mesial aspect. A wide variety of psychic phenomena may be associated, including illusions, hallucinations, dyscognitive states, and affective experiences. The majority of complex partial seizures (see EPILEPSY, COMPLEX PARTIAL) originate from the temporal lobes. Temporal lobe seizures may be classified by etiology as cryptogenic, familial, or symptomatic (i.e., related to an identified disease process or lesion). (From Adams et al., Principles of Neurology, 6th ed, p321) Epilepsy, Post-Traumatic [Disease/Finding] 1022785 N0000001133 75023009 C0014557 C2444 M0007580 D004834 Post-Traumatic Seizure Disorder Epilepsy, Post-Traumatic Recurrent seizures causally related to CRANIOCEREBRAL TRAUMA. Seizure onset may be immediate but is typically delayed for several days after the injury and may not occur for up to two years. The majority of seizures have a focal onset that correlates clinically with the site of brain injury. Cerebral cortex injuries caused by a penetrating foreign object (CRANIOCEREBRAL TRAUMA, PENETRATING) are more likely than closed head injuries (HEAD INJURIES, CLOSED) to be associated with epilepsy. Concussive convulsions are nonepileptic phenomena that occur immediately after head injury and are characterized by tonic and clonic movements. (From Rev Neurol 1998 Feb;26(150):256-261; Sports Med 1998 Feb;25(2):131-6) Seizure Disorder, Post-Traumatic Epilepsy, Post-Traumatic Epilepsy, Traumatic Erythema [Disease/Finding] Erythema 86735004 M0007679 D004890 Erythema N0000001144 C2466 C0041834 1023390 Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of causes. Erythema Multiforme [Disease/Finding] A skin and mucous membrane disease characterized by an eruption of macules, papules, nodules, vesicles, and/or bullae with characteristic "bull's-eye" lesions usually occurring on the dorsal aspect of the hands and forearms. D004892 36715001 M0007681 Erythema Multiforme Erythema Multiforme C2470 C0014742 1027514 N0000001146 Erythema Nodosum [Disease/Finding] An erythematous eruption commonly associated with drug reactions or infection and characterized by inflammatory nodules that are usually tender, multiple, and bilateral. These nodules are located predominantly on the shins with less common occurrence on the thighs and forearms. They undergo characteristic color changes ending in temporary bruise-like areas. This condition usually subsides in 3-6 weeks without scarring or atrophy. Erythema Nodosum C2472 32861005 D004893 1027500 M0007682 Erythema Nodosum N0000001147 C0014743 Escherichia coli Infections [Disease/Finding] Infections, E coli C2486 Infections, Escherichia coli D004927 N0000001154 985413 Escherichia coli Infections Escherichia coli Infections E coli Infections Infections with bacteria of the species ESCHERICHIA COLI. 71057007 C0014836 M0007733 Esophageal Diseases [Disease/Finding] Esophageal Diseases C0014852 990942 Esophageal Diseases C2496 N0000001159 Pathological processes in the ESOPHAGUS. D004935 M0007747 37657006 Esophageal Neoplasms [Disease/Finding] C2502 Neoplasms, Esophageal Esophagus Neoplasm M0007750 1023659 C0014859 Esophageal Neoplasms Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS. N0000001162 D004938 126817006 Esophagitis [Disease/Finding] INFLAMMATION, acute or chronic, of the ESOPHAGUS caused by BACTERIA, chemicals, or TRAUMA. 1022660 16761005 Esophagitis Esophagitis N0000001165 C0014868 M0007753 D004941 C2508 Eye Diseases [Disease/Finding] D005128 Eye Diseases Eye Diseases N0000001181 194183009 M0008088 1023594 C2540 C0015397 Eyelid Diseases [Disease/Finding] C0015423 C2552 N0000001187 1025672 Eyelid Diseases D005141 M0008105 Eyelid Diseases 60113004 Facial Dermatoses [Disease/Finding] 1028247 M0008112 Facial Dermatoses C0015456 C2558 D005148 Facial Dermatosis Facial Dermatoses N0000001190 Female Urogenital Diseases and Pregnancy Complications [Disease/Finding] D005261 C2626 M0008309 Female Urogenital Diseases and Pregnancy Complications N0000001224 Female Urogenital Diseases and Pregnancy Complications C1720765 Pathological processes of the female URINARY TRACT, the reproductive system (GENITALIA, FEMALE), and disorders related to PREGNANCY. 985609 Fever [Disease/Finding] An abnormal elevation of body temperature, usually as a result of a pathologic process. M0008421 Hyperthermia 1021819 367493005 D005334 Fever 386661006 Pyrexia 50177009 C0015967 Fever N0000001242 C2662 Fibrosis [Disease/Finding] C0016059 1024477 Fibrosis M0008453 N0000001249 C2676 Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury. D005355 Fibrosis 112674009 Foot Dermatoses [Disease/Finding] 1024965 C0016509 Foot Dermatosis M0008722 C2728 D005533 Skin diseases of the foot, general or unspecified. Foot Dermatoses Foot Dermatoses N0000001275 Foot Diseases [Disease/Finding] N0000001276 D005534 986717 Foot Diseases C0016510 Anatomical and functional disorders affecting the foot. C2730 M0008723 118932009 Foot Diseases Gastroenteritis [Disease/Finding] D005759 N0000001317 Gastroenteritis Gastroenteritis 1024672 INFLAMMATION of any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Causes of gastroenteritis are many including genetic, infection, HYPERSENSITIVITY, drug effects, and CANCER. 25374005 C2812 M0009018 C0017160 Gastroesophageal Reflux [Disease/Finding] 235595009 M0009024 Gastroesophageal Reflux D005764 Gastroesophageal Reflux Esophageal Reflux GERD Reflux, Gastroesophageal C2816 Gastro-Esophageal Reflux N0000001319 Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER. Gastroesophageal Reflux Disease 1022040 C0017168 Gastro-oesophageal Reflux Gastrointestinal Diseases [Disease/Finding] 119292006 M0009033 C2818 1022118 N0000001320 Gastrointestinal Diseases Gastrointestinal Diseases D005767 C0017178 Diseases in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Gastrointestinal Neoplasms [Disease/Finding] 1025588 M0009038 D005770 Gastrointestinal Neoplasms Neoplasms, Gastrointestinal C0017185 126768004 Gastrointestinal Neoplasms Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL. C2820 N0000001321 Genital Diseases, Female [Disease/Finding] Female Genital Diseases D005831 Gynecologic Diseases N0000001323 244938009 C2824 310789003 1026095 C0017411 Genital Diseases, Female M0009154 Pathological processes involving the female reproductive tract (GENITALIA, FEMALE). Genital Diseases, Female Genital Diseases, Male [Disease/Finding] C0017412 M0009155 N0000001324 C2826 64557000 Genital Diseases, Male Genital Diseases, Male 1021837 Male Genital Diseases D005832 Pathological processes involving the male reproductive tract (GENITALIA, MALE). Genital Neoplasms, Female [Disease/Finding] C0017416 1024023 Female Genital Neoplasms M0009156 Gynecologic Neoplasms Neoplasms, Gynecologic Genital Neoplasms, Female 126907002 C2828 D005833 N0000001325 Genital Neoplasms, Female Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE). Neoplasms, Female Genital Genital Neoplasms, Male [Disease/Finding] C2830 Neoplasms, Male Genital 1028573 126895004 Male Genital Neoplasms D005834 Genital Neoplasms, Male Genital Neoplasms, Male Tumor or cancer of the MALE GENITALIA. N0000001326 M0009157 C0017417 Giardiasis [Disease/Finding] Giardiasis An infection of the SMALL INTESTINE caused by the flagellated protozoan GIARDIA LAMBLIA. It is spread via contaminated food and water and by direct person-to-person contact. 58265007 C0017536 Giardiasis M0009224 988685 Lambliasis D005873 N0000001331 C2840 10679007 Tourette Syndrome [Disease/Finding] N0000001334 Combined Multiple Motor and Vocal Tic Disorder Tourette's Disease Multiple Motor and Vocal Tic Disorder, Combined Combined Vocal and Multiple Motor Tic Disorder Tic Disorder, Combined Vocal and Multiple Motor Tourette Syndrome Gilles de la Tourette Syndrome D005879 A neuropsychological disorder related to alterations in DOPAMINE metabolism and neurotransmission involving frontal-subcortical neuronal circuits. Both multiple motor and one or more vocal tics need to be present with TICS occurring many times a day, nearly daily, over a period of more than one year. The onset is before age 18 and the disturbance is not due to direct physiological effects of a substance or a general medical condition. The disturbance causes marked distress or significant impairment in social, occupational, or other important areas of functioning. (From DSM-IV, 1994; Neurol Clin 1997 May;15(2):357-79) C0040517 Tourette Disease C2846 Tourette Disorder 1024192 M0009230 Tourette Syndrome Gilles de la Tourette's Disease Tourette's Syndrome 5158005 Tourette's Disorder Glaucoma [Disease/Finding] N0000001345 D005901 C2868 Glaucoma M0009260 C0017601 1022133 23986001 An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed) Glaucoma Glaucoma, Open-Angle [Disease/Finding] 46168003 Glaucoma, Compensated Glaucoma, Open Angle Glaucoma, Pigmentary Glaucoma, Simple 193538009 Glaucoma in which the angle of the anterior chamber is open and the trabecular meshwork does not encroach on the base of the iris. C0017612 M0009261 1023893 N0000001346 84494001 Glaucoma, Compensative Glaucoma, Open-Angle Glaucoma, Open-Angle Open-Angle Glaucoma C2870 Glaucoma Simplex D005902 Glioblastoma [Disease/Finding] C0017636 Astrocytoma, Grade IV M0009269 Glioblastoma Glioblastoma N0000001347 A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. C2872 1025895 D005909 63634009 Glioma [Disease/Finding] C2874 Glioma D005910 Glial Cell Tumors 1025030 Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21) M0009271 C0017638 N0000001348 Glioma 115240006 Glomerulonephritis [Disease/Finding] 36171008 Glomerulonephritis Glomerulonephritis 236391006 N0000001351 C2880 C0017658 M0009300 Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY. D005921 1021985 Glomerulosclerosis, Focal Segmental [Disease/Finding] Focal Segmental Glomerulosclerosis Glomerulosclerosis, Focal C0017668 D005923 Glomerulonephritis, Focal Sclerosing M0009302 N0000001353 Glomerulosclerosis, Focal Segmental Glomerulosclerosis, Focal Segmental 25821008 C2884 1026699 A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary. Clinical features include PROTEINURIA, reduced GLOMERULAR FILTRATION RATE, and EDEMA. Kidney biopsy initially indicates focal segmental glomerular consolidation (hyalinosis) or scarring which can progress to globally sclerotic glomeruli leading to eventual KIDNEY FAILURE. Goiter [Disease/Finding] Goiter Goiter Enlargement of the THYROID GLAND that may increase from about 20 grams to hundreds of grams in human adults. Goiter is observed in individuals with normal thyroid function (euthyroidism), thyroid deficiency (HYPOTHYROIDISM), or hormone overproduction (HYPERTHYROIDISM). Goiter may be congenital or acquired, sporadic or endemic (GOITER, ENDEMIC). C0018021 3716002 M0009516 N0000001371 D006042 C2920 1022351 Gonadal Disorders [Disease/Finding] Gonadal Disorders Pathological processes of the OVARIES or the TESTES. 986338 C0018050 N0000001376 D006058 Gonadal Disorders M0009536 C2930 Gonorrhea [Disease/Finding] C0018081 988436 D006069 C2938 Gonorrhea Gonorrhea 15628003 M0009553 N0000001380 Acute infectious disease characterized by primary invasion of the urogenital tract. The etiologic agent, NEISSERIA GONORRHOEAE, was isolated by Neisser in 1879. Gout [Disease/Finding] Hereditary metabolic disorder characterized by recurrent acute arthritis, hyperuricemia and deposition of sodium urate in and around the joints, sometimes with formation of uric acid calculi. Gout C0018099 Gout N0000001382 M0009557 90560007 D006073 C2942 1026223 Graft vs Host Disease [Disease/Finding] N0000001384 Homologous Wasting Disease C2946 D006086 M0009578 Graft-vs-Host Disease 1024721 234646005 The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. Graft vs Host Disease Graft vs Host Disease C0018133 Graft-Versus-Host Disease Runt Disease Gynecomastia [Disease/Finding] Gynecomastia Male Breast Enlargement N0000001396 4754008 M0009717 D006177 Gynecomastia Enlargement of the BREAST in the males, caused by an excess of ESTROGENS. Physiological gynecomastia is normally observed in NEWBORNS; ADOLESCENT; and AGING males. C0018418 1022299 C2970 Haemophilus Infections [Disease/Finding] Infections, Hemophilus Hemophilus Infections Haemophilus Infections C0018482 Haemophilus Infections N0000001398 Infections, Haemophilus Infections with bacteria of the genus HAEMOPHILUS. C2974 1021899 41659003 D006192 M0009740 Hand Dermatoses [Disease/Finding] D006229 C2998 Hand Dermatosis Hand Dermatoses Hand Dermatoses M0009782 N0000001410 C0018567 1028376 Head and Neck Neoplasms [Disease/Finding] Head, Neck Neoplasms C3010 255055008 Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651) Neoplasms, Head and Neck C0018671 M0009818 D006258 Head and Neck Neoplasms Head and Neck Neoplasms N0000001416 1024324 Craniocerebral Trauma [Disease/Finding] Craniocerebral Trauma M0009821 1024743 Injuries, Craniocerebral 82271004 Traumatic injuries involving the cranium and intracranial structures (i.e., BRAIN; CRANIAL NERVES; MENINGES; and other structures). Injuries may be classified by whether or not the skull is penetrated (i.e., penetrating vs. nonpenetrating) or whether there is an associated hemorrhage. Craniocerebral Trauma C3012 C0018674 Head Injuries N0000001417 D006259 Head Trauma Craniocerebral Injuries Injuries, Head Trauma, Head Heart Block [Disease/Finding] M0009945 233916004 C3038 1023276 Heart Block N0000001430 C0018794 Impaired conduction of cardiac impulse that can occur anywhere along the conduction pathway, such as between the SINOATRIAL NODE and the right atrium (SA block) or between atria and ventricles (AV block). Heart blocks can be classified by the duration, frequency, or completeness of conduction block. Reversibility depends on the degree of structural or functional defects. Heart Block D006327 Heart Defects, Congenital [Disease/Finding] Congenital Heart Defect N0000001431 204413006 D006330 M0009950 Heart Defect, Congenital 1022077 C3040 Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life. Heart Defects, Congenital Heart Abnormalities Heart Defects, Congenital C0018798 Congenital Heart Defects Abnormality, Heart Defects, Congenital Heart Heart Diseases [Disease/Finding] D006331 Heart Diseases Cardiac Diseases M0009951 Pathological conditions involving the HEART including its structural and functional abnormalities. C0018799 C3042 56265001 N0000001432 1022072 Heart Diseases Cardiomegaly [Disease/Finding] C0018800 C3044 Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES. 8186001 Enlarged Heart 1023747 D006332 Cardiomegaly Cardiomegaly Heart Enlargement M0009952 N0000001433 Heart Failure [Disease/Finding] Heart Failure 1024953 C3046 C0018802 42343007 A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure N0000001434 D006333 M0009953 Heart Failure Heartburn [Disease/Finding] C0018834 C3066 16331000 Substernal pain or burning sensation, usually associated with regurgitation of gastric juice into the esophagus. Pyrosis D006356 Heartburn Heartburn N0000001444 M0009980 1022047 Hemangioma [Disease/Finding] Hemangioma Hemangioma C3080 A vascular anomaly due to proliferation of BLOOD VESSELS that forms a tumor-like mass. The common types involve CAPILLARIES and VEINS. It can occur anywhere in the body but is most frequently noticed in the SKIN and SUBCUTANEOUS TISSUE. (from Stedman, 27th ed, 2000) 400210000 189194008 N0000001451 M0010031 987582 D006391 C0018916 Hematologic Diseases [Disease/Finding] Hematologic Diseases N0000001459 Blood Diseases C3096 D006402 Hematological Diseases 1021953 Disorders of the blood and blood forming tissues. 191402006 C0018939 267573000 M0010044 Hematologic Diseases Hemic and Lymphatic Diseases [Disease/Finding] Hemic and Lymphatic Diseases C0018981 Hematologic diseases and diseases of the lymphatic system collectively. Hemic diseases include disorders involving the formed elements (e.g., ERYTHROCYTE AGGREGATION, INTRAVASCULAR) and chemical components (e.g., BLOOD PROTEIN DISORDERS); lymphatic diseases include disorders relating to lymph, lymph nodes, and lymphocytes. C3110 D006425 Hemic and Lymphatic Diseases M0010072 N0000001466 1026878 Hemochromatosis [Disease/Finding] N0000001469 M0010098 Diabetes, Bronze Hemochromatosis 399187006 399144008 D006432 1023441 C3116 Hemochromatosis C0018995 A disorder due to the deposition of hemosiderin in the parenchymal cells, causing tissue damage and dysfunction of the liver, pancreas, heart, and pituitary. Full development of the disease in women is restricted by menstruation, pregnancy, and lower dietary intake of iron. Acquired hemochromatosis may be the result of blood transfusions, excessive dietary iron, or secondary to other disease. Idiopathic or genetic hemochromatosis is an autosomal recessive disorder of metabolism associated with a gene tightly linked to the A locus of the HLA complex on chromosome 6. (From Dorland, 27th ed) Hemoglobinopathies [Disease/Finding] 80141007 C0019045 M0010129 A group of inherited disorders characterized by structural alterations within the hemoglobin molecule. Hemoglobinopathies 1023547 D006453 C3122 N0000001472 Hemoglobinopathies Hemorrhage [Disease/Finding] N0000001481 C0019080 M0010152 Bleeding 1023287 Bleeding or escape of blood from a vessel. D006470 Hemorrhage Hemorrhage C3140 195511004 Gastrointestinal Hemorrhage [Disease/Finding] Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. C0017181 M0010153 Gastrointestinal Hemorrhage Gastrointestinal Hemorrhage Hemorrhage, Gastrointestinal 266477005 D006471 74474003 C3142 1024534 N0000001482 Hemorrhagic Disorders [Disease/Finding] 1023732 D006474 N0000001485 Hemorrhagic Disorders 191331006 C3148 C0019087 M0010157 Spontaneous or near spontaneous bleeding caused by a defect in clotting mechanisms (BLOOD COAGULATION DISORDERS) or another abnormality causing a structural flaw in the blood vessels (HEMOSTATIC DISORDERS). Hemorrhagic Disorders Hemorrhagic Diathesis Hemorrhoids [Disease/Finding] M0010177 Hemorrhoids Hemorrhoids D006484 70153002 C3164 1023434 C0019112 Swollen veins in the lower part of the RECTUM or ANUS. Hemorrhoids can be inside the anus (internal), under the skin around the anus (external), or protruding from inside to outside of the anus. People with hemorrhoids may or may not exhibit symptoms which include bleeding, itching, and pain. N0000001493 Hepatitis [Disease/Finding] C0019158 M0010205 INFLAMMATION of the LIVER. 989819 C3176 D006505 128241005 197351001 Hepatitis Hepatitis N0000001499 Hepatitis, Chronic [Disease/Finding] D006521 Chronic Hepatitis N0000001504 989540 Hepatitis, Chronic 197286002 M0010227 C3186 197288001 INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors. 76783007 Hepatitis, Chronic C0019189 Hepatitis, Viral, Human [Disease/Finding] INFLAMMATION of the LIVER in humans due to infection by VIRUSES. There are several significant types of human viral hepatitis with infection caused by enteric-transmission (HEPATITIS A; HEPATITIS E) or blood transfusion (HEPATITIS B; HEPATITIS C; and HEPATITIS D). M0010233 990781 N0000001508 C3194 Hepatitis, Viral, Human Hepatitis, Viral, Human D006525 C0019195 Hepatitis C [Disease/Finding] Parenterally-Transmitted Non-A, Non-B Hepatitis M0010234 D006526 C0019196 1024879 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally, and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. N0000001509 Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted 50711007 186634008 PT-NANBH Hepatitis C C3196 Carcinoma, Hepatocellular [Disease/Finding] N0000001511 A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. D006528 Liver Cell Carcinoma, Adult C2239176 M0010236 109841003 Carcinoma, Hepatocellular Carcinoma, Hepatocellular Hepatoma 1021881 Hepatocellular Carcinoma Liver Cancer, Adult 187769009 C3200 Hepatocellular Cancer Herpes Genitalis [Disease/Finding] M0010276 C0019342 N0000001527 Herpes Simplex Virus Genital Infection Herpes Genitalis Genital Herpes 33839006 D006558 Herpes Simplex, Genital C3232 1025755 Infection of the genitals (GENITALIA) with HERPES SIMPLEX VIRUS in either the males or the females. 271463009 Herpes Genitalis Herpes Simplex [Disease/Finding] C0019348 Herpes Simplex Herpes Simplex A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.) 88594005 C3238 N0000001530 1023866 M0010279 D006561 Herpes Zoster [Disease/Finding] Herpes Zoster C3240 1022292 M0010280 Zona Shingles Zoster An acute infectious, usually self-limited, disease believed to represent activation of latent varicella-zoster virus (HERPESVIRUS 3, HUMAN) in those who have been rendered partially immune after a previous attack of CHICKENPOX. It involves the SENSORY GANGLIA and their areas of innervation and is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area. (From Dorland, 27th ed) Herpes Zoster N0000001531 C0019360 4740000 D006562 Herpesviridae Infections [Disease/Finding] 23513009 Herpesviridae Infections N0000001533 Herpesvirus Infections C0019372 Herpesviridae Infections D006566 Infections, Herpesviridae Virus diseases caused by the HERPESVIRIDAE. 1024733 Infections, Herpesvirus M0010285 C3244 High Pressure Neurological Syndrome [Disease/Finding] High Pressure Neurological Syndrome A syndrome related to increased atmospheric pressure and characterized by tremors, nausea, dizziness, decreased motor and mental performance, and SEIZURES. This condition may occur in those who dive deeply (c. 1000 ft) usually while breathing a mixture of oxygen and helium. The condition is associated with a neuroexcitatory effect of helium. C0019537 M0010353 N0000001536 HPNS C3250 D006610 High Pressure Neural Syndrome High Pressure Neurological Syndrome High Pressure Nervous Syndrome 984887 Histiocytosis, Langerhans-Cell [Disease/Finding] Langerhans-Cell Histiocytosis Schueller-Christian Disease N0000001544 Letterer-Siwe Disease D006646 Hand-Schüller-Christian Disease Histiocytosis, Langerhans-Cell Histiocytosis, Generalized 190955000 C0019621 C3266 Histiocytosis-X 65399007 989741 Histiocytosis X Langerhans-Cell Granulomatosis Histiocytosis, Langerhans-Cell A group of disorders resulting from the abnormal proliferation of and tissue infiltration by LANGERHANS CELLS which can be detected by their characteristic Birbeck granules (X bodies), or by monoclonal antibody staining for their surface CD1 ANTIGENS. Langerhans-cell granulomatosis can involve a single organ, or can be a systemic disorder. Hand-Schueller-Christian Disease M0010406 Hand-Schueller-Christian Syndrome 190956004 Hand-Schüller-Christian Syndrome Histoplasmosis [Disease/Finding] C3270 M0010434 187055002 Infection resulting from inhalation or ingestion of spores of the fungus of the genus HISTOPLASMA, species H. capsulatum. It is worldwide in distribution and particularly common in the midwestern United States. (From Dorland, 27th ed) C0019655 Histoplasmosis Histoplasmosis D006660 N0000001546 1025866 12962009 Hodgkin Disease [Disease/Finding] N0000001550 Hodgkin Disease Hodgkins Disease Lymphogranuloma, Malignant C0019829 Hodgkin Disease 118599009 D006689 A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen. 1022669 Hodgkin's Disease Hodgkin Lymphoma 118606001 M0010484 C3278 188543002 Hodgkin's Lymphoma Hyperaldosteronism [Disease/Finding] 88213004 C0020428 N0000001573 D006929 Hyperaldosteronism M0010808 A condition caused by the overproduction of ALDOSTERONE. It is characterized by sodium retention and potassium excretion with resultant HYPERTENSION and HYPOKALEMIA. Aldosteronism C3324 1022951 Hyperaldosteronism Hypercalcemia [Disease/Finding] D006934 66931009 Hypercalcemia Hypercalcemia Abnormally high level of calcium in the blood. M0010814 1026898 C3332 N0000001577 C0020437 Hypercholesterolemia [Disease/Finding] D006937 C0020443 A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population. Hypercholesterolemia 13644009 N0000001580 Hypercholesteremia C3338 Hypercholesterolemia M0010818 1023485 Hyperlipidemias [Disease/Finding] C3362 M0010830 D006949 1023000 Hyperlipidemia N0000001592 Hyperlipidemias C0020473 Conditions with excess LIPIDS in the blood. 55822004 Hyperlipemia Hyperlipidemias Hyperlipoproteinemias [Disease/Finding] Hyperlipoproteinemias C0020476 1022876 3744001 D006951 Hyperlipoproteinemia Conditions with abnormally elevated levels of LIPOPROTEINS in the blood. They may be inherited, acquired, primary, or secondary. Hyperlipoproteinemias are classified according to the pattern of lipoproteins on electrophoresis or ultracentrifugation. M0010833 N0000001594 Hyperlipoproteinemias C3366 Hyperphagia [Disease/Finding] D006963 1023617 Hyperphagia 267023007 M0010847 Overeating C3390 Hyperphagia N0000001606 C0020505 Ingestion of a greater than optimal quantity of food. 58424009 Hypersensitivity [Disease/Finding] Allergy C3398 M0010851 Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen. 269284003 1022134 N0000001610 Hypersensitivity C0020517 127072000 D006967 106190000 Hypersensitivity Hypersensitivity, Immediate [Disease/Finding] Hypersensitivity, Atopic 1023968 Hypersensitivity, Immediate Hypersensitivity, Type I Hypersensitivity reactions which occur within minutes of exposure to challenging antigen due to the release of histamine which follows the antigen-antibody reaction and causes smooth muscle contraction and increased vascular permeability. M0010854 IgE-Mediated Hypersensitivity D006969 N0000001612 20671006 Hypersensitivity, Immediate C3402 Atopic Hypersensitivity C0020523 Type I Hypersensitivity Hypertension [Disease/Finding] C3410 Blood Pressure, High Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. 1023354 M0010859 D006973 N0000001616 C0020538 Hypertension Hypertension 38341003 Hypertension, Malignant [Disease/Finding] D006974 C0020540 70272006 Hypertension, Malignant N0000001617 C3412 M0010861 A condition of markedly elevated BLOOD PRESSURE with DIASTOLIC PRESSURE usually greater than 120 mm Hg. Malignant hypertension is characterized by widespread vascular damage, PAPILLEDEMA, retinopathy, HYPERTENSIVE ENCEPHALOPATHY, and renal dysfunction. Malignant Hypertension Hypertension, Malignant 1023442 Hyperthyroidism [Disease/Finding] Hypersecretion of THYROID HORMONES from the THYROID GLAND. Elevated levels of thyroid hormones increase BASAL METABOLIC RATE. C3422 D006980 1022325 34486009 Primary Hyperthyroidism N0000001622 M0010871 Hyperthyroidism Hyperthyroidism C0020550 Hypertrophy [Disease/Finding] M0010875 56246009 N0000001625 Hypertrophy Hypertrophy C0020564 General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA). C3428 1023930 D006984 Hypotension [Disease/Finding] C3476 1022536 45007003 D007022 Vascular Hypotension M0010927 Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients. N0000001649 Hypotension C0020649 Hypotension, Vascular Hypotension Blood Pressure, Low Low Blood Pressure Hypothalamic Diseases [Disease/Finding] 1024801 D007027 M0010935 Hypothalamic Diseases C3480 N0000001651 399100005 Hypothalamic Diseases C0020655 Neoplastic, inflammatory, infectious, and other diseases of the hypothalamus. Clinical manifestations include appetite disorders; AUTONOMIC NERVOUS SYSTEM DISEASES; SLEEP DISORDERS; behavioral symptoms related to dysfunction of the LIMBIC SYSTEM; and neuroendocrine disorders. Hypothalamic Neoplasms [Disease/Finding] Benign and malignant tumors of the HYPOTHALAMUS. Pilocytic astrocytomas and hamartomas are relatively frequent histologic types. Neoplasms of the hypothalamus frequently originate from adjacent structures, including the OPTIC CHIASM, optic nerve (see OPTIC NERVE NEOPLASMS), and pituitary gland (see PITUITARY NEOPLASMS). Relatively frequent clinical manifestations include visual loss, developmental delay, macrocephaly, and precocious puberty. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2051) N0000001652 1021928 Tumors, Hypothalamus D007029 Hypothalamic Tumors Hypothalamus Neoplasms Hypothalamic Neoplasms 254968009 C3482 M0010937 C0020659 Hypothalamic Neoplasms Neoplasms, Hypothalamus Neoplasms, Hypothalamic Ileal Diseases [Disease/Finding] Ileal Diseases Ileal Diseases C0020875 N0000001660 C3498 1025763 M0011023 Pathological development in the ILEUM including the ILEOCECAL VALVE. D007077 Ileal Neoplasms [Disease/Finding] 126835002 C3500 1026955 M0011024 Tumors or cancer in the ILEUM region of the small intestine (INTESTINE, SMALL). D007078 N0000001661 C0020876 Ileal Neoplasms Ileal Neoplasms Immunologic Deficiency Syndromes [Disease/Finding] D007153 Deficiency Syndromes, Immunologic Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral. Immunologic Deficiency Syndromes C0021051 Deficiency Syndrome, Immunologic Immunological Deficiency Syndromes 191005003 Immunologic Deficiency Syndrome M0011155 234532001 N0000001667 1022772 C3512 Immunologic Deficiency Syndromes Immune System Diseases [Disease/Finding] M0011156 C0021053 Immune Diseases Immune System Diseases 41266007 Immunologic Diseases Immunological Diseases Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated, or both. Immune Disorders 1022843 C3514 N0000001668 Diseases of Immune System D007154 Immune System Diseases Immunoproliferative Disorders [Disease/Finding] N0000001669 1028023 Immunoproliferative Disorders 127071007 M0011164 D007160 Disorders characterized by abnormal proliferation of primary cells of the immune system or by excessive production of immunoglobulins. C3516 C0021070 Immunoproliferative Disorders Erectile Dysfunction [Disease/Finding] Male Impotence 1023399 The inability in the male to have a PENILE ERECTION due to psychological or organ dysfunction. Erectile Dysfunction M0011178 D007172 Impotence Male Sexual Impotence 397803000 N0000001672 C0242350 Erectile Dysfunction C3522 Infant, Newborn, Diseases [Disease/Finding] C3534 Infant, Newborn, Diseases C0021290 D007232 1024869 22925008 Diseases of newborn infants present at birth (congenital) or developing within the first month of birth. It does not include hereditary diseases not manifesting at birth or within the first 30 days of life nor does it include inborn errors of metabolism. Both HEREDITARY DISEASES and METABOLISM, INBORN ERRORS are available as general concepts. Infant, Newborn, Diseases N0000001678 M0011286 Infection [Disease/Finding] M0011294 C0021311 D007239 Invasion of the host organism by microorganisms that can cause pathological conditions or diseases. N0000001681 C3540 40733004 1022093 Infection Infection Infertility [Disease/Finding] 1023984 Infertility Infertility D007246 8619003 Inability to reproduce after a specified period of unprotected intercourse. Reproductive sterility is permanent infertility. M0011302 C0021359 C3546 N0000001684 Inflammation [Disease/Finding] M0011307 Inflammation N0000001687 A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. C3552 D007249 Inflammation 23583003 987778 C0021368 Sleep Initiation and Maintenance Disorders [Disease/Finding] Disorders characterized by impairment of the ability to initiate or maintain sleep. This may occur as a primary disorder or in association with another medical or psychiatric condition. 194437008 N0000001691 C3560 D007319 DIMS (Disorders of Initiating and Maintaining Sleep) Sleep Initiation and Maintenance Disorders 1026171 Disorders of Initiating and Maintaining Sleep C0021603 M0011403 Sleep Initiation and Maintenance Disorders Intestinal Diseases [Disease/Finding] 1023320 Intestinal Diseases N0000001698 M0011569 85919009 Pathological processes in any segment of the INTESTINE from DUODENUM to RECTUM. D007410 C3574 Intestinal Diseases C0021831 Intestinal Diseases, Parasitic [Disease/Finding] Intestinal Diseases, Parasitic Intestinal Diseases, Parasitic 1021992 Parasitic Intestinal Diseases D007411 C0021832 N0000001699 Infections of the INTESTINES with PARASITES, commonly involving PARASITIC WORMS. Infections with roundworms (NEMATODE INFECTIONS) and tapeworms (CESTODE INFECTIONS) are also known as HELMINTHIASIS. C3576 87282003 M0011570 Intestinal Neoplasms [Disease/Finding] Neoplasms, Intestinal 1023921 N0000001701 Intestinal Neoplasms 126769007 D007414 Intestinal Neoplasms Intestines Neoplasms M0011574 Tumors or cancer of the INTESTINES. C0021841 C3580 Intestinal Obstruction [Disease/Finding] Intestinal Obstruction 1023737 81060008 D007415 M0011575 N0000001702 Any impairment, arrest, or reversal of the normal flow of INTESTINAL CONTENTS toward the ANAL CANAL. C0021843 C3582 Intestinal Obstruction Intestinal Perforation [Disease/Finding] Intestinal Perforation C0021845 D007416 56905009 Opening or penetration through the wall of the INTESTINES. 1027177 C3584 Intestinal Perforation M0011577 N0000001703 Iris Diseases [Disease/Finding] Iris Diseases Iris Diseases 85478004 1027428 C3596 Diseases, dysfunctions, or disorders of or located in the iris. M0011716 D007499 N0000001709 C0022078 Iritis [Disease/Finding] Iritis Iritis N0000001710 C3598 65074000 Inflammation of the iris characterized by circumcorneal injection, aqueous flare, keratotic precipitates, and constricted and sluggish pupil along with discoloration of the iris. M0011717 1025397 D007500 C0022081 Ischemia [Disease/Finding] Ischemia M0011734 N0000001711 C3600 D007511 C0022116 1025819 Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION. 52674009 Joint Diseases [Disease/Finding] N0000001727 M0011860 399269003 C0022408 1022553 Joint Diseases D007592 C3632 Joint Diseases Keratitis [Disease/Finding] M0011962 N0000001734 1023965 D007634 Keratitis Inflammation of the cornea. Keratitis C3646 5888003 C0022568 Keratosis [Disease/Finding] 254666005 C3660 Keratosis C0022593 Any horny growth such as a wart or callus. N0000001741 D007642 Keratosis 1026745 M0011970 Kidney Diseases [Disease/Finding] C0022658 D007674 N0000001748 Pathological processes of the KIDNEY or its component tissues. M0012014 Kidney Diseases C3674 Kidney Diseases 1022215 90708001 Kidney Failure, Chronic [Disease/Finding] 90688005 Kidney Failure, Chronic End-Stage Renal Disease D007676 Renal Disease, End-Stage N0000001750 ESRD M0012016 C3678 End-Stage Kidney Disease Renal Failure, End-Stage C0022661 The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. Kidney Failure, Chronic Renal Failure, Chronic Chronic Kidney Failure 988914 Kidney Neoplasms [Disease/Finding] 1026062 Neoplasms, Kidney Tumors or cancers of the KIDNEY. Kidney Neoplasms Kidney Neoplasms Renal Neoplasms D007680 126880001 N0000001751 M0012021 C0022665 C3680 Klebsiella Infections [Disease/Finding] Infections, Klebsiella Infections with bacteria of the genus KLEBSIELLA. C3694 1027202 Klebsiella Infections Klebsiella Infections N0000001758 C0022729 M0012059 D007710 Lead Poisoning [Disease/Finding] 1027250 Lead Poisoning Lead Poisoning C0023176 D007855 N0000001791 C3760 M0012268 38342005 Poisoning, Lead Leg Dermatoses [Disease/Finding] M0012283 N0000001794 C0023219 C3766 1027712 A nonspecific term used to denote any cutaneous lesion or group of lesions, or eruptions of any type on the leg. (From Stedman, 25th ed) Leg Dermatoses Leg Dermatoses Leg Dermatosis D007868 Legionellosis [Disease/Finding] D007876 26726000 N0000001799 Infections with bacteria of the genus LEGIONELLA. Legionellosis C0023240 C3776 Legionellosis 1025570 M0012292 Legionnaires' Disease [Disease/Finding] C3778 Legionella pneumophila Infections An acute, sometimes fatal, pneumonia-like bacterial infection characterized by high fever, malaise, muscle aches, respiratory disorders and headache. It is named for an outbreak at the 1976 Philadelphia convention of the American Legion. Legionnaire Disease 1024785 M0012293 Legionnaires' Disease 269574000 N0000001800 Infections, Legionella pneumophila Legionnaires' Disease D007877 312403005 195889001 C0023241 Leiomyoma [Disease/Finding] Leiomyoma M0012316 N0000001802 Leiomyoma Fibroid D007889 189793008 189787000 A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues. Fibroid Tumor C0023267 189788005 Fibromyoma C3782 1024283 Leishmaniasis [Disease/Finding] C3786 1026755 80612004 Leishmaniasis Leishmaniasis M0012333 D007896 A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL). C0023281 N0000001804 Leishmaniasis, Visceral [Disease/Finding] M0012335 A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African. D007898 186803007 N0000001806 C0023290 1022315 Kala-Azar Black Fever Leishmaniasis, Visceral Leishmaniasis, Visceral C3790 Leprosy [Disease/Finding] 1026701 C3798 Hansen Disease C0023343 Hansen's Disease D007918 A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid. N0000001810 Leprosy Leprosy M0012361 81004002 Leukemia [Disease/Finding] Leukemia M0012382 188762002 C0023418 93143009 D007938 A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) C3808 Leukemia 1021987 N0000001815 Leukemia, Hairy Cell [Disease/Finding] Reticuloendotheliosis, Leukemic 188644003 Hairy Cell Leukemia D007943 Leukemic Reticuloendotheliosis A neoplastic disease of the lymphoreticular cells which is considered to be a rare type of chronic leukemia; it is characterized by an insidious onset, splenomegaly, anemia, granulocytopenia, thrombocytopenia, little or no lymphadenopathy, and the presence of "hairy" or "flagellated" cells in the blood and bone marrow. C0023443 118613001 C3818 Leukemia, Hairy Cell Leukemia, Hairy Cell N0000001820 1022561 M0012387 Leukemia, Lymphoid [Disease/Finding] C3820 1022165 Lymphoid Leukemia C0023448 D007945 Leukemia, Lymphoid N0000001821 Lymphocytic Leukemia Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts. M0012388 Leukemia, Lymphoid Leukemia, Lymphocytic 188725004 Leukemia, Myeloid [Disease/Finding] C3830 C0023470 Leukemia, Granulocytic Granulocytic Leukemia 1023661 188732008 Leukemia, Myelocytic Myelogenous Leukemia Myeloid Leukemia Myelocytic Leukemia M0012396 Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. D007951 Leukemia, Myelogenous Leukemia, Myeloid N0000001826 Leukocyte Disorders [Disease/Finding] M0012409 Leukocyte Disorders Disordered formation of various types of leukocytes or an abnormal accumulation or deficiency of these cells. Leukocyte Disorders 1025909 C0023510 54097007 D007960 N0000001831 C3840 Leukocytosis [Disease/Finding] C3842 D007964 C0023518 N0000001832 A transient increase in the number of leukocytes in a body fluid. 111583006 Leukocytosis Leukocytosis M0012413 1022602 Leukopenia [Disease/Finding] D007970 Leukopenia Leukocytopenia M0012421 C3854 1025463 84828003 N0000001838 Leukopenia C0023530 Liver Cirrhosis [Disease/Finding] Hepatic Cirrhosis C3902 D008103 C0023890 N0000001862 Cirrhosis, Liver Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Liver Cirrhosis M0012636 1024193 Liver Cirrhosis 19943007 Liver Cirrhosis, Biliary [Disease/Finding] Liver Cirrhosis, Biliary C0023892 Biliary Cirrhosis 1024646 Liver Cirrhosis, Biliary D008105 C3906 FIBROSIS of the hepatic parenchyma due to obstruction of BILE flow (CHOLESTASIS) in the intrahepatic or extrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC; BILE DUCTS, EXTRAHEPATIC). Primary biliary cirrhosis involves the destruction of small intra-hepatic bile ducts and bile secretion. Secondary biliary cirrhosis is produced by prolonged obstruction of large intrahepatic or extrahepatic bile ducts from a variety of causes. M0012640 N0000001864 1761006 Liver Diseases [Disease/Finding] Liver Diseases Liver Diseases 1024220 C3910 235856003 M0012644 N0000001866 D008107 C0023895 Pathological processes of the LIVER. Liver Diseases, Alcoholic [Disease/Finding] C0023896 C3912 D008108 Liver Diseases, Alcoholic Liver Diseases, Alcoholic 1024755 N0000001867 M0012646 41309000 Liver diseases associated with ALCOHOLISM. It usually refers to the coexistence of two or more subentities, i.e., ALCOHOLIC FATTY LIVER; ALCOHOLIC HEPATITIS; and ALCOHOLIC CIRRHOSIS. Alcoholic Liver Diseases Liver Neoplasms [Disease/Finding] Liver Neoplasms 1025382 Neoplasms, Liver Tumors or cancer of the LIVER. C0023903 Neoplasms, Hepatic Hepatic Neoplasms Liver Neoplasms D008113 M0012652 126851005 C3916 N0000001869 Lung Diseases [Disease/Finding] M0012744 N0000001879 Lung Diseases C3936 C0024115 Diseases, Pulmonary Lung Diseases Pulmonary Disease Pulmonary Diseases D008171 1021971 Pathological processes involving any part of the LUNG. Disease, Pulmonary 19829001 Lung Diseases, Fungal [Disease/Finding] Lung Diseases, Fungal C0024116 N0000001880 Lung Diseases, Fungal Pulmonary diseases caused by fungal infections, usually through hematogenous spread. Pulmonary Fungal Infections Pulmonary Fungal Diseases C3938 Fungal Lung Diseases M0012745 D008172 1029543 Lung Diseases, Obstructive [Disease/Finding] Lung Diseases, Obstructive Obstructive Lung Diseases Obstructive Pulmonary Diseases Lung Diseases, Obstructive Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent. D008173 C0600260 N0000001881 M0012746 C3940 1025962 Lung Neoplasms [Disease/Finding] 1023224 M0012749 D008175 C3944 N0000001883 Lung Neoplasms Lung Neoplasms Pulmonary Neoplasms Neoplasms, Lung Neoplasms, Pulmonary Tumors or cancer of the LUNG. 126713003 C0024121 Lupus Erythematosus, Cutaneous [Disease/Finding] N0000001885 C3948 C0024137 A form of lupus erythematosus in which the skin may be the only organ involved or in which skin involvement precedes the spread into other body systems. It has been classified into three forms - acute (= LUPUS ERYTHEMATOSUS, SYSTEMIC with skin lesions), subacute, and chronic (= LUPUS ERYTHEMATOSUS, DISCOID). D008178 M0012754 Lupus Erythematosus, Cutaneous Lupus Erythematosus, Cutaneous 7119001 1027393 Lupus Erythematosus, Discoid [Disease/Finding] 238927000 Lupus Erythematosus, Cutaneous, Chronic Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus, Discoid C0024138 C3950 A chronic form of cutaneous lupus erythematosus (LUPUS ERYTHEMATOSUS, CUTANEOUS) in which the skin lesions mimic those of the systemic form but in which systemic signs are rare. It is characterized by the presence of discoid skin plaques showing varying degrees of edema, erythema, scaliness, follicular plugging, and skin atrophy. Lesions are surrounded by an elevated erythematous border. The condition typically involves the face and scalp, but widespread dissemination may occur. D008179 1022154 200938002 M0012756 N0000001886 Lupus Erythematosus, Discoid Lupus Erythematosus, Systemic [Disease/Finding] 1023595 M0012757 D008180 Systemic Lupus Erythematosus C3952 Lupus Erythematosus Disseminatus A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. 55464009 Lupus Erythematosus, Systemic N0000001887 C0024141 Lupus Erythematosus, Systemic Lymphatic Diseases [Disease/Finding] 1024043 111590001 Diseases of LYMPH; LYMPH NODES; or LYMPHATIC VESSELS. C3974 362971004 M0012792 C0024228 N0000001898 Lymphatic Diseases Lymphatic Diseases 234087005 D008206 Lymphoma [Disease/Finding] M0012817 118600007 1024259 Lymphoma Reticulolymphosarcoma Germinoblastoma Sarcoma, Germinoblastic A general term for various neoplastic diseases of the lymphoid tissue. C3988 C0024299 Lymphoma, Malignant Lymphoma D008223 N0000001905 Lymphoma, Non-Hodgkin [Disease/Finding] Lymphoma, Small Cleaved-Cell, Diffuse Lymphoma, Nonhodgkins Lymphoma, Non-Hodgkin's C0024305 Non-Hodgkin's Lymphoma D008228 Lymphoma, Small Cleaved Cell, Diffuse C3998 Lymphoma, Non-Hodgkins N0000001910 Lymphoma, Nonhodgkin's M0012822 Non-Hodgkin Lymphoma 118601006 Lymphoma, Atypical Diffuse Small Lymphoid Diffuse Small Cleaved-Cell Lymphoma Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. 1024301 Lymphoma, Non-Hodgkin Lymphoma, Non-Hodgkin Small Cleaved-Cell Lymphoma, Diffuse Lymphoproliferative Disorders [Disease/Finding] C0024314 D008232 N0000001914 987016 Disorders characterized by proliferation of lymphoid tissue, general or unspecified. M0012826 Duncan's Syndrome Lymphoproliferative Disorders Lymphoproliferative Disorders C4006 277466009 Waldenstrom Macroglobulinemia [Disease/Finding] N0000001915 Lymphoma, Lymphocytic, Plasmacytoid 190817009 C0024419 Waldenstrom's Macroglobulinemia C4008 Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinemia Lymphoma, Lymphoplasmacytoid D008258 Primary Macroglobulinemia Waldenstrom's Macroglobulinaemia A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity. Macroglobulinemia 190818004 1022377 M0012865 Macular Degeneration [Disease/Finding] Macular Dystrophy Maculopathy, Age-Related Macular Degeneration 987866 302891003 Macular Degeneration C0242383 Age-Related Macular Degeneration D008268 N0000001918 M0012875 Age-Related Maculopathies Maculopathies, Age-Related Degenerative changes in the RETINA usually of older adults which results in a loss of vision in the center of the visual field (the MACULA LUTEA) because of damage to the retina. It occurs in dry and wet forms. C4014 Age-Related Maculopathy Malaria [Disease/Finding] D008288 C0024530 Marsh Fever C4026 Malaria Malaria 105649009 61462000 N0000001924 Plasmodium Infections M0012910 1025176 A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia. Paludism Infections, Plasmodium Remittent Fever 186797008 Medulloblastoma [Disease/Finding] C0025149 M0013281 D008527 A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1) Medulloblastoma Medulloblastoma 1026852 N0000001964 83217000 C4106 Megacolon [Disease/Finding] Megacolon M0013292 197144003 Megacolon Dilatation of the COLON, often to alarming dimensions. There are various types of megacolon including congenital megacolon in HIRSCHSPRUNG DISEASE, idiopathic megacolon in CONSTIPATION, and TOXIC MEGACOLON. 1024643 C0025160 C4108 D008531 N0000001965 Megacolon, Toxic [Disease/Finding] Megacolon, Toxic Megacolon, Toxic N0000001966 987192 C4110 M0013293 Toxic Megacolon 28536002 D008532 An acute form of MEGACOLON, severe pathological dilatation of the COLON. It is associated with clinical conditions such as ULCERATIVE COLITIS; CROHN DISEASE; AMEBIC DYSENTERY; or CLOSTRIDIUM ENTEROCOLITIS. C0025162 Melanoma [Disease/Finding] D008545 372244006 A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma Melanoma Melanoma C0025202 M0013309 N0000001969 C4116 1023577 Meningeal Neoplasms [Disease/Finding] Meningeal Tumors 1022381 C4134 C0025284 Meningeal Neoplasms N0000001978 Neoplasms, Meningeal 126965008 Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord. M0013360 D008577 Meningeal Neoplasms Meningitis [Disease/Finding] Meningitis C0025289 D008581 7180009 Meningitis 192678004 1024254 C4140 N0000001981 Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6) 192681009 M0013365 Menstruation Disturbances [Disease/Finding] Menstruation Disturbances Menstruation Disorders N0000001994 M0013402 C4166 1021753 386804004 C0025345 Menstruation Disturbances Variations of menstruation which may be indicative of disease. D008599 Mental Retardation [Disease/Finding] C4168 Subnormal intellectual functioning which originates during the developmental period. This has multiple potential etiologies, including genetic defects and perinatal insults. Intelligence quotient (IQ) scores are commonly used to determine whether an individual is mentally retarded. IQ scores between 70 and 79 are in the borderline mentally retarded range. Scores below 67 are in the retarded range. (Joynt, Clinical Neurology, 1992, Ch55, p28) 1023334 Mental Retardation M0013414 N0000001995 91138005 Retardation, Mental Disability, Intellectual C0025362 D008607 Mental Retardation Mercury Poisoning [Disease/Finding] 1026029 Mercury Poisoning Poisoning, Mercury D008630 N0000001996 85180002 M0013450 C4170 Mercury Poisoning C0025427 Mesothelioma [Disease/Finding] M0013485 D008654 Mesothelioma Mesothelioma 62064005 A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed) N0000002003 1024487 C4184 C0025500 Metabolic Diseases [Disease/Finding] Diseases, Metabolic Metabolic Diseases D008659 Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed) 30390004 1022778 Thesaurismosis 75934005 Metabolic Diseases N0000002004 C0025517 M0013493 C4186 Metabolism, Inborn Errors [Disease/Finding] C4188 Metabolism Errors, Inborn 1024978 C0025521 Inborn Errors of Metabolism Errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero. N0000002005 Metabolism, Inborn Errors Metabolism, Inborn Errors D008661 86095007 M0013496 Metal Metabolism, Inborn Errors [Disease/Finding] Metal Metabolism, Inborn Error Metal Metabolism, Inborn Errors C0025534 M0013499 C4190 990196 N0000002006 D008664 Metal Metabolism, Inborn Errors Stomatognathic Diseases [Disease/Finding] C4246 1027350 General or unspecified diseases of the stomatognathic system, comprising the mouth, teeth, jaws, and pharynx. Stomatognathic Diseases Stomatognathic Diseases Mouth and Tooth Diseases N0000002034 D009057 C0038368 M0014128 Mouth Diseases [Disease/Finding] C0026636 N0000002036 D009059 M0014130 Mouth Diseases Mouth Diseases 118938008 C4250 1027441 Movement Disorders [Disease/Finding] C0026650 C4256 Movement Disorder Syndromes M0014141 Dyskinesia Syndromes Movement Disorders Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions. N0000002039 60342002 Movement Disorders 1024614 D009069 Multiple Myeloma [Disease/Finding] Myeloma, Plasma-Cell 109989006 Myelomatosis A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Kahler Disease Multiple Myeloma D009101 N0000002050 C0026764 Multiple Myeloma 1022141 M0014195 Myeloma-Multiple C4278 Plasma Cell Myeloma Multiple Sclerosis [Disease/Finding] 192928003 MS (Multiple Sclerosis) 1024685 Multiple Sclerosis Multiple Sclerosis 24700007 C0026769 C4282 N0000002052 M0014197 Sclerosis, Disseminated An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) D009103 Muscle Cramp [Disease/Finding] C0026821 D009120 55300003 1026631 Muscle Cramp M0014234 Muscular Cramp N0000002057 C4292 Cramp Muscle Cramp A sustained and usually painful contraction of muscle fibers. This may occur as an isolated phenomenon or as a manifestation of an underlying disease process (e.g., UREMIA; HYPOTHYROIDISM; MOTOR NEURON DISEASE; etc.). (From Adams et al., Principles of Neurology, 6th ed, p1398) Muscle Hypertonia [Disease/Finding] N0000002058 C0026826 Abnormal increase in skeletal or smooth muscle tone. Skeletal muscle hypertonicity may be associated with PYRAMIDAL TRACT lesions or BASAL GANGLIA DISEASES. M0014236 D009122 1023026 C4294 Muscle Tone Increased 41581000 Muscle Hypertonia Muscle Hypertonia Muscular Hypertonicity Hypermyotonia Muscle Rigidity [Disease/Finding] Muscle Rigidity Rigidity, Muscular M0014242 C0026837 D009127 Muscle Rigidity Continuous involuntary sustained muscle contraction which is often a manifestation of BASAL GANGLIA DISEASES. When an affected muscle is passively stretched, the degree of resistance remains constant regardless of the rate at which the muscle is stretched. This feature helps to distinguish rigidity from MUSCLE SPASTICITY. (From Adams et al., Principles of Neurology, 6th ed, p73) 16046003 C4298 1026262 N0000002060 Muscle Spasticity [Disease/Finding] Muscle Spasticity 221360009 D009128 N0000002061 A form of muscle hypertonia associated with upper MOTOR NEURON DISEASE. Resistance to passive stretch of a spastic muscle results in minimal initial resistance (a "free interval") followed by an incremental increase in muscle tone. Tone increases in proportion to the velocity of stretch. Spasticity is usually accompanied by HYPERREFLEXIA and variable degrees of MUSCLE WEAKNESS. (From Adams et al., Principles of Neurology, 6th ed, p54) C0026838 C4300 Muscle Spasticity M0014243 1024482 Muscular Diseases [Disease/Finding] Muscular Diseases D009135 Muscle Disorders M0014252 C0026848 Myopathic Conditions N0000002064 Muscular Diseases 1022424 129565002 C4306 Acquired, familial, and congenital disorders of SKELETAL MUSCLE and SMOOTH MUSCLE. Myopathies Musculoskeletal Diseases [Disease/Finding] C4312 D009140 1022076 928000 Musculoskeletal Diseases C0026857 Diseases of the muscles and their associated ligaments and other connective tissue and of the bones and cartilage viewed collectively. N0000002067 M0014259 Musculoskeletal Diseases Myasthenia Gravis [Disease/Finding] Myasthenia Gravis C4318 N0000002070 91637004 D009157 M0014279 Myasthenia Gravis 1024161 C0026896 A disorder of neuromuscular transmission characterized by weakness of cranial and skeletal muscles. Autoantibodies directed against acetylcholine receptors damage the motor endplate portion of the NEUROMUSCULAR JUNCTION, impairing the transmission of impulses to skeletal muscles. Clinical manifestations may include diplopia, ptosis, and weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles. THYMOMA is commonly associated with this condition. (Adams et al., Principles of Neurology, 6th ed, p1459) Mycobacterium Infections [Disease/Finding] 1022908 Infections with bacteria of the genus MYCOBACTERIUM. M0014287 Mycobacterium Infections D009164 Mycobacterium Infections Infections, Mycobacterium 88415009 C4320 C0026918 N0000002071 Mycobacterium Infections, Atypical [Disease/Finding] 111812000 Mycobacterium Infections, Atypical Infections, Atypical Mycobacterium Atypical Mycobacterium Infections N0000002072 1026349 D009165 Infections with so called atypical mycobacteria (tuberculoid bacilli): M. kansasii, M. marinum, M. scrofulaceum, M. flavescens, M. gordonae, M. obuense, M. gilvum, M. duvali, M. szulgai, M. intracellulare (see MYCOBACTERIUM AVIUM COMPLEX;), M. xenopi (littorale), M. ulcerans, M. buruli, M. terrae, M. fortuitum (minetti, giae), M. chelonae. Infections, Tuberculoid Tuberculoid Infections 111811007 Mycobacterium Infections, Atypical C4322 C0026919 M0014288 Mycoplasma Infections [Disease/Finding] Infections, Mycoplasma N0000002073 C0026936 Infections with species of the genus MYCOPLASMA. Mycoplasma Infections Mycoplasma Infections 1023539 C4324 186464008 186462007 M0014307 D009175 Mycoplasmatales Infections [Disease/Finding] C4326 Infections with bacteria of the order MYCOPLASMATALES. Mycoplasmatales Infections N0000002074 D009180 1030047 M0014312 C0026945 Mycoplasmatales Infections Infections, Mycoplasmatales Mycoses [Disease/Finding] N0000002075 Mycoses 1024676 D009181 M0014313 C4328 3218000 Mycoses Fungus Diseases C0026946 Mycosis Fungoides [Disease/Finding] M0014314 188618003 A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected. Mycosis Fungoides D009182 1024347 N0000002076 118618005 Mycosis Fungoides C4330 C0026948 Myeloproliferative Disorders [Disease/Finding] Myeloproliferative Disorders 414794006 M0014332 414792005 C0027022 D009196 Myeloproliferative Disorders 1022355 128925001 C4342 Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE. N0000002082 Myocardial Infarction [Disease/Finding] 1024565 C0027051 Myocardial Infarction Myocardial Infarct C4348 N0000002085 M0014340 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). D009203 22298006 Myosarcoma [Disease/Finding] A general term for a malignant neoplasm derived from muscular tissue. (Stedman, 25th ed) D009217 M0014359 20667008 1025716 Myosarcoma C0027095 Myosarcoma N0000002093 C4364 Myositis [Disease/Finding] M0014368 128496001 Myopathy, Inflammatory 203110007 Inflammatory Myopathy Myositis C0027121 C4366 Inflammation of a muscle or muscle tissue. D009220 N0000002094 26889001 Myositis Inflammatory Muscle Diseases Muscle Diseases, Inflammatory 1023065 Nail Diseases [Disease/Finding] D009260 1023398 17790008 C4384 N0000002103 Nail Diseases Nail Diseases Diseases of the nail plate and tissues surrounding it. The concept is limited to primates. M0014427 C0027339 Nasal Polyps [Disease/Finding] D009298 N0000002110 C0027430 1026147 C4398 Focal accumulations of EDEMA fluid in the NASAL MUCOSA accompanied by HYPERPLASIA of the associated submucosal connective tissue. Polyps may be NEOPLASMS, foci of INFLAMMATION, degenerative lesions, or malformations. M0014487 Nasal Polyps Nasal Polyps 52756005 Nausea [Disease/Finding] 1023644 Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses. 73879007 C4406 N0000002114 D009325 M0014528 Nausea C0027497 Nelson Syndrome [Disease/Finding] C4414 43019009 A syndrome characterized by HYPERPIGMENTATION, enlarging pituitary mass, visual defects secondary to compression of the OPTIC CHIASM, and elevated serum ACTH. It is caused by the expansion of an underlying ACTH-SECRETING PITUITARY ADENOMA that grows in the absence of feedback inhibition by adrenal CORTICOSTEROIDS, usually after ADRENALECTOMY. Nelson Syndrome N0000002118 C0027577 Nelson Syndrome 1025318 M0014557 D009347 Congenital, Hereditary, and Neonatal Diseases and Abnormalities [Disease/Finding] N0000002121 D009358 M0014570 989203 C4420 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases existing at birth and often before birth, or that develop during the first month of life (INFANT, NEWBORN, DISEASES), regardless of causation. Of these diseases, those characterized by structural deformities are termed CONGENITAL ABNORMALITIES. Congenital, Hereditary, and Neonatal Diseases and Abnormalities C0027612 Neoplasms [Disease/Finding] 55342001 Neoplasms Neoplasms 189526009 189525008 Tumors C0027651 D009369 M0014585 C4434 1022284 New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. N0000002128 Neoplasms by Histologic Type [Disease/Finding] D009370 Neoplasms by Histologic Type Neoplasms by Histological Type C4436 Neoplasms by Histologic Type A collective term for the various histological types of NEOPLASMS. It is more likely to be used by searchers than by indexers and catalogers. Histological Type of Neoplasm N0000002129 M0014588 Histological Types of Neoplasms C0027652 986146 Neoplasms by Site [Disease/Finding] Sites, Neoplasm Neoplasms by Site Neoplasms by Sites C0027653 Site, Neoplasm C4438 N0000002130 A collective term for precoordinated organ/neoplasm headings locating neoplasms by organ, as BRAIN NEOPLASMS; DUODENAL NEOPLASMS; LIVER NEOPLASMS; etc. D009371 M0014589 1026659 Neoplasms by Site Neoplasms, Connective Tissue [Disease/Finding] C4440 126598008 1026975 D009372 M0014590 Neoplasms composed of connective tissue, including elastic, mucous, reticular, osseous, and cartilaginous tissue. The concept does not refer to neoplasms located in connective tissue. N0000002131 Neoplasms, Connective Tissue C0027656 Neoplasms, Connective Tissue Connective Tissue Neoplasms Neoplasms, Germ Cell and Embryonal [Disease/Finding] D009373 Neoplasms, Germ Cell and Embryonic C4442 N0000002132 M0014592 1026873 Germ Cell and Embryonic Neoplasms Neoplasms, Germ Cell and Embryonal Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS. Germ Cell and Embryonal Neoplasms C0027658 Neoplasms, Germ Cell and Embryonal Neoplasms, Experimental [Disease/Finding] Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. N0000002133 M0014595 C0027659 Experimental Neoplasms D009374 1025199 Neoplasms, Experimental Neoplasms, Experimental C4444 Neoplasms, Glandular and Epithelial [Disease/Finding] Neoplasms, Glandular and Epithelial Neoplasms, Glandular and Epithelial Glandular and Epithelial Neoplasms C0027660 Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue. D009375 1028442 N0000002134 Neoplasms, Glandular Epithelial M0014596 C4446 Neoplasms, Muscle Tissue [Disease/Finding] N0000002138 C0027664 Muscle Tissue Neoplasms D009379 Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles. M0014603 1030677 Neoplasms, Muscle Tissue Neoplasms, Muscle Tissue C4454 Neoplasms, Nerve Tissue [Disease/Finding] Nerve Tissue Neoplasms Neoplasms, Nerve Tissue Neoplasms, Nerve Tissue Neoplasms composed of nerve tissue. This concept does not refer to neoplasms located in the nervous system or its component nerves. C0027665 C4456 985772 D009380 Nervous Tissue Neoplasms M0014605 Neoplasms, Nervous Tissue N0000002139 Neoplasms, Vascular Tissue [Disease/Finding] C4462 D009383 Neoplasms, Vascular Tissue Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels. M0014610 Vascular Tissue Neoplasms N0000002142 Blood Vessel Tumors C0282607 1023689 Neoplasms, Vascular Tissue Paraneoplastic Endocrine Syndromes [Disease/Finding] D009384 1027737 N0000002143 C4464 C0027670 M0014611 Paraneoplastic Endocrine Syndromes Syndromes resulting from inappropriate production of HORMONES or hormone-like materials by NEOPLASMS in non-endocrine tissues or not by the usual ENDOCRINE GLANDS. Such hormone outputs are called ectopic hormone (HORMONES, ECTOPIC) secretion. Ectopic Hormone Syndromes Paraneoplastic Endocrine Syndromes Neoplastic Processes [Disease/Finding] N0000002144 The pathological mechanisms and forms taken by tissue during degeneration into a neoplasm and its subsequent activity. C0027671 D009385 1026939 Processes, Neoplastic Neoplastic Processes M0014612 Neoplastic Processes C4466 Nephritis [Disease/Finding] D009393 C4472 52845002 M0014626 Nephritis Inflammation of any part of the KIDNEY. N0000002147 C0027697 Nephritis 1022904 Nephritis, Interstitial [Disease/Finding] N0000002149 Inflammation of the interstitial tissue of the kidney. This term is generally used for primary inflammation of KIDNEY TUBULES and/or surrounding interstitium. For primary inflammation of glomerular interstitium, see GLOMERULONEPHRITIS. Infiltration of the inflammatory cells into the interstitial compartment results in EDEMA, increased spaces between the tubules, and tubular renal dysfunction. C0027707 Nephritis, Interstitial Nephritis, Interstitial 28689008 M0014628 Interstitial Nephritis D009395 C4476 1022491 Nephrosis [Disease/Finding] C4484 M0014635 Nephrosis Nephrosis Pathological processes of the KIDNEY without inflammatory or neoplastic components. Nephrosis may be a primary disorder or secondary complication of other diseases. It is characterized by the NEPHROTIC SYNDROME indicating the presence of PROTEINURIA and HYPOALBUMINEMIA with accompanying EDEMA. N0000002153 1025384 D009401 C0027720 90708001 Nephrotic Syndrome [Disease/Finding] N0000002155 C0027726 52254009 D009404 M0014639 A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction. Nephrotic Syndrome Nephrotic Syndrome C4488 1026285 Nervous System Diseases [Disease/Finding] C0027765 1026444 Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle. N0000002159 D009422 Nervous System Diseases M0014667 Neurologic Disorders C4496 Nervous System Disorders Neurological Disorders 118940003 Nervous System Diseases Nervous System Neoplasms [Disease/Finding] Nervous System Neoplasms C4498 N0000002160 Nervous System Neoplasms M0014668 Neoplasms, Nervous System 1024871 Tumors of the Nervous System Nervous System Tumors 126950007 D009423 Benign and malignant neoplastic processes arising from or involving components of the central, peripheral, and autonomic nervous systems, cranial nerves, and meninges. Included in this category are primary and metastatic nervous system neoplasms. C0027766 Neuralgia [Disease/Finding] D009437 16269008 Neurodynia C0027796 Neuralgia Neuralgia N0000002162 C4502 Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve. Neuropathic Pain M0014687 1024078 203115002 Neuroblastoma [Disease/Finding] D009447 1026096 C0027819 A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51) 87364003 Neuroblastoma Neuroblastoma N0000002167 C4512 M0014699 Neurologic Manifestations [Disease/Finding] Clinical signs and symptoms caused by nervous system injury or dysfunction. 1025946 C0027854 Neurologic Manifestations Neurologic Manifestations Neurologic Signs and Symptoms Neurologic Manifestation Manifestations, Neurologic Manifestations, Neurological M0014716 N0000002173 C4524 Neurological Manifestations D009461 Neuromuscular Diseases [Disease/Finding] N0000002176 C4530 Neuromuscular Diseases M0014726 D009468 1026561 255522009 257277002 Neuromuscular Diseases A general term encompassing lower MOTOR NEURON DISEASE; PERIPHERAL NERVOUS SYSTEM DISEASES; and certain MUSCULAR DISEASES. Manifestations include MUSCLE WEAKNESS; FASCICULATION; muscle ATROPHY; SPASM; MYOKYMIA; MUSCLE HYPERTONIA, myalgias, and MUSCLE HYPOTONIA. C0027868 Neutropenia [Disease/Finding] A decrease in the number of neutrophilic leukocytes in the blood. (Dorland, 27th ed) 1023774 C4542 303011007 Neutropenia C0027947 M0014782 D009503 N0000002182 Neutropenia Nose Diseases [Disease/Finding] C0028432 N0000002194 C4566 89488007 1024498 D009668 Nose Diseases Disorders of the nose, general or unspecified. Nasal Diseases Nasal Disorders Nose Diseases M0015012 Nutrition Disorders [Disease/Finding] C0028709 D009748 Nutritional Disorders N0000002196 2492009 M0015120 C4570 1024039 Nutrition Disorders Nutrition Disorders Disorders caused by nutritional imbalance, either overnutrition or undernutrition. Nutritional and Metabolic Diseases [Disease/Finding] A collective term for nutritional disorders resulting from poor absorption or nutritional imbalance, and metabolic disorders resulting from defects in biosynthesis (ANABOLISM) or breakdown (CATABOLISM) of endogenous substances. C4572 M0015124 Nutritional and Metabolic Diseases 1026553 N0000002197 C0028715 D009750 Nutritional and Metabolic Diseases Obsessive-Compulsive Disorder [Disease/Finding] Anankastic Personality Neurosis, Obsessive-Compulsive Obsessive-Compulsive Disorder Obsessive-Compulsive Disorder C0028768 C4584 D009771 191736004 M0015170 An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension. N0000002203 1022585 Occupational Diseases [Disease/Finding] C4588 C0028797 Occupational Diseases D009784 N0000002205 Diseases, Occupational 1027957 115966001 Occupational Diseases M0015191 Diseases caused by factors involved in one's employment. Ocular Hypertension [Disease/Finding] M0015213 N0000002207 Hypertension, Ocular D009798 C4592 Ocular Hypertension C0028840 4210003 A condition in which the intraocular pressure is elevated above normal and which may lead to glaucoma. 1024796 Ocular Hypertension Opportunistic Infections [Disease/Finding] 61274003 N0000002225 1025670 M0015350 Opportunistic Infections Opportunistic Infections C0029118 D009894 C4628 An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression. Optic Nerve Diseases [Disease/Finding] C4632 C0029132 Optic Nerve Diseases Conditions which produce injury or dysfunction of the second cranial or optic nerve, which is generally considered a component of the central nervous system. Damage to optic nerve fibers may occur at or near their origin in the retina, at the optic disk, or in the nerve, optic chiasm, optic tract, or lateral geniculate nuclei. Clinical manifestations may include decreased visual acuity and contrast sensitivity, impaired color vision, and an afferent pupillary defect. Second Cranial Nerve Diseases 985060 Cranial Nerve II Diseases Neural-Optical Lesion M0015358 N0000002227 77157004 Cranial Nerve II Disorder Optic Nerve Diseases D009901 Optic Neuropathy Optic Neuritis [Disease/Finding] D009902 C0029134 1023808 Inflammation of the optic nerve. Commonly associated conditions include autoimmune disorders such as MULTIPLE SCLEROSIS, infections, and granulomatous diseases. Clinical features include retro-orbital pain that is aggravated by eye movement, loss of color vision, and contrast sensitivity that may progress to severe visual loss, an afferent pupillary defect (Marcus-Gunn pupil), and in some instances optic disc hyperemia and swelling. Inflammation may occur in the portion of the nerve within the globe (neuropapillitis or anterior optic neuritis) or the portion behind the globe (retrobulbar neuritis or posterior optic neuritis). Optic Neuritis Optic Neuritis 66760008 194052008 N0000002228 M0015359 C4634 Ossification, Heterotopic [Disease/Finding] Pathologic Ossification C4658 1023221 128491006 M0015505 The development of bony substance in normally soft structures. C0029396 Ossification, Heterotopic D009999 Ossification, Ectopic N0000002240 Ossification, Pathologic Ossification, Heterotopic Ossification, Pathological Osteoarthritis [Disease/Finding] M0015509 D010003 1022131 Osteoarthrosis Osteoarthritis C4666 A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans. 396275006 N0000002244 Arthritis, Degenerative 225655006 Osteoarthritis C0029408 Osteomalacia [Disease/Finding] 190642003 D010018 4598005 Osteomalacia C0029442 C4688 1024754 M0015543 N0000002255 A condition marked by softening of the bones (due to impaired mineralization, with excess accumulation of osteoid), with pain, tenderness, muscular weakness, anorexia, and loss of weight, resulting from deficiency of vitamin D and calcium. (Dorland, 27th ed) Osteomalacia Osteomyelitis [Disease/Finding] C0029443 1022411 111253001 203207005 60168000 268020008 D010019 M0015544 Osteomyelitis Osteomyelitis N0000002256 C4690 Otorhinolaryngologic Diseases [Disease/Finding] N0000002269 Pathological processes of the ear, the nose, and the throat, also known as the ENT diseases. Otorhinolaryngologic Diseases M0015572 Otolaryngological Diseases Otorhinolaryngologic Disease ENT Diseases C4716 985940 Otorhinolaryngological Disease D010038 Otorhinolaryngologic Diseases C0029896 Otolaryngologic Diseases Ovarian Diseases [Disease/Finding] Ovarian Diseases Pathological processes of the OVARY. 1027825 C4724 5552004 Ovarian Diseases D010049 C0029928 M0015590 N0000002273 Ovarian Neoplasms [Disease/Finding] Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. N0000002274 Ovary Neoplasms C0919267 C4726 M0015593 Ovarian Neoplasms 1022316 Neoplasms, Ovarian 123843001 Ovarian Neoplasms D010051 Paget Disease, Extramammary [Disease/Finding] A rare cutaneous neoplasm that occurs in the elderly. It develops more frequently in women and predominantly involves apocrine gland-bearing areas, especially the vulva, scrotum, and perianal areas. The lesions develop as erythematous scaly patches that progress to crusted, pruritic, erythematous plaques. The clinical differential diagnosis includes squamous cell carcinoma in situ and superficial fungal infection. It is generally thought to be an adenocarcinoma of the epidermis, from which it extends into the contiguous epithelium of hair follicles and eccrine sweat ducts. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1478) Paget Disease, Extramammary Paget's Disease, Extramammary Paget Disease, Extra-Mammary Extra-Mammary Paget's Disease C0030186 C4732 Paget Disease, Extramammary Paget's Disease, Extra-Mammary 1024557 Extra-Mammary Paget Disease D010145 71447003 Paget Disease Extramammary Extramammary Paget Disease M0015741 N0000002277 Extramammary Paget's Disease Pain [Disease/Finding] An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS. Pain C4734 Pain D010146 1021856 M0015742 C0030193 N0000002278 22253000 Pain, Postoperative [Disease/Finding] N0000002280 1022740 C4738 D010149 C0030201 Pain during the period after surgery. Pain, Postoperative Postoperative Pain Pain, Postoperative M0015751 213299007 Pancreatic Diseases [Disease/Finding] Pathological processes of the PANCREAS. C4748 N0000002285 3855007 Pancreatic Diseases C0030286 D010182 M0015794 1022020 Pancreatic Diseases Pancreatic Neoplasms [Disease/Finding] 1026434 126859007 C4754 Neoplasms, Pancreatic M0015803 C0030297 N0000002288 Pancreatic Neoplasms Pancreatic Neoplasms Pancreas Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). D010190 Paracoccidioidomycosis [Disease/Finding] M0015861 59925007 Paracoccidioidomycosis Blastomycosis, South American 1021870 N0000002298 D010229 C4774 C0030409 A mycosis affecting the skin, mucous membranes, lymph nodes, and internal organs. It is caused by Paracoccidioides brasiliensis. It is also called paracoccidioidal granuloma. Superficial resemblance of P. brasiliensis to Blastomyces brasiliensis (BLASTOMYCES) may cause misdiagnosis. 36866003 Paracoccidioidomycosis Paranasal Sinus Diseases [Disease/Finding] N0000002309 7393007 Diseases affecting or involving the PARANASAL SINUSES and generally manifesting as inflammation, abscesses, cysts, or tumors. 1024100 M0015892 C4796 Paranasal Sinus Diseases Paranasal Sinus Diseases D010254 C0030469 Paraneoplastic Syndromes [Disease/Finding] C0030472 N0000002311 M0015895 Paraneoplastic Syndromes C4800 Paraneoplastic Syndromes 49783001 1022521 In patients with neoplastic diseases a wide variety of clinical pictures which are indirect and usually remote effects produced by tumor cell metabolites or other products. D010257 Paraproteinemias [Disease/Finding] Paraproteinemias Paraimmunoglobulinemias C0030489 1022681 C4812 N0000002317 D010265 M0015905 190816000 A group of related diseases characterized by an unbalanced or disproportionate proliferation of immunoglobulin-producing cells, usually from a single clone. These cells frequently secrete a structurally homogeneous immunoglobulin (M-component) and/or an abnormal immunoglobulin. Paraproteinemias Parasitic Diseases [Disease/Finding] C4816 Parasitic Diseases 987316 Parasitic Diseases Infections or infestations with parasitic organisms. They are often contracted through contact with an intermediate vector, but may occur as the result of direct exposure. C0030499 M0015919 N0000002319 D010272 17322007 Paresis [Disease/Finding] C4828 Paresis 26544005 987955 C0030552 M0015948 D010291 Muscular Paresis Paresis N0000002325 Muscle Paresis A general term referring to a mild to moderate degree of muscular weakness, occasionally used as a synonym for PARALYSIS (severe or complete loss of motor function). In the older literature, paresis often referred specifically to paretic neurosyphilis (see NEUROSYPHILIS). "General paresis" and "general paralysis" may still carry that connotation. Bilateral lower extremity paresis is referred to as PARAPARESIS. Parkinson Disease [Disease/Finding] Primary Parkinsonism Parkinson Disease, Idiopathic 1022466 Paralysis Agitans Lewy Body Parkinson Disease Idiopathic Parkinson's Disease N0000002327 Lewy Body Parkinson's Disease Parkinson Disease Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) 49049000 D010300 Idiopathic Parkinson Disease M0015963 C4832 Parkinson's Disease, Lewy Body Parkinson's Disease C0030567 Parkinson's Disease, Idiopathic Pathologic Processes [Disease/Finding] 370135005 C0030660 Pathologic Processes M0016012 1025320 N0000002338 Pathologic Processes 308489006 C4854 Processes, Pathologic D010335 Pathological Processes The abnormal mechanisms and forms involved in the dysfunctions of tissues and organs. Pemphigus [Disease/Finding] Group of chronic blistering diseases characterized histologically by ACANTHOLYSIS and blister formation within the EPIDERMIS. C0030807 1025707 C4872 M0016112 Pemphigus D010392 N0000002347 65172003 Pemphigus Peptic Ulcer [Disease/Finding] M0016211 Peptic Ulcer Peptic Ulcer 13200003 196697002 266437002 1024813 N0000002351 D010437 C0030920 C4880 Gastroduodenal Ulcer Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS). Familial Mediterranean Fever [Disease/Finding] Periodic Disease, Wolff's C0031069 Recurrent Polyserositis Benign Paroxysmal Peritonitis Periodic Peritonitis Familial Mediterranean Fever A group of HEREDITARY AUTOINFLAMMATION DISEASES, characterized by recurrent fever, abdominal pain, headache, rash, PLEURISY; and ARTHRITIS. ORCHITIS; benign MENINGITIS; and AMYLOIDOSIS may also occur. Homozygous or compound heterozygous mutations in marenostrin gene result in autosomal recessive transmission; simple heterozygous, autosomal dominant form of the disease. Mediterranean Fever, Familial Familial Mediterranean Fever 1023411 Periodic Disease 12579009 Wolff's Periodic Disease Wolff Periodic Disease Familial Paroxysmal Polyserositis C4912 D010505 N0000002367 M0016320 Peripheral Nervous System Diseases [Disease/Finding] Peripheral Nervous System Disease Peripheral Nervous System Diseases Peripheral Nervous System Disorders C0031117 D010523 Peripheral Nervous System Diseases 42658009 M0016347 Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves. Peripheral Neuropathies Peripheral Nerve Diseases C4928 PNS (Peripheral Nervous System) Diseases N0000002375 PNS Diseases 302226006 989352 Pharyngeal Diseases [Disease/Finding] C0031345 195832000 Pathological processes involving the PHARYNX. N0000002385 C4948 D010608 Pharynx Diseases Pharyngeal Diseases Pharyngeal Diseases 75860007 1024885 Diseases of Pharynx M0016479 Phlebitis [Disease/Finding] C4964 Inflammation of a vein, often a vein in the leg. Phlebitis associated with a blood clot is called (THROMBOPHLEBITIS). N0000002393 Phlebitis Phlebitis 61599003 986358 M0016608 C0031542 D010689 Phobic Disorders [Disease/Finding] 386810004 N0000002394 M0016622 1023113 C4966 Phobias C0349231 Phobic Disorders Phobic Disorders Neuroses, Phobic D010698 Phobic Neuroses Anxiety disorders in which the essential feature is persistent and irrational fear of a specific object, activity, or situation that the individual feels compelled to avoid. The individual recognizes the fear as excessive or unreasonable. Pituitary Diseases [Disease/Finding] 399244003 C0032002 Hypophyseal Disorders 1023299 D010900 N0000002407 Pituitary Diseases Disorders involving either the ADENOHYPOPHYSIS or the NEUROHYPOPHYSIS. These diseases usually manifest as hypersecretion or hyposecretion of PITUITARY HORMONES. Neoplastic pituitary masses can also cause compression of the OPTIC CHIASM and other adjacent structures. M0016908 Pituitary Disorders C4992 Pituitary Gland Diseases Pituitary Diseases Pituitary Neoplasms [Disease/Finding] 1027456 C0032019 127024001 D010911 Pituitary Neoplasms Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA. Pituitary Tumors N0000002408 M0016922 C4994 Pituitary Neoplasms Plague [Disease/Finding] An acute infectious disease caused by YERSINIA PESTIS that affects humans, wild rodents, and their ectoparasites. This condition persists due to its firm entrenchment in sylvatic rodent-flea ecosystems throughout the world. Bubonic plague is the most common form. C5008 Plague D010930 Plague 1027188 186290009 C0032064 58750007 M0016945 N0000002415 Pneumococcal Infections [Disease/Finding] 988639 N0000002430 Infections, Streptococcus pneumoniae Pneumococcal Infections Infections, Pneumococcal C0032269 16814004 Streptococcus pneumoniae Infections D011008 C5038 Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE. Pneumococcal Infections M0017055 Pneumonia [Disease/Finding] D011014 C5042 233604007 Pulmonary Inflammation Pneumonitis M0017064 Pneumonia Pneumonia Lung Inflammation N0000002432 1022757 C0032285 Inflammation of any part, segment or lobe, of the lung parenchyma. 205237003 Pneumonia, Pneumococcal [Disease/Finding] Pneumonia, Pneumococcal 233607000 N0000002435 278516003 Pneumonia, Pneumococcal 1024902 D011018 266350000 C5048 M0017071 A febrile disease caused by STREPTOCOCCUS PNEUMONIAE. C0155862 Pneumonia, Pneumocystis [Disease/Finding] Pneumocystis Pneumonia C0032305 Pneumonia, Pneumocystis carinii M0017073 Pneumocystosis Pneumonia, Pneumocystis C5052 N0000002437 88860002 Pneumonia, Pneumocystis 415125002 Pneumonia, Interstitial Plasma Cell Pneumocystis carinii Pneumonia D011020 A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis. 1023656 Poisoning [Disease/Finding] C5072 C0032343 A condition or physical state produced by the ingestion, injection, inhalation of or exposure to a deleterious agent. M0017099 1026915 Poisoning Poisoning N0000002447 75478009 D011041 Polychondritis, Relapsing [Disease/Finding] M0017161 An acquired disease of unknown etiology, chronic course, and tendency to recur. It is characterized by inflammation and degeneration of cartilage and can result in deformities such as floppy ear and saddle nose. Loss of cartilage in the respiratory tract can lead to respiratory obstruction. N0000002451 Polychondritis, Relapsing D011081 1023111 Polychondritis, Chronic Atrophic 72275000 Polychondritis, Relapsing C0032453 C5080 Polycythemia Vera [Disease/Finding] C5086 Polycythemia Vera A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs. 109992005 N0000002454 Polycythemia Rubra Vera 1023815 M0017168 Polycythemia Vera C0032463 Osler-Vaquez Disease D011087 Erythremia Polyps [Disease/Finding] 1024250 C5094 C0032584 D011127 Discrete abnormal tissue masses that protrude into the lumen of the DIGESTIVE TRACT or the RESPIRATORY TRACT. Polyps can be spheroidal, hemispheroidal, or irregular mound-shaped structures attached to the MUCOUS MEMBRANE of the lumen wall either by a stalk, pedunculus, or by a broad base. 41329004 M0017240 Polyps N0000002458 Polyps Porphyrias [Disease/Finding] D011164 Porphyrias Porphyria Porphyrias 418470004 29094004 C0032708 C5106 1022410 M0017334 N0000002464 371628009 A diverse group of metabolic diseases characterized by errors in the biosynthetic pathway of HEME in the LIVER, the BONE MARROW, or both. They are classified by the deficiency of specific enzymes, the tissue site of enzyme defect, or the clinical features that include neurological (acute) or cutaneous (skin lesions). Porphyrias can be hereditary or acquired as a result of toxicity to the hepatic or erythropoietic marrow tissues. Postoperative Complications [Disease/Finding] Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Postoperative Complications M0017367 Postoperative Complications D011183 1022600 N0000002467 385486001 C5112 C0032787 Complication, Postoperative Pre-Excitation Syndromes [Disease/Finding] Preexcitation Syndrome N0000002474 D011226 C0032915 C5126 Pre-Excitation Syndromes Pre-Excitation Syndromes 1026072 A group of conditions in which HEART VENTRICLE activation by the atrial impulse is faster than the normal impulse conduction from the SINOATRIAL NODE. In these pre-excitation syndromes, atrial impulses often bypass the ATRIOVENTRICULAR NODE delay and travel via ACCESSORY CONDUCTING PATHWAYS connecting the atrium directly to the BUNDLE OF HIS. M0017444 Pregnancy Complications [Disease/Finding] Pregnancy Complications 1023402 Complications, Pregnancy D011248 Conditions or pathological processes associated with pregnancy. They can occur during or after pregnancy, and range from minor discomforts to serious diseases that require medical interventions. They include diseases in pregnant females, and pregnancies in females with diseases. N0000002478 C0032962 90821003 198881004 C5134 Pregnancy Complications M0017474 Pregnancy Complications, Infectious [Disease/Finding] M0017477 The co-occurrence of pregnancy and an INFECTION. The infection may precede or follow FERTILIZATION. Pregnancy, Infectious Complications Complications, Infectious Pregnancy C0032965 Pregnancy Complications, Infectious C5140 Infectious Pregnancy Complications 1025778 D011251 N0000002481 Pregnancy Complications, Infectious Pregnancy Complications, Neoplastic [Disease/Finding] Pregnancy Complications, Neoplastic D011252 Pregnancy, Neoplastic Complications The co-occurrence of pregnancy and NEOPLASMS. The neoplastic disease may precede or follow FERTILIZATION. Complications, Neoplastic Pregnancy M0017478 Neoplastic Pregnancy Complications C0032966 C5142 Pregnancy Complications, Neoplastic N0000002482 1025596 Pregnancy, Abdominal [Disease/Finding] Pregnancy, Abdominal N0000002485 Pregnancy, Abdominal C0032984 Abdominal Pregnancy D011269 A type of ectopic pregnancy in which the EMBRYO, MAMMALIAN implants in the ABDOMINAL CAVITY instead of in the ENDOMETRIUM of the UTERUS. C5148 1028274 82661006 M0017497 Pregnancy, Ectopic [Disease/Finding] Pregnancy, Ectopic M0017499 Pregnancy, Ectopic C0032987 C5150 Ectopic Pregnancy A potentially life-threatening condition in which the EMBRYO, MAMMALIAN implants outside the cavity of the UTERUS. Most ectopic pregnancies (>96%) occur in the FALLOPIAN TUBES, known as TUBAL PREGNANCY. They can be in other locations, such as UTERINE CERVIX; OVARY; and abdominal cavity (PREGNANCY, ABDOMINAL). 1021784 N0000002486 34801009 D011271 Proctitis [Disease/Finding] Proctitis C0033246 M0017632 C5164 INFLAMMATION of the MUCOUS MEMBRANE of the RECTUM, the distal end of the large intestine (INTESTINE, LARGE). N0000002493 3951002 D011349 1023205 Proctitis Prostatic Diseases [Disease/Finding] M0017828 Pathological processes involving the PROSTATE or its component tissues. C5174 Prostatic Diseases N0000002498 30281009 D011469 Prostatic Diseases 1022359 C0033575 Prostatic Hyperplasia [Disease/Finding] C5176 N0000002499 367483003 D011470 M0017830 197958000 Prostatic Hyperplasia Prostatic Hyperplasia 1103694 Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both. C2937421 Prostatic Neoplasms [Disease/Finding] C0033578 Tumors or cancer of the PROSTATE. C5178 Neoplasms, Prostatic Prostatic Neoplasms 126906006 Prostate Neoplasms Neoplasms, Prostate 1022598 M0017833 Prostatic Neoplasms N0000002500 D011471 Prostatitis [Disease/Finding] Prostatitis Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment. 9713002 N0000002501 M0017835 D011472 C5180 C0033581 Prostatitis 984334 Proteus Infections [Disease/Finding] 1024609 Infections with bacteria of the genus PROTEUS. Proteus Infections N0000002507 186437007 M0017900 C0033700 D011512 Proteus Infections Infections, Proteus C5192 Protozoan Infections [Disease/Finding] Infections with unicellular organisms formerly members of the subkingdom Protozoa. M0017926 C0033740 N0000002508 1021795 D011528 Protozoan Infections 95896000 Infections, Protozoan C5194 Protozoan Infections Pruritus [Disease/Finding] C5202 1023996 M0017935 Pruritis An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief. Itching Pruritus Pruritus N0000002512 C0033774 279333002 D011537 Pruritus Ani [Disease/Finding] Intense chronic itching in the anal area. D011538 Pruritus Ani Pruritus Ani N0000002513 C5204 M0017936 90446007 C0033775 1022806 Pseudomonas Infections [Disease/Finding] Infections, Pseudomonas 63398001 N0000002519 C0033817 1028699 Pseudomonas Infections C5216 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. D011552 M0017955 Psoriasis [Disease/Finding] M0017975 C0033860 N0000002526 A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis. C5230 9014002 Psoriasis Psoriasis D011565 200961000 1022582 Psychomotor Agitation [Disease/Finding] D011595 A feeling of restlessness associated with increased motor activity. This may occur as a manifestation of nervous system drug toxicity or other conditions. 1024246 Restlessness Agitation, Psychomotor 24199005 47295007 C5232 M0018023 Psychomotor Agitation 162221009 N0000002527 Psychomotor Hyperactivity C0085631 Psychomotor Agitation Excitement, Psychomotor Psychomotor Restlessness Psychomotor Disorders [Disease/Finding] C5234 D011596 Abnormalities of motor function that are associated with organic and non-organic cognitive disorders. Psychomotor Disorders Psychomotor Disorders M0018026 986879 N0000002528 C0033922 Psychotic Disorders [Disease/Finding] Psychotic Disorders Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994) C0033975 69322001 D011618 M0018060 C5242 Psychotic Disorders Psychoses 1023496 N0000002532 Puberty, Precocious [Disease/Finding] D011629 M0018083 C5248 Precocious Puberty 1023098 N0000002535 Development of SEXUAL MATURATION in boys and girls at a chronological age that is 2.5 standard deviations below the mean age at onset of PUBERTY in the population. This early maturation of the hypothalamic-pituitary-gonadal axis results in sexual precocity, elevated serum levels of GONADOTROPINS and GONADAL STEROID HORMONES such as ESTRADIOL and TESTOSTERONE. C0034013 Puberty, Precocious Puberty, Precocious 400179000 123527003 Pulmonary Edema [Disease/Finding] Excessive accumulation of extravascular fluid in the lung, an indication of a serious underlying disease or disorder. Pulmonary edema prevents efficient PULMONARY GAS EXCHANGE in the PULMONARY ALVEOLI, and can be life-threatening. 1024136 19242006 C5258 M0018125 N0000002540 Pulmonary Edemas Pulmonary Edema Pulmonary Edema Edema, Pulmonary C0034063 Wet Lung Edemas, Pulmonary D011654 Purine-Pyrimidine Metabolism, Inborn Errors [Disease/Finding] 1028018 Purine Pyrimidine Metabolism, Inborn Errors D011686 C0034139 238006008 N0000002552 Purine-Pyrimidine Metabolism, Inborn Errors M0018168 C5282 Purine-Pyrimidine Metabolism, Inborn Errors Pyelitis [Disease/Finding] 27174002 M0018193 N0000002558 197780007 1022138 Inflammation of the KIDNEY PELVIS and KIDNEY CALICES where urine is collected before discharge, but does not involve the renal parenchyma (the NEPHRONS) where urine is processed. D011702 Pyelitis C5294 C0034183 Pyelitis Pyelonephritis [Disease/Finding] 197779009 C0034186 N0000002559 Pyelonephritis Pyelonephritis C5296 M0018195 D011704 45816000 1022761 Inflammation of the KIDNEY involving the renal parenchyma (the NEPHRONS); KIDNEY PELVIS; and KIDNEY CALICES. It is characterized by ABDOMINAL PAIN; FEVER; NAUSEA; VOMITING; and occasionally DIARRHEA. Rectal Diseases [Disease/Finding] Pathological developments in the RECTUM region of the large intestine (INTESTINE, LARGE). D012002 1024401 C0034882 5964004 M0018654 C5334 N0000002578 Rectal Diseases Rectal Diseases Rectal Neoplasms [Disease/Finding] D012004 C0034885 990333 Tumors or cancer of the RECTUM. M0018657 Neoplasms, Rectal Rectum Neoplasms C5338 Rectal Neoplasms Rectal Neoplasms N0000002580 126847008 Respiration Disorders [Disease/Finding] C0035204 M0018879 D012120 50043002 Respiration Disorders C5368 N0000002595 1022107 Diseases of the respiratory system in general or unspecified or for a specific respiratory disease not available. Respiration Disorders Respiratory Distress Syndrome, Adult [Disease/Finding] Adult Respiratory Distress Syndrome Shock Lung Respiratory Distress Syndrome, Adult 95437004 D012128 990085 67782005 Acute Respiratory Distress Syndrome Respiratory Distress Syndrome, Acute C0035222 Respiratory Distress Syndrome, Adult M0018891 N0000002597 C5372 ARDS, Human A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA. Respiratory Hypersensitivity [Disease/Finding] N0000002598 M0018896 Respiratory Hypersensitivity Hypersensitivity, Respiratory C5374 C0035228 A form of hypersensitivity affecting the respiratory tract. It includes ASTHMA and RHINITIS, ALLERGIC, SEASONAL. 1025923 D012130 Respiratory Hypersensitivity Respiratory Insufficiency [Disease/Finding] M0018897 409623005 N0000002599 D012131 C5376 Failure to adequately provide oxygen to cells of the body and to remove excess carbon dioxide from them. (Stedman, 25th ed) Respiratory Insufficiency 1023246 C0035229 Respiratory Insufficiency Respiratory Tract Diseases [Disease/Finding] C5382 N0000002602 M0018918 C0035242 Respiratory Tract Diseases Respiratory Tract Diseases D012140 1024163 Respiratory Tract Infections [Disease/Finding] Infections, Respiratory Tract 1025855 275498002 Infections, Respiratory Respiratory Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases. D012141 M0018919 C0035243 N0000002603 Respiratory Tract Infections Respiratory Tract Infections C5384 Respiratory Tract Neoplasms [Disease/Finding] 986366 Respiratory Tract Neoplasms N0000002604 D012142 C0035244 126667002 Respiratory Tract Neoplasms M0018921 C5386 Retinal Degeneration [Disease/Finding] A retrogressive pathological change in the retina, focal or generalized, caused by genetic defects, inflammation, trauma, vascular disease, or aging. Degeneration affecting predominantly the macula lutea of the retina is MACULAR DEGENERATION. (Newell, Ophthalmology: Principles and Concepts, 7th ed, p304) C5392 C0035304 95695004 D012162 1026317 M0018942 Retinal Degeneration N0000002607 Retinal Degeneration Retinal Diseases [Disease/Finding] Retinal Diseases Retinal Diseases N0000002609 399625000 C0035309 C5396 1023467 29555009 D012164 M0018945 Retinitis [Disease/Finding] M0018959 C0035333 C5404 D012173 1026421 Retinitis N0000002613 Inflammation of the RETINA. It is rarely limited to the retina, but is commonly associated with diseases of the choroid (CHORIORETINITIS) and of the OPTIC DISK (neuroretinitis). 399463004 Retinitis Retroviridae Infections [Disease/Finding] D012192 Infections, Retrovirus M0018986 N0000002623 Retroviridae Infections 105635000 1025440 Virus diseases caused by the RETROVIRIDAE. Infections, Retroviridae Retroviridae Infections C5424 Retrovirus Infections C0035369 Rhabdomyosarcoma [Disease/Finding] N0000002628 C0035412 302847003 M0019001 C5434 Rhabdomyosarcoma Rhabdomyosarcoma A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9) D012208 1021776 Rheumatic Fever [Disease/Finding] D012213 Polyarthritis Rheumatica N0000002629 C5436 1023414 Rheumatic Arthritis A febrile disease occurring as a delayed sequela of infections with STREPTOCOCCUS PYOGENES. It is characterized by multiple focal inflammatory lesions of the connective tissue structures, such as the heart, blood vessels, and joints (POLYARTHRITIS) and brain, and by the presence of ASCHOFF BODIES in the myocardium and skin. 58718002 Acute Rheumatic Fever Arthritis, Rheumatic, Acute 81077008 Arthritis, Acute Rheumatic Rheumatic Fever C0035436 Rheumatism, Acute Articular M0019009 Rheumatic Fever Inflammatory Rheumatism Rheumatism, Articular, Acute Rheumatic Diseases [Disease/Finding] 1022758 Rheumatic Diseases C0035435 D012216 203100003 N0000002632 Disorders of connective tissue, especially the joints and related structures, characterized by inflammation, degeneration, or metabolic derangement. Rheumatic Diseases Rheumatism C5442 396332003 M0019014 Rhinitis [Disease/Finding] Nasal Catarrh M0019019 N0000002634 Rhinitis Rhinitis Inflammation of the NASAL MUCOSA, the mucous membrane lining the NASAL CAVITIES. 70076002 C5446 1023076 D012220 C0035455 Rhinitis, Allergic, Perennial [Disease/Finding] C0035457 D012221 N0000002635 Rhinitis, Allergic, Perennial Inflammation of the mucous membrane of the nose similar to that found in hay fever except that symptoms persist throughout the year. The causes are usually air-borne allergens, particularly dusts, feathers, molds, animal fur, etc. C5448 1025485 38103000 M0019020 Rhinitis, Allergic, Nonseasonal Rhinitis, Allergic, Perennial RNA Virus Infections [Disease/Finding] M0019160 RNA Virus Infections D012327 Infections, RNA Virus 1027571 RNA Virus Infections C5478 N0000002650 C0035690 Rosacea [Disease/Finding] C5484 398909004 Acne Rosacea C0035854 D012393 1024747 N0000002653 M0019267 Rosacea Rosacea A cutaneous disorder primarily of convexities of the central part of the FACE, such as FOREHEAD; CHEEK; NOSE; and CHIN. It is characterized by FLUSHING; ERYTHEMA; EDEMA; RHINOPHYMA; papules; and ocular symptoms. It may occur at any age but typically after age 30. There are various subtypes of rosacea: erythematotelangiectatic, papulopustular, phymatous, and ocular (National Rosacea Society's Expert Committee on the Classification and Staging of Rosacea, J Am Acad Dermatol 2002; 46:584-7). Salivary Gland Diseases [Disease/Finding] C0036093 M0019375 N0000002662 10890000 C5502 987342 Salivary Gland Diseases Salivary Gland Diseases D012466 Salmonella Infections [Disease/Finding] M0019393 Infections with bacteria of the genus SALMONELLA. Salmonellosis Salmonella Infections 90974009 302231008 Infections, Salmonella C0036117 D012480 Salmonella Infections C5510 1025316 N0000002666 Sarcoma [Disease/Finding] C5520 A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant. D012509 Sarcoma, Soft Tissue 269469005 1021824 Sarcoma Sarcoma C1261473 M0019428 N0000002671 Sarcoma, Ewing's [Disease/Finding] C0553580 76909002 M0019433 N0000002674 Sarcoma, Ewing's Sarcoma, Ewing's Ewing's Tumor C5526 D012512 1023147 A malignant tumor of the bone which always arises in the medullary tissue, occurring more often in cylindrical bones. There are conspicuous foci of necrosis in association with irregular masses of small, regular, rounded or ovoid cells with very scanty cytoplasm. The tumor occurs usually before the age of 20, about twice as frequently in males as in females. (From Dorland, 27th ed; Stedman, 25th ed) Sarcoma, Kaposi [Disease/Finding] D012514 Kaposi's Sarcoma 1027423 109385007 Sarcoma, Kaposi A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause. C0036220 N0000002676 Kaposi Sarcoma C5530 Sarcoma, Kaposi M0019437 Osteosarcoma [Disease/Finding] N0000002678 1022808 M0019439 Sarcoma, Osteogenic Osteosarcoma Osteosarcoma 21708004 A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed) C5534 Osteosarcoma Tumor C0029463 D012516 Scalp Dermatoses [Disease/Finding] Scalp Dermatoses 1028528 402694007 Scalp Dermatoses D012536 M0019465 C0036271 Scalp Dermatosis N0000002682 C5542 Schizophrenia [Disease/Finding] N0000002690 C5558 58214004 191526005 M0019489 191528006 Schizophrenia Dementia Praecox Schizophrenia D012559 C0036341 Schizophrenic Disorders A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. 1022169 Seizures [Disease/Finding] Seizures C0036572 Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or "seizure disorder." M0019597 D012640 1023130 91175000 C5604 N0000002713 Septicemia [Disease/Finding] D018805 C5610 Systemic disease associated with the presence of pathogenic microorganisms or their toxins in the blood. Poisoning, Blood 105592009 1024926 Septicemia Blood Poisoning M0019666 N0000002716 Septicemia C0036690 Disorders of Sex Development [Disease/Finding] 39179006 In gonochoristic organisms, congenital conditions in which development of chromosomal, gonadal, or anatomical sex is atypical. Effects from exposure to abnormal levels of GONADAL HORMONES in the maternal environment, or disruption of the function of those hormones by ENDOCRINE DISRUPTORS are included. Sex Development Disorders Disorders of Sexual Development Disorders of Sex Development C0036875 Sexual Development Disorders D012734 N0000002722 M0019735 C5622 1027351 Disorders of Sex Development Sexually Transmitted Diseases [Disease/Finding] C5626 Sexually Transmitted Diseases Sexually Transmitted Diseases M0019758 Diseases due to or propagated by sexual contact. Venereal Diseases C0036916 STDs D012749 N0000002724 8098009 1023328 Sezary Syndrome [Disease/Finding] Sezary's Lymphoma N0000002725 A form of cutaneous T-cell lymphoma manifested by generalized exfoliative ERYTHRODERMA; PRURITUS; peripheral lymphadenopathy, and abnormal hyperchromatic mononuclear (cerebriform) cells in the skin, LYMPH NODES, and peripheral blood (Sezary cells). Sezary Syndrome 188629004 C0036920 D012751 Sezary Syndrome C5628 118611004 Erythroderma, Sezary M0019760 1022616 Shock [Disease/Finding] Circulatory Failure Shock C5634 D012769 Shock M0019782 C0036974 N0000002728 274729009 1023333 27942005 A pathological condition manifested by failure to perfuse or oxygenate vital organs. Circulatory Collapse Shock, Cardiogenic [Disease/Finding] M0019783 C0036980 D012770 C5636 Shock resulting from diminution of cardiac output in heart disease. Shock, Cardiogenic 89138009 1026337 N0000002729 Shock, Cardiogenic Shock, Septic [Disease/Finding] N0000002731 M0019786 C0036983 Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include, but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status. Septic Shock C5640 D012772 Shock, Septic Shock, Septic 1025847 76571007 Sick Sinus Syndrome [Disease/Finding] Sick Sinus Syndrome Sick Sinus Node Syndrome N0000002743 M0019828 A condition caused by dysfunctions related to the SINOATRIAL NODE including impulse generation (CARDIAC SINUS ARREST) and impulse conduction (SINOATRIAL EXIT BLOCK). It is characterized by persistent BRADYCARDIA, chronic ATRIAL FIBRILLATION, and failure to resume sinus rhythm following CARDIOVERSION. This syndrome can be congenital or acquired, particularly after surgical correction for heart defects. 36083008 1025538 D012804 C5664 C0037052 Sick Sinus Syndrome Sigmoid Diseases [Disease/Finding] Sigmoid Diseases Sigmoid Colon Diseases Sigmoid Diseases C0037072 C5670 M0019836 N0000002746 D012810 989225 Pathological processes in the SIGMOID COLON region of the large intestine (INTESTINE, LARGE). Signs and Symptoms [Disease/Finding] 1024593 M0019845 Clinical manifestations that can be either objective when observed by a physician, or subjective when perceived by the patient. Signs and Symptoms N0000002748 D012816 C0037088 Signs and Symptoms C5674 Signs and Symptoms, Digestive [Disease/Finding] Signs and Symptoms, Digestive Signs and Symptoms, Digestive D012817 Digestive system manifestations of diseases of the gastrointestinal system or of other organs. N0000002749 1029901 C5676 M0019846 C0037089 Sinusitis [Disease/Finding] Inflammation of the NASAL MUCOSA in one or more of the PARANASAL SINUSES. 1021979 C5690 Sinusitis Sinusitis C0037199 M0019901 36971009 D012852 N0000002756 Skin Abnormalities [Disease/Finding] 268292002 C0037268 M0019926 D012868 199879009 1023316 N0000002759 Congenital structural abnormalities of the skin. Skin Abnormalities 38164009 Skin Abnormalities C5696 Abnormalities, Skin Skin Diseases [Disease/Finding] Skin Diseases M0019929 D012871 Skin Diseases 1022858 N0000002761 Dermatosis C5700 C0037274 95320005 Dermatoses Skin Diseases, Vesiculobullous [Disease/Finding] 1027633 Skin diseases characterized by local or general distributions of blisters. They are classified according to the site and mode of blister formation. Lesions can appear spontaneously or be precipitated by infection, trauma, or sunlight. Etiologies include immunologic and genetic factors. (From Scientific American Medicine, 1990) Vesiculobullous Dermatoses Vesiculobullous Skin Diseases C0037275 Skin Diseases, Vesiculobullous M0019930 N0000002762 D012872 Skin Diseases, Vesiculobullous C5702 Skin Diseases, Genetic [Disease/Finding] C5704 N0000002763 Skin Diseases, Genetic Skin Diseases, Genetic M0019934 Genetic Skin Diseases C0037277 Diseases of the skin with a genetic component, usually the result of various inborn errors of metabolism. D012873 986094 239001006 Skin Diseases, Infectious [Disease/Finding] N0000002764 Infectious Skin Diseases C5706 108365000 Skin Diseases, Infectious C0037278 M0019935 D012874 1025346 Skin diseases caused by bacteria, fungi, parasites, or viruses. Skin Diseases, Infectious Skin Diseases, Metabolic [Disease/Finding] C0037279 M0019936 C5708 N0000002765 Diseases of the skin associated with underlying metabolic disorders. D012875 Metabolic Skin Diseases 1027237 Skin Diseases, Metabolic Skin Diseases, Metabolic Skin Diseases, Parasitic [Disease/Finding] M0019937 Skin Diseases, Parasitic D012876 1023415 Skin Diseases, Parasitic C0037280 Parasitic Skin Diseases Skin diseases caused by ARTHROPODS; HELMINTHS; or other parasites. N0000002766 128938009 C5710 33042004 Skin Manifestations [Disease/Finding] D012877 C5712 990515 Skin Manifestations Dermatologic disorders attendant upon non-dermatologic disease or injury. C0037285 M0019938 Skin Manifestations N0000002767 Skin Neoplasms [Disease/Finding] C5714 C0037286 Tumors or cancer of the SKIN. Skin Neoplasms Neoplasms, Skin 1025991 126488004 M0019939 D012878 N0000002768 Skin Neoplasms Skin Ulcer [Disease/Finding] 46742003 N0000002769 M0019944 Skin Ulcer Skin Ulcer C5716 C0037299 D012883 1023651 247454005 Sleep Disorders [Disease/Finding] C5726 Conditions characterized by disturbances of usual sleep patterns or behaviors. Sleep disorders may be divided into three major categories: DYSSOMNIAS (i.e. disorders characterized by insomnia or hypersomnia), PARASOMNIAS (abnormal sleep behaviors), and sleep disorders secondary to medical or psychiatric disorders. (From Thorpy, Sleep Disorders Medicine, 1994, p187) N0000002774 39898005 C0851578 M0019966 D012893 Sleep Disorders Sleep Disorders 1022589 Slow Virus Diseases [Disease/Finding] Diseases of viral origin, characterized by incubation periods of months to years, insidious onset of clinical manifestations, and protracted clinical course. Though the disease process is protracted, viral multiplication may not be unusually slow. Conventional viruses produce slow virus diseases such as SUBACUTE SCLEROSING PANENCEPHALITIS, progressive multifocal leukoencephalopathy (LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL), and AIDS. Diseases produced by unconventional agents were originally considered part of this group. They are now called PRION DISEASES. M0019974 C5728 Slow Virus Diseases Slow Virus Diseases C0037341 N0000002775 D012897 1030191 Soft Tissue Neoplasms [Disease/Finding] 1024360 N0000002780 M0020121 Soft Tissue Neoplasms 387837005 Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc. C5738 D012983 C0037579 Soft Tissue Neoplasms Spasm [Disease/Finding] 988397 C5748 An involuntary contraction of a muscle or group of muscles. Spasms may involve SKELETAL MUSCLE or SMOOTH MUSCLE. 45352006 N0000002785 Muscle Spasm Spasm M0020203 C0037763 D013035 Muscular Spasm Spasm Spasms, Infantile [Disease/Finding] Infantile Spasms An epileptic syndrome characterized by the triad of infantile spasms, hypsarrhythmia, and arrest of psychomotor development at seizure onset. The majority present between 3-12 months of age, with spasms consisting of combinations of brief flexor or extensor movements of the head, trunk, and limbs. The condition is divided into two forms: cryptogenic (idiopathic) and symptomatic (secondary to a known disease process such as intrauterine infections; nervous system abnormalities; BRAIN DISEASES, METABOLIC, INBORN; prematurity; perinatal asphyxia; TUBEROUS SCLEROSIS; etc.). (From Menkes, Textbook of Child Neurology, 5th ed, pp744-8) West Syndrome M0020204 Spasms, Infantile 1024258 N0000002786 Lightning Attacks C0037769 D013036 C5750 28055006 Spasms, Infantile Spinal Diseases [Disease/Finding] M0020315 267968002 240210004 302934007 1024732 Spinal Diseases N0000002797 D013122 C0037933 Spinal Diseases C5772 Spirochaetales Infections [Disease/Finding] M0020349 Infections with bacteria of the order SPIROCHAETALES. 41116009 Spirochaetales Infections C5784 Spirochaetales Infections Spirochete Infections C0037974 Infections, Spirochete D013145 Infections, Spirochaetales N0000002803 1022229 Spondylitis [Disease/Finding] C0038012 84172003 202649003 D013166 Inflammation of the SPINE. This includes both arthritic and non-arthritic conditions. Spondylitis 1024598 M0020376 C5796 399096009 N0000002809 Spondylitis Sporotrichosis [Disease/Finding] 1025783 Sporotrichosis Sporotrichosis The commonest and least serious of the deep mycoses, characterized by nodular lesions of the cutaneous and subcutaneous tissues. It is caused by inhalation of contaminated dust or by infection of a wound. M0020384 C0038034 42094007 C5804 D013174 N0000002813 Staphylococcal Infections [Disease/Finding] D013203 Infections, Staphylococcal N0000002817 56038003 Staphylococcal Infections 1023915 C0038160 Staphylococcal Infections M0020423 Infections with bacteria of the genus STAPHYLOCOCCUS. C5812 Status Asthmaticus [Disease/Finding] 57546000 Asthmatic Shock N0000002821 1023330 C5820 C0038218 D013224 M0020462 Status Asthmaticus Status Asthmaticus Asthmatic Crisis A sudden intense and continuous aggravation of a state of asthma, marked by dyspnea to the point of exhaustion and collapse and not responding to the usual therapeutic efforts. Status Epilepticus [Disease/Finding] C0038220 N0000002822 A prolonged seizure or seizures repeated frequently enough to prevent recovery between episodes occurring over a period of 20-30 minutes. The most common subtype is generalized tonic-clonic status epilepticus, a potentially fatal condition associated with neuronal injury and respiratory and metabolic dysfunction. Nonconvulsive forms include petit mal status and complex partial status, which may manifest as behavioral disturbances. Simple partial status epilepticus consists of persistent motor, sensory, or autonomic seizures that do not impair cognition (see also EPILEPSIA PARTIALIS CONTINUA). Subclinical status epilepticus generally refers to seizures occurring in an unresponsive or comatose individual in the absence of overt signs of seizure activity. (From N Engl J Med 1998 Apr 2;338(14):970-6; Neurologia 1997 Dec;12 Suppl 6:25-30) Status Epilepticus, Generalized D013226 Status Epilepticus M0020463 1027856 C5822 Status Epilepticus 230456007 Stomach Diseases [Disease/Finding] 988579 Pathological processes involving the STOMACH. Gastric Diseases D013272 N0000002826 C0038354 C5830 29384001 Stomach Diseases Stomach Diseases M0020542 Stomach Neoplasms [Disease/Finding] Neoplasms, Gastric N0000002828 126824007 Gastric Neoplasms Stomach Neoplasms Stomach Neoplasms Neoplasms, Stomach M0020544 1022499 D013274 Tumors or cancer of the STOMACH. C5834 C0038356 Stomach Ulcer [Disease/Finding] Stomach Ulcer Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS). 397825006 196642007 Gastric Ulcer C5838 M0020546 C0038358 Stomach Ulcer N0000002830 D013276 1023584 Stomatitis [Disease/Finding] D013280 1025502 N0000002832 C0038362 Stomatitis C5842 61170000 INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP. Stomatitis M0020550 Stomatitis, Aphthous [Disease/Finding] N0000002833 C0038363 D013281 321258009 Ulcer, Aphthous A recurrent disease of the oral mucosa of unknown etiology. It is characterized by small white ulcerative lesions, single or multiple, round or oval. Two to eight crops of lesions occur per year, lasting for 7 to 14 days and then heal without scarring. (From Jablonski's Dictionary of Dentistry, 1992, p742) 1023942 M0020551 Stomatitis, Aphthous Stomatitis, Aphthous C5844 Canker Sore Aphthae Streptococcal Infections [Disease/Finding] D013290 C0038395 85769006 M0020568 N0000002837 C5852 Infections with bacteria of the genus STREPTOCOCCUS. Infections, Streptococcal 1022383 Streptococcal Infections Streptococcal Infections Stress Disorders, Post-Traumatic [Disease/Finding] D013313 C0038436 PTSD N0000002839 Stress Disorder, Post Traumatic Post-Traumatic Stress Disorders Stress Disorders, Post-Traumatic Posttraumatic Stress Disorders Stress Disorders, Posttraumatic M0020602 1022702 A class of traumatic stress disorders with symptoms that last more than one month. There are various forms of post-traumatic stress disorder, depending on the time of onset and the duration of these stress symptoms. In the acute form, the duration of the symptoms is between 1 to 3 months. In the chronic form, symptoms last more than 3 months. With delayed onset, symptoms develop more than 6 months after the traumatic event. 47505003 Stress Disorders, Post-Traumatic C5856 Neuroses, Post-Traumatic Neuroses, Posttraumatic Substance Withdrawal Syndrome [Disease/Finding] N0000002855 C0038587 D013375 Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug. Substance Withdrawal Syndrome 1027256 C5888 Substance Withdrawal Syndrome M0020676 Suppuration [Disease/Finding] A pathologic process consisting in the formation of pus. C0038862 1028480 Suppuration Suppuration C5902 M0020847 255320000 N0000002862 D013492 Surgical Wound Infection [Disease/Finding] 58126003 C5908 N0000002865 D013530 Postoperative Wound Infection M0020904 1026690 C0038941 Infection, Surgical Wound Wound Infection, Postoperative Surgical Wound Infection Surgical Wound Infection Wound Infection, Surgical Infection, Postoperative Wound Infection occurring at the site of a surgical incision. 213285008 Pathological Conditions, Signs and Symptoms [Disease/Finding] 984268 M0020949 N0000002872 C5922 Pathological Conditions, Signs and Symptoms D013568 Symptoms and General Pathology Abnormal anatomical or physiological conditions and objective or subjective manifestations of disease, not classified as disease or syndrome. C0039058 Pathological Conditions, Signs and Symptoms Syncope [Disease/Finding] Fainting C0039070 Syncope 309585006 A transient loss of consciousness and postural tone caused by diminished blood flow to the brain (i.e., BRAIN ISCHEMIA). Presyncope refers to the sensation of lightheadedness and loss of strength that precedes a syncopal event or accompanies an incomplete syncope. (From Adams et al., Principles of Neurology, 6th ed, pp367-9) 271594007 C5924 D013575 Syncope N0000002873 272030005 1023272 M0020955 Syphilis [Disease/Finding] 76272004 A contagious venereal disease caused by the spirochete TREPONEMA PALLIDUM. D013587 C0039128 C5940 Great Pox N0000002881 M0020966 Syphilis Syphilis 1023903 Tachycardia [Disease/Finding] Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia. 86651002 Tachycardia N0000002888 Tachycardia 1023558 3424008 D013610 C5954 C0039231 M0020996 Tachycardia, Supraventricular [Disease/Finding] C0039240 6456007 D013617 Tachycardia, Supraventricular Tachycardia, Supraventricular 1022287 M0021006 A generic expression for any tachycardia that originates above the BUNDLE OF HIS. C5968 N0000002895 Testicular Diseases [Disease/Finding] N0000002912 D013733 Testicular Diseases Testicular Diseases C0039584 M0021188 1024150 C6002 64910008 Pathological processes of the TESTIS. Testicular Neoplasms [Disease/Finding] Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms. M0021192 126900000 Neoplasms, Testis Testicular Neoplasms C0039590 Testis Neoplasms Neoplasms, Testicular C6006 D013736 1026876 N0000002914 Testicular Neoplasms Tetanus [Disease/Finding] 276202003 M0021200 76902006 D013742 C0039614 A disease caused by tetanospasmin, a powerful protein toxin produced by CLOSTRIDIUM TETANI. Tetanus usually occurs after an acute injury, such as a puncture wound or laceration. Generalized tetanus, the most common form, is characterized by tetanic muscular contractions and hyperreflexia. Localized tetanus presents itself as a mild condition with manifestations restricted to muscles near the wound. It may progress to the generalized form. 1022251 C6008 Tetanus N0000002915 Tetanus Thoracic Neoplasms [Disease/Finding] D013899 Thoracic Neoplasms Thoracic Neoplasms N0000002927 C0039981 255058005 1029082 C6032 M0021397 Thrombocythemia, Essential [Disease/Finding] Thrombocythemia, Idiopathic Hemorrhagic Thrombocythemia Thrombocythemia, Essential Thrombocythemia, Essential 1022170 C6040 109994006 Thrombocythemia, Primary A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets. M0021427 D013920 Thrombocythemia, Hemorrhagic C0040028 N0000002931 Thrombocytopenia [Disease/Finding] A subnormal level of BLOOD PLATELETS. C6042 Thrombopenia C0040034 M0021428 N0000002932 Thrombocytopenia Thrombocytopenia D013921 302215000 1024914 Thrombocytosis [Disease/Finding] 1022830 Thrombocytosis Thrombocytosis D013922 6631009 C0836924 M0021429 N0000002933 Increased numbers of platelets in the peripheral blood. (Dorland, 27th ed) C6044 Thrombocythemia Thromboembolism [Disease/Finding] 371039008 C0040038 1027317 N0000002934 Thromboembolism Thromboembolism D013923 Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream. M0021430 C6046 Thrombophlebitis [Disease/Finding] N0000002935 Thrombophlebitis Inflammation of a vein associated with a blood clot (THROMBUS). M0021432 D013924 C6048 Thrombophlebitis 64156001 C0040046 1025289 Thrombosis [Disease/Finding] Thrombosis C6050 118927008 Thrombosis C0040053 M0021435 Formation and development of a thrombus or blood clot in the blood vessel. D013927 1022873 N0000002936 Thyroid Crisis [Disease/Finding] Thyroid Crisis N0000002941 C0040127 Thyroid Crisis 1023119 C6060 A dangerous life-threatening hypermetabolic condition characterized by high FEVER and dysfunction of the cardiovascular, the nervous, and the gastrointestinal systems. Crisis, Thyrotoxic D013958 29028009 M0021477 Thyrotoxic Crisis Thyrotoxic Storm Thyroid Storm Thyroid Diseases [Disease/Finding] C6062 Thyroid Diseases D013959 Pathological processes involving the THYROID GLAND. M0021478 C0040128 1024048 N0000002942 Thyroid Diseases 14304000 Thyrotoxicosis [Disease/Finding] M0021495 1023059 D013971 C6074 C0040156 Thyrotoxicosis 286909009 A hypermetabolic syndrome caused by excess THYROID HORMONES which may come from endogenous or exogenous sources. The endogenous source of hormone may be thyroid HYPERPLASIA; THYROID NEOPLASMS; or hormone-producing extrathyroidal tissue. Thyrotoxicosis is characterized by NERVOUSNESS; TACHYCARDIA; FATIGUE; WEIGHT LOSS; heat intolerance; and excessive SWEATING. 90739004 Thyrotoxicosis N0000002948 Tic Disorders [Disease/Finding] 1023189 Disorders characterized by recurrent TICS that may interfere with speech and other activities. Tics are sudden, rapid, nonrhythmic, stereotyped motor movements or vocalizations which may be exacerbated by stress and are generally attenuated during absorbing activities. Tic disorders are distinguished from conditions which feature other types of abnormal movements that may accompany general medical conditions. (From DSM-IV, 1994) C6078 M0021514 C0040188 Tic Disorders 568005 D013981 N0000002950 Tic Disorders Tinea [Disease/Finding] 1025429 47382004 C0040247 Ringworm Tinea D014005 N0000002955 A general term describing various dermatophytoses. Specific types include TINEA CAPITIS (ringworm of the scalp), TINEA FAVOSA (of scalp and skin), TINEA PEDIS (athlete's foot), and tinea unguium (see ONYCHOMYCOSIS, ringworm of the nails). (Dorland, 27th ed) C6088 Tinea M0021562 Onychomycosis [Disease/Finding] Nail Fungus C6096 C0040261 D014009 Onychomycosis Tinea Unguium M0021567 A fungal infection of the nail plate, usually caused by a DERMATOPHYTES; YEASTS; or nondermatophyte MOLDS. 402134005 414941008 N0000002959 1022836 Onychomycosis Tobacco Use Disorder [Disease/Finding] Tobacco-Use Disorder M0021604 C0040336 N0000002962 D014029 1025347 Tobacco used to the detriment of a person's health or social functioning. Tobacco dependence is included. Tobacco Use Disorder Tobacco Use Disorder C6102 Toxoplasmosis [Disease/Finding] M0021732 C0040558 1022005 Toxoplasmosis Infection, Toxoplasma gondii The acquired form of infection by Toxoplasma gondii in animals and man. D014123 187192000 N0000002989 C6156 Toxoplasmosis Toxoplasma gondii Infection Treponemal Infections [Disease/Finding] C6192 D014211 76272004 N0000003007 1025333 C0040843 Treponemal Infections Treponemal Infections M0021878 Infections, Treponemal Infections with bacteria of the genus TREPONEMA. Trichomonas Infections [Disease/Finding] 1024821 C6196 Infections in birds and mammals produced by various species of Trichomonas. Infections, Trichomonas 56335008 Trichomonas Infections Trichomonas Infections C0040921 105648001 N0000003009 M0021928 D014245 Trichomonas Vaginitis [Disease/Finding] 1026784 276877003 C6198 500000 D014247 Inflammation of the vagina, marked by a purulent discharge. This disease is caused by the protozoan TRICHOMONAS VAGINALIS. Trichomonas Vaginitis C0040923 M0021930 N0000003010 Trichomonas Vaginitis 81598001 Trigeminal Neuralgia [Disease/Finding] Epileptiform Neuralgia Trigeminal Neuralgia 31681005 D014277 Trigeminal Neuralgia A syndrome characterized by recurrent episodes of excruciating pain lasting several seconds or longer in the sensory distribution of the trigeminal nerve. Pain may be initiated by stimulation of trigger points on the face, lips, or gums or by movement of facial muscles or chewing. Associated conditions include MULTIPLE SCLEROSIS, vascular anomalies, ANEURYSMS, and neoplasms. (Adams et al., Principles of Neurology, 6th ed, p187) C0040997 N0000003018 1024205 Tic Douloureux C6214 M0021966 Fothergill Disease Trifacial Neuralgia Trophoblastic Neoplasms [Disease/Finding] Trophoblast Neoplasms Trophoblastic growth, which may be gestational or nongestational in origin. Trophoblastic neoplasia resulting from pregnancy is often described as gestational trophoblastic disease to distinguish it from germ cell tumors which frequently show trophoblastic elements, and from the trophoblastic differentiation which sometimes occurs in a wide variety of epithelial cancers. Gestational trophoblastic growth has several forms, including HYDATIDIFORM MOLE and CHORIOCARCINOMA. (From Holland et al., Cancer Medicine, 3d ed, p1691) N0000003023 C6224 Trophoblastic Neoplasms 1028174 C0041182 M0022033 Trophoblastic Tumor Trophoblast Tumor Neoplasms, Trophoblastic D014328 Trophoblastic Neoplasms 115234004 Trypanosomiasis [Disease/Finding] M0022072 D014352 Trypanosomiasis Infection with protozoa of the genus TRYPANOSOMA. 1025319 N0000003025 C6228 78940002 C0041227 Trypanosomiasis Tuberculosis [Disease/Finding] Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM. Kochs Disease C6238 Tuberculosis D014376 1023231 56717001 C0041296 Koch's Disease N0000003030 M0022106 Tuberculosis 373576009 Tuberculosis, Cutaneous [Disease/Finding] Tuberculosis, Cutaneous Tuberculosis of the skin. It includes scrofuloderma and tuberculid, but not LUPUS VULGARIS. C0041309 Tuberculosis, Cutaneous N0000003034 C6246 D014382 M0022111 Skin Tuberculosis 66986005 1025807 Tuberculosis, Ocular [Disease/Finding] 1022945 C0041322 Tuberculous infection of the eye, primarily the iris, ciliary body, and choroid. Tuberculosis, Ocular C6266 N0000003044 M0022124 D014392 49107007 Tuberculosis, Ocular Ocular Tuberculosis Tuberculosis, Pulmonary [Disease/Finding] 1025418 154283005 Tuberculosis, Pulmonary C0041327 C6276 N0000003049 Tuberculosis, Pulmonary Tuberculoses, Pulmonary 397190009 Pulmonary Phthisis Pulmonary Tuberculoses D014397 MYCOBACTERIUM infections of the lung. Pulmonary Tuberculosis M0022131 Pulmonary Consumption Tularemia [Disease/Finding] C0041351 D014406 M0022145 Tularemia A plague-like disease of rodents, transmissible to man. It is caused by FRANCISELLA TULARENSIS and is characterized by fever, chills, headache, backache, and weakness. 19265001 N0000003055 C6288 Francisella tularensis Infection Tularemia 1023428 Tumor Virus Infections [Disease/Finding] N0000003056 Tumor Virus Infections C0041374 Infections produced by oncogenic viruses. The infections caused by DNA viruses are less numerous but more diverse than those caused by the RNA oncogenic viruses. Infections, Tumor Virus D014412 M0022156 C6290 988538 Tumor Virus Infections Typhoid Fever [Disease/Finding] D014435 M0022185 C6296 1026044 Enteric Fever 4834000 An acute systemic febrile infection caused by SALMONELLA TYPHI, a serotype of SALMONELLA ENTERICA. Typhus, Abdominal Typhoid N0000003059 Typhoid Fever Typhoid Fever C0041466 Unconsciousness [Disease/Finding] 419045004 D014474 C0041657 M0022251 Unconsciousness 418107008 Unconscious State C6306 Loss of the ability to maintain awareness of self and environment combined with markedly reduced responsiveness to environmental stimuli. (From Adams et al., Principles of Neurology, 6th ed, pp344-5) Consciousness, Loss of Unconsciousness N0000003064 1026031 Ureteral Diseases [Disease/Finding] 988834 N0000003068 C0041954 D014515 Ureteral Diseases C6314 Pathological processes involving the URETERS. M0022325 Ureteral Diseases Ureteral Obstruction [Disease/Finding] C0041956 Blockage in any part of the URETER causing obstruction of urine flow from the kidney to the URINARY BLADDER. The obstruction may be congenital, acquired, unilateral, bilateral, complete, partial, acute, or chronic. Depending on the degree and duration of the obstruction, clinical features vary greatly such as HYDRONEPHROSIS and obstructive nephropathy. C6318 20018005 Ureteral Obstruction D014517 N0000003070 1023031 Ureteral Obstruction M0022327 Urethral Diseases [Disease/Finding] C6322 4985009 M0022332 N0000003072 Urethral Diseases Urethral Diseases Pathological processes involving the URETHRA. C0041969 D014522 1022102 Urethral Obstruction [Disease/Finding] Partial or complete blockage in any part of the URETHRA that can lead to difficulty or inability to empty the URINARY BLADDER. It is characterized by an enlarged, often damaged, bladder with frequent urges to void. C0041972 985086 Urethral Obstruction C6326 95588004 D014524 Urethral Obstruction M0022334 N0000003074 Urinary Tract Infections [Disease/Finding] Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA. C0042029 1022108 68566005 N0000003081 Urinary Tract Infections Urinary Tract Infections D014552 M0022373 C6340 Urination Disorders [Disease/Finding] 1025163 Urination Disorders C0042035 M0022377 N0000003082 Urination Disorders C6342 D014555 Abnormalities in the process of URINE voiding, including bladder control, frequency of URINATION, as well as the volume and composition of URINE. Urogenital Abnormalities [Disease/Finding] C6344 D014564 M0022390 Congenital structural abnormalities of the UROGENITAL SYSTEM in either the male or the female. Genitourinary Abnormalities Urogenital Abnormalities 287085006 N0000003083 C0042063 Urogenital Abnormalities Abnormalities, Urogenital 990562 Urogenital Neoplasms [Disease/Finding] Tumors or cancer of the UROGENITAL SYSTEM in either the male or the female. Urogenital Neoplasms N0000003084 C0042065 1025116 Urogenital Neoplasms Genitourinary Neoplasms D014565 C6346 Genito-urinary Neoplasm Neoplasms, Urogenital Neoplasms, Genitourinary M0022391 Male Urogenital Diseases [Disease/Finding] Male Genitourinary Diseases M0489510 Pathological processes of the male URINARY TRACT and the reproductive system (GENITALIA, MALE). C1720894 1027597 Male Urogenital Diseases D052801 CMSHM0489510 Male Urogenital Diseases N0000003085 Urologic Diseases [Disease/Finding] Urinary Tract Diseases Urological Diseases 128606002 1022769 Urologic Diseases M0022400 Pathological processes of the URINARY TRACT in both males and females. C0042075 197951006 C6350 41368006 N0000003086 D014570 Urologic Diseases Urologic Neoplasms [Disease/Finding] 126879004 Neoplasms, Urologic D014571 Tumors or cancer of the URINARY TRACT in either the male or the female. C6352 C0042076 M0022401 Urologic Neoplasms Urinary Tract Neoplasms 254913005 1023305 N0000003087 Urological Neoplasms Urologic Neoplasms Urticaria [Disease/Finding] Urticaria Urticaria 1023461 N0000003088 D014581 C6354 M0022414 A vascular reaction of the skin characterized by erythema and wheal formation due to localized increase of vascular permeability. The causative mechanism may be allergy, infection, or stress. C0042109 Hives 126485001 Uterine Diseases [Disease/Finding] C0042131 C6358 Pathological processes involving any part of the UTERUS. Uterine Diseases Uterine Diseases N0000003090 D014591 M0022426 12337004 1025904 Uterine Neoplasms [Disease/Finding] Uterine Neoplasms Neoplasms, Uterus Neoplasms, Uterine M0022431 126908007 N0000003093 Uterus Neoplasms 1022983 C6364 Tumors or cancer of the UTERUS. C0042138 D014594 Uterine Neoplasms Uveal Diseases [Disease/Finding] Diseases of the uvea. Uveal Diseases Uveal Diseases M0022443 D014603 1022942 C0042161 95678007 C6372 N0000003097 Uveitis [Disease/Finding] 128473001 N0000003099 M0022445 C0042164 C6376 Inflammation of part or all of the uvea, the middle (vascular) tunic of the eye, and commonly involving the other tunics (sclera and cornea, and the retina). (Dorland, 27th ed) Uveitis Uveitis 1022718 D014605 Uveitis, Anterior [Disease/Finding] 410692006 1028387 Inflammation of the anterior uvea comprising the iris, angle structures, and the ciliary body. Manifestations of this disorder include ciliary injection, exudation into the anterior chamber, iris changes, and adhesions between the iris and lens (posterior synechiae). Intraocular pressure may be increased or reduced. Uveitis, Anterior D014606 N0000003100 M0022446 C0042165 Uveitis, Anterior C6378 Vaginal Diseases [Disease/Finding] Pathological processes of the VAGINA. Vaginal Diseases M0022482 Vaginal Diseases D014623 C0042251 1026314 N0000003104 C6386 25658005 Vaginitis [Disease/Finding] C0042267 1021851 N0000003107 198213001 Vaginitis C6392 Vaginitis M0022488 D014627 Inflammation of the vagina characterized by pain and a purulent discharge. 30800001 Vascular Diseases [Disease/Finding] D014652 Vascular Diseases 27550009 N0000003111 1024109 M0022535 C0042373 Vascular Diseases C6400 Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body. Vasculitis [Disease/Finding] 1026759 C6404 Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body. C0042384 Vasculitis Vasculitis 31996006 N0000003113 Angiitis D014657 M0022540 Ventricular Fibrillation [Disease/Finding] C0042510 1024218 Ventricular Fibrillation N0000003118 C6414 D014693 71908006 Ventricular Fibrillation M0022595 A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST. Virus Diseases [Disease/Finding] C6434 1022696 D014777 M0022758 Virus Diseases 34014006 Viral Diseases C0042769 A general term for diseases produced by viruses. N0000003128 Virus Diseases Vitamin D Deficiency [Disease/Finding] 1024200 A nutritional condition produced by a deficiency of VITAMIN D in the diet, insufficient production of vitamin D in the skin, inadequate absorption of vitamin D from the diet, or abnormal conversion of vitamin D to its bioactive metabolites. It is manifested clinically as RICKETS in children and OSTEOMALACIA in adults. (From Cecil Textbook of Medicine, 19th ed, p1406) C6446 C0042870 M0022798 N0000003134 Vitamin D Deficiency Vitamin D Deficiency D014808 34713006 Deficiency, Vitamin D Vomiting [Disease/Finding] Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH. Vomiting C6460 1025810 C0042963 M0022844 N0000003141 Emesis 15387003 D014839 Vulvar Diseases [Disease/Finding] Vulvar Diseases Vulvar Diseases C6468 C0042994 M0022856 N0000003145 Pathological processes of the VULVA. 5089007 1024723 D014845 Vulvitis [Disease/Finding] M0022858 63144007 N0000003147 C0042996 D014847 Vulvitis Inflammation of the VULVA. It is characterized by PRURITUS and painful urination. 1023099 266586003 Vulvitis C6472 Vulvovaginitis [Disease/Finding] 1025805 Vulvovaginitis D014848 C6474 53277000 198215008 C0042998 N0000003148 Inflammation of the VULVA and the VAGINA, characterized by discharge, burning, and PRURITUS. Vulvovaginitis M0022859 Warts [Disease/Finding] M0022875 1022255 C6482 C0043037 Warts Warts N0000003152 D014860 Verruca 57019003 Benign epidermal proliferations or tumors; some are viral in origin. Water-Electrolyte Imbalance [Disease/Finding] Water-Electrolyte Imbalance C6486 1028873 Disturbances in the body's WATER-ELECTROLYTE BALANCE. D014883 C0043065 Water-Electrolyte Imbalance M0022901 N0000003154 West Nile Fever [Disease/Finding] A mosquito-borne viral illness caused by the WEST NILE VIRUS, a FLAVIVIRUS and endemic to regions of Africa, Asia, and Europe. Common clinical features include HEADACHE; FEVER; maculopapular rash; gastrointestinal symptoms; and lymphadenopathy. MENINGITIS; ENCEPHALITIS; and MYELITIS may also occur. The disease may occasionally be fatal or leave survivors with residual neurologic deficits. (From Joynt, Clinical Neurology, 1996, Ch26, p13; Lancet 1998 Sep 5;352(9130):767-71) C6500 D014901 West Nile Fever C0043124 N0000003161 M0022928 1024531 West Nile Fever Wolff-Parkinson-White Syndrome [Disease/Finding] Auriculoventricular Accessory Pathway Syndrome A form of ventricular pre-excitation characterized by a short PR interval and a long QRS interval with a delta wave. In this syndrome, atrial impulses are abnormally conducted to the HEART VENTRICLES via an ACCESSORY CONDUCTING PATHWAY that is located between the wall of the right or left atria and the ventricles, also known as a BUNDLE OF KENT. The inherited form can be caused by mutation of PRKAG2 gene encoding a gamma-2 regulatory subunit of AMP-activated protein kinase. M0022990 Wolff-Parkinson-White Syndrome D014927 N0000003166 C6510 74390002 False Bundle-Branch Block Syndrome C0043202 Wolf-Parkinson-White Syndrome 1023880 Anomalous Ventricular Excitation Syndrome WPW Syndrome Wolff-Parkinson-White Syndrome Wound Infection [Disease/Finding] C0043241 D014946 M0023017 N0000003168 Invasion of the site of trauma by pathogenic microorganisms. Wound Infection 1024471 C6514 Infection, Wound Wound Infection 76844004 Wounds and Injuries [Disease/Finding] Wounds and Injury Injuries, Wounds 19130008 C6516 N0000003169 Wounds, Injury Trauma D014947 Injuries and Wounds 1022221 C0043251 Wounds and Injuries Wounds and Injuries Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity. M0023019 Xerostomia [Disease/Finding] Asialia 1025018 C0043352 D014987 N0000003179 C6536 56893005 Xerostomia Xerostomia 87715008 Hyposalivation Decreased salivary flow. Mouth Dryness M0023067 Yersinia Infections [Disease/Finding] Infections with bacteria of the genus YERSINIA. Yersinia Infections Yersinia Infections M0023096 D015009 1022068 C6544 N0000003183 Infections, Yersinia 83436008 C0043407 Zollinger-Ellison Syndrome [Disease/Finding] D015043 N0000003185 C6548 Zollinger-Ellison Syndrome C0043515 1025255 A syndrome that is characterized by the triad of severe PEPTIC ULCER, hypersecretion of GASTRIC ACID, and GASTRIN-producing tumors of the PANCREAS or other tissue (GASTRINOMA). This syndrome may be sporadic or be associated with MULTIPLE ENDOCRINE NEOPLASIA TYPE 1. Zollinger-Ellison Syndrome M0023152 53132006 Esophageal Motility Disorders [Disease/Finding] 266434009 M0023297 C6556 D015154 Esophageal Dysmotility N0000003189 1022716 Esophageal Motility Disorders Esophageal Motility Disorders C0014858 Disorders affecting the motor function of the UPPER ESOPHAGEAL SPHINCTER; LOWER ESOPHAGEAL SPHINCTER; the ESOPHAGUS body, or a combination of these parts. The failure of the sphincters to maintain a tonic pressure may result in gastric reflux of food and acid into the esophagus (GASTROESOPHAGEAL REFLUX). Other disorders include hypermotility (spastic disorders) and markedly increased amplitude in contraction (nutcracker esophagus). Supratentorial Neoplasms [Disease/Finding] Supratentorial Tumors C0038874 M0023322 Supratentorial Neoplasms D015173 N0000003195 Supratentorial Neoplasms C6568 Neoplasms, Supratentorial Primary and metastatic (secondary) tumors of the brain located above the tentorium cerebelli, a fold of dura mater separating the CEREBELLUM and BRAIN STEM from the cerebral hemispheres and DIENCEPHALON (i.e., THALAMUS and HYPOTHALAMUS and related structures). In adults, primary neoplasms tend to arise in the supratentorial compartment, whereas in children they occur more frequently in the infratentorial space. Clinical manifestations vary with the location of the lesion, but SEIZURES; APHASIA; HEMIANOPSIA; hemiparesis; and sensory deficits are relatively common features. Metastatic supratentorial neoplasms are frequently multiple at the time of presentation. 1026849 Colorectal Neoplasms [Disease/Finding] C0009404 Colorectal Neoplasms Colorectal Tumors Neoplasms, Colorectal D015179 C6574 1022247 Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. Colorectal Neoplasms M0023329 N0000003198 126837005 Arthritis, Gouty [Disease/Finding] 190828008 201662001 1022914 N0000003204 Arthritis, especially of the great toe, as a result of gout. Acute gouty arthritis often is precipitated by trauma, infection, surgery, etc. The initial attacks are usually monoarticular but later attacks are often polyarticular. Arthritis, Gouty Gouty Arthritis 48440001 D015210 M0023372 C6586 Arthritis, Gouty C0003868 Inflammatory Bowel Diseases [Disease/Finding] 24526004 Bowel Diseases, Inflammatory Inflammatory Bowel Diseases C0021390 M0023374 C6590 Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS. 1023128 Inflammatory Bowel Diseases D015212 N0000003206 Hypertriglyceridemia [Disease/Finding] M0023401 N0000003210 C6598 302870006 C0020557 1026278 D015228 Hypertriglyceridemia A condition of elevated levels of TRIGLYCERIDES in the blood. Hypertriglyceridemia Sexually Transmitted Diseases, Viral [Disease/Finding] Viral Venereal Diseases N0000003211 Viral Sexually Transmitted Disease C0036918 D015229 Sexually Transmitted Diseases, Viral Viral diseases which are transmitted or propagated by sexual conduct. Sexually Transmitted Diseases, Viral 1027279 Sexually Transmitted Disease, Viral Venereal Diseases, Viral C6600 Viral Sexually Transmitted Diseases M0023402 Sexually Transmitted Diseases, Bacterial [Disease/Finding] Venereal Diseases, Bacterial Bacterial Venereal Diseases Bacterial Sexually Transmitted Disease Bacterial Sexually Transmitted Diseases Sexually Transmitted Diseases, Bacterial C0036917 Sexually Transmitted Disease, Bacterial Sexually Transmitted Diseases, Bacterial M0023404 Bacterial diseases transmitted or propagated by sexual conduct. 1027541 D015231 N0000003212 C6602 Leprosy, Lepromatous [Disease/Finding] A chronic communicable infection which is a principal or polar form of LEPROSY. This disorder is caused by MYCOBACTERIUM LEPRAE and produces diffuse granulomatous skin lesions in the form of nodules, macules, or papules. The peripheral nerves are involved symmetrically and neural sequelae occur in the advanced stage. C6662 21560005 D015440 Leprosy, Lepromatous C0023348 N0000003242 Leprosy, Lepromatous M0023793 1022804 Leukemia, B-Cell [Disease/Finding] Lymphocytic Leukemia, B-Cell Leukemia, Lymphocytic, B Cell A malignant disease of the B-LYMPHOCYTES in the bone marrow and/or blood. M0023806 C6670 N0000003246 C2004493 B-Lymphocytic Leukemia Leukemia, B-Cell 988278 D015448 Leukemia, Lymphocytic, B-Cell Leukemia, B-Cell B-Cell Leukemia Leukemia, Lymphocytic, Chronic, B-Cell [Disease/Finding] Lymphoma, Lymphocytic, Well Differentiated Chronic Lymphocytic Leukemia Lymphoma, Lymphoplasmacytoid, CLL Lymphocytic Lymphoma Lymphoma, Small-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease. Small-Cell Lymphoma Leukemia, Lymphocytic, Chronic Lymphocytic Leukemia, Chronic Leukemia, B-Cell, Chronic Lymphocytic Lymphoma, Diffuse, Well Differentiated Leukemia, Lymphocytic, Chronic, B-Cell B-Cell Chronic Lymphocytic Leukemia B-Cell Leukemia, Chronic Lymphoma, Lymphocytic, Well-Differentiated 277473004 B-Lymphocytic Leukemia, Chronic Lymphoplasmacytoid Lymphoma, CLL Lymphoma, Small Lymphocytic, Plasmacytoid C0023434 Lymphocytic Leukemia, Chronic, B Cell Diffuse Well-Differentiated Lymphocytic Lymphoma Lymphocytic Lymphoma, Diffuse, Well-Differentiated Lymphocytic Lymphoma, Well Differentiated Lymphocytic Leukemia, Chronic, B-Cell Lymphoma, Lymphocytic, Diffuse, Well Differentiated Leukemia, Lymphocytic, Chronic, B Cell Lymphoma, Small Lymphocytic Leukemia, Lymphocytic, Chronic, B-Cell Leukemia, Lymphoblastic, Chronic Lymphoblastic Leukemia, Chronic D015451 Lymphocytic Lymphoma, Well-Differentiated Lymphoma, Lymphocytic M0023808 N0000003248 C6674 Leukemia, B Cell, Chronic Lymphoma, Lymphocytic, Diffuse, Well-Differentiated 1021888 Leukemia, Myelogenous, Chronic, BCR-ABL Positive [Disease/Finding] M0023821 Leukemia, Myeloid, Ph1-Positive Myelogenous Leukemia, Ph1-Positive Myelogenous Leukemia, Chronic 92818009 Leukemia, Myelogenous, Chronic Leukemia, Myelogenous, Chronic, BCR-ABL Positive Myelocytic Leukemia, Chronic Myeloid Leukemia, Ph1-Positive Leukemia, Myeloid, Chronic Leukemia, Myeloid, Ph1 Positive D015464 Leukemia, Myeloid, Philadelphia Positive C0023473 N0000003261 Leukemia, Myeloid, Philadelphia-Positive C6700 Leukemia, Myelogenous, Ph1 Positive 1021752 Leukemia, Granulocytic, Chronic Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS. Granulocytic Leukemia, Chronic Leukemia, Myelogenous, Ph1-Positive Leukemia, Myelocytic, Chronic Myeloid Leukemia, Philadelphia-Positive Myeloid Leukemia, Chronic Leukemia, Myeloid, Acute [Disease/Finding] Myelogenous Leukemia, Acute Leukemia, Nonlymphoblastic, Acute N0000003267 Leukemia, Myelogenous, Acute D015470 Nonlymphoblastic Leukemia, Acute Leukemia, Myeloid, Acute Leukemia, Myeloid, Acute Leukemia, Myeloblastic, Acute ANLL 1022145 Myeloid Leukemia, Acute C6712 Myeloblastic Leukemia, Acute Nonlymphocytic Leukemia, Acute M0023827 C0023467 Leukemia, Myelocytic, Acute 17788007 91861009 Myelocytic Leukemia, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES. 413443009 Acute Myeloid Leukemia Leukemia, Nonlymphocytic, Acute Renal Tubular Transport, Inborn Errors [Disease/Finding] C0035091 N0000003278 Kidney Tubular Transport, Inborn Error M0023861 Renal Tubular Transport Errors Kidney Tubular Transport, Inborn Errors Renal Tubular Transport, Inborn Error Renal Tubular Transport, Inborn Errors D015499 Genetic defects in the selective or non-selective transport functions of the KIDNEY TUBULES. C6734 Renal Tubular Transport, Inborn Errors 1026778 Maxillary Sinusitis [Disease/Finding] C6744 1025988 N0000003283 M0023883 D015523 Inflammation of the NASAL MUCOSA in the MAXILLARY SINUS. In many cases, it is caused by an infection of the bacteria HAEMOPHILUS INFLUENZAE; STREPTOCOCCUS PNEUMONIAE; or STAPHYLOCOCCUS AUREUS. Maxillary Sinusitis Maxillary Sinusitis Sinusitis, Maxillary 88348008 C0024959 Arthritis, Psoriatic [Disease/Finding] 1024237 D015535 C6752 A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor. Psoriasis Arthropathica Arthritis, Psoriatic C0003872 M0023901 N0000003287 Arthritis, Psoriatic Psoriasis, Arthritic 33339001 Histiocytosis [Disease/Finding] C6766 N0000003294 1022662 D015614 C0019618 Histiocytosis Histiocytosis General term for the abnormal appearance of histiocytes in the blood. Based on the pathological features of the cells involved rather than on clinical findings, the histiocytic diseases are subdivided into three groups: HISTIOCYTOSIS, LANGERHANS CELL; HISTIOCYTOSIS, NON-LANGERHANS-CELL; and HISTIOCYTIC DISORDERS, MALIGNANT. 190957008 M0023956 HIV Infections [Disease/Finding] N0000003302 C0019693 M0023997 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III-LAV Infections HTLV-III Infections C6782 T-Lymphotropic Virus Type III Infections, Human D015658 86406008 1022756 HIV Infections Fatigue Syndrome, Chronic [Disease/Finding] Postviral Fatigue Syndrome Fatigue Syndrome, Postviral N0000003304 Chronic Fatigue Syndrome 51771007 A syndrome characterized by persistent or recurrent fatigue, diffuse musculoskeletal pain, sleep disturbances, and subjective cognitive impairment of 6 months duration or longer. Symptoms are not caused by ongoing exertion; are not relieved by rest; and result in a substantial reduction of previous levels of occupational, educational, social, or personal activities. Minor alterations of immune, neuroendocrine, and autonomic function may be associated with this syndrome. There is also considerable overlap between this condition and FIBROMYALGIA. (From Semin Neurol 1998;18(2):237-42; Ann Intern Med 1994 Dec 15;121(12): 953-9) D015673 Royal Free Disease Myalgic Encephalomyelitis Infectious Mononucleosis-Like Syndrome, Chronic Chronic Fatigue and Immune Dysfunction Syndrome 52702003 Chronic Fatigue-Fibromyalgia Syndrome 1024042 C6786 Encephalomyelitis, Myalgic C0015674 Chronic Fatigue Disorder Fatigue Syndrome, Chronic M0024027 Fatigue Syndrome, Chronic Abdominal Pain [Disease/Finding] D015746 Abdominal Pain Abdominal Pain Sensation of discomfort, distress, or agony in the abdominal region; generally associated with functional disorders, tissue injuries, or diseases. C6796 N0000003309 1022336 C0000737 21522001 M0024135 Glaucoma, Angle-Closure [Disease/Finding] 392291006 A form of glaucoma in which the intraocular pressure increases because the angle of the anterior chamber is blocked and the aqueous humor cannot drain from the anterior chamber. C0017605 Glaucoma, Narrow-Angle 1022331 C6820 N0000003321 Glaucoma, Closed-Angle Glaucoma, Angle Closure Glaucoma, Angle-Closure Glaucoma, Uncompensative D015812 Glaucoma, Uncompensated Glaucoma, Angle-Closure M0024213 Eye Infections [Disease/Finding] M0024227 D015817 C6824 Infection, moderate to severe, caused by bacteria, fungi, or viruses, which occurs either on the external surface of the eye or intraocularly with probable inflammation, visual impairment, or blindness. Eye Infections Eye Infections 128351009 Ocular Infections N0000003323 1026014 C0015403 Eye Infections, Bacterial [Disease/Finding] Ocular Infections, Bacterial 128984004 N0000003324 Infections, Bacterial Ocular 988235 D015818 M0024228 Bacterial Eye Infections Infections in the inner or external eye caused by microorganisms belonging to several families of bacteria. Some of the more common genera found are Haemophilus, Neisseria, Staphylococcus, Streptococcus, and Chlamydia. Bacterial Ocular Infections Eye Infections, Bacterial Eye Infections, Bacterial C6826 C0015404 Infections, Bacterial Eye Eye Infections, Fungal [Disease/Finding] Mycotic Infections, Ocular Oculomycosis C6830 1023743 Infection by a variety of fungi, usually through four possible mechanisms: superficial infection producing conjunctivitis, keratitis, or lacrimal obstruction; extension of infection from neighboring structures - skin, paranasal sinuses, nasopharynx; direct introduction during surgery or accidental penetrating trauma; or via the blood or lymphatic routes in patients with underlying mycoses. D015821 C0015405 N0000003326 Mycosis, Ocular Eye Infections, Fungal Ocular Infections, Fungal M0024239 Eye Infections, Fungal Fungal Eye Infections 31194008 Eye Infections, Viral [Disease/Finding] N0000003331 1027485 Ocular Infections, Viral Eye Infections, Viral C0015407 Viral Eye Infections C6840 M0024246 Infections of the eye caused by minute intracellular agents. These infections may lead to severe inflammation in various parts of the eye - conjunctiva, iris, eyelids, etc. Several viruses have been identified as the causative agents. Among these are Herpesvirus, Adenovirus, Poxvirus, and Myxovirus. D015828 Eye Infections, Viral 312132001 Panuveitis [Disease/Finding] Inflammation in which both the anterior and posterior segments of the uvea are involved and a specific focus is not apparent. It is often severe and extensive and a serious threat to vision. Causes include systemic diseases such as tuberculosis, sarcoidosis, and syphilis, as well as malignancies. The intermediate segment of the eye is not involved. Panuveitis C0030343 75614007 M0024288 Panuveitis 990541 D015864 C6868 N0000003345 Lentivirus Infections [Disease/Finding] Lentivirus Infections M0024697 Lentivirus Infections Virus diseases caused by the Lentivirus genus. They are multi-organ diseases characterized by long incubation periods and persistent infection. D016180 C0079680 1024090 N0000003384 24907000 C6946 Infections, Lentivirus Lymphoma, B-Cell [Disease/Finding] C0079731 D016393 Lymphoma, B-Cell 109979007 1026747 C6964 M0025074 N0000003393 B-Cell Lymphoma A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes. Lymphoma, B-Cell Lymphoma, T-Cell [Disease/Finding] A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes. C0079772 N0000003398 D016399 Lymphoma, T-Cell 109978004 C6974 M0025079 1023910 T-Cell Lymphoma Lymphoma, T-Cell Lymphoma, T-Cell, Cutaneous [Disease/Finding] C0079773 400122007 N0000003409 M0025093 1025184 A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders. Cutaneous T-Cell Lymphoma Lymphoma, T-Cell, Cutaneous C6996 D016410 T-Cell Lymphoma, Cutaneous Lymphoma, T-Cell, Cutaneous Lymphoma, T Cell, Cutaneous Fungemia [Disease/Finding] Fungemia N0000003415 C7008 C0085082 D016469 M0025155 399314004 The presence of fungi circulating in the blood. Opportunistic fungal sepsis is seen most often in immunosuppressed patients with severe neutropenia or in postoperative patients with intravenous catheters and usually follows prolonged antibiotic therapy. Fungemia 1023738 Helicobacter Infections [Disease/Finding] Infections, Helicobacter C7016 Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease. D016481 Helicobacter Infections Helicobacter Infections M0025165 C0079487 N0000003419 989696 Peripheral Vascular Diseases [Disease/Finding] 400047006 Pathological processes involving any one of the BLOOD VESSELS in the vasculature outside the HEART. D016491 C0085096 N0000003422 M0025176 Vascular Diseases, Peripheral C7022 Peripheral Vascular Diseases 1022504 Peripheral Vascular Diseases Peripheral Angiopathies Diseases, Peripheral Vascular Bronchial Hyperreactivity [Disease/Finding] Tendency of the smooth muscle of the tracheobronchial tree to contract more intensely in response to a given stimulus than it does in the response seen in normal individuals. This condition is present in virtually all symptomatic patients with asthma. The most prominent manifestation of this smooth muscle contraction is a decrease in airway caliber that can be readily measured in the pulmonary function laboratory. 1027389 C7040 195967001 Bronchial Hyperreactivity M0025237 N0000003431 C0085129 Bronchial Hyperreactivity D016535 Central Nervous System Neoplasms [Disease/Finding] 126951006 D016543 M0025244 Central Nervous System Tumors Tumors, Central Nervous System 1025007 Central Nervous System Neoplasms Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges. Neoplasms, Central Nervous System C0085136 N0000003434 C7046 Central Nervous System Neoplasms Panic Disorder [Disease/Finding] C0030319 371631005 A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait. M0025297 C7062 Panic Disorder D016584 N0000003442 Panic Disorder 1022562 Vaginosis, Bacterial [Disease/Finding] Bacterial Vaginosis C0085166 Vaginitis, Bacterial Vaginitis, Nonspecific Bacterial Vaginitides Vaginosis, Bacterial N0000003443 419760006 Vaginosis, Bacterial D016585 Bacterial Vaginoses C7064 Vaginoses, Bacterial Polymicrobial, nonspecific vaginitis associated with positive cultures of Gardnerella vaginalis and other anaerobic organisms and a decrease in lactobacilli. It remains unclear whether the initial pathogenic event is caused by the growth of anaerobes or a primary decrease in lactobacilli. M0025299 Bacterial Vaginitis 1022414 Vaginitides, Bacterial Embolism and Thrombosis [Disease/Finding] A collective term for pathological conditions which are caused by the formation of a blood clot (THROMBUS) in a blood vessel, or by blocking of a blood vessel with an EMBOLUS, undissolved materials in the blood stream. 1031715 C0085307 195440003 D016769 Embolism and Thrombosis N0000003473 Embolism and Thrombosis M0025559 C7124 Malaria, Falciparum [Disease/Finding] M0025570 Plasmodium falciparum Malaria N0000003481 Malaria, Falciparum C7140 C0024535 Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations. 62676009 1023574 Malaria, Falciparum D016778 Malaria, Vivax [Disease/Finding] Malaria caused by PLASMODIUM VIVAX. This form of malaria is less severe than MALARIA, FALCIPARUM, but there is a higher probability for relapses to occur. Febrile paroxysms often occur every other day. C0024537 N0000003483 Malaria, Vivax Plasmodium vivax Malaria C7144 M0025572 D016780 27052006 Malaria, Vivax 1022708 Keratitis, Herpetic [Disease/Finding] C0019357 Keratitis, Herpetic 186542001 M0025643 A superficial, epithelial Herpesvirus hominis infection of the cornea, characterized by the presence of small vesicles which may break down and coalesce to form dendritic ulcers (KERATITIS, DENDRITIC). (Dictionary of Visual Science, 3d ed) Keratitis, Herpetic Ocular Herpes Simplex 9389005 N0000003485 Herpes Simplex Keratitis D016849 C7148 1024044 Herpes Simplex, Ocular Bacillaceae Infections [Disease/Finding] N0000003488 Infections with bacteria of the family BACILLACEAE. 989075 C0085389 C7154 D016863 Bacillaceae Infections Bacillaceae Infections M0025666 Infections, Bacillaceae Bacteroidaceae Infections [Disease/Finding] Infections, Bacteroidaceae Bacteroidaceae Infections 988895 Infections with bacteria of the family BACTEROIDACEAE. D016866 C0085392 C7158 Bacteroidaceae Infections N0000003490 M0025669 Serratia Infections [Disease/Finding] C7160 Serratia Infections M0025671 N0000003491 Infections with bacteria of the genus SERRATIA. D016868 Infections, Serratia 1026441 71120004 Serratia Infections C0085394 Neisseriaceae Infections [Disease/Finding] M0025673 C0085396 C7164 N0000003493 D016870 Neisseriaceae Infections Neisseriaceae Infections 1025935 Infections, Neisseriaceae Infections with bacteria of the family NEISSERIACEAE. Pasteurellaceae Infections [Disease/Finding] Infections with bacteria of the family PASTEURELLACEAE. N0000003494 C0085397 Infections, Pasteurellaceae D016871 C7166 Pasteurellaceae Infections Pasteurellaceae Infections M0025674 985866 Endometrial Neoplasms [Disease/Finding] Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells. Neoplasms, Endometrial C7182 N0000003502 Endometrial Neoplasms 989735 123844007 M0025700 D016889 Endometrial Neoplasms C0014170 Gram-Negative Bacterial Infections [Disease/Finding] Gram-Negative Bacterial Infections Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method. Gram-Negative Bacterial Infections C7190 D016905 N0000003506 C0085423 1023284 M0025725 Bacterial Infections, Gram-Negative Infections, Gram-Negative Bacterial Gram-Positive Bacterial Infections [Disease/Finding] N0000003507 C7192 Bacterial Infections, Gram-Positive Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method. D016908 Infections, Gram-Positive Bacterial 1022700 C0085426 Gram-Positive Bacterial Infections Gram-Positive Bacterial Infections M0025728 Meningitis, Cryptococcal [Disease/Finding] M0025746 C0085436 Meningitis, Cryptococcal C7200 N0000003511 14232007 Meningitis, Cryptococcal Cryptococcal Meningitis Meningeal inflammation produced by CRYPTOCOCCUS NEOFORMANS, an encapsulated yeast that tends to infect individuals with ACQUIRED IMMUNODEFICIENCY SYNDROME and other immunocompromised states. The organism enters the body through the respiratory tract, but symptomatic infections are usually limited to the lungs and nervous system. The organism may also produce parenchymal brain lesions (torulomas). Clinically, the course is subacute and may feature HEADACHE; NAUSEA; PHOTOPHOBIA; focal neurologic deficits; SEIZURES; cranial neuropathies; and HYDROCEPHALUS. (From Adams et al., Principles of Neurology, 6th ed, pp721-2) 1026828 D016919 Meningitis, Fungal [Disease/Finding] Meningitis, Fungal Meningitis, Fungal N0000003513 24321005 Meningitis caused by fungal agents which may occur as OPPORTUNISTIC INFECTIONS or arise in immunocompetent hosts. Fungal Meningitis C0085438 C7204 1022688 D016921 M0025748 AIDS-Related Opportunistic Infections [Disease/Finding] AIDS-Related Opportunistic Infections N0000003524 AIDS-Related Opportunistic Infections HIV-Related Opportunistic Infections C7226 1025910 M0025965 Opportunistic Infections, HIV-Related C0162526 Opportunistic Infections, AIDS-Related D017088 Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus. Colitis, Ischemic [Disease/Finding] 30588004 Colitis, Ischemic Inflammation of the COLON due to colonic ISCHEMIA resulting from alterations in systemic circulation or local vasculature. C0162529 D017091 M0025968 1021896 N0000003525 Ischemic Colitis Colitis, Ischemic C7228 Liver Failure [Disease/Finding] 1021954 C0085605 59927004 Hepatic Failure N0000003527 Liver Failure Liver Failure C7232 D017093 Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed) M0025970 Kidney Failure [Disease/Finding] N0000003529 C0035078 Renal Failure Kidney Failure 42399005 M0025974 266553002 1022860 A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. D051437 Kidney Failure C7236 Low Back Pain [Disease/Finding] Low Back Pain N0000003535 Low Back Ache Low Backache Low Back Pain 279039007 Acute or chronic pain in the lumbar or sacral regions, which may be associated with musculo-ligamentous SPRAINS AND STRAINS; INTERVERTEBRAL DISK DISPLACEMENT; and other conditions. Lower Back Pain C0024031 M0026008 1021791 D017116 Lumbago C7248 Tachycardia, Ventricular [Disease/Finding] D017180 N0000003541 Tachycardia, Ventricular Tachycardia, Ventricular 1023929 C0042514 M0026083 25569003 C7260 Ventricular Tachycardia An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation). Skin Diseases, Bacterial [Disease/Finding] D017192 N0000003546 C7270 M0026097 984383 Skin Diseases, Bacterial Skin Diseases, Bacterial 128936008 C0162627 Skin diseases caused by bacteria. Bacterial Skin Diseases Skin Diseases, Viral [Disease/Finding] Skin Diseases, Viral 1029386 M0026098 Skin diseases caused by viruses. D017193 Skin Diseases, Viral C0162628 C7272 Viral Skin Diseases 128937004 N0000003547 Myocardial Ischemia [Disease/Finding] 1022046 C7278 M0026104 A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION). 414545008 D017202 Myocardial Ischemia N0000003550 C0151744 Heart Disease, Ischemic Ischemic Heart Disease Ischemia, Myocardial Myocardial Ischemia 414795007 Gastric Outlet Obstruction [Disease/Finding] Gastric Outlet Obstruction M0026129 C7288 1025976 D017219 The hindering of output from the STOMACH into the SMALL INTESTINE. This obstruction may be of mechanical or functional origin such as EDEMA from PEPTIC ULCER; NEOPLASMS; FOREIGN BODIES; or AGING. N0000003555 244815007 C0162651 Gastric Outlet Obstruction Tick-Borne Diseases [Disease/Finding] Tick-Borne Diseases 414018003 N0000003567 1025615 Tick-Borne Diseases Bacterial, viral, or parasitic diseases transmitted to humans and animals by the bite of infected ticks. The families Ixodidae and Argasidae contain many bloodsucking species that are important pests of man and domestic birds and mammals and probably exceed all other arthropods in the number and variety of disease agents they transmit. Many of the tick-borne diseases are zoonotic. C0162700 M0026236 C7312 D017282 Hypertrophy, Left Ventricular [Disease/Finding] Left Ventricular Hypertrophy Hypertrophy, Left Ventricular Hypertrophy, Left Ventricular Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality. 55827005 M0026394 N0000003570 C7318 D017379 1023472 C0149721 Ventricular Hypertrophy, Left Skin and Connective Tissue Diseases [Disease/Finding] C0175166 M0026454 N0000003573 C7324 A collective term for diseases of the skin and its appendages and of connective tissue. 1027511 D017437 Skin and Connective Tissue Diseases Skin and Connective Tissue Diseases Skin Diseases, Eczematous [Disease/Finding] D017443 Eczematous Disorders Any of a variety of eruptive skin disorders characterized by erythema, oozing, vesiculation, and scaling. Etiology is varied. C0162817 C7330 Skin Diseases, Eczematous Eczematous Skin Diseases N0000003576 M0026466 1022475 Skin Diseases, Eczematous Skin Diseases, Papulosquamous [Disease/Finding] Skin Diseases, Papulosquamous Skin Diseases, Papulosquamous C7332 C0162818 22585003 1024350 D017444 N0000003577 Papulosquamous Skin Diseases Papulosquamous Disorders A group of dermatoses with distinct morphologic features. The primary lesion is most commonly a papule, usually erythematous, with a variable degree of scaling on the surface. Plaques form through the coalescing of primary lesions. M0026467 Skin Diseases, Vascular [Disease/Finding] C0162819 Skin diseases affecting or involving the cutaneous blood vessels and generally manifested as inflammation, swelling, erythema, or necrosis in the affected area. M0026469 11263005 N0000003578 Vascular Skin Diseases Skin Diseases, Vascular 1024271 D017445 C7334 Skin Diseases, Vascular Lung Diseases, Interstitial [Disease/Finding] N0000003603 Diffuse Parenchymal Lung Diseases A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features. Interstitial Lung Diseases Lung Diseases, Interstitial Lung Diseases, Interstitial 233703007 C7384 M0026626 C0206062 D017563 1028101 Neuroectodermal Tumors [Disease/Finding] M0026668 C7404 253096008 D017599 N0000003613 1022212 Neuroectodermal Tumors Neuroectodermal Tumors 73676002 Malignant neoplasms arising in the neuroectoderm, the portion of the ectoderm of the early embryo that gives rise to the central and peripheral nervous systems, including some glial cells. C0206093 Hypereosinophilic Syndrome [Disease/Finding] A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of eosinophils in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs. It is often referred to as idiopathic. N0000003620 C7418 M0026741 Hypereosinophilic Syndrome 1024984 C1540912 128835008 Hypereosinophilic Syndrome D017681 Pelvic Pain [Disease/Finding] N0000003626 Pain in the pelvic region of genital and non-genital origin and of organic or psychogenic etiology. Frequent causes of pain are distension or contraction of hollow viscera, rapid stretching of the capsule of a solid organ, chemical irritation, tissue ischemia, and neuritis secondary to inflammatory, neoplastic, or fibrotic processes in adjacent organs. (Kase, Weingold & Gershenson: Principles and Practice of Clinical Gynecology, 2d ed, pp479-508) C0030794 30473006 C7430 Pelvic Pain M0026763 1022303 Pelvic Pain D017699 Community-Acquired Infections [Disease/Finding] Infections, Community-Acquired C0206171 C7436 Community-Acquired Infections Community-Acquired Infections M0026784 D017714 Any infection acquired in the community, that is, contrasted with those acquired in a health care facility (CROSS INFECTION). An infection would be classified as community-acquired if the patient had not recently been in a health care facility or been in contact with someone who had been recently in a health care facility. N0000003629 1032631 Cytomegalovirus Retinitis [Disease/Finding] 22455005 1026504 D017726 Cytomegaloviral Retinitis M0026791 Retinitis, Cytomegalovirus Cytomegalovirus Retinitis Infection of the retina by cytomegalovirus characterized by retinal necrosis, hemorrhage, vessel sheathing, and retinal edema. Cytomegalovirus retinitis is a major opportunistic infection in AIDS patients and can cause blindness. N0000003631 C7440 C0206178 Cytomegalovirus Retinitis Flavivirus Infections [Disease/Finding] M0027404 Flavivirus Infections C0206608 N0000003657 Infections with viruses of the genus FLAVIVIRUS, family FLAVIVIRIDAE. 1027981 Flavivirus Infections C7492 D018177 Infections, Flavivirus Flaviviridae Infections [Disease/Finding] M0027405 1027902 Flaviviridae Infections Infections, Flaviviridae D018178 C0206609 C7494 N0000003658 Flaviviridae Infections Infections with viruses of the family FLAVIVIRIDAE. Paramyxoviridae Infections [Disease/Finding] Infections with viruses of the family PARAMYXOVIRIDAE. This includes MORBILLIVIRUS INFECTIONS; RESPIROVIRUS INFECTIONS; PNEUMOVIRUS INFECTIONS; HENIPAVIRUS INFECTIONS; AVULAVIRUS INFECTIONS; and RUBULAVIRUS INFECTIONS. N0000003660 D018184 M0027412 1028342 C7498 C0206613 Paramyxoviridae Infections Paramyxoviridae Infections Infections, Paramyxoviridae Pneumovirus Infections [Disease/Finding] D018186 C0206615 Infections, Pneumovirus C7502 N0000003662 Pneumovirus Infections 1023009 Infections with viruses of the genus PNEUMOVIRUS, family PARAMYXOVIRIDAE. This includes RESPIRATORY SYNCYTIAL VIRUS INFECTIONS, an important cause of respiratory disease in humans. M0027415 Pneumovirus Infections Neoplasms, Connective and Soft Tissue [Disease/Finding] 1028165 Neoplasms, Connective and Soft Tissue D018204 Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue. C7534 Connective and Soft Tissue Neoplasms C0206765 N0000003678 M0027433 Neoplasms, Connective and Soft Tissue Neoplasms, Bone Tissue [Disease/Finding] Neoplasms composed of bony tissue, whether normal or of a soft tissue which has become ossified. The concept does not refer to neoplasms located in bones. N0000003687 Bony Tissue Neoplasms Neoplasms, Bony Tissue Neoplasms, Bone Tissue C0206639 C7552 D018213 M0027442 1027523 Bone Tissue Neoplasms Neoplasms, Bone Tissue Neuroectodermal Tumors, Primitive, Peripheral [Disease/Finding] 1022217 C7608 Neuroectodermal Tumors, Primitive, Peripheral Neuroectodermal Tumors, Primitive, Peripheral 253096008 254764001 Peripheral Primitive Neuroectodermal Tumors Neuroectodermal Neoplasm, Peripheral Primitive Peripheral Primitive Neuroectodermal Neoplasm Neuroectodermal Tumor, Peripheral Primitive A group of highly cellular primitive round cell neoplasms which occur extracranially in soft tissue and bone and are derived from embryonal neural crest cells. These tumors occur primarily in children and adolescents and share a number of characteristics with Ewing's Sarcoma (SARCOMA, EWING'S). They may arise from the chest wall, skin, orbit, kidney, and other structures and tend to be locally invasive or metastasize, although relatively benign forms may occur. Characteristic histologic features include a tendency to form Homer-Wright rosettes and to stain positively with neuron-specific enolase and vimentin. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2113; J Clin Oncol 1998 Mar;16(3):1150-7) Neuroectodermal Tumor, Peripheral D018241 M0027470 C0684337 N0000003715 Extracranial Primitive Neuroectodermal Tumor (pPNET) Peripheral Primitive Neuroectodermal Tumors Primitive Neuroectodermal Tumor, Extracranial Neuroectodermal Tumors, Primitive [Disease/Finding] Neuroepithelial Tumors, Primitive Neuroepithelial Neoplasms, Primitive C0206663 PNET D018242 Neoplasms, Primitive Neuroepithelial Neuroectodermal Tumors, Primitive 1025367 Primitive Neuroepithelial Neoplasms M0027471 A group of malignant tumors of the nervous system that feature primitive cells with elements of neuronal and/or glial differentiation. Use of this term is limited by some authors to central nervous system tumors and others include neoplasms of similar origin which arise extracranially (i.e., NEUROECTODERMAL TUMORS, PRIMITIVE, PERIPHERAL). This term is also occasionally used as a synonym for MEDULLOBLASTOMA. In general, these tumors arise in the first decade of life and tend to be highly malignant. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2059) 39781001 Neuroectodermal Tumors, Primitive C7610 Neuroectodermal Tumor, Primitive N0000003716 Mesothelioma, Cystic [Disease/Finding] Mesothelioma, Cystic 1029066 N0000003729 C7636 M0027490 86562005 C0206680 A peritoneal mesothelioma affecting mainly young females and producing cysts of variable size and number lined by a single layer of benign mesothelial cells. The disease follows a benign course and is compatible with a normal life expectancy, requiring occasionally partial excision or decompression for relief of pain or other symptoms. Malignant potential is exceptional. (From Holland et al., Cancer Medicine, 3d ed, p1345) D018261 Mesothelioma, Cystic Carcinoma, Small Cell [Disease/Finding] Carcinoma, Oat Cell Carcinoma, Small Cell Carcinoma, Small Cell D018288 N0000003752 Small Cell Carcinoma An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7) 1024767 C7682 M0027519 Oat Cell Carcinoma C0262584 254632001 254633006 Neoplasms, Basal Cell [Disease/Finding] 1026910 Neoplasms composed of cells from the deepest layer of the epidermis. The concept does not refer to neoplasms located in the stratum basale. C7696 M0027529 Neoplasms, Basal Cell Neoplasms, Basal Cell C0206710 N0000003759 D018295 Basal Cell Neoplasms 30649006 Neoplasms, Ductal, Lobular, and Medullary [Disease/Finding] C0206768 1023140 D018299 189704005 N0000003763 C7704 Neoplasms, Ductal, Lobular, and Medullary M0027533 Neoplasms, usually carcinoma, located within the center of an organ or within small lobes, and in the case of the breast, intraductally. The emphasis of the name is on the location of the neoplastic tissue rather than on its histological type. Most cancers of this type are located in the breast. Ductal, Lobular, and Medullary Neoplasms Neoplasms, Ductal, Lobular, and Medullary Neoplasms, Mesothelial [Disease/Finding] Neoplasms, Mesothelial 115232000 1025409 M0027535 Neoplasms composed of tissue of the mesothelium, the layer of flat cells, derived from the mesoderm, which lines the body cavity of the embryo. In the adult it forms the simple squamous epithelium which covers all true serous membranes (peritoneum, pericardium, pleura). The concept does not refer to neoplasms located in these organs. (From Dorland, 27th ed) N0000003765 Mesothelial Neoplasms C7708 C0206714 Neoplasms, Mesothelial D018301 Neoplasms, Neuroepithelial [Disease/Finding] M0027536 C7710 Neoplasms, Neuroepithelial Neoplasms, Neuroepithelial Neuroepithelial Neoplasms Neuroepithelial Tumors 1025270 C0206715 Neoplasms composed of neuroepithelial cells, which have the capacity to differentiate into NEURONS, oligodendrocytes, and ASTROCYTES. The majority of craniospinal tumors are of neuroepithelial origin. (From Dev Biol 1998 Aug 1;200(1):1-5) D018302 N0000003766 Nevi and Melanomas [Disease/Finding] M0027561 C7752 Nevi and Melanomas 1027690 Nevi and Melanomas A collective term for the various types of nevi and melanomas. N0000003787 Melanomas and Nevi 189747005 C0206769 D018326 Melanoma, Amelanotic [Disease/Finding] N0000003789 An unpigmented malignant melanoma. It is an anaplastic melanoma consisting of cells derived from melanoblasts but not forming melanin. (Dorland, 27th ed; Stedman, 25th ed) C7756 Melanoma, Amelanotic D018328 C0206735 1024326 Melanoma, Amelanotic M0027563 70594002 Respiratory Syncytial Virus Infections [Disease/Finding] Pneumovirus infections caused by the RESPIRATORY SYNCYTIAL VIRUSES. Humans and cattle are most affected but infections in goats and sheep have been reported. N0000003803 Respiratory Syncytial Virus Infections D018357 55735004 C0035235 M0027589 C7784 Infections, Respiratory Syncytial Virus Respiratory Syncytial Virus Infections 986730 Neuroendocrine Tumors [Disease/Finding] Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition. M0027590 D018358 C0206754 1024535 N0000003804 Neuroendocrine Tumors Neuroendocrine Tumors C7786 255046005 Cardiovascular Abnormalities [Disease/Finding] Cardiovascular Abnormalities N0000003808 D018376 Cardiovascular Abnormalities 1026475 Abnormalities, Cardiovascular Congenital, inherited, or acquired anomalies of the CARDIOVASCULAR SYSTEM, including the HEART and BLOOD VESSELS. C0243050 M0027602 9904008 C7794 Pneumonia, Bacterial [Disease/Finding] C7802 1025309 Pneumonia, Bacterial Bacterial Pneumonia M0027639 Inflammation of the lung parenchyma that is caused by bacterial infections. C0004626 D018410 Pneumonia, Bacterial 53084003 N0000003812 Soft Tissue Infections [Disease/Finding] Soft Tissue Infections C7824 M0027697 Soft Tissue Infections Infections, Soft Tissue D018461 Infections of non-skeletal tissue, i.e., exclusive of bone, ligaments, cartilage, and fibrous tissue. The concept is usually referred to as skin and soft tissue infections and usually subcutaneous and muscle tissue are involved. The predisposing factors in anaerobic infections are trauma, ischemia, and surgery. The organisms often derive from the fecal or oral flora, particularly in wounds associated with intestinal surgery, decubitus ulcer, and human bites. (From Cecil Textbook of Medicine, 19th ed, p1688) 95880003 C0149778 N0000003823 1023005 Ventricular Dysfunction, Left [Disease/Finding] D018487 990592 C0242698 N0000003826 Ventricular Dysfunction, Left Left Ventricular Dysfunction Ventricular Dysfunction, Left C7830 M0027729 A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall. Mononegavirales Infections [Disease/Finding] Infections with viruses of the order MONONEGAVIRALES. The concept includes FILOVIRIDAE INFECTIONS; PARAMYXOVIRIDAE INFECTIONS; and RHABDOVIRIDAE INFECTIONS. C7868 M0028015 C0242916 1023194 Mononegavirales Infections N0000003845 D018701 Infections, Mononegavirales Mononegavirales Infections Systemic Inflammatory Response Syndrome [Disease/Finding] C0242966 N0000003848 238149007 M0028081 1023779 A systemic inflammatory response to a variety of clinical insults, characterized by two or more of the following conditions: (1) fever >38 degrees C or HYPOTHERMIA <36 degrees C; (2) TACHYCARDIA >90 beat/minute; (3) tachypnea >24 breaths/minute; (4) LEUKOCYTOSIS >12,000 cells/cubic mm or 10% immature forms. While usually related to infection, SIRS can also be associated with noninfectious insults such as TRAUMA; BURNS; or PANCREATITIS. If infection is involved, a patient with SIRS is said to have SEPSIS. Systemic Inflammatory Response Syndrome D018746 Systemic Inflammatory Response Syndrome 238150007 Inflammatory Response Syndrome, Systemic C7874 Sepsis Syndrome Ventricular Dysfunction [Disease/Finding] D018754 A condition in which HEART VENTRICLES exhibit impaired function. Ventricular Dysfunction C0242973 N0000003849 1022391 C7876 M0028090 Ventricular Dysfunction Impotence, Vasculogenic [Disease/Finding] M0028121 D018783 Impotence, Vasculogenic 986774 C0243000 Impotence, Vasculogenic Inability to achieve and maintain an erection (ERECTILE DYSFUNCTION) due to defects in the arterial blood flow to the PENIS, defect in venous occlusive function allowing blood drainage (leakage) from the erectile tissue (corpus cavernosum penis), or both. N0000003855 C7888 Encephalitis, Viral [Disease/Finding] C0243010 Encephalitis, Viral M0028131 N0000003858 Viral Encephalitis 1025326 C7894 Encephalomyelitis, Infectious, Viral Inflammation of brain parenchymal tissue as a result of viral infection. Encephalitis may occur as primary or secondary manifestation of TOGAVIRIDAE INFECTIONS; HERPESVIRIDAE INFECTIONS; ADENOVIRIDAE INFECTIONS; FLAVIVIRIDAE INFECTIONS; BUNYAVIRIDAE INFECTIONS; PICORNAVIRIDAE INFECTIONS; PARAMYXOVIRIDAE INFECTIONS; ORTHOMYXOVIRIDAE INFECTIONS; RETROVIRIDAE INFECTIONS; and ARENAVIRIDAE INFECTIONS. D018792 Infectious Encephalomyelitis, Viral 34476008 Encephalitis, Viral Sepsis [Disease/Finding] Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK. C0243026 Sepsis M0028155 91302008 C7900 D018805 Sepsis N0000003861 1023184 Iron Metabolism Disorders [Disease/Finding] D019189 N0000003901 C7980 M0028591 C0012715 Iron Metabolism Disorders 30913008 1022206 Iron Metabolism Disorders Disorders in the processing of iron in the body: its absorption, transport, storage, and utilization. (From Mosby's Medical, Nursing, & Allied Health Dictionary, 4th ed) Iron Overload [Disease/Finding] C7982 An excessive accumulation of iron in the body due to a greater than normal absorption of iron from the gastrointestinal tract or from parenteral injection. This may arise from idiopathic hemochromatosis, excessive iron intake, chronic alcoholism, certain types of refractory anemia, or transfusional hemosiderosis. (From Churchill's Illustrated Medical Dictionary, 1989) C0282193 60737008 D019190 Iron Overload Iron Overload M0028592 N0000003902 1024798 Neurodegenerative Diseases [Disease/Finding] Degenerative Neurologic Diseases C0524851 Neurologic Degenerative Conditions Neurodegenerative Diseases Neurodegenerative Diseases Nervous System Degenerative Diseases Degenerative Neurologic Disorders Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures. N0000003949 Degenerative Diseases, Neurologic M0029135 Neurodegenerative Disorders D019636 1022112 C8076 Neurologic Diseases, Degenerative Neurologic Degenerative Diseases Degenerative Diseases, Nervous System Hepatitis, Autoimmune [Disease/Finding] C8082 408335007 C0241910 D019693 Hepatitis, Autoimmune Hepatitis, Autoimmune 1021796 Autoimmune Chronic Hepatitis Autoimmune Hepatitis N0000003952 M0029243 A chronic self-perpetuating hepatocellular INFLAMMATION of unknown cause, usually with HYPERGAMMAGLOBULINEMIA and serum AUTOANTIBODIES. Hepatitis C, Chronic [Disease/Finding] Chronic Hepatitis C M0029252 N0000003954 D019698 Hepatitis C, Chronic C0524910 Hepatitis C, Chronic INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS. 1025809 128302006 C8086 Mental Disorders Diagnosed in Childhood [Disease/Finding] Those psychiatric disorders usually first diagnosed in infancy, childhood, or adolescence. These disorders can also be first diagnosed during other life stages. 987008 N0000003966 M0029626 Mental Disorders Diagnosed in Childhood C8110 D019952 Mental Disorders Diagnosed in Childhood C0525040 Disorders Usually Diagnosed in Infancy, Childhood or Adolescence Neurobehavioral Manifestations [Disease/Finding] N0000003967 Neurobehavioral Signs and Symptoms M0333801 C8112 Cognitive Symptoms Signs and Symptoms, Neurobehavioral Signs and symptoms of higher cortical dysfunction caused by organic conditions. These include certain behavioral alterations and impairments of skills involved in the acquisition, processing, and utilization of knowledge or information. 1025867 C0525041 Neurobehavioral Manifestations Neurobehavioral Manifestations Cognitive Manifestations D019954 Attention Deficit and Disruptive Behavior Disorders [Disease/Finding] C0236964 D019958 1031543 Attention Deficit and Disruptive Behavior Disorders C8120 N0000003971 Attention Deficit and Disruptive Behavior Disorders M0029636 Elimination Disorders [Disease/Finding] 1164009 Excretory-related psychiatric disorders usually diagnosed in infancy or childhood. M0029639 1024444 C8124 D019960 Elimination Disorders Elimination Disorders C0013895 N0000003973 Mood Disorders [Disease/Finding] M0029642 1022464 Mood Disorders C0525045 C8128 D019964 Those disorders that have a disturbance in mood as their predominant feature. N0000003975 Affective Disorders Mood Disorders 46206005 Delirium, Dementia, Amnestic, Cognitive Disorders [Disease/Finding] 106014008 C0029227 111479008 M0029645 Delirium, Dementia, Amnestic, Cognitive Disorders D019965 Cognitive disorders including delirium, dementia, and other cognitive disorders. These may be the result of substance use, trauma, or other causes. Mental Disorders, Organic Delirium, Dementia, Amnestic, Cognitive Disorders N0000003976 1022574 Organic Mental Disorders C8130 Substance-Related Disorders [Disease/Finding] Disorders related to substance abuse, the side effects of a medication, or toxin exposure. N0000003977 Substance-Related Disorders 1027904 M0029657 C8132 D019966 Substance-Related Disorders C0236969 Schizophrenia and Disorders with Psychotic Features [Disease/Finding] N0000003978 Schizophrenia and Disorders with Psychotic Features Schizophrenia and Disorders with Psychotic Features C8134 984843 Marked disorders of thought (delusions, hallucinations, or other thought disorder accompanied by disordered affect or behavior), and deterioration from a previous level of functioning. M0029660 D019967 C0525046 Sexual and Gender Disorders [Disease/Finding] D019968 C8136 Mental disorders related to sexual dysfunction, paraphilias, and gender identity disorders. C0525047 984634 N0000003979 Sexual and Gender Disorders Sexual and Gender Disorders M0029661 Alcohol-Related Disorders [Disease/Finding] 1025655 C0236664 M0029672 D019973 N0000003982 29212009 Alcohol-Related Disorders Alcohol-Related Disorders Disorders related to or resulting from abuse or mis-use of alcohol. C8142 Sexual Dysfunctions, Psychological [Disease/Finding] D020018 Sexual Dysfunctions, Psychological Psychosexual Disorders Psychosexual Dysfunctions Sexual Dysfunctions, Psychological M0029727 56627002 C8146 1025159 C0033953 Disturbances in sexual desire and the psychophysiologic changes that characterize the sexual response cycle and cause marked distress and interpersonal difficulty. (APA, DSM-IV, 1994) N0000003984 Zygomycosis [Disease/Finding] M0029826 D020096 1027910 Zygomycosis Zygomycosis 59277005 N0000003994 C8166 Infection in humans and animals caused by fungi in the class Zygomycetes. It includes MUCORMYCOSIS and entomophthoramycosis. The latter is a tropical infection of subcutaneous tissue or paranasal sinuses caused by fungi in the order Entomophthorales. Phycomycosis, closely related to zygomycosis, describes infection with members of Phycomycetes, an obsolete classification. C0043541 Hemostatic Disorders [Disease/Finding] 21112004 D020141 C0600502 1023569 M0029879 Vascular Hemostatic Disorders Hemostatic Disorders Hemostatic Disorders, Vascular C8176 Hemostatic Disorders Pathological processes involving the integrity of blood circulation. Hemostasis depends on the integrity of BLOOD VESSELS, blood fluidity, and BLOOD COAGULATION. Majority of the hemostatic disorders are caused by disruption of the normal interaction between the VASCULAR ENDOTHELIUM, the plasma proteins (including BLOOD COAGULATION FACTORS), and PLATELETS. N0000003999 Trauma, Nervous System [Disease/Finding] M0328650 Injuries, Nervous System Nervous System Injuries Trauma, Nervous System D020196 Traumatic injuries to the brain, cranial nerves, spinal cord, autonomic nervous system, or neuromuscular system, including iatrogenic injuries induced by surgical procedures. N0000004034 1031188 C8246 Trauma, Nervous System 128239009 C0751792 Venous Thrombosis [Disease/Finding] 1023173 111293003 The formation or presence of a blood clot (THROMBUS) within a vein. Venous Thrombosis Phlebothrombosis C0042487 Thrombosis, Venous N0000004074 18266009 C8326 D020246 M0029908 Venous Thrombosis Postoperative Nausea and Vomiting [Disease/Finding] 1488000 1028343 Nausea and Vomiting, Postoperative C0520909 Emesis and queasiness occurring after anesthesia. N0000004075 M0029915 D020250 Postoperative Nausea and Vomiting PONV Postoperative Nausea and Vomiting C8328 Neurotoxicity Syndromes [Disease/Finding] Neurotoxin Disorders Poisoning, Nervous System Neurotoxic Disorders M0328313 Neurotoxin Diseases 19466003 985040 C8338 Neurotoxicity Syndromes N0000004080 Nervous System Poisoning D020258 C0235032 Neurologic disorders caused by exposure to toxic substances through ingestion, injection, cutaneous application, or other method. This includes conditions caused by biologic, chemical, and pharmaceutical agents. Neurotoxicity Syndromes Heavy Metal Poisoning, Nervous System [Disease/Finding] C8340 C0751850 Heavy Metal Poisoning, Nervous System N0000004081 D020260 M0328325 Conditions associated with damage or dysfunction of the nervous system caused by exposure to heavy metals, which may cause a variety of central, peripheral, or autonomic nervous system injuries. Poisoning, Heavy Metals, Nervous System 988177 Heavy Metal Poisoning, Nervous System Lead Poisoning, Nervous System [Disease/Finding] Lead Poisoning, Nervous System Nervous System Poisoning, Lead Neurotoxicity Syndrome, Lead Lead Poisoning, Nervous System Nervous System Diseases, Lead-Induced Poisoning, Lead, Nervous System C0751859 1023920 Injury to the nervous system secondary to exposure to lead compounds. Two distinct clinical patterns occur in children (LEAD POISONING, NERVOUS SYSTEM, CHILDHOOD) and adults (LEAD POISONING, NERVOUS SYSTEM, ADULT). In children, lead poisoning typically produces an encephalopathy. In adults, exposure to toxic levels of lead is associated with a peripheral neuropathy. Poisoning, Lead, Neurologic C8346 Plumbism, Neurologic Lead-Induced Nervous System Diseases D020263 Lead Poisoning, Neurologic Plumbism, Nervous System N0000004084 M0328619 Lead Poisoning, Nervous System, Childhood [Disease/Finding] 1022058 Lead-Induced Nervous System Disease, Childhood Plumbism, Neurologic, Childhood Lead Poisoning, Nervous System, Childhood M0328531 Neurologic disorders occurring in children following lead exposure. The most frequent manifestation of childhood lead toxicity is an encephalopathy associated with chronic ingestion of lead that usually presents between the ages of 1 and 3 years. Clinical manifestations include behavioral changes followed by lethargy; CONVULSIONS; HALLUCINATIONS; DELIRIUM; ATAXIA; and vomiting. Elevated intracranial pressure (HYPERTENSION, INTRACRANIAL) and CEREBRAL EDEMA may occur. (From Adams et al., Principles of Neurology, 6th ed, p1210-2) Poisoning, Lead, Nervous System, Childhood Neurologic Saturnism, Childhood D020264 N0000004085 Lead Poisoning, Neurologic, Childhood Poisoning, Lead, Neurologic, Childhood Nervous System Disease, Lead-Induced, Childhood Neurotoxicity Syndrome, Lead, Childhood C0751861 Nervous System Poisoning, Lead, Childhood C8348 Lead Poisoning, Nervous System, Childhood Heredodegenerative Disorders, Nervous System [Disease/Finding] Nervous System Diseases, Degenerative, Hereditary C8360 985698 Nervous System Degenerative Hereditary Diseases Inherited disorders characterized by progressive atrophy and dysfunction of anatomically or physiologically related neurologic systems. M0328330 Neurodegenerative Diseases, Hereditary Degenerative Disease, Nervous System, Hereditary Degenerative Hereditary Disorders, Nervous System D020271 C0751870 Nervous System Hereditary Degenerative Diseases Hereditary Neurodegenerative Diseases Hereditary Diseases, Neurodegenerative Heredodegenerative Disorders, Nervous System Hereditary-Degenerative Disorders, Nervous System N0000004091 Heredodegenerative Disorders, Nervous System Degenerative Hereditary Diseases, Nervous System Autoimmune Diseases of the Nervous System [Disease/Finding] Autoimmune Diseases, Nervous System Autoimmune Diseases of the Nervous System C8362 Autoimmune Diseases, Neurologic Autoimmune Diseases of the Nervous System N0000004092 C0751871 Autoimmune Disorders of the Nervous System Autoimmune Nervous System Diseases M0328129 Nervous System Autoimmune Diseases 1025977 D020274 Disorders caused by cellular or humoral immune responses primarily directed towards nervous system autoantigens. The immune response may be directed towards specific tissue components (e.g., myelin) and may be limited to the central nervous system (e.g., MULTIPLE SCLEROSIS) or the peripheral nervous system (e.g., GUILLAIN-BARRE SYNDROME). Neurologic Autoimmune Diseases Autoimmune Disorders, Nervous System Demyelinating Autoimmune Diseases, CNS [Disease/Finding] Demyelinating Autoimmune Diseases, CNS Demyelinating Autoimmune Disorders, CNS Demyelinating Autoimmune Diseases, CNS D020278 CNS Autoimmune Demyelinating Disorders 989466 Conditions characterized by loss or dysfunction of myelin (see MYELIN SHEATH) in the brain, spinal cord, or optic nerves secondary to autoimmune mediated processes. This may take the form of a humoral or cellular immune response directed toward myelin or OLIGODENDROGLIA associated autoantigens. M0328372 Autoimmune Demyelinating Disorders, CNS C8368 CNS Demyelinating Autoimmune Diseases Demyelinating Autoimmune Diseases, Central Nervous System Autoimmune Demyelinating Diseases, Central Nervous System Demyelinating Disease, Autoimmune, CNS C0751873 N0000004095 Autoimmune Demyelinating Diseases, CNS Central Nervous System Fungal Infections [Disease/Finding] D020314 C8388 N0000004105 Mycoses, Central Nervous System Central Nervous System Fungal Infections Fungal Infections, Central Nervous System C0729544 Infections, Fungal, Central Nervous System 1025141 M0328044 128120005 Central Nervous System Mycoses MYCOSES of the brain, spinal cord, and meninges which may result in ENCEPHALITIS; MENINGITIS, FUNGAL; MYELITIS; BRAIN ABSCESS; and EPIDURAL ABSCESS. Certain types of fungi may produce disease in immunologically normal hosts, while others are classified as opportunistic pathogens, causing illness primarily in immunocompromised individuals (e.g., ACQUIRED IMMUNODEFICIENCY SYNDROME). Central Nervous System Fungal Infections Paraparesis [Disease/Finding] Paraparesis N0000004116 D020335 C8410 1030098 Paraparesis Mild to moderate loss of bilateral lower extremity motor function, which may be a manifestation of SPINAL CORD DISEASES; PERIPHERAL NERVOUS SYSTEM DISEASES; MUSCULAR DISEASES; INTRACRANIAL HYPERTENSION; parasagittal brain lesions; and other conditions. M0328241 1845001 C0221166 Paraparesis, Spastic [Disease/Finding] Paraparesis, Spastic Lower Extremity Weakness, Spastic D020336 312444006 M0023856 Spastic Lower Extremity Weakness 1025702 Paraparesis, Spastic N0000004117 C0037771 Mild or moderate loss of motor function accompanied by spasticity in the lower extremities. This condition is a manifestation of CENTRAL NERVOUS SYSTEM DISEASES that cause injury to the motor cortex or descending motor pathways. C8412 Spastic Paraparesis Enterocolitis, Necrotizing [Disease/Finding] C8420 M0029980 Enterocolitis, Necrotizing C0520459 2707005 D020345 N0000004121 1022711 Enterocolitis, Necrotizing 397729009 Necrotizing Enterocolitis ENTEROCOLITIS with extensive ulceration (ULCER) and NECROSIS. It is observed primarily in LOW BIRTH WEIGHT INFANT. Trigeminal Nerve Diseases [Disease/Finding] Trigeminal Nerve Disorders 64309007 M0328651 C8472 Fifth Cranial Nerve Diseases Cranial Nerve V Diseases Trigeminal Nerve Diseases Trigeminal Neuropathy C0152177 Diseases of the trigeminal nerve or its nuclei, which are located in the pons and medulla. The nerve is composed of three divisions: ophthalmic, maxillary, and mandibular, which provide sensory innervation to structures of the face, sinuses, and portions of the cranial vault. The mandibular nerve also innervates muscles of mastication. Clinical features include loss of facial and intra-oral sensation and weakness of jaw closure. Common conditions affecting the nerve include brain stem ischemia, INFRATENTORIAL NEOPLASMS, and TRIGEMINAL NEURALGIA. D020433 Trigeminal Nerve Diseases N0000004147 1025232 Neuromuscular Junction Diseases [Disease/Finding] Neuromuscular Junction Diseases Conditions characterized by impaired transmission of impulses at the NEUROMUSCULAR JUNCTION. This may result from disorders that affect receptor function, pre- or postsynaptic membrane function, or ACETYLCHOLINESTERASE activity. The majority of diseases in this category are associated with autoimmune, toxic, or inherited conditions. 984412 M0328288 C0751950 Neuromuscular Transmission Disorders Neuromuscular Junction Diseases C8484 128213006 N0000004153 D020511 Neuromuscular Junction Disorders Brain Infarction [Disease/Finding] Tissue NECROSIS in any area of the brain, including the CEREBRAL HEMISPHERES, the CEREBELLUM, and the BRAIN STEM. Brain infarction is the result of a cascade of events initiated by inadequate blood flow through the brain that is followed by HYPOXIA and HYPOGLYCEMIA in brain tissue. Damage may be temporary, permanent, selective or pan-necrosis. M0328169 1027116 Brain Infarction Brain Infarction C8496 N0000004159 D020520 C0751955 Stroke [Disease/Finding] Cerebral Stroke Apoplexy Cerebrovascular Accident Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810) 270883006 N0000004160 Cerebrovascular Apoplexy Vascular Accident, Brain C8498 Cerebrovascular Stroke CVA (Cerebrovascular Accident) 1024488 D020521 230690007 M0328070 Stroke C0038454 Parkinsonian Disorders [Disease/Finding] 987649 N0000004168 Parkinsonian Disorders Parkinsonian Syndromes C0242422 D020734 M0328250 A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA. Parkinsonian Syndrome Parkinsonian Disorders C8514 32798002 Parkinsonism Parkinsonian Diseases Alcohol-Induced Disorders [Disease/Finding] C8518 M0328025 Alcohol-Induced Disorders C0236970 Alcohol-Induced Disorders 1025678 N0000004170 Disorders stemming from the misuse and abuse of alcohol. D020751 Pathological Conditions, Anatomical [Disease/Finding] An abnormal structural condition of the human body, usually macroscopic, that is common to a variety of different diseases. C8534 N0000004178 1026773 D020763 Pathological Conditions, Anatomical Pathological Conditions, Anatomical M0328642 C0752135 Headache Disorders [Disease/Finding] C0393735 Headache Syndromes M0328324 230461009 Headache Disorders 1023986 N0000004182 Various conditions with the symptom of HEADACHE. Headache disorders are classified into major groups, such as PRIMARY HEADACHE DISORDERS (based on characteristics of their headache symptoms) and SECONDARY HEADACHE DISORDERS (based on their etiologies). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1) C8542 D020773 Headache Disorders Cephalgia Syndromes Central Nervous System Viral Diseases [Disease/Finding] Viral Infections, Central Nervous System Central Nervous System Viral Diseases C8568 Central Nervous System Viral Infections N0000004195 Central Nervous System Viral Diseases Infections, CNS, Viral Infections, Viral CNS 1025144 D020805 M0328064 Viral Diseases, Central Nervous System Viral infections of the brain, spinal cord, meninges, or perimeningeal spaces. C0348165 302810003 Dyskinesias [Disease/Finding] Abnormal Movements 9748009 1021897 C8586 Abnormal involuntary movements which primarily affect the extremities, trunk, or jaw that occur as a manifestation of an underlying disease process. Conditions which feature recurrent or persistent episodes of dyskinesia as a primary manifestation of disease may be referred to as dyskinesia syndromes (see MOVEMENT DISORDERS). Dyskinesias are also a relatively common manifestation of BASAL GANGLIA DISEASES. Dyskinesias Dyskinesias M0014140 D020820 N0000004204 C0013384 Neuromuscular Manifestations [Disease/Finding] Signs and symptoms associated with diseases of the muscle, neuromuscular junction, or peripheral nerves. Neuromuscular Manifestations N0000004213 C8604 1027972 Neuromuscular Signs and Symptoms D020879 M0328296 C0752252 Signs and Symptoms, Neuromuscular Neuromuscular Manifestations Sleep Disorders, Intrinsic [Disease/Finding] Sleep Disorders, Intrinsic N0000004219 Sleep Disorders, Intrinsic D020919 M0328301 C0752287 C8616 Intrinsic Sleep Disorders 1030136 Dyssomnias (i.e., insomnias or hypersomnias) associated with dysfunction of internal sleep mechanisms or secondary to a sleep-related medical disorder (e.g., sleep apnea, post-traumatic sleep disorders, etc.). (From Thorpy, Sleep Disorders Medicine, 1994, p187) Dyssomnias [Disease/Finding] N0000004220 44186003 C8618 D020920 1022841 Dyssomnias A broad category of sleep disorders characterized by either hypersomnolence or insomnia. The three major subcategories include intrinsic (i.e., arising from within the body) (SLEEP DISORDERS, INTRINSIC), extrinsic (secondary to environmental conditions or various pathologic conditions), and disturbances of circadian rhythm. (From Thorpy, Sleep Disorders Medicine, 1994, p187) C0700201 M0328379 Dyssomnias Carcinoma, Pancreatic Ductal [Disease/Finding] Duct-Cell Carcinoma of the Pancreas Carcinoma, Ductal, Pancreatic Pancreatic Ductal Carcinoma C8660 Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS. C0887833 N0000004241 Ductal Carcinoma of the Pancreas Carcinoma, Pancreatic Ductal Carcinoma, Pancreatic Ductal D021441 Pancreatic Duct Cell Carcinoma 985550 Duct-Cell Carcinoma, Pancreas M0352972 amprenavir [Chemical/Ingredient] C0754188 M0250495 amprenavir C095108 tetrahydro-3-furyl N-(3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxypropyl)carbamate Amprenavir N0000004336 amprenavir C11148 228656 basiliximab [Chemical/Ingredient] C11518 N0000004374 basiliximab basiliximab basiliximab M0292349 C113157 196102 C0676831 cefepime [Chemical/Ingredient] cefepime Pyrrolidinium, 1-((7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methyl-, hydroxide, inner salt, (6R-(6alpha,7beta(Z)))- C0055003 cefepim cefepime C043266 20481 C12390 M0127410 N0000004493 cefepime cevimeline [Chemical/Ingredient] 44281 M0164858 2-methyspiro(1,3-oxathiolane-5,3)quinuclidine C12616 C059240 cevimeline C0093437 cevimeline cevimeline N0000004524 efavirenz [Chemical/Ingredient] 195085 M0258297 N0000004738 C0674428 6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one efavirenz efavirenz efavirenz C098320 C14150 exemestane [Chemical/Ingredient] 258494 C0851344 C056516 6-methyleneandrosta-1,4-diene-3,17-dione N0000004783 exemestane exemestane M0158502 C14510 exemestane gatifloxacin [Chemical/Ingredient] N0000004840 C078049 M0209340 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo- C0753645 gatifloxacin 1-cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid gatifloxacin gatifloxacin 228476 C14992 moxifloxacin [Chemical/Ingredient] C17464 C104727 N0000005131 C0536495 139462 M0273433 moxifloxacin moxifloxacin moxifloxacin 1-cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid rabeprazole [Chemical/Ingredient] 114979 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole N0000005413 C063129 C19458 M0174415 rabeprazole rabeprazole C0378482 rabeprazole rituximab [Chemical/Ingredient] rituximab C0393022 M0244307 N0000005430 C092560 rituximab C19594 CD20 antibody, rituximab 121191 rituximab rivastigmine [Chemical/Ingredient] C072506 rivastigmine C0649350 rivastigmine M0196402 183379 (S)-N-ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate Carbamic acid, ethylmethyl-, 3-(1-(dimethylamino)ethyl)phenyl ester, (S)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1) C19598 N0000005431 rivastigmine sparfloxacin [Chemical/Ingredient] C20242 N0000005508 C0052585 18469 C061363 sparfloxacin M0170192 sparfloxacin sparfloxacin trastuzumab [Chemical/Ingredient] 224905 trastuzumab C0728747 C112748 N0000005608 trastuzumab M0291428 C21054 trastuzumab ropinirole [Chemical/Ingredient] 4-(2-(di-n-propylamino)ethyl)-2(3H)-indolone ropinirol M0135070 C046649 C21732 ropinirole ropinirole ropinirole C0244821 72302 N0000005694 Pentamidine [Chemical/Ingredient] Pentamidine Pentamidine Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. M0016169 Benzenecarboximidamide, 4,4'-(1,5-pentanediylbis(oxy))bis- C21762 7994 Pentamidin N0000005709 Pentamidine D010419 C0030863 Nortriptyline [Chemical/Ingredient] C21772 N0000005714 M0015002 C0028420 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N-methyl- A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions. Nortriptyline Nortriptyline Desitriptyline Desmethylamitriptylin D009661 Nortriptyline 7531 Methylprednisolone [Chemical/Ingredient] Methylprednisolone N0000005719 6902 Methylprednisolone M0013662 C0025815 Metipred Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6alpha,11beta)- Methylprednisolone 6-Methylprednisolone A PREDNISOLONE derivative with similar anti-inflammatory action. D008775 C21782 Carbohydrates [Chemical/Ingredient] The largest class of organic compounds, including STARCH; GLYCOGEN; CELLULOSE; POLYSACCHARIDES; and simple MONOSACCHARIDES. Carbohydrates are composed of carbon, hydrogen, and oxygen in a ratio of Cn(H2O)n. Carbohydrates Carbohydrates D002241 M0003360 C21790 C0007004 2028 N0000005723 docetaxel [Chemical/Ingredient] C0246415 docetaxol docetaxel N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol C21822 docetaxel docetaxel N0000005739 M0184558 Benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-y C067311 72962 Mitoxantrone [Chemical/Ingredient] Mitozantrone C21824 Mitoxantrone M0013954 7005 An anthracenedione-derived antineoplastic agent. Mitoxantrone D008942 9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)- C0026259 N0000005740 Mitoxantrone DHAQ Metolazone [Chemical/Ingredient] C0025854 Metolazone A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic RENAL FAILURE. It also tends to lower BLOOD PRESSURE and increase POTASSIUM loss. D008788 Metolazone 6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo- C21836 6916 Metolazone M0013684 N0000005746 Aminosalicylic Acids [Chemical/Ingredient] 700 D000636 A group of 2-hydroxybenzoic acids that can be substituted by amino groups at any of the 3-, 4-, 5-, or 6-positions. N0000005760 M0000971 Aminosalicylic Acids Aminosalicylic Acids C21864 C0002591 Amiodarone [Chemical/Ingredient] Amiodarone C21866 703 Amiodarone Amiodarone D000638 Methanone, (2-butyl-3-benzofuranyl)(4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl)- N0000005761 M0000973 An antianginal and antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting Na,K-activated myocardial adenosine triphosphatase. There is a resulting decrease in heart rate and in vascular resistance. C0002598 Amitriptyline [Chemical/Ingredient] M0000975 Amitriptyline Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines. 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- C0002600 D000639 704 Amitriptyline C21870 N0000005763 Amitriptyline Mesalamine [Chemical/Ingredient] M0029386 5-Aminosalicylic Acid C21876 mesalamine Mesalamine C0127615 D019804 N0000005766 m-Aminosalicylic Acid meta-Aminosalicylic Acid An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed) Mesalamine Mesalazine 52582 fluticasone [Chemical/Ingredient] C0082607 S-(Fluoromethyl) 6a,9-difluoro-11b,17-dihydroxy-16a-methyl-3-oxoandrosta-1,4-diene-17b-carbothioate N0000005771 C065382 fluticasone fluticasone fluticasone M0179832 41126 C21886 Losartan [Chemical/Ingredient] Losartan 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol D019808 52175 Losartan M0029400 An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II. C0126174 C21892 N0000005774 Losartan Metronidazole [Chemical/Ingredient] C21896 2-Methyl-5-nitroimidazole-1-ethanol M0013695 N0000005776 C0025872 Metronidazole Metronidazole Metronidazole D008795 A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS. It has also been proposed as a radiation sensitizer for hypoxic cells. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985, p133), this substance may reasonably be anticipated to be a carcinogen (Merck, 11th ed). 6922 1H-Imidazole-1-ethanol, 2-methyl-5-nitro- Omeprazole [Chemical/Ingredient] Omeprazole A highly effective inhibitor of gastric acid secretion used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits the H(+)-K(+)-ATPase (H(+)-K(+)-EXCHANGING ATPASE) in the proton pump of GASTRIC PARIETAL CELLS. Omeprazole C21948 Omeprazole 1H-Benzimidazole, 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)- 7646 D009853 N0000005802 C0028978 M0015293 Benzoic Acid [Chemical/Ingredient] Benzoic acid D019817 Benzoic Acid A fungistatic compound that is widely used as a food preservative. It is conjugated to GLYCINE in the liver and excreted as hippuric acid. Benzoic Acid M0029415 C0053225 C21950 18989 N0000005803 Benzoic Acid Proteins [Chemical/Ingredient] C21978 Proteins Proteins 8859 C0033684 N0000005817 M0017890 Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. D011506 Proteins Simvastatin [Chemical/Ingredient] M0029425 36567 Simvastatin Simvastatin C0074554 C22028 A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL. Synvinolin Simvastatin N0000005842 D019821 ziprasidone [Chemical/Ingredient] C22030 N0000005843 115698 C092292 M0243639 ziprasidone ziprasidone ziprazidone C0380393 ziprasidone 5-(2-(4-(3-benzisothiazolyl)piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one Nevirapine [Chemical/Ingredient] 53654 N0000005849 A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV infection and AIDS. C0132326 C22042 Nevirapine Nevirapine D019829 6H-Dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- Nevirapine M0029429 alosetron [Chemical/Ingredient] C0291772 85248 C090840 alosetron alosetron alosetron C22092 M0240025 N0000005874 zonisamide [Chemical/Ingredient] C022189 1,2-benzisoxazole-3-methanesulfonamide zonisamide zonisamide zonisamide C0078844 N0000005875 39998 M0077929 3-sulfamoylmethyl-1,2-benzisoxazole C22094 Tobramycin [Chemical/Ingredient] N0000005883 Nebramycin Factor 6 An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species. Tobramycin C22110 Tobramycin M0021611 C0040341 D014031 10627 D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl-(1-4))-2-deoxy- Tobramycin Streptomycin [Chemical/Ingredient] C22124 C0038425 An antibiotic produced by the soil actinomycete Streptomyces griseus. It acts by inhibiting the initiation and elongation processes during protein synthesis. Streptomycin 10109 M0020595 D013307 N0000005890 Streptomycin Streptomycin D-Streptamine, O-2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl-(1-2)-O-5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl-(1-4)-N,N'-bis(aminoiminomethyl)- Ribavirin [Chemical/Ingredient] C0035525 Ribavirin D012254 Tribavirin Ribavirin C22128 M0019062 A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. N0000005892 1H-1,2,4-Triazole-3-carboxamide, 1-beta-D-ribofuranosyl- Ribovirin 9344 Ribavirin Benzoates [Chemical/Ingredient] Salts and esters of BENZOIC ACID that possess antibacterial and antifungal properties. They are used as preservatives in pharmaceuticals, cosmetics, and foods. Benzoates N0000005901 Benzoates D001565 M0002350 C22146 C0005058 1398 Pergolide [Chemical/Ingredient] Pergolide D010479 Pergolide N0000005908 Pergolide C0031007 A long-acting dopamine agonist which has been used to treat PARKINSON DISEASE and HYPERPROLACTINEMIA but withdrawn from some markets due to potential for HEART VALVE DISEASES. 8047 Ergoline, 8-((methylthio)methyl)-6-propyl-, (8beta)- M0016279 C22160 Protriptyline [Chemical/Ingredient] Tricyclic antidepressant similar in action and side effects to IMIPRAMINE. It may produce excitation. C0033743 8886 Protriptyline Protriptyline 5H-Dibenzo(a,d)cycloheptene-5-propanamine, N-methyl- D011530 M0017928 N0000005915 Protriptyline C22174 cyclobenzaprine [Chemical/Ingredient] N,N-dimethyl-3-(dibenzo(a,d)cycloheptene-4-ylidene)propylamine 21949 C004704 C0056732 M0045849 cyclobenzaprine cyclobenzaprine cyclobenzaprine N0000005926 C22196 Tolmetin [Chemical/Ingredient] C22200 Tolmetin Tolmetin N0000005928 C0040377 A non-steroidal anti-inflammatory agent (ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL) similar in mode of action to INDOMETHACIN. 1H-Pyrrole-2-acetic acid, 1-methyl-5-(4-methylbenzoyl)- D014046 10636 M0021631 Tolmetin Dihydroergotamine [Chemical/Ingredient] N0000005941 C0012291 D004087 C22226 Dihydroergotamine Ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha,10alpha)- Dihydroergotamine M0006401 Dihydroergotamine 3418 A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS. Phenylalanine [Chemical/Ingredient] M0016544 8156 Phenylalanine Phenylalanine C22228 An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE. C0031453 L-Phenylalanine D010649 Phenylalanine, L-Isomer Phenylalanine N0000005942 Cyclophosphamide [Chemical/Ingredient] 2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide Cyclophosphane Cyclophosphamide Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. N0000005951 C0010583 C22246 3002 M0005485 D003520 Cytophosphan Cyclophosphamide capecitabine [Chemical/Ingredient] N0000005958 N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine M0287377 194000 capecitabine C0671970 C110904 capecitabine capecitabine C22260 Triamcinolone [Chemical/Ingredient] A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. (From Martindale, The Extra Pharmacopoeia, 30th ed, p739) C0040864 C22306 Triamcinolone Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha)- Triamcinolone Triamcinolone M0021894 10759 D014221 N0000005981 Cyproheptadine [Chemical/Ingredient] Cyproheptadine A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc. Cyproheptadine 3013 N0000005988 C22320 M0005519 D003533 Piperidine, 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-methyl- Cyproheptadine C0010620 Gold [Chemical/Ingredient] D006046 Gold Gold N0000005996 A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts. C22336 M0009521 C0018026 4975 Triazolam [Chemical/Ingredient] C0040879 N0000006001 A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries. C22346 Triazolam Triazolam Triazolam 4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-(2-chlorophenyl)-1-methyl- 10767 D014229 M0021910 Aurothioglucose [Chemical/Ingredient] C0018033 A thioglucose derivative used as an antirheumatic and experimentally to produce obesity in animals. C22370 Aurothioglucose Aurothioglucose N0000006013 Thioglucosoaurate D006051 M0009526 Gold Thioglucose 4980 Aurothioglucose Gold, (1-thio-D-glucopyranosato-O2,S1)- Gold Sodium Thiomalate [Chemical/Ingredient] Sodium Aurothiomalate M0009527 Sodium Gold Thiomalate Gold Sodium Thiomalate D006052 A variable mixture of the mono- and disodium salts of gold thiomalic acid used mainly for its anti-inflammatory action in the treatment of rheumatoid arthritis. It is most effective in active progressive rheumatoid arthritis and of little or no value in the presence of extensive deformities or in the treatment of other forms of arthritis. C22374 4981 Mercaptobutanedioic Acid Monogold(1+) Sodium Salt Butanedioic acid, mercapto-, monogold(1+) sodium salt Gold Sodium Thiomalate Gold Sodium Thiomalate Sodium Thiomalatoaurate N0000006015 C0018034 Phenytoin [Chemical/Ingredient] Phenytoin C22390 M0016580 N0000006023 8183 Phenytoin An anticonvulsant that is used in a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. C0031507 Diphenylhydantoin 5,5-Diphenylhydantoin D010672 2,4-Imidazolidinedione, 5,5-diphenyl- Fenitoin Phenytoin Rifampin [Chemical/Ingredient] C0035608 Rifampicin Benemycin Rifampin C22396 Rifamycin, 3-(((4-methyl-1-piperazinyl)imino)methyl)- D012293 A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) 9384 Rifampin N0000006026 M0019110 Rifampin linezolid [Chemical/Ingredient] N-((3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide C098010 linezolid linezolid C0663241 linezolid M0257529 190376 C22398 N0000006027 cerivastatin [Chemical/Ingredient] cerivastatin N0000006045 C086276 C0528023 C22434 596723 cerivastatin M0228730 Haloperidol [Chemical/Ingredient] M0009771 1-Butanone, 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)- C0018546 D006220 Haloperidol Haloperidol C22440 A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in MENTAL RETARDATION and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) 5093 N0000006048 Haloperidol Sulfasalazine [Chemical/Ingredient] D012460 C0036078 Sulphasalazine Salicylazosulfapyridine 9524 C22452 Benzoic acid, 2-hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)- Sulfasalazine Sulfasalazine A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907) Salazosulfapyridine Sulfasalazine N0000006054 M0019365 fludarabine [Chemical/Ingredient] 9-beta-D-arabinofuranosyl-2-fluoroadenine 2-fluoroadenine arabinoside F-ara-A 9H-purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- N0000006079 24698 C024352 fludarabine M0082555 C22502 fludarabine C0059985 fludarabine Cytarabine [Chemical/Ingredient] D003561 Cytosine Arabinoside Arabinofuranosylcytosine 2(1H)-Pyrimidinone, 4-amino-1-beta-D-arabinofuranosyl- Arabinosylcytosine C22504 Aracytidine N0000006080 Cytarabine Cytarabine Cytarabine C0010711 M0005564 A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) 3041 Selegiline [Chemical/Ingredient] Benzeneethanamine, N,alpha-dimethyl-N-2-propynyl-, (R)- D012642 Selegiline C0036579 C22546 9639 L-Deprenyl Selegiline Selegyline N0000006101 Selegiline, (R)-Isomer A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl. M0019601 Selegiline Zalcitabine [Chemical/Ingredient] A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy. N0000006107 M0024532 Zalcitabine Dideoxycytidine D016047 ddC (Antiviral) C0012132 C22558 2',3'-Dideoxycytidine Zalcitabine 3363 Cytidine, 2',3'-dideoxy- Zalcitabine Didanosine [Chemical/Ingredient] C22566 C0012133 D016049 3364 Didanosine Didanosine N0000006111 2',3'-Dideoxyinosine Dideoxyinosine Inosine, 2',3'-dideoxy- A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite. M0024535 Didanosine ddI (Antiviral) Pimozide [Chemical/Ingredient] Pimozide Pimozide C22574 M0016871 A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to HALOPERIDOL for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403) N0000006115 Pimozide 8331 D010868 2H-Benzimidazol-2-one, 1-(1-(4,4-bis(4-fluorophenyl)butyl)-4-piperidinyl)-1,3-dihydro- C0031935 lansoprazole [Chemical/Ingredient] C058687 C22582 N0000006119 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)-1H-benzimidazole lansoprazole lansoprazole C0050940 17128 lanzoprazole lansoprazole M0163558 Dexamethasone [Chemical/Ingredient] Methylfluorprednisolone D003907 Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11beta,16alpha)- Dexamethasone 3264 M0006099 C0011777 C22598 An anti-inflammatory 9-fluoro-glucocorticoid. Hexadecadrol N0000006127 Dexamethasone Dexamethasone Chlorambucil [Chemical/Ingredient] Chloraminophene 4-(Bis(2-chloroethyl)amino)benzenebutanoic Acid Benzenebutanoic acid, 4-(bis(2-chloroethyl)amino)- C22626 N,N-Di-(2-chloroethyl)-p-aminophenylbutyric Acid N0000006141 Chlorambucil M0004118 D002699 2346 Chlorbutin A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed) Chlorambucil Chlorambucil C0008163 Teniposide [Chemical/Ingredient] N0000006147 A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle. Teniposide Teniposide C22638 M0021161 C0039512 Demethyl Epipodophyllotoxin Thenylidine Glucoside 10362 D013713 Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-((4,6-O-(2-thienylmethylene)-beta-D-glucopyranosyl)oxy)-, (5R-(5alpha,5abeta,8aalpha,9beta(R*)))- Teniposide Tyrosine [Chemical/Ingredient] para-Tyrosine M0022203 Tyrosine, L-isomer C0041485 A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin. 10962 C22648 L-Tyrosine N0000006152 Tyrosine Tyrosine D014443 Tyrosine Lipids [Chemical/Ingredient] Lipids C22714 Lipids N0000006185 C0023779 6411 D008055 A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) M0012553 Enalapril [Chemical/Ingredient] C0014025 3827 D004656 C22736 Enalapril L-Proline, 1-(N-(1-(ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-, (S)- N0000006195 One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS that is used to treat hypertension. Enalapril M0007330 Enalapril Trimipramine [Chemical/Ingredient] D014299 Trimipramine 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl- Trimeprimine C0041056 Trimipramine Trimipramine C22748 10,11 Dihydro-N,N,beta-trimethyl-5H-dibenz(b,f)azepine-5-propanamine N0000006201 10834 M0021995 Tricyclic antidepressant similar to IMIPRAMINE, but with more antihistaminic and sedative properties. topiramate [Chemical/Ingredient] topiramate topiramate C052342 M0148600 C0076829 N0000006204 2,3-4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate C22754 38404 topiramate olsalazine [Chemical/Ingredient] M0101640 azodisalicylate C032587 N0000006231 C0069454 C22808 Benzoic acid, 3,3'-azobis(6-hydroxy)-, 32385 olsalazine olsalazine olsalazine Amlodipine [Chemical/Ingredient] C0051696 A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION. 3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester D017311 C22882 17767 M0026284 N0000006268 Amlodipine Amlodipine Amlodipine lomefloxacin [Chemical/Ingredient] 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid lomefloxacin C22892 C053091 lomefloxacin 3-Quinolinecarboxylic acid, 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-, monohydrochloride 28872 lomenfloxacin N0000006273 M0150494 C0065162 lomefloxacin Interferon Alfa-2a [Chemical/Ingredient] C0021734 D015380 Interferon Alfa-2a Interferon Alfa-2a 5879 A recombinant alfa interferon consisting of 165 amino acids with lysine at position 23 and histidine at position 34. It is used extensively as an antiviral and antineoplastic agent. M0023693 C22928 N0000006291 Interferon Alfa-2a Recombinant Interferon alpha-2a Recombinant Interferon Alfa-2a Interferon Alfa-2b [Chemical/Ingredient] N0000006294 Recombinant Interferon Alfa-2b Interferon Alfa-2b Interferon Alfa-2b Inteferon alpha 2b (human leukocyte clone Hif-SN 206 protein moiety reduced). 5880 A recombinant alfa interferon consisting of 165 amino acid residues with arginine in position 23 and histidine in position 34. It is used extensively as an antiviral and antineoplastic agent. D015381 Recombinant Interferon alpha-2b C0021735 C22934 Interferon Alfa-2b M0023695 Cladribine [Chemical/Ingredient] 2-Chlorodeoxyadenosine Adenosine, 2-chloro-2'-deoxy- An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. N0000006317 44157 D017338 2-Chloro-2'-deoxyadenosine C22982 C0092801 M0026332 Cladribine 2'-Deoxy-2-chloroadenosine Cladribine Cladribine Fluconazole [Chemical/Ingredient] C23010 Triazole antifungal agent that is used to treat oropharyngeal candidiasis and cryptococcal meningitis in AIDS. 4450 N0000006331 M0024111 1H-1,2,4-Triazole-1-ethanol, alpha-(2,4-difluorophenyl)-alpha-(1H-1,2,4-triazol-1-ylmethyl)- D015725 C0016277 Fluconazole Fluconazole Fluconazole Ergotamine [Chemical/Ingredient] N0000006354 D004878 Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha)- A vasoconstrictor found in ergot of Central Europe. It is a serotonin agonist that has been used as an oxytocic agent and in the treatment of MIGRAINE DISORDERS. Ergotamine C0014710 Ergotamine Ergotamine C23056 4025 M0007662 bexarotene [Chemical/Ingredient] bexarotene M0250478 bexarotene 4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid C095105 N0000006359 C0765273 3-methyl-TTNEB bexarotene C23066 233272 Thalidomide [Chemical/Ingredient] 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)- D013792 Thalidomide C0039736 A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action. 10432 C23082 Thalidomide Thalidomide N0000006367 M0021267 Propofol [Chemical/Ingredient] Propofol Propofol N0000006386 Disoprofol An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS. D015742 M0024130 2,6-Diisopropylphenol C0033487 2,6-Bis(1-methylethyl)phenol Propofol Phenol, 2,6-bis(1-methylethyl)- 8782 C23120 Warfarin [Chemical/Ingredient] M0022871 D014859 11289 Warfarin Warfarin An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide. C23154 N0000006403 Warfarin C0043031 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one 2H-1-Benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)- Bupropion [Chemical/Ingredient] M0025361 Bupropion Bupropion A unicyclic, aminoketone antidepressant. The mechanism of its therapeutic actions is not well understood, but it does appear to block dopamine uptake. The hydrochloride is available as an aid to smoking cessation treatment. N0000006417 D016642 Amfebutamone C23182 (+-)-1-(3-Chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone 42347 C0085208 1-Propanone, 1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)- Bupropion Paroxetine [Chemical/Ingredient] Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3S-trans)- C23192 Paroxetine N0000006422 Paroxetine Paroxetine D017374 C0070122 A serotonin uptake inhibitor that is effective in the treatment of depression. 32937 M0026386 Lisinopril [Chemical/Ingredient] Lysinopril One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure. L-Proline, 1-(N2-(1-carboxy-3-phenylpropyl)-L-lysyl)-, dihydrate, (S)- C0065374 29046 N0000006450 Lisinopril Lisinopril Lisinopril M0026771 D017706 C23248 leflunomide [Chemical/Ingredient] N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide leflunomide C23250 C0063041 leflunomide leflunomide C045463 27169 N0000006451 4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl)- M0132172 Hydrocortisone [Chemical/Ingredient] N0000006460 The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Hydrocortisone D006854 Hydrocortisone M0010707 C23268 Cortisol Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- C0020268 5492 Hydrocortisone Bepridil [Chemical/Ingredient] C23270 1-Pyrrolidineethanamine, beta-((2-methylpropoxy)methyl)-N-phenyl-N-(phenylmethyl)- C0005116 A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. Bepridil Bepridil N0000006461 D015764 1436 M0024153 Bepridil Mefloquine [Chemical/Ingredient] Mefloquine Mephloquine C23282 N0000006467 D015767 6694 Mefloquine A phospholipid-interacting antimalarial drug (ANTIMALARIALS). It is very effective against PLASMODIUM FALCIPARUM with very few side effects. 4-Quinolinemethanol, alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-, (R*,S*)-(+-)- C0025153 Mefloquine M0024162 Ticlopidine [Chemical/Ingredient] Ticlopidine is an effective inhibitor of platelet aggregation. The drug has been found to significantly reduce infarction size in acute myocardial infarcts and is an effective antithrombotic agent in arteriovenous fistulas, aorto-coronary bypass grafts, ischemic heart disease, venous thrombosis, and arteriosclerosis. N0000006471 D013988 Ticlopidine Thieno(3,2-c)pyridine, 5-((2-chlorophenyl)methyl)-4,5,6,7-tetrahydro- Ticlopidine 10594 C0040207 M0021526 C23290 Ticlopidine Ganciclovir [Chemical/Ingredient] C0017066 Gancyclovir D015774 An ACYCLOVIR analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. M0024168 C23338 N0000006495 Ganciclovir Ganciclovir Ganciclovir 4678 6H-Purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)- zolmitriptan [Chemical/Ingredient] C23352 M0237257 zolmitriptan zolmitriptan zolmitriptan C089750 C0528166 N0000006502 135775 4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone Clonidine [Chemical/Ingredient] D003000 C0009014 Clonidine Clonidine M0004605 An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION. C23358 Clofenil 2599 Klofenil Clonidine N0000006505 1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro- Acetic Acid [Chemical/Ingredient] 168 C23382 N0000006517 C0000983 D019342 Acetic Acid Acetic Acid Glacial M0028791 Product of the oxidation of ethanol and of the destructive distillation of wood. It is used locally, occasionally internally, as a counterirritant and also as a reagent. (Stedman, 26th ed) Acetic Acid Glacial Acetic Acid Acetic Acid zafirlukast [Chemical/Ingredient] N0000006523 C062735 C23394 M0173494 114970 zafirlukast zafirlukast zafirlukast 4-(5-cyclopentyloxycarbonylamino-2-methylindol-3-yl-methyl)-3-methoxy-N-O-tolylsulfonylbenzamide C0378466 venlafaxine [Chemical/Ingredient] C23396 39786 N0000006524 C047426 venlafaxine venlafaxine venlafaxine C0078569 1-(2-dimethylamino-1-(4-methoxyphenyl)ethyl)cyclohexan-1-ol M0136964 iopromide [Chemical/Ingredient] 27781 iopromide N0000006526 C0063817 lopromid C23400 N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-(2-methoxyacetamido)-N-methylisophthalamide iopromide iopromide M0115091 iopromid C038192 rofecoxib [Chemical/Ingredient] 232158 C116926 C23406 rofecoxib 4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one C0762662 N0000006529 rofecoxib M0300376 rofecoxib Betaxolol [Chemical/Ingredient] D015784 M0024177 1520 C23412 C0005320 2-Propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)- N0000006532 A cardioselective beta-1-adrenergic antagonist with no partial agonist activity. Betaxolol Betaxolol Betaxolol Podophyllotoxin [Chemical/Ingredient] Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-, (5R-(5alpha,5abeta,8aalpha,9alpha))- D011034 Podofilox Podophyllotoxin Podophyllotoxin C23442 A lignan (LIGNANS) found in PODOPHYLLIN resin from the roots of PODOPHYLLUM plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic. It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do some of its congeners and derivatives. C0032334 podofilox 8463 N0000006547 M0017087 gemcitabine [Chemical/Ingredient] N0000006563 2',2'-difluoro-2'-deoxycytidine C23474 C0045093 2'-deoxy-2'-difluorocytidine dFdCyd C056507 gemcitabine 2',2'-difluorodeoxycytidine gemcitabine gemcitabine 12574 2',2'-DFDC M0158478 Glycerol [Chemical/Ingredient] A trihydroxy sugar alcohol that is an intermediate in carbohydrate and lipid metabolism. It is used as a solvent, emollient, pharmaceutical agent, and sweetening agent. 1,2,3-Propanetriol Glycerin Glycerine M0009417 Glycerin Glycerol Glycerol C23480 N0000006566 4910 C0017861 D005990 1,2,3-Trihydroxypropane Nitroglycerin [Chemical/Ingredient] Glyceryl Trinitrate M0009426 N0000006574 1,2,3-Propanetriol, trinitrate C23496 C0017887 4917 Nitroglycerin A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives. Nitroglycerin Nitroglycerin D005996 Cisapride [Chemical/Ingredient] C23528 N0000006590 C0072916 M0029858 A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed) Cisapride Cisapride D020117 Benzamide, 4-amino-5-chloro-N-(1-(3-(4-fluorophenoxy)propyl)-3-methoxy -4-piperidinyl)-2-methoxy-, cis- 35255 Cisapride Sirolimus [Chemical/Ingredient] C23558 Rapamycin Sirolimus C0072980 M0029863 A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties. 35302 D020123 N0000006605 Sirolimus Sirolimus Alprazolam [Chemical/Ingredient] Alprazolam Alprazolam Alprazolan 4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-1-methyl-6-phenyl- Alprazolam A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238) C0002333 596 C23570 D000525 N0000006611 M0000806 Nitriles [Chemical/Ingredient] N0000006620 Nitriles Nitriles 7443 D009570 Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE. M0014878 C23588 C0028131 Metformin [Chemical/Ingredient] C0025598 D008687 N0000006631 A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289) Metformin Metformin Metformin Imidodicarbonimidic diamide, N,N-dimethyl- Dimethylguanylguanidine Dimethylbiguanidine M0013535 C23610 6809 ropivacaine [Chemical/Ingredient] N0000006648 C037663 C0073571 1-propyl-2',6'-pipecoloxylidide ropivacaine 35780 C23644 ropivacaine M0113809 ropivacaine Nitrofurantoin [Chemical/Ingredient] C23646 2,4-Imidazolidinedione, 1-(((5-nitro-2-furanyl)methylene)amino)- C0028156 A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression. 7454 Nitrofurantoin Nitrofurantoin Nitrofurantoin M0014893 D009582 N0000006649 Sotalol [Chemical/Ingredient] Sotalol N0000006665 Sotalol Sotalol 9947 C23678 Methanesulfonamide, N-(4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)phenyl)- D013015 C0037707 An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias. M0020177 Prednisolone [Chemical/Ingredient] Prednisolone D011239 N0000006669 Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- Prednisolone C23686 C0032950 8638 prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. M0017460 Amantadine [Chemical/Ingredient] Adamantylamine N0000006670 Tricyclo(3.3.1.13,7)decan-1-amine An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake. D000547 Amantadine Amantadine 620 C23688 C0002403 M0000847 Amantadine 1-Aminoadamantane tolcapone [Chemical/Ingredient] C23692 tolcapone tolcapone C0246330 72937 M0182081 N0000006672 C066340 tolcapone 3,4-dihydroxy-5'-methyl-5-nitrobenzophenone Diltiazem [Chemical/Ingredient] D004110 M0006434 3443 A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions. C23712 Diltiazem Diltiazem Diltiazem C0012373 1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-(2-(dimethylamino)ethyl)-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)- N0000006682 Carmustine [Chemical/Ingredient] N,N'-Bis(2-Chloroethyl)-N-Nitrosourea 2105 Carmustine Urea, N,N'-bis(2-chloroethyl)-N-nitroso- C23716 Carmustine 1,3-Bis(2-Chloroethyl)-1-Nitrosourea FIVB C0007257 N0000006684 A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed) D002330 BCNU Carmustine M0003490 Succimer [Chemical/Ingredient] Succimer meso-Dimercaptosuccinic Acid M0006442 N0000006686 Succimer C23720 3446 A mercaptodicarboxylic acid used as an antidote to heavy metal poisoning because it forms strong chelates with them. Butanedioic acid, 2,3-dimercapto-, (R*,S*)- C0012384 DMSA 2,3-Dimercaptosuccinic Acid Succimer D004113 Propafenone [Chemical/Ingredient] http://www.accessdata.fda.gov/drugsatfda_docs/anda/2000/75203_Propafenone%20Hydrochloride_Prntlbl.pdf D011405 Propafenone 1-Propanone, 1-(2-(2-hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl- M0017736 8754 Propafenone C23732 N0000006692 An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. Propafenone C0033429 Levodopa [Chemical/Ingredient] Levodopa Levodopa N0000006700 3-Hydroxy-L-tyrosine C0023570 M0012434 6375 D007980 L-3,4-Dihydroxyphenylalanine C23748 The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. Levodopa L-Dopa Midazolam [Chemical/Ingredient] C0026056 Midazolam Midazolam D008874 6960 N0000006704 M0013843 4H-Imidazo(1,5-a)(1,4)benzodiazepine, 8-chloro-6-(2-fluorophenyl)-1-methyl- C23756 A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH. Midazolam Gonadotropin-Releasing Hormone [Chemical/Ingredient] FSH-Releasing Hormone 5-oxoPro-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 (human or pig) Gonadotropin-Releasing Hormone GnRH LFRH A decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. GnRH is produced by neurons in the septum PREOPTIC AREA of the HYPOTHALAMUS and released into the pituitary portal blood, leading to stimulation of GONADOTROPHS in the ANTERIOR PITUITARY GLAND. LHRH N0000006708 M0012446 C23764 D007987 LH/FSH-RH LH-Releasing Hormone LH-RH 6384 LHFSHRH LHFSH Releasing Hormone Luteinizing Hormone-Releasing Hormone Gonadoliberin Gonadorelin Gn-RH Luliberin C0023610 LH-FSH Releasing Hormone Gonadotropin-Releasing Hormone Gonadorelin Interferon-alpha [Chemical/Ingredient] Interferon, Leukocyte M0025711 One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways. Interferon, Lymphoblastoid D016898 N0000006710 Interferon-alpha alpha-Interferon Interferon, alpha Interferon-alpha Interferon-alpha Interferon Alfa Interferon, Lymphoblast C23768 541 C0002199 Polyethylene Glycols [Chemical/Ingredient] Polyethylene Glycol Polyethylene Oxide Polyoxyethylenes Polyethyleneoxide Macrogols D011092 M0017182 Polyethylene Glycols C23784 Polyethylene Glycols Polyethylene Glycols N0000006718 C0032483 8516 Polymers of ETHYLENE OXIDE and water, and their ethers. They vary in consistency from liquid to solid depending on the molecular weight indicated by a number following the name. They are used as SURFACTANTS, dispersing agents, solvents, ointment and suppository bases, vehicles, and tablet excipients. Some specific groups are NONOXYNOLS, OCTOXYNOLS, and POLOXAMERS. Colchicine [Chemical/Ingredient] Acetamide, N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)-, (S)- A major alkaloid from Colchicum autumnale L. and found also in other Colchicum species. Its primary therapeutic use is in the treatment of gout, but it has been used also in the therapy of familial Mediterranean fever (PERIODIC DISEASE). Colchicine Colchicine M0004732 D003078 N0000006724 C0009262 Colchicine 2683 C23796 Itraconazole [Chemical/Ingredient] M0027131 28031 D017964 C0064113 N0000006753 3H-1,2,4-Triazol-3-one, 4-(4-(4-(4-((2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-2,4-dihydro-2-(1-methylpropyl)- Itraconazole Itraconazole A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis. Itraconazole C23856 Glutamic Acid [Chemical/Ingredient] 25916 N0000006756 L-Glutamic Acid Glutamic Acid A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM. M0028010 Glutamic Acid C23862 L-Glutamic acid D018698 C0061472 Glutamic Acid Propylthiouracil [Chemical/Ingredient] C23924 Propylthiouracil C0033511 D011441 4(1H)-Pyrimidinone, 2,3-dihydro-6-propyl-2-thioxo- 8794 M0017784 Propylthiouracil N0000006787 A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534) 6-Propyl-2-Thiouracil Propylthiouracil Doxorubicin [Chemical/Ingredient] M0006784 N0000006795 D004317 Doxorubicin Doxorubicin Doxorubicin 3639 C23940 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. C0013089 Etoposide [Chemical/Ingredient] Etoposide Eposide Etoposide Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, 9-((4,6-O-ethylidene-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (5R-(5alpha,5abeta,8aalpha,9beta(R*)))- C23946 M0007930 4179 N0000006798 Demethyl Epipodophyllotoxin Ethylidine Glucoside D005047 C0015133 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Penicillamine [Chemical/Ingredient] 7975 N0000006803 D-Penicillamine Mercaptovaline D-Valine, 3-mercapto- Penicillamine M0016122 C0030817 beta,beta-Dimethylcysteine 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease. C23956 D010396 Penicillamine Penicillamine D-3-Mercaptovaline Dimethylcysteine Amino Acids [Chemical/Ingredient] C0002520 M0000922 D000596 Organic compounds that generally contain an amino (-NH2) and a carboxyl (-COOH) group. Twenty alpha-amino acids are the subunits which are polymerized to form proteins. C23962 N0000006806 Amino Acids Amino Acids Amino Acids 658 aldesleukin [Chemical/Ingredient] 2-133-Interleukin 2 (human reduced), 125-L-serine- C082598 C0218986 M0220038 C23974 aldesleukin 70223 N0000006812 aldesleukin Aldesleukin Topotecan [Chemical/Ingredient] 9-Dimethylaminomethyl-10-hydroxycamptothecin An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I. Hycamtamine D019772 M0029340 57308 C24014 C0146224 Topotecan N0000006832 Topotecan Topotecan Fatty Acids [Chemical/Ingredient] Fatty Acids 4297 Fatty Acids N0000006847 D005227 C24044 C0015684 M0008265 Organic, monobasic acids derived from hydrocarbons by the equivalent of oxidation of a methyl group to an alcohol, aldehyde, and then acid. Fatty acids are saturated and unsaturated (FATTY ACIDS, UNSATURATED). (Grant & Hackh's Chemical Dictionary, 5th ed) Dapsone [Chemical/Ingredient] DADPS Sulfonyldianiline Diaminodiphenylsulfone D003622 A sulfone active against a wide range of bacteria but mainly employed for its actions against MYCOBACTERIUM LEPRAE. Its mechanism of action is probably similar to that of the SULFONAMIDES which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with PYRIMETHAMINE in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8) 4,4'-Diaminophenyl Sulfone C0010980 N0000006908 Dapsone Dapsone 3108 M0005661 C24166 Dapsone Diaphenylsulfone Daunorubicin [Chemical/Ingredient] M0005683 3109 Daunorubicin Daunorubicin Rubomycin 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)- D003630 C24212 A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. N0000006931 Dauno-Rubidomycine Rubidomycin C0011015 Daunorubicin Daunomycin Zidovudine [Chemical/Ingredient] Zidovudine AZT, Antiviral Azidothymidine AZT Antiviral Zidovudine 3'-Azido-3'-deoxythymidine N0000006933 A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. D015215 M0023377 3'-Azido-2',3'-Dideoxythymidine Thymidine, 3'-azido-3'-deoxy- C0043474 C24216 Zidovudine 11413 AZT (Antiviral) Flecainide [Chemical/Ingredient] C24282 4441 Flecainide N0000006966 A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial arrhythmias and tachycardias. Paradoxically, however, in myocardial infarct patients with either symptomatic or asymptomatic arrhythmia, flecainide exacerbates the arrhythmia and is not recommended for use in these patients. C0016229 Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)- Flecainide M0008556 Flecainide D005424 Indomethacin [Chemical/Ingredient] 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- C0021246 M0011240 D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits the enzyme cyclooxygenase necessary for the formation of prostaglandins and other autacoids. It also inhibits the motility of polymorphonuclear leukocytes. C24330 Indomethacin 5781 Indometacin Indomethacin N0000006990 Urea [Chemical/Ingredient] C0041942 Urea Urea M0022315 D014508 N0000006999 A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. Carbamide C24348 11002 Urea Flucytosine [Chemical/Ingredient] Flucytosine 4451 A fluorinated cytosine analog that is used as an antifungal agent. Flucytosine 5-Fluorocytosine M0008576 C24356 C0016278 Flucytosine D005437 2(1H)-Pyrimidinone, 4-amino-5-fluoro- N0000007003 Ofloxacin [Chemical/Ingredient] C24388 7623 Ofloxacin D015242 Ofloxacin M0023430 A synthetic fluoroquinolone (FLUOROQUINOLONES) antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION. (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7- -oxo-7H-pyrido(1,2,3-de)- -1,4-benzoxazine-6-carboxylic acid N0000007019 C0028902 Ofloxacin Ofloxacine vinorelbine [Chemical/Ingredient] N0000007026 M0097344 39541 5'-nor-anhydrovinblastine C0078257 vinorelbine vinorelbine C'-Norvincaleukoblastine, 3',4'-didehydro-4'-deoxy- C24402 C030852 vinorelbine Fentanyl [Chemical/Ingredient] C0015846 D005283 Fentanyl C24408 Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- M0008338 A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078) Phentanyl 4337 N0000007029 Fentanyl Fentanyl Gemfibrozil [Chemical/Ingredient] C24428 D015248 4719 N0000007039 C0017245 Pentanoic acid, 5-(2,5-dimethylphenoxy)-2,2-dimethyl- Gemfibrozil Gemfibrozil M0023484 Gemfibrosil A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol. These decreases occur primarily in the VLDL fraction and less frequently in the LDL fraction. Gemfibrozil increases HDL subfractions HDL2 and HDL3 as well as apolipoproteins A-I and A-II. Its mechanism of action has not been definitely established. Gemfibrozil Tamoxifen [Chemical/Ingredient] 10324 Tamoxifen C0039286 C24432 Tamoxifen Ethanamine, 2-(4-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-, (Z)- M0021024 N0000007041 D013629 One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM. Tamoxifen Ifosfamide [Chemical/Ingredient] 5657 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide Iso-Endoxan C24440 Ifosfamide Isophosphamide C0020823 Isofosfamide N0000007045 Iphosphamide Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent. Ifosfamide Ifosfamide D007069 M0010999 Ciprofloxacin [Chemical/Ingredient] Ciprofloxacin A broad-spectrum antimicrobial carboxyfluoroquinoline. 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)- D002939 C24442 Ciprofloxacin 2551 N0000007046 M0004498 C0008809 Ciprofloxacin zaleplon [Chemical/Ingredient] Acetamide, N-(3-(3-cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethyl- C0251504 N0000007050 zaleplon C085665 zaleplon zaleplon 74667 C24450 M0227287 N-(3-(3-cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide Pravastatin [Chemical/Ingredient] M0025879 An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES). C0085542 N0000007054 Eptastatin 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))- Pravastatin Pravastatin Pravastatin C24460 42463 D017035 Cisplatin [Chemical/Ingredient] C0008838 cis-Diamminedichloroplatinum(II) C24476 cis-Diamminedichloroplatinum cis-Dichlorodiammineplatinum(II) 2555 cis-Platinum M0004505 Dichlorodiammineplatinum Platinum Diamminodichloride D002945 Cisplatin Cisplatin Platinum, diamminedichloro-, (SP-4-2)- N0000007062 An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Cisplatin Deferoxamine [Chemical/Ingredient] Desferrioxamine B N0000007065 Desferrioxamine Deferrioxamine B Butanediamide, N'-(5-((4-((5-(acetylhydroxyamino)pentyl)amino)-1,4-dioxobutyl)hydroxyamino)pentyl)-N-(5-aminopentyl)-N-hydroxy- 3131 D003676 M0005750 Desferioximine C0011145 Deferoxamine Deferoxamine C24482 Desferroxamine Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. Deferoximine Deferoxamine B Deferoxamine Fructose [Chemical/Ingredient] C24544 Fructose Levulose 4570 A monosaccharide in sweet fruits and honey that is soluble in water, alcohol, or ether. It is used as a preservative and an intravenous infusion in parenteral feeding. Fructose C0016745 M0008855 D005632 Fructose N0000007096 Fluorouracil [Chemical/Ingredient] 5-Fluorouracil 4492 2,4(1H,3H)-Pyrimidinedione, 5-fluoro- C24550 5-FU N0000007099 C0016360 Fluorouracil Fluorouracil Fluorouracil Fluoruracil D005472 5FU A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. M0008631 Fluoxetine [Chemical/Ingredient] N0000007101 Benzenepropanamine, N-methyl-gamma-(4-(trifluoromethyl)phenoxy)-, (+-)- D005473 M0008635 Fluoxetine Fluoxetin Fluoxetine Fluoxetine N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine C0016365 C24554 4493 The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants. tizanidine [Chemical/Ingredient] C0146011 M0081344 C24558 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole C023754 tizanidine tizanidine N0000007103 tizanidine 2,1,3-Benzothiadiazol-4-amine, 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)- 57258 Lovastatin [Chemical/Ingredient] Monacolin K N0000007106 Butanoic acid, 2-methyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (1S-(1alpha(R*),3alpha,7beta,8beta(2S*,4S*),8abeta))- 6-Methylcompactin 6472 A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver. D008148 C0024027 M0012707 Lovastatin Lovastatin Lovastatin Mevinolin C24564 montelukast [Chemical/Ingredient] C24588 C0298130 C093875 montelukast N0000007118 88249 montelukast montelukast M0247416 Stavudine [Chemical/Ingredient] Stavudine C0164662 2',3'-Didehydro-3'-deoxythymidine Stavudine C24610 D018119 N0000007129 Thymidine, 2',3'-didehydro-3'-deoxy- 2',3'-Didehydro-2',3'-dideoxythmidine D4T A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. 59763 Stavudine M0027323 Erythromycin [Chemical/Ingredient] C0014806 N0000007133 M0007715 C24618 A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erythromycin Erythromycin 4053 Erythromycin A D004917 Erythromycin Paclitaxel [Chemical/Ingredient] 56946 C24658 C0144576 Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalph A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death. D017239 N0000007153 Paclitaxel M0026156 Paclitaxel Paclitaxel Carboplatin [Chemical/Ingredient] Carboplatin CBDCA Platinum, diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)- M0024707 C24680 C0079083 An organoplatinum compound that possesses antineoplastic activity. 40048 Carboplatin Carboplatin D016190 N0000007164 cis-Diammine(cyclobutanedicarboxylato)platinum II Foscarnet [Chemical/Ingredient] Phosphonoformic Acid M0026166 Foscarnet N0000007166 Phosphinecarboxylic acid, dihydroxy-, oxide Foscarnet Foscarnet An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV. 33562 C24684 C0070895 D017245 Clomipramine [Chemical/Ingredient] 2597 Clomipramine Clomipramine C24716 Chlorimipramine A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine. M0004598 5H-Dibenz(b,f)azepine-5-propanamine, 3-chloro-10,11-dihydro-N,N-dimethyl- C0009010 N0000007182 Chlomipramine D002997 Clomipramine Vidarabine [Chemical/Ingredient] 11194 Ara-A M0022659 C24724 C0042646 beta-Ara A alpha-Ara A Ara A A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus. 9H-Purin-6-amine, 9-beta-D-arabinofuranosyl- N0000007186 alpha-D-Arabinofuranosyladenine 9-beta-Arabinofuranosyladenine Arabinofuranosyladenine 9-beta-D-Arabinofuranosyladenine D014740 Adenine Arabinoside Vidarabine Arabinosyladenine Vidarabine Vidarabine Kanamycin [Chemical/Ingredient] M0011917 C24728 Kanamycin C0022487 N0000007188 D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-4))-2-deoxy- D007612 6099 Kanamycin Kanamycin Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components. Desipramine [Chemical/Ingredient] N0000007195 Desmethylimipramine Desipramine D003891 Desipramine Desipramine A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors. Demethylimipramine 3247 C0011685 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N-methyl- M0006074 C24742 Ramipril [Chemical/Ingredient] N0000007202 C0072973 A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat. Ramipril Ramipril Ramipril Cyclopenta(b)pyrrole-2-carboxylic acid, 1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-, (2S-(1(R*(R*)),2alpha,3abeta,6abeta))- C24756 D017257 35296 M0026184 Vinblastine [Chemical/Ingredient] M0022672 Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) C0042670 D014747 Vincaleukoblastine Vinblastine Vinblastine N0000007206 C24764 11198 Vinblastine Etidronic Acid [Chemical/Ingredient] M0020098 Etidronic Acid Etidronic Acid C24784 D012968 (1-hydroxyethylene)diphosphonic acid A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover. 4172 Hydroxyethylidene Diphosphonic Acid C0015121 N0000007216 Iohexol [Chemical/Ingredient] Iohexol Iohexol 350 An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. N0000007257 C0022005 M0011673 5956 Iohexol Iohexol D007472 1,3-Benzenedicarboxamide, 5-(acetyl(2,3-dihydroxypropyl)amino)-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo- C24866 Altretamine [Chemical/Ingredient] M0010310 C24884 C0019453 Altretamine 5296 Altretamine D006585 1,3,5-Triazine-2,4,6-triamine, N,N,N',N',N'',N''-hexamethyl- Hexamethylmelamine Hemel N0000007266 A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine. Altretamine Iopamidol [Chemical/Ingredient] 1,3-Benzenedicarboxamide, N,N'-bis(2-hydroxy-1-(hydroxymethyl)ethyl)-5-((2-hydroxy-1-oxopropyl)amino)-2,4,6-triiodo- A non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiological procedures. C0022026 Iopamidol Jopamidol N0000007268 M0011680 D007479 5966 Iopamidol Iopamidol C24888 Acyclovir [Chemical/Ingredient] 6H-Purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)- M0000326 281 N0000007269 C24890 A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes. Acycloguanosine Aciclovir 9-((2-Hydroxyethoxy)methyl)guanine Acyclovir Acyclovir D000212 C0001367 Acyclovir Sumatriptan [Chemical/Ingredient] http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020080s049lbl.pdf Sumatriptan M0027392 A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS. D018170 1H-Indole-5-methanesulfonamide, 3-(2-(dimethylamino)ethyl)-N-methyl- N0000007273 C24898 Sumatriptan C0075632 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide 37418 Sumatriptan bicalutamide [Chemical/Ingredient] Propanamide, N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methyl-, (+-)- C24904 bicalutamide bicalutamide bicalutamide 83008 M0151653 C0285590 N0000007276 C053541 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide clopidogrel [Chemical/Ingredient] C0070166 methyl 2-(2-chlorophenyl)-2-(4,5,6,7-tetrahydrothieno(3,2-c)pyridin-5-yl)acetate C055162 C24906 clopidogrel clopidogrel M0155432 32968 N0000007277 clopidogrel Hydroxyurea [Chemical/Ingredient] C0020402 M0010790 5552 Hydroxycarbamid D006918 Hydroxyurea An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. Hydroxyurea hydroxyurea Urea, hydroxy- C24938 N0000007293 Nalidixic Acid [Chemical/Ingredient] http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/014214s060lbl.pdf N0000007297 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-1,4-dihydro-7-methyl-4-oxo- 7240 Nalidixic Acid Nalidixin C0027353 Nalidixic Acid Nalidixic Acid M0014437 C24946 A synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA GYRASE. D009268 Tacrolimus [Chemical/Ingredient] Tacrolimus C24956 15,19-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, 5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-(2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl)-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-p M0025261 Tacrolimus A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro. C0085149 N0000007302 42316 D016559 Tacrolimus Ethambutol [Chemical/Ingredient] 1-Butanol, 2,2'-(1,2-ethanediyldiimino)bis-, (S-(R*,R*))- Ethambutol C24966 D004977 M0007814 An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863) Ethambutol Ethambutol N0000007307 4110 C0014964 Adenine [Chemical/Ingredient] M0000347 290 1H-Purin-6-amine C24970 A purine base and a fundamental unit of ADENINE NUCLEOTIDES. N0000007309 Adenine Adenine C0001407 D000225 Vitamin B 4 Adenine Adenine Nucleotides [Chemical/Ingredient] M0000352 Adenine Nucleotides N0000007310 D000227 C24972 Adenosine Phosphates C0001413 Adenine Nucleotides 292 Ketoconazole [Chemical/Ingredient] Broad spectrum antifungal agent used for long periods at high doses, especially in immunosuppressed patients. Piperazine, 1-acetyl-4-(4-((2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-, cis- C0022625 N0000007319 Ketoconazole Ketoconazole Ketoconazole 6135 C24990 M0011987 D007654 Leuprolide [Chemical/Ingredient] Leuprolide D016729 Leuprolide A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. C0085272 N0000007326 Leuprorelin Luteinizing hormone-releasing factor (pig), 6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide- 42375 C25004 Leuprolide M0025473 Methimazole [Chemical/Ingredient] Merkazolil C0025644 1-Methyl-2-mercaptoimidazole Methimazole Methymazol D008713 6835 Mercasolyl Methimazole Tiamazol Thiamazole C25030 A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme. 2H-Imidazole-2-thione, 1,3-dihydro-1-methyl- Methylmercaptoimidazole Thimazol Mercazolyl Methimazole N0000007339 M0013573 Cyclosporine [Chemical/Ingredient] Cyclosporin A C0010592 D016572 3008 Cyclosporine Cyclosporine Cyclosporine M0025279 N0000007346 Ciclosporin Cyclosporin Cyclosporine A A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed). C25044 zolpidem [Chemical/Ingredient] C0078839 N,N,6-trimethyl-2-(4-methylphenyl)imidazo(1,2a)pyridine-3-acetamide hemitartrate C049109 N0000007347 C25046 M0140872 zolpidem zolpidem zolpidem 39993 Adenosine [Chemical/Ingredient] D000241 M0000377 296 C25062 Adenosine A nucleoside that is composed of adenine and d-ribose. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. Adenosine Adenosine C0001443 N0000007355 Delavirdine [Chemical/Ingredient] A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Piperazine, 1-(3-((1-methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1H-indol-2-yl)carbonyl)- Delavirdine Delavirdine N0000007358 83816 D020008 C25068 C0288165 M0029713 Delavirdine Acetates [Chemical/Ingredient] D000085 M0000125 C25076 N0000007362 166 Salts or esters of acetic acid in which the terminal hydrogen atom is replaced by a metal, for instance copper acetate Cu(CH3COO)2, or where substitution is by a radical, for instance ethyl acetate CH3COOC2H5. (From Hawley's Condensed Chemical Dictionary, 12th ed) Acetates Acetates C0000979 dofetilide [Chemical/Ingredient] 1-MSPMPE 49247 1-(4-methanesulfonamidophenoxy)-2-(N-(4-methanesulfonamidophenethyl)-N-methylamine)ethane C25084 C063533 C0114771 dofetilide dofetilide dofetilide N0000007366 M0175350 Methotrexate [Chemical/Ingredient] D008727 M0013595 An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. L-Glutamic acid, N-(4-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)- C0025677 N0000007370 C25092 Methotrexate Methotrexate Methotrexate Amethopterin 6851 Saquinavir [Chemical/Ingredient] 83395 M0028681 C25104 D019258 Saquinavir C0286738 N0000007376 Saquinivir Saquinavir Saquinavir An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases. Lamivudine [Chemical/Ingredient] A reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease. 2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis)- Lamivudine N0000007380 M0028682 Lamivudine Lamivudine 3TC 2',3'-Dideoxy-3'-thiacytidine C0209738 C25112 D019259 68244 Astemizole [Chemical/Ingredient] A long-acting, non-sedative antihistaminic used in the treatment of seasonal allergic rhinitis, asthma, allergic conjunctivitis, and chronic idiopathic urticaria. The drug is well tolerated and has no anticholinergic side effects. 42328 C25118 D016589 1H-Benzimidazol-2-amine, 1-((4-fluorophenyl)methyl)-N-(1-(2-(4-methoxyphenyl)ethyl)-4-piperidinyl)- Astemizole Astemizole Astemizole C0085170 N0000007383 M0025303 Terfenadine [Chemical/Ingredient] C0085173 Terfenadine 1-Piperidinebutanol, alpha-(4-(1,1-dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)- D016593 Terfenadine Terfenadine C25148 42330 Terfenidine N0000007398 M0025307 alpha-(4-(1,1-Dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-1-piperdinebutanol A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME. pantoprazole [Chemical/Ingredient] pantoprazole pantoprazole C0081876 40790 C064276 1H-Benzimidazole, 5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)- pantoprazole C25150 M0177102 N0000007399 Misoprostol [Chemical/Ingredient] A synthetic analog of natural prostaglandin E1. It produces a dose-related inhibition of gastric acid and pepsin secretion, and enhances mucosal resistance to injury. It is an effective anti-ulcer agent and also has oxytocic properties. M0025309 C25156 Prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, (11alpha,13E)- C0085174 42331 Misoprostol Misoprostol Misoprostol D016595 N0000007402 Auranofin [Chemical/Ingredient] Auranofin C0004320 Auranofin M0001971 C25164 Auranofin Gold, (1-thio-beta-D-glucopyranose 2,3,4,6-tetraacetato-S)(triethylphosphine)- 1227 N0000007406 D001310 An oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. Its exact mechanism of action is unknown, but it is believed to act via immunological mechanisms and alteration of lysosomal enzyme activity. Its efficacy is slightly less than that of injected gold salts, but it is better tolerated, and side effects which occur are potentially less serious. Ritonavir [Chemical/Ingredient] Ritonavir 85762 C0292818 Ritonavir D019438 C25198 M0028918 N0000007423 An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. Ritonavir atorvastatin [Chemical/Ingredient] C0286651 83367 C065179 C25208 atorvastatin M0179294 N0000007428 atorvastatin atorvastatin liptonorm Capsaicin [Chemical/Ingredient] N0000007430 D002211 6-Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-, (E)- Capsaicin Capsaicin Capsaicin C0006931 1992 An alkylamide found in CAPSICUM that acts at TRPV CATION CHANNELS. C25212 M0003308 8-Methyl-N-Vanillyl-6-Nonenamide Capsaicine Ethanol [Chemical/Ingredient] 448 Grain Alcohol C0001962 D000431 Ethanol Ethanol Ethanol A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in ALCOHOLIC BEVERAGES. N0000007432 M0000653 Alcohol, Ethyl C25216 Alcohols [Chemical/Ingredient] M0000663 Alkyl compounds containing a hydroxyl group. They are classified according to relation of the carbon atom: primary alcohols, R-CH2OH; secondary alcohols, R2-CHOH; tertiary alcohols, R3-COH. (From Grant & Hackh's Chemical Dictionary, 5th ed) D000438 N0000007439 Alcohols Alcohols Alcohols C25230 455 C0001975 anastrozole [Chemical/Ingredient] N0000007441 C090450 anastrazole 84857 anastrozole anastrozole anastrozole C0290883 C25234 M0238999 1,3-Benzenediacetonitrile, alpha,alpha,alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)- 2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile) fluvastatin [Chemical/Ingredient] 41127 fluindostatin M0179302 C0082608 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoate fluvastatin fluvastatin fluvastatin C25244 N0000007446 C065180 Norfloxacin [Chemical/Ingredient] A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE. Norfloxacin 7517 C0028365 Norfloxacin Norfloxacin 3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)- C25254 D009643 M0014980 N0000007451 Methylergonovine [Chemical/Ingredient] Methylergometrine M0013636 6883 Methylergobasin Methylergonovine C25276 Methylergonovine D008755 C0025760 A homolog of ERGONOVINE containing one more CH2 group. (Merck Index, 11th ed) Methylergometrin Ergoline-8-carboxamide, 9,10-didehydro-N-(1-(hydroxymethyl)propyl)-6-methyl-, (8beta(S))- N0000007462 Methylergonovine Rifabutin [Chemical/Ingredient] N0000007464 Ansamycin C25280 Rifabutin 55672 M0026934 Rifabutin C0140575 Rifabutine A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. Rifamycin XIV, 1',4-didehydro-1-deoxy-1,4-dihydro-5'-(2-methylpropyl)-1-oxo- D017828 Rifabutin Penicillin G [Chemical/Ingredient] C0030827 Penicillin G D010400 A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission. Penicillin G Benzylpenicillin Penicillin G 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-((phenylacetyl)amino)- (2S-(2alpha,5alpha,6beta))- M0016133 N0000007468 C25288 7980 Penicillin G Benzathine [Chemical/Ingredient] N0000007469 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-((phenylacetyl)amino)- (2S-(2alpha,5alpha,6beta))-, compd. with N,N'-bis(phenylmethyl)-1,2-ethanediamine (2:1) M0016138 C0030829 C25290 Penicillin G Benzathine Semisynthetic antibiotic prepared by combining the sodium salt of penicillin G with N,N'-dibenzylethylenediamine. Benzathine Penicillin D010401 penicillin G benzathine Penicillin G Benzathine 7982 Benzathine Benzylpenicillin Carbamazepine [Chemical/Ingredient] M0003328 An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of PHENYTOIN; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. C25292 5H-Dibenz(b,f)azepine-5-carboxamide 2002 N0000007470 D002220 Carbamazepine C0006949 Carbamazepine Carbamazepine Amino Acids, Essential [Chemical/Ingredient] C0002525 D000601 Amino Acids, Essential M0000927 C25296 N0000007472 Essential Amino Acids 663 Amino acids that are not synthesized by the human body in amounts sufficient to carry out physiological functions. They are obtained from dietary foodstuffs. Amino Acids, Essential sildenafil [Chemical/Ingredient] C0529793 C101426 M0265894 sildenafil 136411 N0000007479 sildenafil sildenafil C25310 Buspirone [Chemical/Ingredient] 1827 N0000007480 N-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-1-cyclopentanediacetamide 8-Azaspiro(4.5)decane-7,9-dione, 8-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)- C0006462 D002065 An anxiolytic agent and a serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the benzodiazepines, but it has an efficacy comparable to DIAZEPAM. Buspirone M0003077 C25312 Buspirone Buspirone Carbolines [Chemical/Ingredient] Carbolines 2030 A group of pyrido-indole compounds. Included are any points of fusion of pyridine with the five-membered ring of indole and any derivatives of these compounds. These are similar to CARBAZOLES which are benzo-indoles. Pyrido(4,3-b)Indoles C25354 N0000007499 C0007007 M0003364 D002243 Carbolines Alkaloids [Chemical/Ingredient] Alkaloids C0002062 496 Alkaloids D000470 Organic nitrogenous bases. Many alkaloids of medical importance occur in the animal and vegetable kingdoms, and some have been synthesized. (Grant & Hackh's Chemical Dictionary, 5th ed) C25362 M0000713 N0000007503 Oligopeptides [Chemical/Ingredient] 7639 Peptides composed of between two and twelve amino acids. D009842 Oligopeptides M0015279 Oligopeptides N0000007507 C0028954 C25370 Anilides [Chemical/Ingredient] Anilides N0000007515 C0003035 D000813 842 C25386 M0001214 Anilides Benzamides [Chemical/Ingredient] Benzamides BENZOIC ACID amides. C25396 C0005029 1381 Benzamides M0002327 N0000007520 D001549 Benzamidines [Chemical/Ingredient] C25402 1382 N0000007523 C0005030 Amidines substituted with a benzene group. Benzamidine and its derivatives are known as peptidase inhibitors. Benzamidines Benzamidines M0002328 D001550 Benzazepines [Chemical/Ingredient] M0002330 Benzazepines C0005034 1384 C25404 D001552 N0000007524 Benzazepines Compounds with BENZENE fused to AZEPINES. Benzene Derivatives [Chemical/Ingredient] 1387 D001555 C0005037 C25406 Benzene Derivatives Benzene Derivatives N0000007525 M0002333 Phenethylamines [Chemical/Ingredient] D010627 N0000007526 Phenylethylamines Phenethylamines C25408 M0016506 C0031399 A group of compounds that are derivatives of beta- aminoethylbenzene which is structurally and pharmacologically related to amphetamine. (From Merck Index, 11th ed) 8127 Phenethylamines Benzenesulfonates [Chemical/Ingredient] D001557 C25410 N0000007527 Organic salts and esters of benzenesulfonic acid. C0005040 Benzenesulfonates Benzenesulfonates M0002336 1389 Benzhydryl Compounds [Chemical/Ingredient] Benzhydryl Compounds D001559 Diphenylmethyl Compounds N0000007528 C25412 1392 C0005046 Compounds which contain the methyl radical substituted with two benzene rings. Permitted are any substituents, but ring fusion to any of the benzene rings is not allowed. M0002345 Benzhydryl Compounds Macrolides [Chemical/Ingredient] Macrolides M0028311 Macrolides D018942 A group of macrocyclic compounds formed by chain extension of multiple PROPIONATES and cyclized into a large (typically 12, 14, 16) membered lactone. They are often glycosylated. Many of them are ANTIBIOTICS. C25414 N0000007529 586370 C0282563 Anthracyclines [Chemical/Ingredient] C25416 M0028312 D018943 Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine. Anthracyclines N0000007530 C0282564 82158 Anthracyclines Spiro Compounds [Chemical/Ingredient] N0000007532 M0020345 A group of compounds consisting in part of two rings sharing one carbon atom in common. Spiro Compounds D013141 9993 C0037968 Spiro Compounds C25420 Benzimidazoles [Chemical/Ingredient] Compounds with a BENZENE fused to IMIDAZOLES. C0005050 D001562 C25428 M0002348 Benzimidazoles Benzimidazoles 1396 N0000007536 Phenols [Chemical/Ingredient] M0016520 Phenols C25436 8140 C0031428 N0000007540 Phenols Carbol D010636 Anions [Chemical/Ingredient] D000838 C25438 Anions N0000007541 M0001248 C0003075 Anions 853 Negatively charged atoms, radicals or groups of atoms which travel to the anode or positive pole during electrolysis. Benzodiazepines [Chemical/Ingredient] Benzodiazepine Compounds A group of two-ring heterocyclic compounds consisting of a benzene ring fused to a diazepine ring. C0005064 M0002356 1402 Benzodiazepines Benzodiazepine C25440 D001569 Benzodiazepines N0000007542 Benzofurans [Chemical/Ingredient] D001572 C0005068 M0002359 Compounds that contain a BENZENE ring fused to a furan ring. N0000007548 Benzofurans Coumarones 1405 C25452 Benzofurans Phenyl Ethers [Chemical/Ingredient] N0000007549 M0016542 C25454 Phenyl Ethers 8154 C0031449 Ethers that are linked to a benzene ring structure. Phenyl Ethers D010647 Benzophenones [Chemical/Ingredient] 1410 Benzophenones C0005077 Benzophenones M0002366 C25460 D001577 N0000007552 Benzopyrans [Chemical/Ingredient] Benzopyrans Benzopyrans M0002367 C0005078 1411 C25462 N0000007553 D001578 Chromenes Compounds with a core of fused benzo-pyran rings. Dihydropyridines [Chemical/Ingredient] Dihydropyridines C25468 N0000007556 C0012315 D004095 M0006414 Pyridine moieties which are partially saturated by the addition of two hydrogen atoms in any position. Dihydropyridines 3427 Triazines [Chemical/Ingredient] N0000007561 C0040877 Heterocyclic rings containing three nitrogen atoms, commonly in 1,2,4 or 1,3,5 or 2,4,6 formats. Some are used as HERBICIDES. Triazines 10765 Triazines M0021908 D014227 C25478 Benzyl Compounds [Chemical/Ingredient] Benzyl Compounds M0002387 C0005103 D001593 C25482 Benzyl Compounds 1428 N0000007563 Pyrazines [Chemical/Ingredient] C0034240 Pyrazines 8988 M0018225 N0000007565 C25486 Pyrazines D011719 Triazoles [Chemical/Ingredient] Triazoles D014230 Triazoles N0000007567 M0021911 C25490 C0040880 10768 Oxazolidinones [Chemical/Ingredient] M0361132 C25492 Oxazolidinones Oxazolidinones C0887953 N0000007568 D023303 Derivatives of oxazolidin-2-one. They represent an important class of synthetic antibiotic agents. 267582 Pyridines [Chemical/Ingredient] C0034255 Pyridines Pyridines D011725 8995 Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES. N0000007570 C25496 M0018233 Anthracenes [Chemical/Ingredient] A group of compounds with three aromatic rings joined in linear arrangement. Anthracenes C25504 C0003163 M0001303 Anthracenes D000873 871 N0000007574 Salicylic Acids [Chemical/Ingredient] M0019370 C0036080 Derivatives and salts of SALICYLIC ACID. N0000007582 9526 Salicylic Acids Salicylic Acids D012461 C25520 Anthraquinones [Chemical/Ingredient] M0001314 Anthracenediones N0000007583 D000880 Anthraquinones Anthraquinones Compounds based on ANTHRACENES which contains two KETONES in any position. Substitutions can be in any position except on the ketone groups. 879 C25522 Anthranoids C0003174 Biogenic Monoamines [Chemical/Ingredient] C25528 D015306 1565 Biogenic Monoamines M0023566 C0005497 N0000007586 Biogenic amines having only one amine moiety. Included in this group are all natural monoamines formed by the enzymatic decarboxylation of natural amino acids. Monoamines, Biogenic Biogenic Monoamines Pyrimidines [Chemical/Ingredient] Pyrimidines N0000007587 M0018260 C25530 Pyrimidines C0034289 9015 D011743 A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates. Pyrimidinones [Chemical/Ingredient] M0018261 Pyrimidinones N0000007588 9016 C25532 D011744 C0034290 Pyrimidinones Pyrones [Chemical/Ingredient] M0018272 Keto-pyrans. 9028 Pyrones C0034314 C25536 D011753 Pyrones N0000007590 Pyrroles [Chemical/Ingredient] C0034325 Azoles of one NITROGEN and two double bonds that have aromatic chemical properties. Pyrroles D011758 Pyrroles N0000007592 M0018276 C25540 9033 1-aza-2,4-cyclopentadiene Pyrrolidines [Chemical/Ingredient] 9034 M0018277 D011759 C0034326 Pyrrolidines Pyrrolidines C25542 N0000007593 Triiodobenzoic Acids [Chemical/Ingredient] Triiodobenzoic Acids N0000007599 M0021975 C0041013 D014283 10813 C25556 Triiodobenzoic Acids Triiodo-substituted derivatives of BENZOIC ACID. Hexoses [Chemical/Ingredient] D006601 Hexoses M0010338 C0019494 C25568 Hexoses N0000007604 5318 Quinazolines [Chemical/Ingredient] 9064 N0000007605 Quinazolines Quinazolines M0018336 C25570 C0034407 D011799 Quinolones [Chemical/Ingredient] Ketoquinolines C25572 Quinolinones Quinolones Oxoquinolines 9080 N0000007606 D015363 A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID. M0023650 Quinolones C0034428 Interferon Type I, Recombinant [Chemical/Ingredient] C25584 N0000007612 A type I interferon with antiviral and antineoplastic activity produced by recombinant DNA technology. It can be a mixture of alpha and beta interferons. C0021733 5878 Interferon Type I, Recombinant D015379 Interferon Type I, Recombinant M0023692 Interferon Type I [Chemical/Ingredient] Interferon Type I M0011489 C25588 Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I 5884 D007370 Type I Interferon N0000007614 Interferon Type I C0021743 Type I Interferons Globulins [Chemical/Ingredient] C25590 C0017649 Globulins D005916 Globulins 4825 M0009293 N0000007615 Thymidine [Chemical/Ingredient] C0040077 D013936 M0021446 C25592 Thymidine N0000007616 10544 Thymidine Ergolines [Chemical/Ingredient] N0000007618 C25596 C0014699 Ergolines 4020 M0007652 D004873 A series of structurally-related alkaloids that contain the ergoline backbone structure. Ergolines Ergonovine [Chemical/Ingredient] Ergobasin N0000007619 C25598 M0007653 Ergonovine C0014704 Ergoline-8-carboxamide, 9,10-didehydro-N-(2-hydroxy-1-methylethyl)-6-methyl-, (8beta(S))- Ergometrin Ergonovine 4021 D004874 An ergot alkaloid (ERGOT ALKALOIDS) with uterine and VASCULAR SMOOTH MUSCLE contractile properties. Ergometrine Ergonovine Ergot Alkaloids [Chemical/Ingredient] Ergot Alkaloids Clavine Alkaloids Ergots Alkaloids originally isolated from the ergot fungus Claviceps purpurea (Hypocreaceae). They include compounds that are structurally related to ergoline (ERGOLINES) and ergotamine (ERGOTAMINES). Many of the ergot alkaloids act as alpha-adrenergic antagonists. Ergot Alkaloids 4023 C25600 C0014707 M0007656 Ergot Alkaloids N0000007620 D004876 Ergotamines [Chemical/Ingredient] C25602 C0014711 4026 A series of structurally-related alkaloids containing the ergotaman backbone structure. Ergotamines M0007665 N0000007621 D004879 Ergotamines Acids [Chemical/Ingredient] Acids M0000220 D000143 230 C0001128 C25612 Chemical compounds which yield hydrogen ions or protons when dissolved in water, whose hydrogen can be replaced by metals or basic radicals, or which react with bases to form salts and water (neutralization). An extension of the term includes substances dissolved in media other than water. (Grant & Hackh's Chemical Dictionary, 5th ed) Acids N0000007626 Acids, Acyclic [Chemical/Ingredient] Acyclic Acids Acids, Acyclic Acids, Acyclic M0000221 231 D000144 C0001129 N0000007627 C25614 Carboxylic acids that have open-chain molecular structures as opposed to ring-shaped structures. Acids, Carbocyclic [Chemical/Ingredient] Carbocyclic Acids Carboxylic acids that have a homocyclic ring structure in which all the ring atoms are carbon. Acids, Carbocyclic 233 D000146 N0000007628 C25616 M0000223 Acids, Carbocyclic C0001131 Acids, Noncarboxylic [Chemical/Ingredient] D000148 Inorganic acids with a non metal, other than carbon, attached to hydrogen, or an acid radical containing no carbon. 235 N0000007630 C25620 Noncarboxylic Acids Acids, Noncarboxylic Acids, Noncarboxylic M0000225 C0001133 Glucosides [Chemical/Ingredient] M0009358 Glucosides Glucosides 4871 D005960 C0017765 N0000007634 C25628 2-Chloroadenosine [Chemical/Ingredient] N0000007635 2-Chloroadenosine 2-Chloroadenosine 40 2-Chloroadenosine. A metabolically stable analog of adenosine which acts as an adenosine receptor agonist. The compound has a potent effect on the peripheral and central nervous system. D015762 C25630 Adenosine, 2-chloro- C0000275 M0024149 Glutamates [Chemical/Ingredient] Glutamates M0009376 C0017789 Glutamates N0000007638 Salts and esters of glutamic acid. D005971 C25636 4883 Lactams [Chemical/Ingredient] C0022914 D007769 Lactams Lactams M0012143 6195 Cyclic AMIDES formed from aminocarboxylic acids by the elimination of water. Lactims are the enol forms of lactams. C25644 N0000007642 Lactones [Chemical/Ingredient] N0000007646 M0012175 C0022947 D007783 Lactones C25652 Cyclic esters of hydroxy carboxylic acids, containing a 1-oxacycloalkan-2-one structure. Large cyclic lactones of over a dozen atoms are MACROLIDES. Lactones 6209 Nitrates [Chemical/Ingredient] Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical. C25654 M0014874 Nitrates D009566 7439 C0028125 N0000007647 Nitrates Nitrofurans [Chemical/Ingredient] C25676 7453 Nitrofurans C0028155 D009581 Nitrofurans M0014892 N0000007658 Nitrogen Mustard Compounds [Chemical/Ingredient] M0014901 C0028165 Nitrogen Mustard Compounds D009588 7461 A group of alkylating agents derived from mustard gas, with the sulfur replaced by nitrogen. They were formerly used as toxicants and vesicants, but now function as antineoplastic agents. These compounds are also powerful mutagens, teratogens, immunosuppressants, and carcinogens. Nitrogen Mustard Compounds N0000007659 C25678 Polyamines [Chemical/Ingredient] D011073 C25684 M0017151 8495 Polyamines Polyamines N0000007662 C0032433 Nitroimidazoles [Chemical/Ingredient] N0000007663 C0028179 7468 C25686 D009593 Nitroimidazoles Nitroimidazoles M0014907 Propanolamines [Chemical/Ingredient] C25698 M0017745 Aminopropanols C0033442 D011412 Propanolamines AMINO ALCOHOLS containing the propanolamine (NH2CH2CHOHCH2) group and its derivatives. 8760 N0000007669 Propanolamines Organic Chemicals [Chemical/Ingredient] C25712 Organic Chemicals Organic Chemicals A broad class of substances containing carbon and its derivatives. Many of these chemicals will frequently contain hydrogen with or without oxygen, nitrogen, sulfur, phosphorus, and other elements. They exist in either carbon chain or carbon ring form. C0029224 N0000007676 D009930 M0015401 7692 Propiophenones [Chemical/Ingredient] Propiophenones 8780 N0000007679 D011427 M0017764 C25718 C0033483 Propiophenones Amides [Chemical/Ingredient] Organic compounds containing the -CO-NH2 radical. Amides are derived from acids by replacement of -OH by -NH2 or from ammonia by the replacement of H by an acyl group. (From Grant & Hackh's Chemical Dictionary, 5th ed) C0002482 C25722 Amides Amides N0000007681 M0000897 633 D000577 Organometallic Compounds [Chemical/Ingredient] C25726 Organometallic Compounds N0000007683 A class of compounds of the type R-M, where a C atom is joined directly to any other element except H, C, N, O, F, Cl, Br, I, or At. (Grant & Hackh's Chemical Dictionary, 5th ed) Metallo-Organic Compounds D009942 M0015420 C0029252 Organometallic Compounds 7695 Organophosphorus Compounds [Chemical/Ingredient] C0029254 N0000007684 Organophosphorus Compounds Organic compounds that contain phosphorus as an integral part of the molecule. Included under this heading is broad array of synthetic compounds that are used as PESTICIDES and DRUGS. M0015421 7696 Organophosphorus Compounds D009943 C25728 Organoplatinum Compounds [Chemical/Ingredient] N0000007685 C0029255 Organic compounds which contain platinum as an integral part of the molecule. 7697 M0015422 Organoplatinum Compounds C25730 D009944 Organoplatinum Compounds Propylamines [Chemical/Ingredient] Propylamines N0000007691 C25742 D011437 Propylamines M0017781 8790 C0033504 Benzoic Acids [Chemical/Ingredient] Benzoic Acids Benzoic Acids M0029896 C25744 Acids, salts, and derivatives of BENZOIC ACID. 155099 C0600423 N0000007692 D020185 Phosphorus Acids [Chemical/Ingredient] N0000007696 C0206451 67101 D017976 C25752 Phosphorus Acids Phosphorus Acids M0027146 Inorganic acids that contain phosphorus as an integral part of the molecule. Dipeptides [Chemical/Ingredient] Dipeptides 3496 Peptides composed of two amino acid units. M0006502 D004151 C25754 Dipeptides C0012512 N0000007697 Biguanides [Chemical/Ingredient] C25756 C0005382 Biguanides 1532 D001645 N0000007698 M0002471 Biguanides Amino Acids, Cyclic [Chemical/Ingredient] 660 M0000924 N0000007703 C25766 Amino Acids, Cyclic A class of amino acids characterized by a closed ring structure. Cyclic Amino Acids D000598 Amino Acids, Cyclic C0002522 Prostaglandins [Chemical/Ingredient] Prostanoids C25772 N0000007706 8803 Prostaglandins Prostaglandins M0017805 D011453 A group of compounds derived from unsaturated 20-carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway. They are extremely potent mediators of a diverse group of physiological processes. C0033554 Diphosphonates [Chemical/Ingredient] Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents. D004164 Bisphosphonates Diphosphonates N0000007707 C25774 C0012544 Diphosphonates 3508 M0006519 Prostaglandins E, Synthetic [Chemical/Ingredient] C25780 N0000007710 M0017811 Prostaglandins E, Synthetic Prostaglandin E Analogs C0033560 Analogs or derivatives of prostaglandins E that do not occur naturally in the body. They do not include the product of the chemical synthesis of hormonal PGE. Prostaglandin E Analogues PGE Synthetic 8809 D011459 Prostaglandins E, Synthetic Synthetic Prostaglandins E Fatty Acids, Monounsaturated [Chemical/Ingredient] N0000007714 4299 M0008269 C25788 Fatty Acids, Monounsaturated C0015687 Fatty acids which are unsaturated in only one position. Fatty Acids, Monounsaturated D005229 Catecholamines [Chemical/Ingredient] N0000007715 Catecholamines M0003647 D002395 Sympathins 2146 A general class of ortho-dihydroxyphenylalkylamines derived from tyrosine. C0007412 C25790 Catecholamines Catechols [Chemical/Ingredient] Catechols 2147 Catechols Pyrocatechols M0003648 ortho-Dihydroxybenzenes D002396 C0007413 o-Dihydroxybenzenes C25792 A group of 1,2-benzenediols that contain the general formula R-C6H5O2. N0000007716 Fatty Acids, Unsaturated [Chemical/Ingredient] M0008271 Fatty Acids, Unsaturated Fatty Acids, Unsaturated C0015690 C25794 FATTY ACIDS in which the carbon chain contains one or more double or triple carbon-carbon bonds. N0000007717 D005231 4302 Fatty Alcohols [Chemical/Ingredient] M0008274 Fatty Alcohols Fatty Alcohols 4304 C0015694 Usually high-molecular-weight, straight-chain primary alcohols, but can also range from as few as 4 carbons, derived from natural fats and oils, including lauryl, stearyl, oleyl, and linoleyl alcohols. They are used in pharmaceuticals, cosmetics, detergents, plastics, and lube oils and in textile manufacture. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) N0000007718 C25796 D005233 Steroids [Chemical/Ingredient] N0000007720 A group of polycyclic compounds closely related biochemically to TERPENES. They include cholesterol, numerous hormones, precursors of certain vitamins, bile acids, alcohols (STEROLS), and certain natural drugs and poisons. Steroids have a common nucleus, a fused, reduced 17-carbon atom ring system, cyclopentanoperhydrophenanthrene. Most steroids also have two methyl groups and an aliphatic side-chain attached to the nucleus. (From Hawley's Condensed Chemical Dictionary, 11th ed) 10072 M0020527 D013256 Steroids C25800 C0038317 Steroids Phosphonoacetic Acid [Chemical/Ingredient] N0000007721 8250 C0031681 D010746 C25802 Acetic acid, phosphono- Phosphonoacetic Acid Phosphonoacetic Acid Phosphonacetic Acid M0016688 A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent. Steroids, Fluorinated [Chemical/Ingredient] Fluorinated Steroids Steroids, Fluorinated Steroids, Fluorinated N0000007725 10075 D013259 C25810 Steroids which are substituted with one or more fluorine atoms in any position. C0038320 M0020530 Biogenic Amines [Chemical/Ingredient] D001679 M0002518 Amines, Biogenic N0000007726 C25812 C0005496 Biogenic Amines 1564 Biogenic Amine Biogenic Amines A group of naturally occurring amines derived by enzymatic decarboxylation of the natural amino acids. Many have powerful physiological effects (e.g., histamine, serotonin, epinephrine, tyramine). Those derived from aromatic amino acids, and also their synthetic analogs (e.g., amphetamine), are of use in pharmacology. Quinidine [Chemical/Ingredient] C25816 An optical isomer of quinine, extracted from the bark of the Cinchona tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular action potential, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission. Cinchonan-9-ol, 6'-methoxy-, (9S)- 9068 Chinidin Quinidine M0018341 N0000007728 Quinidine Quinidine D011802 C0034414 Quinolines [Chemical/Ingredient] D011804 C25822 C0034424 N0000007731 9077 M0018350 Quinolines Quinolines Phosphoramide Mustards [Chemical/Ingredient] C0031692 A group of nitrogen mustard compounds which are substituted with a phosphoramide group or its derivatives. They are usually cytotoxic and used as antineoplastic agents. C25826 Phosphoramide Mustards Phosphoramide Mustards D010752 N0000007733 M0016714 8256 Stilbenes [Chemical/Ingredient] Organic compounds that contain 1,2-diphenylethylene as a functional group. Stilbenes M0020537 N0000007736 D013267 10081 C25832 C0038333 Stilbenes Quinuclidines [Chemical/Ingredient] Quinuclidines Quinuclidines N0000007740 C0034439 D011812 9086 M0018359 C25840 Phthalimides [Chemical/Ingredient] D010797 8291 Phthalimides The imide of phthalic acids. C25866 C0031785 N0000007753 Phthalimides M0016770 Deoxyadenosines [Chemical/Ingredient] C25882 Deoxyadenosines N0000007761 Adenylyldeoxyribonucleosides Deoxyadenosines Adenine Deoxyribonucleosides C0011476 Adenosine molecules which can be substituted in any position, but are lacking one hydroxyl group in the ribose part of the molecule. M0005990 D003839 3193 Deoxycytidine [Chemical/Ingredient] Cytosine Deoxyribonucleoside C0011485 D003841 Deoxycytidine Cytidine, 2'-deoxy- N0000007762 CDR Cytosine Deoxyriboside M0005997 Deoxycytidine C25884 3195 Deoxyribonucleosides [Chemical/Ingredient] C0011528 M0006016 Deoxyribonucleosides N0000007768 A purine or pyrimidine base bonded to DEOXYRIBOSE. D003853 Deoxyribonucleosides C25896 3215 Imidazoles [Chemical/Ingredient] Imidazoles D007093 C25898 5684 M0011048 Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES). C0020924 N0000007769 Imidazoles Furans [Chemical/Ingredient] M0008898 Compounds with a 5-membered ring of four carbons and an oxygen. They are aromatic heterocycles. The reduced form is tetrahydrofuran. Furans Furans C25910 4600 C0016850 D005663 N0000007775 Vinca Alkaloids [Chemical/Ingredient] C25920 Vinca Alkaloids Vinca Alkaloids C0042672 M0022674 N0000007780 A group of indole-indoline dimers which are ALKALOIDS obtained from the VINCA genus of plants. They inhibit polymerization of TUBULIN into MICROTUBULES thus blocking spindle formation and arresting cells in METAPHASE. They are some of the most useful ANTINEOPLASTIC AGENTS. D014748 11200 gamma-Aminobutyric Acid [Chemical/Ingredient] 4-Aminobutanoic Acid N0000007783 The most common inhibitory neurotransmitter in the central nervous system. D005680 4-Aminobutyric Acid 4617 M0008927 gamma-Aminobutyric Acid gamma-Aminobutyric Acid GABA C25926 C0016904 Aminalon Aminalone gamma-Aminobutyric Acid Butanoic acid, 4-amino- Adamantane [Chemical/Ingredient] N0000007793 M0000336 287 A tricyclo bridged hydrocarbon. Adamantane Adamantane C25946 C0001392 Tricyclo(3.3.1.1(3,7))decane Diamantane D000218 Chlorine Compounds [Chemical/Ingredient] N0000007794 M0026679 Chlorine Compounds Chlorine Compounds, Inorganic C25948 C0206759 D017606 Inorganic compounds that contain chlorine as an integral part of the molecule. Chlorine Compounds 67167 Megestrol [Chemical/Ingredient] Megestrol C25950 Megestrol 6703 Pregna-4,6-diene-3,20-dione, 17-hydroxy-6-methyl- 17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione. A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer. M0013296 N0000007795 C0025175 D008535 Megestrol Solanaceous Alkaloids [Chemical/Ingredient] Solanum Alkaloids Alkaloids, mainly tropanes, elaborated by plants of the family Solanaceae, including Atropa, Hyoscyamus, Mandragora, Nicotiana, Solanum, etc. Some act as cholinergic antagonists; most are very toxic; many are used medicinally. M0020134 9929 C0037600 C25956 D012991 Solanaceous Alkaloids Solanaceous Alkaloids N0000007798 Ethanolamines [Chemical/Ingredient] Aminoethanols D004983 M0007823 4116 C0014983 Ethanolamines Ethanolamines AMINO ALCOHOLS containing the ETHANOLAMINE; (-NH2CH2CHOH) group and its derivatives. N0000007805 C25970 Naphthalenes [Chemical/Ingredient] C0027378 7251 D009281 C25978 N0000007809 M0014459 Naphthalenes Naphthalenes Two-ring crystalline hydrocarbons isolated from coal tar. They are used as intermediates in chemical synthesis, as insect repellents, fungicides, lubricants, preservatives, and, formerly, as topical antiseptics. Nitrosourea Compounds [Chemical/Ingredient] N0000007812 D009607 Nitrosourea Compounds Nitrosourea Compounds M0014925 C0028210 C25984 7484 Bicyclo Compounds, Heterocyclic [Chemical/Ingredient] C25986 Bicyclo Compounds, Heterocyclic Bicyclo Compounds, Heterocyclic Heterocyclic Cpds, Bicyclic N0000007813 A class of saturated compounds consisting of two rings only, having two or more atoms in common, containing at least one hetero atom, and that take the name of an open chain hydrocarbon containing the same total number of atoms. (From Riguady et al., Nomenclature of Organic Chemistry, 1979, p31) D019086 C0282650 Bicyclic Heterocyclic Compounds M0028488 82186 Heterocyclic Bicyclo Compounds Naphthyridines [Chemical/Ingredient] N0000007815 C25990 M0014465 C0027392 Naphthyridines Naphthyridines D009287 7257 Polymers [Chemical/Ingredient] C0032521 M0017208 Compounds formed by the joining of smaller, usually repeating, units linked by covalent bonds. These compounds often form large macromolecules (e.g., BIOPOLYMERS; PLASTICS). C26000 N0000007820 8534 Polymers Polymers D011108 Oxazines [Chemical/Ingredient] Oxazines Oxazines C26020 N0000007830 C0030001 Six-membered heterocycles containing an oxygen and a nitrogen. 7783 M0015639 D010078 Amino Acids, Dicarboxylic [Chemical/Ingredient] Amino Acids, Dicarboxylic Amino Acids, Dicarboxylic M0000926 C26024 D000600 N0000007832 Dicarboxylic Amino Acids 662 C0002524 Amino Acids, Peptides, and Proteins [Chemical/Ingredient] Amino Acids, Peptides, and Proteins C26026 664 N0000007833 Amino acids and chains of amino acids connected by peptide linkages. C0002526 D000602 Amino Acids, Peptides, and Proteins M0000928 Oxazoles [Chemical/Ingredient] D010080 M0015641 N0000007835 Oxazoles Oxazoles C26030 1,3-Oxazole Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions. C0030004 7785 Amino Acids, Sulfur [Chemical/Ingredient] Sulfur Amino Acids D000603 M0000929 N0000007836 C26032 Amino Acids, Sulfur 665 C0002527 Amino Acids, Sulfur Amino Alcohols [Chemical/Ingredient] C0002530 M0000931 Amino Alcohols C26036 667 N0000007838 Compounds possessing both a hydroxyl (-OH) and an amino group (-NH2). D000605 Amino Alcohols Platinum Compounds [Chemical/Ingredient] N0000007845 C0206135 M0026727 Inorganic compounds which contain platinum as the central atom. C26050 Platinum Compounds, Inorganic D017671 Platinum Compounds Platinum Compounds 67018 Nitrogen Compounds [Chemical/Ingredient] D017672 7457 N0000007847 C26054 Nitrogen Compounds Nitrogen Compounds M0026728 Inorganic compounds that contain nitrogen as an integral part of the molecule. C0028159 Aminoglycosides [Chemical/Ingredient] D000617 Aminoglycosides 678 M0000946 Glycosylated compounds in which there is an amino substituent on the glycoside. Some of them are clinically important ANTIBIOTICS. N0000007853 C26066 Aminoglycosides C0002556 Pentanoic Acids [Chemical/Ingredient] Pentanoic Acids D010421 M0016175 C26072 N0000007856 7999 Pentanoic Acids C0030869 Aminopterin [Chemical/Ingredient] M0000962 692 C0002583 L-Glutamic acid, N-(4-(((2,4-diamino-6-pteridinyl)methyl)amino)benzoyl)- A folic acid derivative used as a rodenticide that has been shown to be teratogenic. Aminopterin D000630 N0000007861 C26082 Aminopterin Butyrophenones [Chemical/Ingredient] C26086 C0006525 Butyrophenones 1856 Compounds containing phenyl-1-butanone. N0000007863 D002090 M0003113 Butyrophenones Peptides [Chemical/Ingredient] 8036 Peptides Peptides M0016238 N0000007874 Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES. C0030956 C26108 D010455 Peptides, Cyclic [Chemical/Ingredient] M0016239 Peptides, Cyclic Peptides, Cyclic Cyclic Peptides C26110 Peptides whose amino and carboxy ends are linked together with a peptide bond forming a circular chain. Some of them are ANTI-INFECTIVE AGENTS. Some of them are biosynthesized non-ribosomally (PEPTIDE BIOSYNTHESIS, NON-RIBOSOMAL). 8037 N0000007875 D010456 C0030957 Succinic Acids [Chemical/Ingredient] D019822 134500 Succinic Acids Succinic Acids C0524962 N0000007876 C26112 A class of dicarboxylic acids with the general structure of butanedioic acid (succinic acid). They are used in perfumery and as a chemical intermediate in medicine. M0029427 Biphenyl Compounds [Chemical/Ingredient] Biphenyl Compounds C26120 C0005580 D001713 Biphenyl Compounds M0002570 N0000007880 1590 Cyclohexanes [Chemical/Ingredient] N0000007890 C0010568 Six-carbon alicyclic hydrocarbons. D003510 2989 M0005469 Cyclohexanes C26140 Cyclohexanes Cyclohexanols [Chemical/Ingredient] D003511 C26142 Cyclohexanols N0000007891 Monohydroxy derivatives of cyclohexanes that contain the general formula R-C6H11O. They have a camphorlike odor and are used in making soaps, insecticides, germicides, dry cleaning, and plasticizers. C0010570 2991 M0005471 Cyclohexanols Ribonucleosides [Chemical/Ingredient] Ribonucleosides M0019074 Ribonucleosides C0035546 9356 C26148 Nucleosides in which the purine or pyrimidine base is combined with ribose. (Dorland, 28th ed) D012263 N0000007894 Cycloparaffins [Chemical/Ingredient] C26152 Alicyclic hydrocarbons in which three or more of the carbon atoms in each molecule are united in a ring structure and each of the ring carbon atoms is joined to two hydrogen atoms or alkyl groups. The simplest members are cyclopropane (C3H6), cyclobutane (C4H8), cyclohexane (C6H12), and derivatives of these such as methylcyclohexane (C6H11CH3). (From Sax, et al., Hawley's Condensed Chemical Dictionary, 11th ed) Cyclic Olefins Cycloalkanes D003516 N0000007896 C0010578 Cycloparaffins Cycloparaffins 2997 M0005477 Glycosides [Chemical/Ingredient] N0000007897 Any compound that contains a constituent sugar, in which the hydroxyl group attached to the first carbon is substituted by an alcoholic, phenolic, or other group. They are named specifically for the sugar contained, such as glucoside (glucose), pentoside (pentose), fructoside (fructose), etc. Upon hydrolysis, a sugar and nonsugar component (aglycone) are formed. (From Dorland, 28th ed; From Miall's Dictionary of Chemistry, 5th ed) C26154 C0017977 M0009500 Glycosides Glycosides D006027 4958 Ribonucleotides [Chemical/Ingredient] C0035548 D012265 Ribonucleotides 9358 M0019076 N0000007898 C26156 Nucleotides in which the purine or pyrimidine base is combined with ribose. (Dorland, 28th ed) Ribonucleotides Ribonucleoside Phosphates Cyclosporins [Chemical/Ingredient] D003524 C26166 N0000007903 M0005493 Cyclosporins Cyclosporins C0010594 3009 A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection. Cyclosporines 4-Hydroxycoumarins [Chemical/Ingredient] M0023241 N0000007905 4-Hydroxycoumarins 4-Hydroxycoumarins Substances found in many plants, containing the 4-hydroxycoumarin radical. They interfere with vitamin K and the blood clotting mechanism, are tightly protein-bound, inhibit mitochondrial and microsomal enzymes, and are used as oral anticoagulants. D015110 82 C0000506 C26170 Rifamycins [Chemical/Ingredient] Rifamycins D012294 Rifamycins Rifomycins 9385 C26184 N0000007911 C0035609 M0019113 A group of ANTI-BACTERIAL AGENTS characterized by a chromophoric naphthohydroquinone group spanned by an aliphatic bridge not previously found in other known ANTI-BACTERIAL AGENTS. They have been isolated from fermentation broths of Streptomyces mediterranei. Rifamycins Elements [Chemical/Ingredient] C0013879 3802 Elements M0007227 N0000007912 D004602 Substances that comprise all matter. Each element is made up of atoms that are identical in number of electrons and protons and in nuclear charge, but may differ in mass or number of neutrons. Elements C26186 Cytidine [Chemical/Ingredient] A pyrimidine nucleoside that is composed of the base CYTOSINE linked to the five-carbon sugar D-RIBOSE. Cytosine Riboside C0010715 Cytosine Ribonucleoside M0005567 Cytidine Cytidine N0000007916 3042 D003562 C26194 Dihydroxyphenylalanine [Chemical/Ingredient] beta-Hydroxytyrosine 3-Hydroxy-DL-tyrosine M0006754 3,4-Dihydroxyphenylalanine D004295 3627 Dihydroxyphenylalanine Dihydroxyphenylalanine N0000007917 DL-Tyrosine, 3-hydroxy- C26196 Dopa A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific. C0013023 Immunoglobulins [Chemical/Ingredient] C0021027 Immunoglobulin N0000007920 D007136 Immunoglobulins Immunoglobulins M0011122 Globulins, Immune Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses. 5720 C26202 Immunoglobulins Immune Globulins Blood Proteins [Chemical/Ingredient] C26204 D001798 N0000007921 Blood Proteins Blood Proteins Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins. M0002710 C0005832 1653 Piperazines [Chemical/Ingredient] Piperazines Piperazines C0031958 8341 C26216 N0000007927 D010879 M0016884 Piperidines [Chemical/Ingredient] 8343 A family of hexahydropyridines. C26220 M0016885 Piperidines D010880 C0031960 Piperidines N0000007929 Piperidones [Chemical/Ingredient] M0016886 Piperidones C0031961 N0000007930 Piperidones D010881 C26222 8344 Cytosine [Chemical/Ingredient] C26226 3083 Cytosine N0000007932 2(1H)-Pyrimidinone, 4-amino- C0010843 M0005618 Cytosine A pyrimidine base that is a fundamental unit of nucleic acids. D003596 Terpenes [Chemical/Ingredient] M0021183 Terpenoids Terpenes D013729 A class of compounds composed of repeating 5-carbon units of HEMITERPENES. 10372 C26242 C0039561 Terpenes N0000007940 Indans [Chemical/Ingredient] M0011206 5763 Indans Indans D007189 Aryl CYCLOPENTANES that are a reduced (protonated) form of INDENES. C26250 C0021184 N0000007944 Indenes [Chemical/Ingredient] C26258 C0021188 N0000007947 Indenes D007192 A family of fused-ring hydrocarbons isolated from coal tar that act as intermediates in various chemical reactions and are used in the production of coumarone-indene resins. M0011209 Indenes 5766 Tetrahydronaphthalenes [Chemical/Ingredient] M0021234 10408 Tetralins Tetrahydronaphthalenes Tetrahydronaphthalenes Partially saturated 1,2,3,4-tetrahydronaphthalene compounds. C0039673 N0000007952 D013764 C26268 Uracil [Chemical/Ingredient] Uracil Uracil 2,4(1H,3H)-Pyrimidinedione M0022302 Uracil N0000007953 C26270 10995 D014498 C0041917 Recombinant Proteins [Chemical/Ingredient] D011994 Proteins prepared by recombinant DNA technology. Biosynthetic Proteins C26276 M0018641 Recombinant Proteins Recombinant Proteins 9218 C0034861 Proteins, Biosynthetic N0000007956 Tetrazoles [Chemical/Ingredient] 10423 N0000007957 Tetrazoles Tetrazoles D013777 M0021253 C26278 C0039703 Nebramycin [Chemical/Ingredient] N0000007959 M0014531 D009328 7277 C0027521 Nebramycin Nebramycin C26282 A complex of antibiotic substances produced by Streptomyces tenebrarius. Isoquinolines [Chemical/Ingredient] D007546 6056 C26284 C0022248 N0000007960 M0011785 A group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine. (From Stedman, 25th ed) Isoquinolines Isoquinolines Dibenzazepines [Chemical/Ingredient] C0012029 Dibenzazepines Dibenzazepines 3331 M0006249 N0000007962 D003984 C26288 Compounds with two BENZENE rings fused to AZEPINES. Dibenzocycloheptenes [Chemical/Ingredient] C26292 A family of tricyclic hydrocarbons whose members include many of the commonly used tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC). D003986 N0000007964 Dibenzocycloheptenes C0012032 M0006250 Dibenzocycloheptenes 3333 Isoxazoles [Chemical/Ingredient] M0011807 Isoxazoles 1-Oxa-2-azacyclopentadiene C0022266 Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions. N0000007968 C26300 D007555 Isoxazoles 6065 Hydantoins [Chemical/Ingredient] Imidazolidine-2,4-Diones Compounds based on imidazolidine dione. Some derivatives are ANTICONVULSANTS. N0000007970 Hydantoins D006827 C26304 5469 C0020209 M0010672 Hydantoins Dicarboxylic Acids [Chemical/Ingredient] M0006263 Dicarboxylic Acids Dicarboxylic Acids N0000007971 D003998 C26306 3346 C0012063 Hydrocarbons [Chemical/Ingredient] N0000007973 Hydrocarbons Hydrocarbons C0020242 M0010687 D006838 5476 C26310 Hydrocarbons, Halogenated [Chemical/Ingredient] Hydrocarbons, Halogenated Halogenated Hydrocarbons M0010696 D006846 5484 C26318 C0020250 N0000007977 Hydrocarbons, Halogenated Hydroxamic Acids [Chemical/Ingredient] C0020314 A class of weak acids with the general formula R-CONHOH. Hydroxamic Acid N0000007981 C26326 5512 Hydroxamic Acids D006877 M0010739 Hydroxamic Acids Hydroxy Acids [Chemical/Ingredient] Hydroxy Acids 5515 C26330 C0020317 Organic compounds containing both the hydroxyl and carboxyl radicals. M0010745 D006880 Hydroxy Acids N0000007983 Hydroxybenzoic Acids [Chemical/Ingredient] 5518 Hydroxybenzoic Acids Benzoic acid substituted by one or more hydroxy groups in any position on the benzene ring. M0010748 D006883 N0000007984 Hydroxybenzoic Acids C26332 C0020327 Arabinonucleosides [Chemical/Ingredient] Nucleosides containing arabinose as their sugar moiety. C26344 1069 Arabinonucleosides N0000007990 Arabinofuranosylnucleosides M0001642 C0003680 D001087 Arabinonucleosides Camptothecin [Chemical/Ingredient] Camptothecin 1953 C0006812 Camptothecine M0003242 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (S)- D002166 Camptothecin C26362 N0000007999 An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity. Pregnadienes [Chemical/Ingredient] C0032959 N0000008001 D011245 Pregnadienes Pregnadienes M0017468 C26366 8642 Pregnane derivatives containing two double bonds anywhere within the ring structures. Pregnadienetriols [Chemical/Ingredient] Trihydroxypregnadienes 8643 C26368 D011246 Pregnadienetriols C0032960 Doubly unsaturated pregnane derivatives substituted with three hydroxy groups anywhere within the ring structure or side chains. M0017469 Pregnadienetriols N0000008002 Ethylamines [Chemical/Ingredient] Ethylamines C26386 N0000008011 C0015069 Ethylamines M0007897 D005021 4146 Androstadienes [Chemical/Ingredient] Androstadienes Androstadienes Derivatives of the steroid androstane having two double bonds at any site in any of the rings. C26388 779 D000730 M0001108 N0000008012 C0002852 Ethylene Glycols [Chemical/Ingredient] 4155 C0015086 Dihydroxyethanes N0000008014 M0007901 Ethanediols D005026 Ethylene Glycols Ethylene Glycols An ethylene compound with two hydroxy groups (-OH) located on adjacent carbons. They are viscous and colorless liquids. Some are used as anesthetics or hypnotics. However, the class is best known for their use as a coolant or antifreeze. C26392 Barbiturates [Chemical/Ingredient] Barbiturates A class of chemicals derived from barbituric acid or thiobarbituric acid. Many of these are GABA MODULATORS used as HYPNOTICS AND SEDATIVES, as ANESTHETICS, or as ANTICONVULSANTS. C26396 C0004745 N0000008016 D001463 Barbiturates 1326 M0002177 Androstenes [Chemical/Ingredient] M0001114 C26398 Unsaturated derivatives of the steroid androstane containing at least one double bond at any site in any of the rings. D000736 Androstenes Androstenes N0000008017 C0002862 785 Ethylenediamines [Chemical/Ingredient] C0015093 C26400 M0007904 D005029 4159 Ethylenediamines Ethylenediamines N0000008018 Tosyl Compounds [Chemical/Ingredient] N0000008020 C26404 Toluenesulfonyl Compounds Tosyl Compounds 10656 D014105 C0040493 Tosyl Compounds M0021712 Pregnenediones [Chemical/Ingredient] Diketopregnenes N0000008024 Dioxopregnenes Pregnenediones 8665 C26412 C0033013 Unsaturated pregnane derivatives containing two keto groups on side chains or ring structures. Pregnenediones D011282 M0017514 Pregnenes [Chemical/Ingredient] C26414 8666 N0000008025 C0033014 Unsaturated derivatives of PREGNANES. Pregnenes Pregnenes M0017515 D011283 Sugar Alcohols [Chemical/Ingredient] M0020728 C26422 Alcohols, Sugar Alditols 10163 Sugar Alcohols D013402 C0038654 Polyhydric alcohols having no more than one hydroxy group attached to each carbon atom. They are formed by the reduction of the carbonyl group of a sugar to a hydroxyl group.(From Dorland, 28th ed) Sugar Alcohols N0000008029 Pteridines [Chemical/Ingredient] 8929 Pteridines M0018072 N0000008032 Compounds based on pyrazino[2,3-d]pyrimidine which is a pyrimidine fused to a pyrazine, containing four NITROGEN atoms. D011621 Pteridines C26428 Pyrazinopyrimidines C0033991 Pterins [Chemical/Ingredient] C0033992 Compounds based on 2-amino-4-hydroxypteridine. C26430 N0000008033 M0018073 Pterins Pterins 8930 D011622 Guanidines [Chemical/Ingredient] C0018320 C26440 N0000008038 A family of iminourea derivatives. The parent compound has been isolated from mushrooms, corn germ, rice hulls, mussels, earthworms, and turnip juice. Derivatives may have antiviral and antifungal properties. Guanidines Guanidines 5038 M0009678 D006146 Guanine [Chemical/Ingredient] M0009679 5039 C0018321 C26442 6H-Purin-6-one, 2-amino-1,7-dihydro- Guanine Guanine N0000008039 D006147 Sulfhydryl Compounds [Chemical/Ingredient] Thiols Sulfhydryl Compounds N0000008041 D013438 Sulfhydryl Compounds M0020768 Mercaptans C0038734 C26446 10200 Compounds containing the -SH radical. Mercapto Compounds Dideoxynucleosides [Chemical/Ingredient] 3365 C26450 Nucleosides that have two hydroxy groups removed from the sugar moiety. The majority of these compounds have broad-spectrum antiretroviral activity due to their action as antimetabolites. The nucleosides are phosphorylated intracellularly to their 5'-triphosphates and act as chain-terminating inhibitors of viral reverse transcription. Dideoxynucleosides Dideoxynucleosides N0000008043 M0023387 D015224 ddNus C0012136 Sulfonamides [Chemical/Ingredient] 10215 C0038760 C26460 Sulfonamides Sulfonamides M0020790 A group of compounds that contain the structure SO2NH2. Members of this group, also known as sulfa drugs, are derivatives of sulfanilamide, which competitively inhibit folic acid synthesis in microorganisms, and are bacteriostatic. They have been largely supplanted by more effective and less toxic antibiotics. (From Dorland, 28th ed) N0000008048 D013449 Indoles [Chemical/Ingredient] N0000008052 Indoles Indoles D007211 M0011238 C26468 Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring. 5779 C0021242 Sulfones [Chemical/Ingredient] C26470 10216 M0020791 Sulfones Sulfones C0038761 N0000008053 D013450 Sulfoxides [Chemical/Ingredient] D013454 Sulfoxides C0038771 C26474 M0020796 N0000008055 Organic compounds that have the general formula R-SO-R. They are obtained by oxidation of mercaptans (analogous to the ketones). (From Hackh's Chemical Dictionary, 4th ed) 10222 Sulfoxides Cinchona Alkaloids [Chemical/Ingredient] Cinchona Alkaloids Alkaloids extracted from various species of Cinchona. D002930 C26480 N0000008058 2545 M0004487 Cinchona Alkaloids C0008792 Purine Nucleosides [Chemical/Ingredient] Purine Nucleosides Purine Nucleosides 8950 C26486 M0018166 Purines with a RIBOSE attached that can be phosphorylated to PURINE NUCLEOTIDES. N0000008061 D011684 C0034136 Purine Nucleotides [Chemical/Ingredient] D011685 C0034137 8951 C26488 Purines attached to a RIBOSE and a phosphate that can polymerize to form DNA and RNA. M0018167 Purine Nucleotides Purine Nucleotides N0000008062 Purines [Chemical/Ingredient] C0034140 M0018169 C26494 Purines N0000008065 D011687 A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the metabolic end product of purine metabolism. Purines 8952 Morpholines [Chemical/Ingredient] Tetrahydro-1,4-Oxazines C26510 7058 M0014072 D009025 Morpholines Morpholines C0026561 N0000008073 Heptanoic Acids [Chemical/Ingredient] 7-carbon saturated monocarboxylic acids. N0000008080 C0019227 Heptanoic Acids M0010246 C26524 5257 Heptanoic Acids D006538 Thiazines [Chemical/Ingredient] M0021332 N0000008085 10467 Thiazines C0039858 D013843 Thiazines C26534 Thiazoles [Chemical/Ingredient] Thiazoles Thiazoles N0000008087 M0021333 D013844 10468 C26538 C0039859 Inosine [Chemical/Ingredient] M0011366 C26544 Inosine C0021528 A purine nucleoside that has hypoxanthine linked by the N9 nitrogen to the C1 carbon of ribose. It is an intermediate in the degradation of purines and purine nucleosides to uric acid and in pathways of purine salvage. It also occurs in the anticodon of certain transfer RNA molecules. (Dorland, 28th ed) D007288 N0000008090 5826 Inosine Heterocyclic Compounds [Chemical/Ingredient] C0019398 C26554 Ring compounds having atoms other than carbon in their nuclei. (Grant & Hackh's Chemical Dictionary, 5th ed) Heterocyclic Compounds 5283 M0010290 D006571 N0000008095 Heterocyclic Compounds Heterocyclic Compounds, 3-Ring [Chemical/Ingredient] N0000008096 Heterocyclic Compounds, 3-Ring Heterocyclic Compounds, 3-Ring A class of organic compounds containing three ring structures, one of which is made up of more than one kind of atom, usually carbon plus another atom. The heterocycle may be either aromatic or nonaromatic D006575 5286 C26556 M0010294 C0019401 Heterocyclic Cpds, 3 Ring Metals, Heavy [Chemical/Ingredient] C26560 Heavy Metals C0347988 N0000008098 101909 Metals, Heavy Metals, Heavy D019216 M0028622 Metals with high specific gravity, typically larger than 5. They have complex spectra, form colored salts and double salts, have a low electrode potential, are mainly amphoteric, yield weak bases and weak acids, and are oxidizing or reducing agents (From Grant & Hackh's Chemical Dictionary, 5th ed) Thiomalates [Chemical/Ingredient] D013870 C26562 N0000008099 Thiomalates C0039914 M0021360 Thiomalates 10489 Thiophenes [Chemical/Ingredient] M0021371 D013876 10496 Thiophenes Thiophenes C0039931 C26570 N0000008103 Thiouracil [Chemical/Ingredient] 10512 4(1H)-Pyrimidinone, 2,3-dihydro-2-thioxo- C0039957 Occurs in seeds of Brassica and Crucifera species. Thiouracil has been used as antithyroid, coronary vasodilator, and in congestive heart failure although its use has been largely supplanted by other drugs. It is known to cause blood dyscrasias and suspected of terato- and carcinogenesis. C26576 N0000008106 M0021385 Thiouracil Thiouracil D013889 Ketones [Chemical/Ingredient] C26582 Ketones N0000008109 C0022634 M0011995 Ketones 6141 D007659 Ketoses [Chemical/Ingredient] C0022637 Ketoses N0000008111 M0011999 Ketoses D007661 C26586 Keto Sugars 6143 Propanols [Chemical/Ingredient] Propanols Propanols C26588 C0175804 D020005 Isomeric forms and derivatives of PROPANOL (C3H7OH). Alcohols, Propyl N0000008112 62221 M0029710 Acetamides [Chemical/Ingredient] C0000968 N0000008113 Acetamides C26590 Acetamides D000081 Derivatives of acetamide that are used as solvents, as mild irritants, and in organic synthesis. 160 M0000113 Acetic Acids [Chemical/Ingredient] M0000132 Acetic acid and its derivatives which may be formed by substitution reactions. Mono- and di-substituted, as well as halogenated compounds have been synthesized. Acetic Acids D000088 N0000008114 C26592 C0000985 169 Acetic Acids Neuropeptides [Chemical/Ingredient] 7368 Neuropeptide C26610 Neuropeptides Peptides released by NEURONS as intercellular messengers. Many neuropeptides are also hormones released by non-neuronal cells. C0027895 N0000008123 M0014748 Neuropeptides D009479 Carbamates [Chemical/Ingredient] Salts or esters of carbamic acid, H2NC(=O)OH, or of N-substituted carbamic acids: R2NC(=O)OR', (R' = hydrocarbyl or a cation). The esters are often called URETHANE or urethan, a usage that is strictly correct only for the ethyl esters. (From IUPAC [Internet]. International Union Of Pure And Applied Chemistry; c1995 [updated 2004 Jan 9; cited 2004 May 3]. Available from http://www.chem.qmul.ac.uk/iupac/class/oneN.html#35/). C26612 N0000008124 Carbamates Carbamates 2001 D002219 C0006948 M0003327 Arylsulfonates [Chemical/Ingredient] Arylsulfonates Organic sulfonic acid esters or salts which contain an aromatic hydrocarbon radical. D001190 C26626 1135 Arylsulfonates C0003928 M0001775 N0000008131 Aryl Sulfonates Alkenes [Chemical/Ingredient] Alkenes C26632 500 Alkenes D000475 Unsaturated hydrocarbons of the type Cn-H2n, indicated by the suffix -ene. (Grant & Hackh's Chemical Dictionary, 5th ed, p408) Olefins M0000718 N0000008134 C0002068 Carboxylic Acids [Chemical/Ingredient] M0003405 D002264 2060 C0007066 N0000008137 Carboxylic Acids Organic compounds containing the carboxy group (-COOH). This group of compounds includes amino acids and fatty acids. Carboxylic acids can be saturated, unsaturated, or aromatic. C26638 Carboxylic Acids Benzocycloheptenes [Chemical/Ingredient] Benzocycloheptenes Benzocycloheptenes D001567 C0005061 N0000008139 C26642 M0002354 1400 Pyrans [Chemical/Ingredient] C0034234 C26646 Pyrans M0018220 8983 D011714 Pyrans N0000008141 Coumarins [Chemical/Ingredient] Coumarines C0010207 2899 M0005258 C26648 Benzopyran-2-ones 1,2-Benzopyrones Coumarins D003374 1,2-Benzo-Pyrones N0000008142 Coumarins Synthetic or naturally occurring substances related to coumarin, the delta-lactone of coumarinic acid. The various coumarins have a wide range of proposed actions and uses including as ANTICOAGULANTS, pharmaceutical aids, indicators and reagents, photoreactive substances, and ANTINEOPLASTIC AGENTS. Benzylidene Compounds [Chemical/Ingredient] Compounds containing the PhCH= radical. N0000008143 D001597 Benzylidene Compounds C0005107 M0002394 1432 Benzylidene Compounds C26650 Pyridazines [Chemical/Ingredient] C26654 C0034250 8993 M0018232 Pyridazines N0000008145 Pyridazines D011724 Pyrimidine Nucleosides [Chemical/Ingredient] Pyrimidine Nucleosides Pyrimidine Nucleosides C26658 D011741 C0034287 9013 Pyrimidines with a RIBOSE attached that can be phosphorylated to PYRIMIDINE NUCLEOTIDES. N0000008147 M0018258 Bridged Compounds [Chemical/Ingredient] D001952 1740 C26662 M0002922 N0000008149 Bridged Compounds Bridged Compounds Cyclic hydrocarbons that contain multiple rings and share one or more atoms. C0006174 Valerates [Chemical/Ingredient] Pentanoates M0022494 N0000008150 C0042280 Valerates 596715 C26664 Valerates D014631 Mustard Compounds [Chemical/Ingredient] Strong alkylating and immunosuppressive agents whose biological activity is based on the presence of bis(2-chloroethyl)- groups. Although otherwise structurally diverse, the compounds have in common the capacity to contribute alkyl groups to DNA. They are generally highly toxic but include among their number many widely used and effective antineoplastic agents. D009150 7115 Mustard Compounds C26670 C0026873 N0000008153 M0014270 Mustard Compounds Interferons [Chemical/Ingredient] Proteins secreted by vertebrate cells in response to a wide variety of inducers. They confer resistance against many different viruses, inhibit proliferation of normal and malignant cells, impede multiplication of intracellular parasites, enhance macrophage and granulocyte phagocytosis, augment natural killer cell activity, and show several other immunomodulatory functions. D007372 N0000008154 Interferon 5886 Interferons Interferons M0011491 C0021747 C26672 Phosphorus Compounds [Chemical/Ingredient] C26676 Inorganic compounds that contain phosphorus as an integral part of the molecule. C0206756 67164 D017553 Phosphorus Compounds M0026614 N0000008156 Phosphorus Compounds Nitro Compounds [Chemical/Ingredient] C0028138 D009574 N0000008159 Nitro Compounds Compounds having the nitro group, -NO2, attached to carbon. When attached to nitrogen they are nitramines and attached to oxygen they are NITRATES. 7447 C26682 Nitro Compounds M0014885 Polycyclic Hydrocarbons, Aromatic [Chemical/Ingredient] A major group of unsaturated cyclic hydrocarbons containing two or more rings. The vast number of compounds of this important group, derived chiefly from petroleum and coal tar, are rather highly reactive and chemically versatile. The name is due to the strong and not unpleasant odor characteristic of most substances of this nature. (From Hawley's Condensed Chemical Dictionary, 12th ed, p96) C0032458 Polycyclic Hydrocarbons, Aromatic Polycyclic Aromatic Hydrocarbons 8504 M0017164 C26692 D011084 N0000008164 Polynuclear Aromatic Hydrocarbons Polycyclic Hydrocarbons, Aromatic Nitric Acid [Chemical/Ingredient] Nitric Acid Nitric acid (HNO3). A colorless liquid that is used in the manufacture of inorganic and organic nitrates and nitro compounds for fertilizers, dye intermediates, explosives, and many different organic chemicals. Continued exposure to vapor may cause chronic bronchitis; chemical pneumonitis may occur. (From Merck Index, 11th ed) N0000008166 Nitric Acid 31835 D017942 M0027104 C26696 Nitric acid C0068808 Amidines [Chemical/Ingredient] 634 D000578 C26698 Amidines Amidines N0000008167 M0000898 C0002483 Amines [Chemical/Ingredient] C0002508 Amines A group of compounds derived from ammonia by substituting organic radicals for the hydrogens. (From Grant & Hackh's Chemical Dictionary, 5th ed) C26700 N0000008168 823705 M0000913 D000588 Amines Bicyclo Compounds [Chemical/Ingredient] Bicyclo Compounds D001643 M0002469 C26706 C0005378 1530 N0000008171 Bicyclo Compounds Prostaglandins, Synthetic [Chemical/Ingredient] Synthetic Prostaglandins Prostaglandins, Synthetic Prostaglandin Analogs C26712 M0017821 8815 Compounds obtained by chemical synthesis that are analogs or derivatives of naturally occurring prostaglandins and that have similar activity. C0033568 Prostaglandin Analogues D011465 Prostaglandins, Synthetic N0000008174 PG Analogs Fatty Acids, Essential [Chemical/Ingredient] C0015686 Fatty Acids, Essential M0008268 C26714 4298 D005228 Fatty Acids, Essential N0000008175 Long chain organic acid molecules that must be obtained from the diet. Examples are LINOLEIC ACIDS and LINOLENIC ACIDS. Fatty Acids, Volatile [Chemical/Ingredient] Fatty Acids, Short-Chain Fatty Acids, Volatile C26716 D005232 N0000008176 C0015691 4303 Short-chain fatty acids of up to six carbon atoms in length. They are the major end products of microbial fermentation in the ruminant digestive tract and have also been implicated in the causation of neurological diseases in humans. Fatty Acids, Volatile M0008273 Phosphonic Acids [Chemical/Ingredient] C26720 M0016684 8248 Phosphonic Acids Phosphonic Acids D010745 Inorganic or organic derivatives of phosphonic acid with the general formula ROP(OH)2 or RP(=O)(OH)2. The tautomeric form of this compound (P(OH)3) is PHOSPHOROUS ACIDS. Nucleoside phosphonates have a phosphate-carbon bond that is more resistant to enzymatic cleavage than the normal phosphate-oxygen bond. N0000008178 C0031679 Quinones [Chemical/Ingredient] C0034435 Hydrocarbon rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups. C26726 N0000008181 D011809 9083 Quinones M0018356 Quinones Biomedical and Dental Materials [Chemical/Ingredient] Biomedical and Dental Materials Biomedical and Dental Materials M0002544 C26728 N0000008182 D001697 Substances used in biomedicine or dentistry predominantly for their physical, as opposed to chemical, properties. C0005538 1580 Hypoxanthines [Chemical/Ingredient] C0020691 N0000008183 Hypoxanthines M0010953 Purine bases related to hypoxanthine, an intermediate product of uric acid synthesis and a breakdown product of adenine catabolism. 5625 C26730 D007042 Hypoxanthines Phthalic Acids [Chemical/Ingredient] D010795 M0016768 Phthalic Acids Phthalic Acids C26736 C0031782 8289 N0000008186 A group of compounds that has the general structure of a dicarboxylic acid-substituted benzene ring. The ortho-isomer is used in dye manufacture. (Dorland, 28th ed) Imides [Chemical/Ingredient] D007094 C26742 M0011049 5685 N0000008189 Imides C0020926 Imides Imines [Chemical/Ingredient] M0011054 Imines Imines C26744 D007097 N0000008190 C0020930 5688 Iodobenzoates [Chemical/Ingredient] Benzoic acid esters or salts substituted with one or more iodine atoms. C26754 C0021976 Iodobenzoates M0011655 5941 Iodobenzoates N0000008195 D007463 Ions [Chemical/Ingredient] C26758 M0011678 Ions 5964 D007477 C0022023 N0000008197 Ions An atom or group of atoms that have a positive or negative electric charge due to a gain (negative charge) or loss (positive charge) of one or more electrons. Atoms with a positive charge are known as CATIONS; those with a negative charge are ANIONS. Naphthacenes [Chemical/Ingredient] C0027374 N0000008200 D009279 Polyacenes with four ortho-fused benzene rings in a straight linear arrangement. This group is best known for the subclass called TETRACYCLINES. Naphthacenes 7248 C26764 Naphthacenes M0014457 Tetracenes Benz(b)Anthracenes Ethers [Chemical/Ingredient] N0000008201 Ethers Ethers D004987 M0007828 C0014996 4121 C26766 Nitroso Compounds [Chemical/Ingredient] M0014921 7481 N0000008203 Nitroso Compounds C0028199 C26770 D009603 Nitroso Compounds Aminobutyric Acids [Chemical/Ingredient] N0000008211 M0000940 Aminobutyric Acids Aminobutyric Acids C26786 D000613 C0002545 674 Aliphatic four carbon acids substituted in any position(s) with amino group(s). They are found in most living things. The best known is GAMMA-AMINOBUTYRIC ACID. Butyric Acids [Chemical/Ingredient] Butanoic Acids C0006523 D002088 N0000008212 4-carbon acids, salts, and derivatives of BUTYRIC ACID. Butyric Acids Butyric Acids 1854 M0003111 C26788 Diterpenes [Chemical/Ingredient] Diterpenes Diterpenes Diterpenoids D004224 M0006609 3557 C0012780 N0000008216 Twenty-carbon compounds derived from MEVALONIC ACID or deoxyxylulose phosphate. C26796 Azoles [Chemical/Ingredient] D001393 C0004504 Azoles Five membered rings containing a NITROGEN atom. N0000008217 M0002083 1269 Azoles C26798 Glycols [Chemical/Ingredient] N0000008218 Glycols C26800 A generic grouping for dihydric alcohols with the hydroxy groups (-OH) located on different carbon atoms. They are viscous liquids with high boiling points for their molecular weights. C0017951 M0009479 Glycols 4943 D006018 Toluene [Chemical/Ingredient] C26802 A widely used industrial solvent. 10640 Toluene Toluene M0021638 N0000008219 D014050 C0040383 Benzene, methyl- Immunoproteins [Chemical/Ingredient] Blood proteins whose activities affect or play a role in the functioning of the immune system. C0021072 N0000008223 Immunoproteins 5744 Immunoproteins M0011167 D007162 C26810 Diamines [Chemical/Ingredient] N0000008224 D003959 Organic chemicals which have two amino groups in an aliphatic chain. Diamines Diamines C26812 C0011957 3313 M0006204 Malates [Chemical/Ingredient] D008293 6605 M0012916 C26816 C0024546 N0000008226 Malates Malates Hydrocarbons, Acyclic [Chemical/Ingredient] Organic compounds composed exclusively of carbon and hydrogen where no carbon atoms join to form a ring structure. Acyclic Hydrocarbons C26818 C0020243 5477 D006839 Hydrocarbons, Acyclic M0010688 N0000008227 Hydrocarbons, Acyclic Hydrocarbons, Alicyclic [Chemical/Ingredient] C0020244 Organic compounds composed exclusively of carbon and hydrogen. Three or more carbon atoms are arranged in a cyclic structure and they possess aliphatic properties. D006840 Alicyclic Hydrocarbons N0000008228 Hydrocarbons, Alicyclic Hydrocarbons, Alicyclic C26820 M0010689 5478 Hydrocarbons, Aromatic [Chemical/Ingredient] N0000008229 5479 C26822 C0020245 Aromatic Hydrocarbons Hydrocarbons, Aromatic M0010690 Organic compounds containing carbon and hydrogen in the form of an unsaturated, usually hexagonal ring structure. The compounds can be single ring, or double, triple, or multiple fused rings. Hydrocarbons, Aromatic D006841 Nucleosides [Chemical/Ingredient] M0015066 N0000008235 7578 Purine or pyrimidine bases attached to a ribose or deoxyribose. (From King & Stansfield, A Dictionary of Genetics, 4th ed) C26834 Nucleosides Nucleosides D009705 C0028621 Nucleotides [Chemical/Ingredient] Nucleotides Nucleotides The monomeric units from which DNA or RNA polymers are constructed. They consist of a purine or pyrimidine base, a pentose sugar, and a phosphate group. (From King & Stansfield, A Dictionary of Genetics, 4th ed) D009711 7584 C26836 C0028630 M0015075 N0000008236 Metals [Chemical/Ingredient] Metals C26838 Metals M0013515 C0025552 6797 N0000008237 Electropositive chemical elements characterized by ductility, malleability, luster, and conductance of heat and electricity. They can replace the hydrogen of an acid and form bases with hydroxyl radicals. (Grant & Hackh's Chemical Dictionary, 5th ed) D008670 Hydroxylamines [Chemical/Ingredient] Hydroxylamines C0020363 D006898 C26840 5535 N0000008238 Organic compounds that contain the (-NH2OH) radical. M0010767 Hydroxylamines Arachidonic Acids [Chemical/Ingredient] C0003701 Arachidonic Acids N0000008239 M0001649 Arachidonic Acids C26842 D001095 1077 Androstanes [Chemical/Ingredient] 780 M0001109 N0000008241 C0002854 D000731 Androstanes C26846 Androstanes The family of steroids from which the androgens are derived. Pregnanes [Chemical/Ingredient] Pregnanes M0017507 D011278 8661 Saturated derivatives of the steroid pregnane. The 5-beta series includes PROGESTERONE and related hormones; the 5-alpha series includes forms generally excreted in the urine. Pregnanes C0033006 C26848 N0000008242 Serum Globulins [Chemical/Ingredient] C0036800 All blood proteins except albumin ( = SERUM ALBUMIN, which is not a globulin) and FIBRINOGEN (which is not in the serum). The serum globulins are subdivided into ALPHA-GLOBULINS; BETA-GLOBULINS; and GAMMA-GLOBULINS on the basis of their electrophoretic mobilities. (From Dorland, 28th ed) D012712 N0000008244 Serum Globulins 9701 M0019698 C26852 Serum Globulins Sulfonic Acids [Chemical/Ingredient] Inorganic or organic oxy acids of sulfur which contain the RSO2(OH) radical. Sulfonic Acids 10217 M0020792 N0000008245 C26854 D013451 Sulfonic Acids C0038762 Sulfur Acids [Chemical/Ingredient] Inorganic or organic acids that contain sulfur as an integral part of the molecule. C0038775 Sulfur Acids D013456 10224 N0000008248 Sulfur Acids C26860 M0020798 Sulfur Compounds [Chemical/Ingredient] Inorganic or organic compounds that contain sulfur as an integral part of the molecule. M0020800 Sulfur Compounds 10225 C26862 N0000008249 Sulfur Compounds D013457 C0038776 Monosaccharides [Chemical/Ingredient] Monosaccharides Monosaccharides N0000008250 C0026492 M0014043 7044 D009005 C26864 Simple sugars, carbohydrates which cannot be decomposed by hydrolysis. They are colorless crystalline substances with a sweet taste and have the same general formula CnH2nOn. (From Dorland, 28th ed) Purinones [Chemical/Ingredient] N0000008251 D011688 Purinones M0018170 Purinones 8953 C0034142 C26866 Oxopurines Boron Compounds [Chemical/Ingredient] D001896 C26870 Boron Compounds C0006031 Inorganic or organic compounds that contain boron as an integral part of the molecule. 1706 Boron Compounds M0002832 N0000008253 Inorganic Chemicals [Chemical/Ingredient] A broad class of substances encompassing all those that do not include carbon and its derivatives as their principal elements. However, carbides, carbonates, cyanides, cyanates, and carbon disulfide are included in this class. D007287 C0021521 N0000008257 M0011365 Inorganic Chemicals C26878 5824 Inorganic Chemicals Heterocyclic Compounds, Bridged-Ring [Chemical/Ingredient] C26880 D006572 5288 A class of organic compounds which contain two rings that share a pair of bridgehead carbon atoms. Heterocyclic Compounds, Bridged-Ring Bridged-Ring Heterocyclic Compounds M0010291 C0019403 N0000008258 Heterocyclic Compounds, Bridged-Ring Heterocyclic Compounds, 1-Ring [Chemical/Ingredient] Heterocyclic Cpds, 1-Ring C0019399 A class of organic compounds containing a ring structure made up of more than one kind of atom, usually carbon plus another atom. The ring structure can be aromatic or nonaromatic. Heterocyclic Compounds, 1-Ring 5284 D006573 N0000008259 C26882 Heterocyclic Compounds, 1-Ring M0010292 Heterocyclic Compounds, 2-Ring [Chemical/Ingredient] C26884 A class of organic compounds containing two ring structures, one of which is made up of more than one kind of atom, usually carbon plus another atom. The heterocycle may be either aromatic or nonaromatic. Heterocyclic Compounds, 2-Ring D006574 5285 N0000008260 M0010293 C0019400 Heterocyclic Compounds, 2-Ring Heterocyclic Compounds with 4 or More Rings [Chemical/Ingredient] C0019402 Heterocyclic Cpds, 4 or More Rings N0000008261 D006576 5287 A class of organic compounds containing four or more ring structures, one of which is made up of more than one kind of atom, usually carbon plus another atom. The heterocycle may be either aromatic or nonaromatic. Heterocyclic Compounds with 4 or More Rings Heterocyclic Compounds with 4 or More Rings C26886 M0010295 Nerve Tissue Proteins [Chemical/Ingredient] N0000008263 Nerve Tissue Proteins Nerve Tissue Proteins 7331 C0027759 C26892 M0014664 D009419 Hexanols [Chemical/Ingredient] D000441 M0000666 N0000008268 Alcohols, Hexyl 458 C0001978 Hexanols Hexanols Isomeric forms and derivatives of hexanol (C6H11OH). Hydroxyhexanes C26902 Eicosanoids [Chemical/Ingredient] 3773 M0024172 D015777 Eicosanoids A class of compounds named after and generally derived from C20 fatty acids (EICOSANOIC ACIDS) that includes PROSTAGLANDINS; LEUKOTRIENES; THROMBOXANES, and HYDROXYEICOSATETRAENOIC ACIDS. They have hormone-like effects mediated by specialized receptors (RECEPTORS, EICOSANOID). C0013725 N0000008271 C26908 Icosanoids Eicosanoids Electrolytes [Chemical/Ingredient] Substances that dissociate into two or more ions, to some extent, in water. Solutions of electrolytes thus conduct an electric current and can be decomposed by it (ELECTROLYSIS). (Grant & Hackh's Chemical Dictionary, 5th ed) C26910 C0013832 M0007189 Electrolytes N0000008272 D004573 3793 Electrolytes Hydrocarbons, Cyclic [Chemical/Ingredient] Organic compounds composed exclusively of carbon and hydrogen forming a closed ring that may be either alicyclic or aromatic. 5482 Hydrocarbons, Cyclic Cyclic Hydrocarbons C0020248 Hydrocarbons, Cyclic D006844 M0010694 N0000008280 C26926 Nucleic Acids, Nucleotides, and Nucleosides [Chemical/Ingredient] D009706 C26930 Complex compounds of high molecular weight occurring in living cells. These are basically of two types, ribonucleic (RNA) and deoxyribonucleic (DNA) acids, both of which consist of nucleotides (nucleoside phosphates linked together by phosphate bridges). Nucleic Acids, Nucleotides, and Nucleosides 7579 N0000008282 C0028622 Nucleic Acids, Nucleotides, and Nucleosides M0015067 Arylsulfonic Acids [Chemical/Ingredient] C26932 Arylsulfonic Acids Arylsulfonic Acids N0000008283 C0206192 Organic sulfonic acid derivatives which contain an aromatic hydrocarbon radical. D017739 M0026806 67027 Membrane Proteins [Chemical/Ingredient] Membrane Proteins D008565 M0013341 Membrane Proteins Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors. C26938 Membrane Protein Membrane-Associated Proteins C0025252 6725 N0000008286 Surface Proteins Cyclooxygenase 2 Inhibitors [MoA] C2757001 Cyclooxygenase II Inhibitors COX-2 Inhibitors C26942 Cyclooxygenase 2 Inhibitors N0000008288 993136 Acetylcholine Activity Alteration [PE] Acetylcholine Activity Alteration 988978 C26946 N0000008290 C1371273 Adrenal Cortical Activity Alteration [PE] C1371274 Adrenal Cortical Activity Alteration 985815 C26948 N0000008291 Arterial Vasoconstriction [PE] C26962 C1371490 986283 N0000008298 Arterial Vasoconstriction Arterial Vasodilation [PE] Arterial Vasodilation C1371278 984618 N0000008299 C26964 Atrial Repolarization [PE] N0000008303 Atrial Repolarization 1032452 C1371280 C26972 Blood & Lymphatic Fluid Function Alteration [PE] C1371289 Blood & Lymphatic Fluid Function Alteration 988284 N0000008307 C26980 Bone Alteration [PE] 985816 C1371288 N0000008308 C26982 Bone Alteration Bone Resorption Alteration [PE] N0000008312 989245 Bone Resorption Alteration C1371284 C26990 Bone Resorption Inhibition [PE] C1371283 C26992 985477 N0000008313 Bone Resorption Inhibition Bronchial Smooth Muscle Tone Alteration [PE] Bronchial Smooth Muscle Tone Alteration C1371300 C27006 N0000008320 988934 Bronchodilation [PE] C1371299 Bronchodilation N0000008322 1034280 C27010 Carbohydrate Metabolism Alteration [PE] C1371294 Carbohydrate Metabolism Alteration N0000008327 1033881 C27020 Cardiac Contractility Alteration [PE] 986415 N0000008328 C27022 C1371293 Cardiac Contractility Alteration Cardiac Rate Alteration [PE] Cardiac Rate Alteration C2825066 985479 N0000008329 C27024 Cardiac Rhythm Alteration [PE] C27026 Cardiac Rhythm Alteration N0000008330 988420 C1371292 Cardiovascular Activity Alteration [PE] C27028 988145 C1371291 N0000008331 Cardiovascular Activity Alteration Cell Glucose Transport Alteration [PE] 985190 Cell Glucose Transport Alteration N0000008333 C1371486 C27032 Cell Membrane Alteration [PE] N0000008334 1031394 C0544958 C27034 Cell Membrane Alteration Cell Wall Alteration [PE] 989278 C1371484 N0000008336 Cell Wall Alteration C27038 Cellular Activity Alteration [PE] Cellular Activity Alteration N0000008337 985006 C1371483 C27040 Cellular Cycle Alteration [PE] N0000008339 C27044 990947 C1371481 Cellular Cycle Alteration Cellular Death Alteration [PE] N0000008340 Cellular Death Alteration C1371480 985191 C27046 Cellular Degradation/Digestion Alteration [PE] Cellular Degradation/Digestion Alteration C1371479 990545 C27048 N0000008341 Cellular Division Phase Alteration [PE] 985659 N0000008342 C27050 C1371478 Cellular Division Phase Alteration Cellular Growth Phase Alteration [PE] C27052 Cellular Growth Phase Alteration C1371477 987428 N0000008343 Cellular Growth Phase Arrest [PE] 986074 Cellular Growth Phase Arrest N0000008344 C1371476 C27054 Cellular Motion Alteration [PE] 988013 C1371475 N0000008345 C27056 Cellular Motion Alteration Cellular Structure Alteration [PE] C27058 C1371474 N0000008346 990421 Cellular Structure Alteration Cellular Synthetic Activity Alteration [PE] C27060 C1371473 N0000008347 Cellular Synthetic Activity Alteration 989470 Cellular Synthetic Phase Alteration [PE] N0000008348 Cellular Synthetic Phase Alteration 985868 C1371314 C27062 Cellular Synthetic Phase Arrest [PE] N0000008349 C27064 Cellular Synthetic Phase Arrest C1371313 987568 Cellular Transport Alteration [PE] C27066 C1371312 N0000008350 985278 Cellular Transport Alteration Cerebral Arterial Vasoconstriction [PE] 990151 N0000008351 Cerebral Arterial Vasoconstriction C1371311 C27068 Cervical Dilation Alteration [PE] C27072 N0000008353 C1371309 Cervical Dilation Alteration 984821 Cervical Function Alteration [PE] C27074 1027593 Cervical Function Alteration C1371308 N0000008354 Cholesterol Metabolism Alteration [PE] 988014 C27086 N0000008360 Cholesterol Metabolism Alteration C1371469 Cholesterol Synthesis Alteration [PE] C27088 N0000008361 C1371468 Cholesterol Synthesis Alteration 988147 Coagulation Factor Activity Alteration [PE] Coagulation Factor Activity Alteration N0000008362 C27090 985279 C1371467 Coagulation Factor Alteration [PE] C1371466 N0000008363 1027093 C27092 Coagulation Factor Alteration Coronary Arterial Vasodilation [PE] 990108 C27116 Coronary Arterial Vasodilation N0000008375 C1371463 DNA Integrity Alteration [PE] N0000008379 C27124 C1371459 DNA Integrity Alteration 984969 DNA Replication Alteration [PE] 985410 N0000008380 C27126 DNA Replication Alteration C1371458 Decreased Adhesion Factor Activity [PE] 989982 Decreased Adhesion Factor Activity C1371329 C27134 N0000008384 Decreased Bradykinin Degradation [PE] N0000008423 C1371406 989574 C27212 Decreased Bradykinin Degradation Decreased Brain Stem Organized Electrical Activity [PE] N0000008445 986371 C1371384 C27256 Decreased Brain Stem Organized Electrical Activity Decreased Brain Stem Substance P Activity [PE] C27260 Decreased Brain Stem Substance P Activity C1371382 N0000008447 990316 Decreased Cell Membrane Integrity [PE] Decreased Cell Membrane Integrity N0000008476 C27318 989770 C1371353 Decreased Cell Membrane Synthesis & Repair [PE] C1371352 989287 C27320 N0000008477 Decreased Cell Membrane Synthesis & Repair Decreased Cell Wall Integrity [PE] 985663 Decreased Cell Wall Integrity N0000008478 C1371351 C27322 Decreased Cell Wall Synthesis & Repair [PE] C1371350 C27324 Decreased Cell Wall Synthesis & Repair N0000008479 989288 Decreased Central Nervous System Disorganized Electrical Activity [PE] 990318 Decreased Central Nervous System Disorganized Electrical Activity N0000008486 C27338 C1371343 Decreased Central Nervous System Glutamate Activity [PE] C1371435 C27354 988724 Decreased Central Nervous System Glutamate Activity N0000008494 Decreased Central Nervous System Organized Electrical Activity [PE] C27368 987431 N0000008501 Decreased Central Nervous System Organized Electrical Activity C1371428 Decreased Central Nervous System Substance P Activity [PE] 984622 C27372 N0000008503 Decreased Central Nervous System Substance P Activity C1371426 Decreased Cholesterol Synthesis [PE] C1371532 N0000008555 987433 C27476 Decreased Cholesterol Synthesis Decreased Complement Activity [PE] C27502 Decreased Complement Activity N0000008568 990113 C1371545 Decreased Complement Production [PE] N0000008570 C27506 Decreased Complement Production C1371547 984976 Decreased Cytokine Activity [PE] C1371548 989703 N0000008571 Decreased Cytokine Activity C27508 Decreased Cytokine Production [PE] N0000008573 C27512 984977 C1371550 Decreased Cytokine Production Decreased DNA Integrity [PE] N0000008576 C1371553 C27518 Decreased DNA Integrity 990547 Decreased DNA Replication [PE] 989476 C1371554 Decreased DNA Replication N0000008577 C27520 Decreased Disorganized Electrical Activity [PE] N0000008578 C1371555 C27522 986372 Decreased Disorganized Electrical Activity Decreased Dopamine Activity [PE] C1371565 C27542 Decreased Dopamine Activity N0000008588 988292 Decreased Eicosanoid Activity [PE] C27546 N0000008590 Decreased Eicosanoid Activity C1371567 984625 Decreased Eicosanoid Production [PE] N0000008592 986162 Decreased Eicosanoid Production C27550 C1371569 Decreased Enteric Nervous System Serotonin Activity [PE] N0000008620 C27606 989990 Decreased Enteric Nervous System Serotonin Activity C1371630 Decreased Glucocorticoid Secretion [PE] Decreased Glucocorticoid Secretion N0000008645 C1371655 988098 C27656 Decreased Gluconeogenesis [PE] C27658 C1371656 984462 N0000008646 Decreased Gluconeogenesis Decreased Glutamate Activity [PE] C27662 C1371658 N0000008648 Decreased Glutamate Activity 986374 Decreased Glycogenesis [PE] N0000008650 988432 Decreased Glycogenesis C27666 C1371660 Decreased Hematopoiesis [PE] 989826 N0000008656 Decreased Hematopoiesis C27678 C2825067 Decreased Histamine Activity [PE] C1371666 990635 C27680 Decreased Histamine Activity N0000008657 Decreased Immunologically Active Biogenic Amine Activity [PE] C27686 986941 Decreased Immunologically Active Biogenic Amine Activity N0000008660 C1371669 Decreased Immunologically Active Biogenic Amine Degradation [PE] N0000008661 986196 C27688 Decreased Immunologically Active Biogenic Amine Degradation C1371670 Decreased Immunologically Active Molecule Activity [PE] C1371672 Decreased Immunologically Active Molecule Activity 988758 C27692 N0000008663 Decreased Immunologically Active Molecule Degradation [PE] Decreased Immunologically Active Molecule Degradation N0000008664 986197 C27694 C1371673 Decreased Immunologically Active Molecule Production [PE] C27696 C1371674 N0000008665 987036 Decreased Immunologically Active Molecule Production Decreased Intravascular Volume [PE] Decreased Intravascular Volume N0000008669 988730 C27704 C1371678 Decreased Iodine Organification [PE] C27706 N0000008670 C1371679 Decreased Iodine Organification 987435 Decreased Kinin Activity [PE] N0000008675 C27716 C1371683 Decreased Kinin Activity 986942 Decreased Kinin Degradation [PE] C1371684 C27718 987233 N0000008676 Decreased Kinin Degradation Decreased Leukotriene Activity [PE] N0000008681 C27728 Decreased Leukotriene Activity C1371689 987436 Decreased Lipid Derived Immunologically Active Molecule Activity [PE] Decreased Lipid Derived Immunologically Active Molecule Activity C1371692 988099 N0000008684 C27734 Decreased Lipid Derived Immunologically Active Molecule Production [PE] C27738 N0000008686 984433 C1371694 Decreased Lipid Derived Immunologically Active Molecule Production Decreased Lymphocyte Cell Production [PE] Decreased Lymphocyte Cell Production N0000008699 C1371707 990429 C27764 Decreased Lysosomal Function [PE] Decreased Lysosomal Function N0000008700 C1371708 989775 C27766 Decreased Mineralocorticoid Secretion [PE] 985529 Decreased Mineralocorticoid Secretion C27828 N0000008731 C1371739 Decreased Mitosis [PE] C1371740 Decreased Mitosis N0000008732 C27830 985016 Decreased Myeloid Cell Production [PE] 984684 Decreased Myeloid Cell Production N0000008759 C27884 C1371767 Decreased Norepinephrine Activity [PE] Decreased Norepinephrine Activity C27894 C2267200 989127 N0000008764 Decreased Organized Electrical Activity [PE] C1371776 987290 Decreased Organized Electrical Activity N0000008768 C27902 Decreased Ovarian Estrogen Secretion [PE] N0000008769 Decreased Ovarian Estrogen Secretion C27904 C1371777 985018 Decreased Peripheral Nervous System Organized Electrical Activity [PE] Decreased Peripheral Nervous System Organized Electrical Activity C28008 989609 N0000008821 C1371829 Decreased Peripheral Nervous System Serotonin Activity [PE] Decreased Peripheral Nervous System Serotonin Activity N0000008822 C28010 989610 C1371830 Decreased Phagocytosis [PE] C1371834 Decreased Phagocytosis 985284 C28018 N0000008826 Decreased Platelet Aggregation [PE] C28030 Decreased Platelet Aggregation C0855739 989580 N0000008832 Decreased Prostaglandin Activity [PE] 984465 C1371841 N0000008834 C28034 Decreased Prostaglandin Activity Decreased Prostaglandin Production [PE] Decreased Prostaglandin Production C28038 N0000008836 987922 C1371843 Decreased Protein Breakdown [PE] C1371846 984986 Decreased Protein Breakdown N0000008839 C28044 Decreased Protein Modification [PE] C28046 990166 N0000008840 C1371847 Decreased Protein Modification Decreased Protein Synthesis [PE] N0000008841 C1371848 987293 C28048 Decreased Protein Synthesis Decreased RNA Integrity [PE] N0000008852 C28070 988443 C1371859 Decreased RNA Integrity Decreased RNA Replication [PE] C1371860 985312 N0000008853 Decreased RNA Replication C28072 Decreased Renal Ion Excretion [PE] C28082 988472 N0000008858 C1371865 Decreased Renal Ion Excretion Decreased Renal K+ Excretion [PE] C1371866 C28084 Decreased Renal K+ Excretion 987923 N0000008859 Decreased Reverse Transcription to DNA [PE] N0000008869 Decreased Reverse Transcription to DNA C28104 C1371876 988941 Decreased Sensory-Somatic Nervous System Organized Electrical Activity [PE] 990252 Decreased Sensory-Somatic Nervous System Organized Electrical Activity C1371896 N0000008889 C28144 Decreased Serotonin Activity [PE] N0000008893 990122 C1371900 C28152 Decreased Serotonin Activity Decreased Serotonin Degradation [PE] N0000008894 Decreased Serotonin Degradation C28154 C1371901 989582 Decreased Striated Muscle Contraction [PE] 987443 C28272 C1371959 N0000008953 Decreased Striated Muscle Contraction Decreased Substance P Activity [PE] Decreased Substance P Activity C28312 C1371979 N0000008973 987042 Decreased T Lymphocyte Production [PE] Decreased T Lymphocyte Production C1372004 986572 C28362 N0000008998 Decreased Testosterone Secretion [PE] C28370 N0000009002 C1372008 Decreased Testosterone Secretion 988479 Decreased Thromboxane Activity [PE] C1372010 986734 Decreased Thromboxane Activity N0000009004 C28374 Decreased Thromboxane Production [PE] C28378 987590 Decreased Thromboxane Production C1372012 N0000009006 Decreased Thyroid Hormone Iodination [PE] C28380 C1372013 990124 N0000009007 Decreased Thyroid Hormone Iodination Decreased Ventilatory Gas Flow [PE] N0000009019 985118 C28404 Decreased Ventilatory Gas Flow C1372025 Dermatologic Activity Alteration [PE] C28406 Dermatologic Activity Alteration C1372026 984838 N0000009020 Digestive/GI System Activity Alteration [PE] N0000009022 990045 Digestive/GI System Activity Alteration C28410 C1372028 Disorganized Electrical Activity Alteration [PE] 987926 C28414 N0000009024 C1372030 Disorganized Electrical Activity Alteration Dopamine Activity Alteration [PE] 986437 Dopamine Activity Alteration C1372031 C28416 N0000009025 Electrical Activity Alteration [PE] N0000009027 C1372033 C28420 Electrical Activity Alteration 985119 Endocrine Activity Alteration [PE] 990694 N0000009036 C1372041 C28438 Endocrine Activity Alteration Female Reproductive System Activity Alteration [PE] Female Reproductive System Activity Alteration C28454 C1372049 985744 N0000009044 Gamma Amino Butyric Acid (GABA) Activity Alteration [PE] N0000009053 C1372058 Gamma Amino Butyric Acid (GABA) Activity Alteration 985029 C28472 Gastric Acid Alteration [PE] Gastric Acid Alteration 986779 N0000009054 C1372059 C28474 Generalized Systemic Effects [PE] C1372062 C28480 N0000009057 990172 Generalized Systemic Effects Glucose Metabolism Alteration [PE] 986438 C1382395 N0000009061 Glucose Metabolism Alteration C28488 Glutamate Activity Alteration [PE] C1372066 N0000009062 Glutamate Activity Alteration 986009 C28490 Glycogen Metabolism Alteration [PE] N0000009064 C1372068 988106 C28494 Glycogen Metabolism Alteration Hematologic Activity Alteration [PE] 986633 Hematologic Activity Alteration N0000009065 C1372069 C28496 Hematological Cell Destruction Alteration [PE] C28498 Hematological Cell Destruction Alteration 987239 N0000009066 C1372070 Hematological Cell Quantity Alteration [PE] C1372071 N0000009067 Hematological Cell Quantity Alteration 989409 C28500 Hematopoiesis Alteration [PE] C1372072 Hematopoiesis Alteration N0000009068 988943 C28502 Hemic/Lymphatic Activity Alteration [PE] N0000009069 C28504 C1372073 990696 Hemic/Lymphatic Activity Alteration Hemostasis Alteration [PE] C1372074 N0000009070 Hemostasis Alteration C28506 989781 Histamine Activity Alteration [PE] 989587 N0000009071 C1372075 Histamine Activity Alteration C28508 Hypothalamic Endocrine Activity Alteration [PE] N0000009072 C1372076 989001 C28510 Hypothalamic Endocrine Activity Alteration Immunologic Activity Alteration [PE] C1372077 C28512 N0000009073 990814 Immunologic Activity Alteration Immunologically Active Molecule Activity Alteration [PE] Immunologically Active Molecule Activity Alteration C28514 C1372078 985286 N0000009074 Immunologically Active Molecule Degradation Alteration [PE] N0000009075 989847 C1372079 Immunologically Active Molecule Degradation Alteration C28516 Immunologically Active Molecule Production Alteration [PE] C1372080 C28518 Immunologically Active Molecule Production Alteration 989133 N0000009076 Increased Acetylcholine Activity [PE] C1372083 990467 N0000009079 Increased Acetylcholine Activity C28524 Increased Adhesion Factor Production [PE] Increased Adhesion Factor Production N0000009082 C28530 C1372086 990435 Increased Brain Stem Serotonin Activity [PE] 987892 C28650 Increased Brain Stem Serotonin Activity N0000009142 C1372146 Increased Cellular Death [PE] C1372180 Increased Cellular Death N0000009176 988110 C28718 Increased Central Nervous System Acetylcholine Activity [PE] Increased Central Nervous System Acetylcholine Activity C28722 988310 N0000009178 C1372182 Increased Central Nervous System Dopamine Activity [PE] N0000009183 C28732 Increased Central Nervous System Dopamine Activity 987895 C1372187 Increased Central Nervous System Norepinephrine Activity [PE] Increased Central Nervous System Norepinephrine Activity C1372200 C28758 N0000009196 990469 Increased Central Nervous System Serotonin Activity [PE] C28762 C1372202 984445 N0000009198 Increased Central Nervous System Serotonin Activity Increased Cervical Dilation [PE] N0000009247 C1372251 Increased Cervical Dilation 984846 C28860 Increased Coagulation Factor Activity [PE] N0000009252 C1372256 C28870 985543 Increased Coagulation Factor Activity Increased Cytokine Activity [PE] 984447 C1372271 Increased Cytokine Activity N0000009267 C28900 Increased Cytokine Production [PE] C1372273 C28904 N0000009269 986583 Increased Cytokine Production Increased Distal Tubule H+ Excretion [PE] C1372279 989312 C28916 N0000009275 Increased Distal Tubule H+ Excretion Increased Distal Tubule K+ Excretion [PE] N0000009277 Increased Distal Tubule K+ Excretion C28920 C1372281 984847 Increased Distal Tubule Na+ Excretion [PE] Increased Distal Tubule Na+ Excretion 987639 C1372283 N0000009279 C28924 Increased Dopamine Activity [PE] Increased Dopamine Activity 989313 C1372286 N0000009282 C28930 Increased Eicosanoid Activity [PE] C28934 N0000009284 988949 Increased Eicosanoid Activity C1372288 Increased GABA Activity [PE] 989591 C29016 N0000009325 Increased GABA Activity C1372329 Increased Glucose Transport into Cells [PE] Increased Glucose Transport into Cells C1372343 N0000009341 988953 C29048 Increased Hematological Cell Destruction [PE] 985291 N0000009349 C29064 C1372350 Increased Hematological Cell Destruction Increased Immunologically Active Biogenic Amine Activity [PE] Increased Immunologically Active Biogenic Amine Activity 986022 C29074 N0000009354 C1372354 Increased Immunologically Active Molecule Activity [PE] N0000009357 C1372357 989011 Increased Immunologically Active Molecule Activity C29080 Increased Immunologically Active Molecule Production [PE] C29084 984906 Increased Immunologically Active Molecule Production N0000009359 C1372359 Increased Lipid Derived Immunologically Active Molecule Activity [PE] C1372375 987936 C29118 N0000009376 Increased Lipid Derived Immunologically Active Molecule Activity Increased Lymphocyte Cell Destruction [PE] Increased Lymphocyte Cell Destruction C29146 C1372389 N0000009390 985905 Increased Norepinephrine Activity [PE] C1372455 C29278 Increased Norepinephrine Activity N0000009456 985294 Increased Prostaglandin Activity [PE] N0000009526 Increased Prostaglandin Activity C29418 987452 C1372524 Increased Protein Breakdown [PE] N0000009531 C29428 C1372529 Increased Protein Breakdown 988785 Increased Renal H+ Excretion [PE] N0000009548 C29462 C1372546 989634 Increased Renal H+ Excretion Increased Renal Ion Excretion [PE] C1372548 Increased Renal Ion Excretion C29466 989861 N0000009550 Increased Renal K+ Excretion [PE] N0000009551 986593 Increased Renal K+ Excretion C1372549 C29468 Increased Renal Na+ Excretion [PE] 986790 N0000009553 C29472 Increased Renal Na+ Excretion C1372551 Increased Serotonin Activity [PE] Increased Serotonin Activity C29536 C1372583 N0000009585 985916 Increased T Lymphocyte Destruction [PE] C1372687 Increased T Lymphocyte Destruction N0000009689 990657 C29744 Increased Testosterone Secretion [PE] Increased Testosterone Secretion C1372692 C29754 987255 N0000009694 Inhibition Gastric Acid Secretion [PE] C29814 C1372721 N0000009724 1030557 Inhibition Gastric Acid Secretion Intravascular Volume Alteration [PE] C1372729 C29830 Intravascular Volume Alteration 987907 N0000009732 Iodine Organification Alteration [PE] N0000009733 984704 C29832 Iodine Organification Alteration C1372730 Lipid Metabolism Alteration [PE] N0000009739 987514 C29844 Lipid Metabolism Alteration C0548934 Lysosomal Function Alteration [PE] Lysosomal Function Alteration C1372737 988749 N0000009741 C29848 Metabolic Activity Alteration [PE] C1372744 N0000009748 990190 Metabolic Activity Alteration C29862 Mitosis Alteration [PE] 988121 C29866 Mitosis Alteration N0000009750 C1372746 Musculoskeletal Activity Alteration [PE] C1372751 N0000009755 C29876 Musculoskeletal Activity Alteration 985711 Negative Chronotropy [PE] N0000009756 Negative Chronotropy C1372752 986396 C29878 Negative Inotropy [PE] N0000009757 C29880 990886 C1372753 Negative Inotropy Nervous System Activity Alteration [PE] C2916815 Nervous System Activity Alteration C29884 987311 N0000009759 Neurotransmitter & Neuromuscular Transmitter Activity Alteration [PE] C29888 Neurotransmitter & Neuromuscular Transmitter Activity Alteration N0000009761 C1372757 989639 Norepinephrine Activity Alteration [PE] 985713 C29896 Norepinephrine Activity Alteration C1372761 N0000009765 Nucleic Acid Replication Alteration [PE] C1372762 989424 N0000009766 Nucleic Acid Replication Alteration C29898 Nucleic Acid Transcription Alteration [PE] N0000009767 C1372763 C29900 Nucleic Acid Transcription Alteration 984912 Organ System Specific Effects [PE] N0000009770 C29906 Organ System Specific Effects 985923 C1372766 Organized Electrical Activity Alteration [PE] Organized Electrical Activity Alteration 988792 N0000009774 C29914 C1372770 Ovarian Endocrine Activity Alteration [PE] C1372773 N0000009777 985043 Ovarian Endocrine Activity Alteration C29920 Ovarian Function Alteration [PE] C29924 986398 N0000009779 Ovarian Function Alteration C1372775 Ovulation Alteration [PE] N0000009781 990274 C29928 Ovulation Alteration C1372777 Penile Venous Vasodilation [PE] N0000009798 C1372794 988321 C29962 Penile Venous Vasodilation Phagocytosis Alteration [PE] N0000009800 C1372796 C29966 985352 Phagocytosis Alteration Photosensitizing Activity [PE] Photosensitizing Activity C29968 N0000009801 C1372797 984179 Physiological Effects [PE] C1372798 N0000009802 C29970 Physiological Effects 984490 Pituitary Gland Activity Alteration [PE] N0000009805 Pituitary Gland Activity Alteration C29976 C1372801 986891 Platelet Aggregation Alteration [PE] C1372803 1030000 C29980 N0000009807 Platelet Aggregation Alteration Post Translation Protein Modification Alteration [PE] C1372806 N0000009810 989327 Post Translation Protein Modification Alteration C29986 Protein Degradation Alteration [PE] 985131 C1372810 N0000009814 Protein Degradation Alteration C29994 RNA Integrity Alteration [PE] 990659 RNA Integrity Alteration N0000009821 C1372852 C30008 RNA Replication Alteration [PE] 985505 RNA Replication Alteration C1372853 N0000009822 C30010 Renal Arterial Vasoconstriction [PE] N0000009825 C1372856 989641 Renal Arterial Vasoconstriction C30016 Renal Arterial Vasodilation [PE] C30018 988963 N0000009826 C1372857 Renal Arterial Vasodilation Renal Ion Transport Alteration [PE] C1372861 C30026 Renal Ion Transport Alteration 984183 N0000009830 Renal/Urological Activity Alteration [PE] N0000009832 988191 C30030 C1372863 Renal/Urological Activity Alteration Reproductive System Activity Alteration [PE] 990488 C1372864 Reproductive System Activity Alteration C30032 N0000009833 Respiratory Smooth Muscle Tone Alteration [PE] C30042 C1372869 987051 Respiratory Smooth Muscle Tone Alteration N0000009838 Respiratory/Pulmonary Activity Alteration [PE] N0000009839 C30044 Respiratory/Pulmonary Activity Alteration C1372870 987910 Reverse Transcription to DNA Alteration [PE] 987911 N0000009840 C1372871 C30046 Reverse Transcription to DNA Alteration Saliva Production Alteration [PE] 986450 Saliva Production Alteration C30048 C1372872 N0000009841 Salivation Stimulation [PE] Salivation Stimulation N0000009843 C1372874 C30052 985049 Serotonin Activity Alteration [PE] 986797 C1372875 Serotonin Activity Alteration C30054 N0000009844 Special Sensory Systems Activity Alteration [PE] N0000009851 C1372882 Special Sensory Systems Activity Alteration C30068 990845 Stimulate Ovulation [PE] 988583 Stimulate Ovulation C1372894 C30092 N0000009863 Striated Muscle Metabolic Alteration [PE] Striated Muscle Metabolic Alteration C2916793 984454 C30118 N0000009876 Striated Muscle Anabolism Alteration [PE] Striated Muscle Anabolism Alteration C30120 C1372908 N0000009877 989427 Striated Muscle Catabolism Alteration [PE] 989644 N0000009878 C1372909 C30122 Striated Muscle Catabolism Alteration Striated Muscle Contraction Alteration [PE] 984654 Striated Muscle Contraction Alteration C1372910 N0000009879 C30124 Substance P Activity Alteration [PE] Substance P Activity Alteration C30126 N0000009880 984655 C1372911 Testicular Endocrine Activity Alteration [PE] C1372918 Testicular Endocrine Activity Alteration C30140 N0000009887 985052 Thyroid Gland Activity Alteration [PE] N0000009889 986798 C30144 Thyroid Gland Activity Alteration C1372920 Thyroid Hormone Iodination Alteration [PE] C1372921 1031140 Thyroid Hormone Iodination Alteration N0000009890 C30146 Translation Alteration [PE] 984492 N0000009894 C1372925 C30154 Translation Alteration Vascular Tone Alteration [PE] Vascular Tone Alteration C30178 C1372937 N0000009906 987659 Vasoconstriction [PE] Vasoconstriction C30182 N0000009908 C0042396 1022844 Vasodilation [PE] C30184 1021984 N0000009909 C0042401 Vasodilation Venous Vasodilation [PE] 989329 N0000009911 C30188 Venous Vasodilation C1372940 Ventilatory Gas Flow Alteration [PE] Ventilatory Gas Flow Alteration C1372941 C30190 N0000009912 985297 Ventricular Repolarization [PE] 986031 Ventricular Repolarization N0000009914 C1372942 C30194 Unknown Cellular or Molecular Interaction [MoA] C1373108 C30196 990716 Unknown Cellular or Molecular Interaction N0000009915 Adrenergic alpha2-Agonists [MoA] C1373110 C30202 Adrenergic alpha2-Agonists N0000009918 1035126 Adrenergic beta1-Antagonists [MoA] Adrenergic beta1-Antagonists C30212 986189 N0000009923 C1373134 Adrenergic beta2-Antagonists [MoA] Adrenergic beta2-Antagonists N0000009924 C1373133 C30214 987660 Unknown Physiological Effect [PE] N0000009925 990891 Unknown Physiological Effect C30216 C1372849 Decreased Cellular Migration [PE] C1372848 989196 Decreased Cellular Migration N0000009928 C30224 Decreased Luteinizing Hormone Secretion [PE] C30228 987320 C1372846 N0000009930 Decreased LH Secretion Decreased Luteinizing Hormone Secretion Vitamin Uptake and Modification Alteration [PE] 985133 C1372844 C30232 N0000009932 Vitamin Uptake and Modification Alteration Decreased Vitamin Uptake and Modification [PE] 988793 C30236 Decreased Vitamin Uptake and Modification C1372842 N0000009934 Decreased Folic Acid Modification [PE] Decreased Folate Modification 988510 N0000009935 C1372841 C30238 Decreased Folic Acid Modification Intraocular Fluid Pressure Alteration [PE] 988969 C30252 C1372834 Intraocular Fluid Pressure Alteration N0000009942 Decreased Intraocular Fluid Pressure [PE] Decreased Intraocular Fluid Pressure 986190 N0000009943 C1372833 C30254 Decreased Intraocular Aqueous Secretion [PE] N0000009944 C1372832 Decreased Intraocular Aqueous Secretion C30256 989197 Para-Aminobenzoic Acid Inhibitors [MoA] C2916799 C30260 PABA Inhibitor N0000009946 984916 Para-Aminobenzoic Acid Inhibitors Non-Nucleoside Reverse Transcriptase Inhibitors [MoA] 989597 C30264 N0000009948 Non-Nucleoside Reverse Transcriptase Inhibitors C1373120 Antibody-Receptor Interactions [MoA] C2267208 985716 C30266 N0000009949 Antibody-Receptor Interactions Tumor Necrosis Factor Receptor Interactions [MoA] N0000009950 C1373118 TNF Receptor Interactions C30268 984657 Tumor Necrosis Factor Receptor Interactions Sterol Synthesis Inhibitors [MoA] Sterol Synthesis Inhibitors C1373112 988794 C30280 N0000009956 Bone Surface Interactions [MoA] 985507 N0000009958 C1373129 Bone Surface Interactions C30284 Respiratory Mucosal Edema Alteration [PE] 990849 C1372831 Respiratory Mucosal Edema Alteration C30296 N0000009964 Decreased Respiratory Mucosal Edema [PE] 989798 C30298 N0000009965 Decreased Respiratory Mucosal Edema C1372830 Decreased Tracheo-Bronchial Mucosal Edema [PE] C30308 Decreased Tracheo-Bronchial Mucosal Edema N0000009970 C1372825 989598 almotriptan [Chemical/Ingredient] M0363903 C30950 N0000010060 C0914729 almotriptan C409045 almotriptan 279645 almotriptan aprepitant [Chemical/Ingredient] N0000010068 C1176306 aprepitant aprepitant 358255 M0447596 C114556 aprepitant C30986 bortezomib [Chemical/Ingredient] N0000010079 C31054 C1176309 358258 bortezomib bortezomib bortezomib M0350110 C400082 eletriptan [Chemical/Ingredient] N0000010109 C0759933 C31206 C115647 eletriptan M0297676 231049 eletriptan eletriptan gemifloxacin [Chemical/Ingredient] 138099 C103274 M0370050 N0000010125 gemifloxacin gemifloxacin gemifloxacin C0533545 7-(3-aminomethyl-4-methoxyimino-pyrrolidine-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-(1,8)-naphthyridine-3-carboxylic acid C31306 oxaliplatin [Chemical/Ingredient] N0000010154 oxaliplatin platinum(II)-1,2-cyclohexanediamine oxalate C0069717 1,2-diaminocyclohexane platinum oxalate 1,2-diamminocyclohexane(trans-1)oxolatoplatinum(II) M0095550 C31522 C030110 oxaliplatin oxaliplatin oxalato-(1,2-cyclohexanediamine)platinum II 32592 oxaliplatine tenofovir [Chemical/Ingredient] tenofovir tenofovir Tenofovir 9-(2-phosphonomethoxypropyl)adenine C096918 C0384228 9-(2-phosphonylmethoxypropyl)adenine N0000010179 117466 C31666 9-PMPA M0254881 valdecoxib [Chemical/Ingredient] C0913246 C406224 N0000010186 4-(5-methyl-3-phenyl-isoxazol-4-yl)benzenesulfonamide 278567 C31698 valdecoxib valdecoxib valdecoxib M0360234 valganciclovir [Chemical/Ingredient] ganciclovir L-valyl ester N0000010187 C0909381 275891 C31702 valganciclovir valganciclovir valganciclovir C121677 M0334922 voriconazole [Chemical/Ingredient] C31722 M0268951 voriconazole voriconazole 121243 C0393080 N0000010191 C102790 voriconazole Pregnancy [Disease/Finding] N0000010195 C31746 289908002 C0032961 Pregnancy 1022794 Physiologic States [Disease/Finding] 989040 C31750 N0000010197 C2916830 Physiologic States Demographic States [Disease/Finding] C31754 N0000010198 Demographic States 985726 C2916805 Age Categories [Disease/Finding] 989345 C31762 N0000010202 C2916832 Age Categories Infant [Disease/Finding] Infant N0000010203 1023674 133931009 C31764 C0021270 Neonate [Disease/Finding] 1022105 N0000010204 C0021289 46068001 C31766 Neonate Child [Disease/Finding] 1025000 410601007 C31768 Child N0000010205 C0008059 Toddler [Disease/Finding] N0000010206 988344 C31770 Toddler C0682053 Young Child [Disease/Finding] C0728836 N0000010207 C31772 74489007 1029003 Young Child Preterm Infant [Disease/Finding] 1022314 395507008 Preterm Infant N0000010208 C0021294 C31774 Older Child [Disease/Finding] 986907 C31776 Older Child N0000010209 31114009 C1455726 Adult [Disease/Finding] 133936004 Adult C31778 N0000010210 1026384 C0001675 Young Adult [Disease/Finding] Young Adult C31780 C0238598 1028035 N0000010211 Middle Aged Adult [Disease/Finding] 1033187 C31782 Middle Aged Adult N0000010212 C0683973 Elderly Adult [Disease/Finding] 207527008 271872005 C31784 207528003 1026765 Elderly Adult N0000010213 C2825054 49808004 Adolescent [Disease/Finding] N0000010214 Adolescent 133937008 59223006 C31786 C0205653 1023260 Transpeptidase Inhibitors [MoA] Transpepsidase Inhibitors PBP inhibitors N0000010215 Transpeptidase Inhibitors penicillin binding protein Inhibitors C1373138 C31788 984931 Lactation [Disease/Finding] 1025167 C0022925 169741004 Lactation C31790 N0000010216 Sterol Metabolism Alteration [PE] C31802 Sterol Metabolism Alteration C1371579 990415 N0000010222 Antibody Interactions [MoA] C2916825 N0000010226 Antibody Interactions C31810 987958 Irritable Bowel Syndrome [Disease/Finding] C31842 10743008 Colon, Irritable D043183 Irritable Bowel Syndrome A disorder with chronic or recurrent colonic symptoms without a clearcut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION. 1022676 Colitis, Mucous N0000010242 M0004816 C0022104 Irritable Bowel Syndrome Pregnancy Second Trimester [Disease/Finding] C0032980 59466002 C31846 255247007 Pregnancy Second Trimester N0000010244 1021885 Pregnancy Third Trimester [Disease/Finding] N0000010245 C31848 41587001 Pregnancy Third Trimester 255248002 C0032981 1023212 Decreased Polymorphonuclear Leukocyte Migration [PE] C31850 C1371595 990417 N0000010246 Decreased Polymorphonuclear Leukocyte Migration Decreased Fibroblast Migration [PE] N0000010248 Decreased Fibroblast Migration C1371593 987533 C31854 Vascular Permeability Alteration [PE] 1025930 N0000010250 Vascular Permeability Alteration C1371588 C31858 Decreased Vascular Permeability [PE] 984932 C31862 N0000010252 C2825069 Decreased Vascular Permeability Decreased Capillary Permeability [PE] C31864 N0000010253 Decreased Capillary Permeability C0232378 985585 Cellular Structure Molecule Interactions [MoA] 989808 C1373148 C31868 N0000010255 Cellular Structure Molecule Interactions Tubulin Interactions [MoA] Tubulin Interactions N0000010256 C31870 C1373147 1023254 beta Tubulin Interactions [MoA] 986466 C31878 beta Tubulin Interactions C1373143 N0000010260 Neurokinin 1 Receptor Interactions [MoA] C31880 NK 1 Receptor Interactions Neurokinin 1 Receptor Interactions N0000010261 Substance P Receptor Interactions C1373142 984193 Neurokinin 1 Antagonists [MoA] N0000010262 C2916827 Substance P Receptor Antagonists Neurokinin 1 Antagonists C31882 988216 NK 1 Receptor Antagonists Smooth Muscle Tone Alteration [PE] C31894 Smooth Muscle Tone Alteration 985732 N0000010268 C1371604 Interleukin 2 Receptor Interactions [MoA] N0000010278 C31914 C1373153 Interleukin 2 Receptor Interactions 984934 IL2 Receptor Interactions Interleukin 2 Receptor Antagonists [MoA] IL2 Receptor Antagonists Interleukin 2 Receptor Blockers 986467 C31916 Interleukin 2 Receptor Antagonists C1373152 IL2 Receptor Inhibitors N0000010279 Interleukin 2 Receptor Inhibitors IL2 Receptor Blockers atazanavir [Chemical/Ingredient] 343047 C1145759 C413408 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-2,5,6,10,13-pentaazatetradecanedioic acid dimethyl ester M0450734 C53850 Atazanavir atazanavir atazanavir N0000010341 Daptomycin [Chemical/Ingredient] N0000010342 D017576 C0057144 C53858 Deptomycin Daptomycin 22299 N-decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine-epsilon1-lactone A cyclic lipopeptide antibiotic that inhibits GRAM-POSITIVE BACTERIA. Daptomycin Daptomycin M0026638 emtricitabine [Chemical/Ingredient] C0909839 emtricitabine beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine N0000010344 276237 C122114 emtricitabine emtricitabine C53866 M0337569 imatinib [Chemical/Ingredient] imatinib C53878 282388 C0935989 C097613 imatinib imatinib M0424454 N0000010347 Memantine [Chemical/Ingredient] C0025242 D008559 AMANTADINE derivative that has some dopaminergic effects. It has been proposed as an antiparkinson agent. N0000010349 Tricyclo(3.3.1.13,7)decan-1-amine, 3,5-dimethyl- Memantine 1,3-Dimethyl-5-aminoadamantane 1-Amino-3,5-dimethyladamantane 6719 C53890 Memantine M0013333 Memantin Memantine miglustat [Chemical/Ingredient] n-butyldeoxynojirimycin miglustat miglustat N-(n-butyl)deoxy-nojirimycin C1321596 C059896 N0000010350 n-butyl deoxynojirimycin 402316 M0461235 N-(n-butyl)deoxynojirimycin Miglustat C53894 Triptorelin [Chemical/Ingredient] GnRH, Trp(6)- D017329 M0026318 D-Trp-6-LH-RH N0000010359 C53938 6-D-Tryptophan-Luteinizing Hormone-Releasing Factor (Pig) 38782 C0077275 Triptorelin 5-oxo-Pro-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2 Triptorelin Triptorelin LHRH, Trp(6)- LHRH, Tryptophyl(6)- A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE with D-tryptophan substitution at residue 6. vardenafil [Chemical/Ingredient] C426063 C0971579 306674 vardenafil vardenafil vardenafil 1-(((3-(3,4-dihydro-5-methyl)-4-oxo-7-propylimidazo(5,1-f)-as-triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethylpiperazine N0000010361 M0387383 C53946 infliximab [Chemical/Ingredient] M0282056 MAb cA2 infliximab 191831 N0000010531 infliximab C108577 monoclonal antibody cA2 C0666743 C273254 infliximab tadalafil [Chemical/Ingredient] N0000010536 Pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione, 6-(1,3- benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R,12aR)- tadalafil C429886 C1176316 tadalafil C273294 M0431130 tadalafil 358263 pemetrexed [Chemical/Ingredient] N-(4-(2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid C273298 L-Glutamic acid, N-(4-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)- pemetrexed C085586 68446 pemetrexed M0227083 pemetrexed C0210657 MTA N0000010538 Tinidazole [Chemical/Ingredient] Tinidazole 1H-Imidazole, 1-(2-(ethylsulfonyl)ethyl)-2-methyl-5-nitro- C273397 Tinidazole 10612 D014011 M0021569 C0040263 N0000010549 A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections. Tinidazole erlotinib [Chemical/Ingredient] M0350388 C273485 337525 erlotinib erlotinib C1135135 N0000010566 C400278 erlotinib Drug Products by Generic Ingredient Combinations C2267084 C288626 987399 N0000010582 Drug Products by Generic Ingredient Combinations A [Preparations] 989498 C288627 N0000010583 A [Preparations] C2267085 B [Preparations] 987472 C288628 N0000010584 C2267086 B [Preparations] C [Preparations] C [Preparations] 987820 C288629 C2267087 N0000010585 D [Preparations] C288630 N0000010586 C2267088 D [Preparations] 990856 E [Preparations] E [Preparations] C2267089 984666 C288631 N0000010587 F [Preparations] 986610 C2267090 N0000010588 C288632 F [Preparations] G [Preparations] N0000010589 C288633 C2267091 986405 G [Preparations] H [Preparations] 985945 C288634 C2741642 N0000010590 H [Preparations] I [Preparations] C288635 N0000010591 C2267092 I [Preparations] 987875 L [Preparations] C288638 L [Preparations] N0000010594 C2267094 984195 M [Preparations] C2267095 989499 C288639 M [Preparations] N0000010595 N [Preparations] 984993 C2267096 C288640 N0000010596 N [Preparations] O [Preparations] N0000010597 O [Preparations] C288641 989096 C2267097 P [Preparations] C2267098 P [Preparations] 987400 C288642 N0000010598 R [Preparations] C288644 N0000010600 987269 C2267100 R [Preparations] S [Preparations] S [Preparations] C2267101 C288645 985848 N0000010601 T [Preparations] N0000010602 989806 T [Preparations] C288646 C2267102 V [Preparations] C2267104 V [Preparations] C288648 984196 N0000010604 Z [Preparations] 987401 N0000010608 C288652 C2267108 Z [Preparations] Spondylarthropathies [Disease/Finding] Heterogeneous group of arthritic diseases sharing clinical and radiologic features. They are associated with the HLA-B27 ANTIGEN and some with a triggering infection. Most involve the axial joints in the SPINE, particularly the SACROILIAC JOINT, but can also involve asymmetric peripheral joints. Subsets include ANKYLOSING SPONDYLITIS; REACTIVE ARTHRITIS; PSORIATIC ARTHRITIS; and others. 1022545 Spondylarthropathy N0000010934 Spondylarthropathies C0949691 372109003 C291287 D025242 Spondylarthropathies M0374011 Hepatic Insufficiency [Disease/Finding] N0000010941 1026586 59927004 C291294 C1306571 Conditions in which the LIVER functions fall below the normal ranges. Severe hepatic insufficiency may cause LIVER FAILURE or DEATH. Treatment may include LIVER TRANSPLANTATION. M0461663 Hepatic Insufficiency Hepatic Insufficiency Liver Insufficiency D048550 Adrenogenital Syndrome [Disease/Finding] C291311 D047808 M0000488 Abnormal SEX DIFFERENTIATION or congenital DISORDERS OF SEX DEVELOPMENT caused by abnormal levels of steroid hormones expressed by the GONADS or the ADRENAL GLANDS, such as in CONGENITAL ADRENAL HYPERPLASIA and ADRENAL CORTEX NEOPLASMS. Due to abnormal steroid biosynthesis, clinical features include VIRILISM in females; FEMINIZATION in males; or precocious sexual development in children. 190511001 C0302280 1024033 271077003 Adrenogenital Syndrome Adrenogenital Syndrome N0000010958 Weight Loss [Disease/Finding] Decrease in existing BODY WEIGHT. M0023779 1024717 N0000010968 C291321 Weight Reduction 262285001 161832001 D015431 Weight Loss Weight Loss C0043096 89362005 Papillomavirus Infections [Disease/Finding] C291356 M0387084 Papillomavirus Infections 1027658 N0000011003 Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression. D030361 Papillomavirus Infections C0950124 Moraxellaceae Infections [Disease/Finding] D045828 C291361 M0449414 C1258225 N0000011008 988873 Moraxellaceae Infections Moraxellaceae Infections Infections with bacteria of the family MORAXELLACEAE. Tauopathies [Disease/Finding] D024801 C291372 1024063 Neurodegenerative disorders involving deposition of abnormal tau protein isoforms (TAU PROTEINS) in neurons and glial cells in the brain. Pathological aggregations of tau proteins are associated with mutation of the tau gene on chromosome 17 in patients with ALZHEIMER DISEASE; DEMENTIA; PARKINSONIAN DISORDERS; progressive supranuclear palsy (SUPRANUCLEAR PALSY, PROGRESSIVE); and corticobasal degeneration. N0000011019 Tauopathies Tauopathies C0949664 Tauopathy M0371891 Gestational Trophoblastic Neoplasms [Disease/Finding] D031901 Gestational Trophoblastic Neoplasms C1135868 M0398989 417475006 A group of interrelated trophoblastic diseases arising from pregnancy. They are commonly associated with hyperplasia of trophoblasts (TROPHOBLAST) and markedly elevated human CHORIONIC GONADOTROPIN. They include HYDATIDIFORM MOLE, invasive mole (HYDATIDIFORM MOLE, INVASIVE), placental-site trophoblastic tumor (TROPHOBLASTIC TUMOR, PLACENTAL SITE), and CHORIOCARCINOMA. These neoplasms have varying propensities for invasion and spread. N0000011045 416402001 Gestational Trophoblastic Neoplasms Trophoblastic Neoplasms, Gestational 1023593 C291398 Spondylarthritis [Disease/Finding] Spondylarthritis 371082009 C291426 Spondylarthritis M0374010 N0000011073 D025241 C0949690 Inflammation of the joints of the SPINE, the intervertebral articulations. Spinal Arthritis Arthritis, Spinal 1024045 Body Weight [Disease/Finding] Body Weight C0005910 D001835 C291429 1027029 The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. N0000011076 Body Weight M0002758 39857003 Carcinoma, Ductal [Disease/Finding] M0445446 Ductal Carcinoma C291440 1025416 82711006 Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND. Carcinoma, Ductal Carcinoma, Ductal N0000011087 D044584 C1176475 Steroid Metabolism, Inborn Errors [Disease/Finding] N0000011088 Steroid Metabolic Diseases, Inborn C1257809 1026290 Errors in metabolic processing of STEROIDS resulting from inborn genetic mutations that are inherited or acquired in utero. Inborn Errors of Steroid Metabolism Steroid Metabolism, Inborn Errors Steroid Metabolism, Inborn Errors Congenital Errors of Steroid Metabolism M0442596 C291441 D043202 Malnutrition [Disease/Finding] 65404009 N0000011099 Undernutrition D044342 70241007 Malnutrition Malnutrition C0162429 1021991 M0015121 C291452 Nutritional Deficiency An imbalanced nutritional status resulted from insufficient intake of nutrients to meet normal physiological requirement. Genetic Diseases, Inborn [Disease/Finding] Genetic Diseases, Inborn Genetic Diseases, Inborn M0385531 D030342 C0950123 Diseases that are caused by genetic mutations present during embryo or fetal development, although they may be observed later in life. The mutations may be inherited from a parent's genome or they may be acquired in utero. C291458 1025368 N0000011105 Inborn Genetic Diseases Glucose Metabolism Disorders [Disease/Finding] Glucose Metabolism Disorders C291476 126877002 M0446458 N0000011123 Glucose Metabolic Disorder 989730 Glucose Metabolic Disorders Pathological conditions in which the BLOOD GLUCOSE cannot be maintained within the normal range, such as in HYPOGLYCEMIA and HYPERGLYCEMIA. Etiology of these disorders varies. Plasma glucose concentration is critical to survival for it is the predominant fuel for the CENTRAL NERVOUS SYSTEM. Glucose Metabolism Disorders Glucose Metabolism Disorder C1257958 D044882 Diabetes Complications [Disease/Finding] Conditions or pathological processes associated with the disease of diabetes mellitus. Due to the impaired control of BLOOD GLUCOSE level in diabetic patients, pathological processes develop in numerous tissues and organs including the EYE, the KIDNEY, the BLOOD VESSELS, and the NERVE TISSUE. Diabetic Complications C291479 C0342257 D048909 Diabetes Complications 1023143 372069003 N0000011126 190422004 Complications of Diabetes Mellitus Diabetes-Related Complications M0462957 Diabetes Complications Pneumocystis Infections [Disease/Finding] M0025462 Pneumocystis carinii Infections 1024257 N0000011153 Infections with species in the genus PNEUMOCYSTIS, a fungus causing interstitial plasma cell pneumonia (PNEUMONIA, PNEUMOCYSTIS) and other infections in humans and other MAMMALS. Immunocompromised patients, especially those with AIDS, are particularly susceptible to these infections. Extrapulmonary sites are rare but seen occasionally. D016720 111918002 Pneumocystis Infections Pneumocystis Infections C0851886 C291506 Stress Disorders, Traumatic [Disease/Finding] Stress Disorders, Traumatic Stress Disorders, Traumatic N0000011157 Anxiety disorders manifested by the development of characteristic symptoms following a psychologically traumatic event that is outside the normal range of usual human experience. Symptoms include re-experiencing the traumatic event, increased arousal, and numbing of responsiveness to or reduced involvement with the external world. Traumatic stress disorders can be further classified by the time of onset and the duration of these symptoms. C0038441 D040921 990033 C291511 M0424629 Cephalosporins [Chemical/Ingredient] A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. 1024008 C291517 Antibiotics, Cephalosporin Cephalosporins Cephalosporins N0000011161 C2266959 M0003827 D002511 beta-Lactams [Chemical/Ingredient] M0012144 C0282215 N0000011162 D047090 C291518 Four-membered cyclic AMIDES, best known for the PENICILLINS based on a bicyclo-thiazolidine, as well as the CEPHALOSPORINS based on a bicyclo-thiazine, and including monocyclic MONOBACTAMS. The BETA-LACTAMASES hydrolyze the beta lactam ring, accounting for BETA-LACTAM RESISTANCE of infective bacteria. 82034 beta-Lactams beta-Lactams Hormones [Chemical/Ingredient] Hormone C291528 M0010538 C0019932 5436 N0000011172 Hormones Hormones Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various ENDOCRINE GLANDS and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects. D006728 Hormones, Hormone Substitutes, and Hormone Antagonists [Chemical/Ingredient] M0010540 5438 N0000011173 Hormones, Hormone Substitutes, and Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists D006730 C291529 C0019934 A collective grouping for both naturally occurring and synthetic hormones, substitutes, and antagonists. Hormones, Substitutes, Antagonists Antibodies, Monoclonal [Chemical/Ingredient] N0000011174 Antibodies, Monoclonal D000911 Monoclonal Antibodies 911 Antibodies produced by a single clone of cells. Antibodies, Monoclonal M0001357 C0003250 C291530 Antibodies [Chemical/Ingredient] Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS). 904 N0000011175 D000906 Antibodies C291531 M0001352 C0003241 Antibodies Recombinant Fusion Proteins [Chemical/Ingredient] N0000011180 Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. C291536 Fusion Proteins, Recombinant Recombinant Fusion Proteins Recombinant Fusion Proteins 9217 M0018640 C0034857 D011993 Secologanin Tryptamine Alkaloids [Chemical/Ingredient] Terpenoid Indole Alkaloids Monoterpenoid Indole Alkaloids D046948 Secologanin Tryptamine Alkaloids C291543 469968 Secologanin Tryptamine Alkaloids Secologanin Indole Alkaloids M0456000 C1449663 Compounds formed by condensation of secologanin with tryptamine resulting in a tetrahydro-beta-carboline which is processed further to a number of bioactive compounds. These are especially found in plants of the APOCYNACEAE; LOGANIACEAE; and RUBIACEAE families. N0000011187 Indole Alkaloids [Chemical/Ingredient] Group of alkaloids containing a benzylpyrrole group (derived from TRYPTOPHAN) D026121 287953 C291544 M0377033 N0000011188 Indole Alkaloids Indole Alkaloids C0949738 Fluoroquinolones [Chemical/Ingredient] D024841 M0372253 Fluoroquinolones Fluoroquinolones C291546 287913 N0000011190 C0949665 A group of QUINOLONES with at least one fluorine atom and a piperazinyl group. Peptide Hormones [Chemical/Ingredient] Peptide Hormones M0409611 D036361 Peptide Hormones C291558 154313 N0000011202 Hormones synthesized from amino acids. They are distinguished from INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS in that their actions are systemic. Hormones, Peptide C0597192 Vidarabine Phosphate [Chemical/Ingredient] C291559 Adenine Arabinoside Monophosphate 1066 Arabinofuranosyladenine Monophosphate N0000011203 9-(5-O-Phosphono-beta-D-arabinofuranosyl)-9H-purin-6-amine Vidarabine Phosphate An adenosine monophosphate analog in which ribose is replaced by an arabinose moiety. It is the monophosphate ester of VIDARABINE with antiviral and possibly antineoplastic properties. D001084 Vidarabine Monophosphate C0003674 9H-Purin-6-amine, 9-(5-O-phosphono-beta-D-arabinofuranosyl)- M0001639 Vidarabine Phosphate Ara-AMP Arabinonucleotides [Chemical/Ingredient] N0000011204 Nucleotides containing arabinose as their sugar moiety. M0001643 Arabinofuranosylnucleotides C291560 D001088 1070 Arabinonucleotides Arabinonucleotides C0003681 Amino Acids, Aromatic [Chemical/Ingredient] N0000011248 Aromatic Amino Acids Amino acids containing an aromatic side chain. M0370111 C0301713 D024322 Amino Acids, Aromatic Amino Acids, Aromatic 89965 C291604 Amino Acid, Aromatic Transition Elements [Chemical/Ingredient] C291611 M0382670 Elements with partially filled d orbitals. They constitute groups 3-12 of the periodic table of elements. C0682906 Transition Elements Transition Elements D028561 196940 N0000011255 Pituitary Hormone-Releasing Hormones [Chemical/Ingredient] Pituitary Hormone-Releasing Hormones Hypophysiotropic Hormones Peptides, natural or synthetic, that stimulate the release of PITUITARY HORMONES. They were first isolated from the extracts of the HYPOTHALAMUS; MEDIAN EMINENCE; PITUITARY STALK; and NEUROHYPOPHYSIS. In addition, some hypophysiotropic hormones control pituitary cell differentiation, cell proliferation, and hormone synthesis. Some can act on more than one pituitary hormone. D010906 N0000011269 Hormones, Pituitary Hormone Releasing 8363 C291625 Pituitary Hormone-Releasing Hormones C0032014 M0016916 Hypothalamic Hormones [Chemical/Ingredient] D007028 Hypothalamic Hormones Hypothalamic Pituitary-Regulating Hormones C0020656 N0000011270 Hypothalamic Pituitary-Regulating Peptides 5617 M0010936 Peptide hormones produced by NEURONS of various regions in the HYPOTHALAMUS. They are released into the pituitary portal circulation to stimulate or inhibit PITUITARY GLAND functions. VASOPRESSIN and OXYTOCIN, though produced in the hypothalamus, are not included here for they are transported down the AXONS to the POSTERIOR LOBE OF PITUITARY before being released into the portal circulation. C291626 Hypothalamic Hormones Phenylcarbamates [Chemical/Ingredient] Phenylcarbamates C1449848 Phenyl-Carbamates Phenyl esters of carbamic acid or of N-substituted carbamic acids. Structures are similar to PHENYLUREA COMPOUNDS with a carbamate in place of the urea. C291629 Phenylcarbamates M0461443 N0000011273 D048448 470109 Penicillins [Chemical/Ingredient] Penicillins M0016152 Penicillins N0000011281 D010406 A group of antibiotics that contain 6-aminopenicillanic acid with a side chain attached to the 6-amino group. The penicillin nucleus is the chief structural requirement for biological activity. The side-chain structure determines many of the antibacterial and pharmacological characteristics. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1065) C0030842 C291637 7986 Antibiotics, Penicillin Biological Factors [Chemical/Ingredient] Factor, Biologic M0002530 C291646 Factor, Biological Biological Factors Factors, Biological D001685 Biological Factor C0005515 1570 N0000011290 Biologic Factors Endogenously-synthesized compounds that may influence biological phenomena or represent quantifiable biomarkers. Biological factors are a variety of extracellular substances that are not otherwise classified under ENZYMES; HORMONES or HORMONE ANTAGONISTS Biological Factors Cytokines [Chemical/Ingredient] 40065 D016207 Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner. Cytokines Cytokines C0079189 N0000011291 C291647 M0024747 Imidazolines [Chemical/Ingredient] C291660 Imidazolines 470102 Imidazolines D048288 N0000011304 Compounds based on reduced IMIDAZOLES containing a single double bond. C1449836 M0461078 17-Hydroxycorticosteroids [Chemical/Ingredient] 17-Hydroxycorticosteroids 17-Hydroxycorticosteroids C0000163 M0023177 19 D015065 A group of hydroxycorticosteroids bearing a hydroxy group at the 17-position. Urinary excretion of these compounds is used as an index of adrenal function. They are used systemically in the free alcohol form, but with esterification of the hydroxy groups, topical effectiveness is increased. C291663 N0000011307 Hydroxycorticosteroids [Chemical/Ingredient] C0020343 5524 D006889 Hydroxycorticosteroids A group of corticosteroids carrying hydroxy groups, usually in the 11- or 17-positions. They comprise the bulk of the corticosteroids used systemically. As they are relatively insoluble in water, salts of various esterified forms are often used for injections or solutions. M0010756 N0000011308 C291664 Hydroxycorticosteroids Adrenal Cortex Hormones [Chemical/Ingredient] C0001617 D000305 C291665 Adrenal Cortex Hormones Adrenal Cortex Hormones 354 Corticoids N0000011309 Corticosteroids M0000480 Imidazolidines [Chemical/Ingredient] M0461079 D048289 470103 Imidazolidines N0000011314 Imidazolidines C291670 Compounds based on reduced IMIDAZOLINES which contain no double bonds in the ring. C1449837 Taxoids [Chemical/Ingredient] Taxoids M0443608 N0000011317 D043823 C291673 382247 C1257832 A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS. Taxoids Cyclodecanes [Chemical/Ingredient] C1257831 Cyclodecanes M0443605 382246 Compounds with a 10-carbon ring. C291674 D043822 Cyclodecanes N0000011318 Aza Compounds [Chemical/Ingredient] M0002056 Aza Compounds 1249 D001372 C291680 N0000011324 Aza Compounds C0004471 Macrocyclic Compounds [Chemical/Ingredient] 469970 Macrocyclic Compounds Macrocycle Compounds M0456185 C291686 Macrocyclic Compounds N0000011330 D047028 C1449665 Cyclic compounds with a ring size of approximately 1-4 dozen atoms. Polycyclic Compounds [Chemical/Ingredient] Compounds consisting of two or more fused ring structures. M0017162 N0000011331 Polycyclic Compounds Polycyclic Compounds C0032456 D011083 8502 C291687 Lymphokines [Chemical/Ingredient] Lymphokines C291701 M0012816 Lymphocyte Mediators Soluble protein factors generated by activated lymphocytes that affect other cells, primarily those involved in cellular immunity. 6522 Lymphokines D008222 C0024297 N0000011345 Antigens [Chemical/Ingredient] Antigens Antigen Antigens 946 D000941 M0001407 N0000011350 Substances that are recognized by the immune system and induce an immune reaction. C0003320 C291706 Antigens, Viral [Chemical/Ingredient] Substances elaborated by viruses that have antigenic activity. M0001448 Antigens, Viral Viral Antigens N0000011353 C0003342 C291709 D000956 965 Antigens, Viral Lignans [Chemical/Ingredient] 28711 C0064971 M0026769 D017705 N0000011369 Lignans A class of dibenzylbutane derivatives which occurs in higher plants and in fluids (bile, serum, urine, etc.) in man and other animals. These compounds, which have a potential anti-cancer role, can be synthesized in vitro by human fecal flora. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed) C291725 Lignans Excitatory Amino Acids [Chemical/Ingredient] Endogenous amino acids released by neurons as excitatory neurotransmitters. Glutamic acid is the most common excitatory neurotransmitter in the brain. Aspartic acid has been regarded as an excitatory transmitter for many years, but the extent of its role as a transmitter is unclear. C0243046 Excitatory Amino Acid Excitatory Amino Acids N0000011371 71687 M0028199 C291727 Amino Acids, Excitatory Excitatory Amino Acids D018846 Amino Acids, Acidic [Chemical/Ingredient] M0370116 D024342 Amino Acid, Acidic Acidic Amino Acids Amino Acids, Acidic 258416 Amino Acids, Acidic N0000011372 C291728 Amino acids with side chains that are negatively charged at physiological pH. C0815040 11-Hydroxycorticosteroids [Chemical/Ingredient] A group of corticosteroids bearing a hydroxy group at the 11-position. C0000119 D015062 12 N0000011376 M0023175 11-Hydroxycorticosteroids 11-Hydroxycorticosteroids C291732 Intercellular Signaling Peptides and Proteins [Chemical/Ingredient] C1136108 Intercellular Signaling Peptides and Proteins Intercellular Signaling Peptides and Proteins M0409590 C291740 D036341 Regulatory proteins and peptides that are signaling molecules involved in the process of PARACRINE COMMUNICATION. They are generally considered factors that are expressed by one cell and are responded to by receptors on another nearby cell. They are distinguished from HORMONES in that their actions are local rather than distal. N0000011384 337799 4-Quinolones [Chemical/Ingredient] N0000011390 M0441453 106885 C291746 D042462 QUINOLONES containing a 4-oxo (a carbonyl in the para position to the nitrogen). They inhibit the A subunit of DNA GYRASE and are used as antimicrobials. Second generation 4-quinolones are also substituted with a 1-piperazinyl group at the 7-position and a fluorine at the 6-position. 4-Oxoquinolines 4-Quinolones 4-Quinolones C0358919 4-Quinolinones Lactams, Macrocyclic [Chemical/Ingredient] C1449667 N0000011415 Cyclams Macrocyclic Lactams M0456188 469972 Lactams, Macrocyclic LACTAMS forming compounds with a ring size of approximately 1-3 dozen atoms. D047029 C291771 Lactams, Macrocyclic Interleukins [Chemical/Ingredient] Interleukin D007378 M0011509 Interleukins Interleukins C0021764 Soluble factors which stimulate growth-related activities of leukocytes as well as other cell types. They enhance cell proliferation and differentiation, DNA synthesis, secretion of other biologically active molecules and responses to immune and inflammatory stimuli. N0000011422 C291779 5896 Interleukin-2 [Chemical/Ingredient] T-Cell Growth Factor Interleukin-2 T-Cell Stimulating Factor 5889 C0021756 TCGF M0011506 Thymocyte Stimulating Factor C291781 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. Lymphocyte Mitogenic Factor D007376 Interleukin II IL-2 N0000011424 Interleukine 2 IL2 HIV Envelope Protein gp41 [Chemical/Ingredient] HIV Envelope Protein gp41 N0000011448 Transmembrane envelope protein of the HUMAN IMMUNODEFICIENCY VIRUS which is encoded by the HIV env gene. It has a molecular weight of 41,000 and is glycosylated. The N-terminal part of gp41 is thought to be involved in CELL FUSION with the CD4 ANTIGENS of T4 LYMPHOCYTES, leading to syncytial formation. Gp41 is one of the most common HIV antigens detected by IMMUNOBLOTTING. Envelope Protein gp41, HIV HIV Envelope Protein gp41 M0024085 C291805 gp41(HIV) gp41 Envelope Protein, HIV env Protein gp41, HIV C0019692 HTLV-III gp41 5370 HIV Transmembrane Protein gp41 D015700 Gene Products, env [Chemical/Ingredient] env Gene Products env Antigens Gene Products, env N0000011449 env Protein C0017278 4727 D015686 Gene Products, env Retroviral proteins, often glycosylated, coded by the envelope (env) gene. They are usually synthesized as protein precursors (POLYPROTEINS) and later cleaved into the final viral envelope glycoproteins by a viral protease. C291806 M0024061 Polyproteins [Chemical/Ingredient] C291807 N0000011450 Proteins which are synthesized as a single polymer and then cleaved into several distinct proteins. M0017889 Polyproteins Polyproteins 8552 C0032583 D020815 Retroviridae Proteins [Chemical/Ingredient] Retroviridae Proteins Proteins from the family Retroviridae. The most frequently encountered member of this family is the Rous sarcoma virus protein. M0018984 D012191 N0000011451 C0035367 Retroviridae Proteins 9302 C291808 Viral Proteins [Chemical/Ingredient] Gene Products, Viral Viral Proteins M0022737 D014764 Proteins found in any species of virus. C0042736 C291809 Viral Gene Products Viral Proteins Viral Gene Proteins 11225 N0000011452 Viral Envelope Proteins [Chemical/Ingredient] C291810 N0000011453 11215 Envelope Proteins, Viral Viral Envelope Proteins Viral Envelope Proteins D014759 Virus Envelope Proteins C0042711 Layers of protein which surround the capsid in animal viruses with tubular nucleocapsids. The envelope consists of an inner layer of lipids and virus specified proteins also called membrane or matrix proteins. The outer layer consists of one or more types of morphological subunits called peplomers which project from the viral envelope; this layer always consists of glycoproteins. M0022717 Viral Structural Proteins [Chemical/Ingredient] D015678 N0000011454 Viral Structural Proteins Viral proteins that are components of the mature assembled VIRUS PARTICLES. They may include nucleocapsid core proteins (gag proteins), enzymes packaged within the virus particle (pol proteins), and membrane components (env proteins). These do not include the proteins encoded in the VIRAL GENOME that are produced in infected cells but which are not packaged in the mature virus particle,i.e. the so called non-structural proteins (VIRAL NONSTRUCTURAL PROTEINS). 11227 M0024034 C0042738 C291811 Virus Structural Proteins Viral Structural Proteins HIV Antigens [Chemical/Ingredient] HTLV-III-LAV Antigens T-Lymphotropic Virus Type III Antigens, Human 5368 HIV Associated Antigens HTLV III Antigens Lymphadenopathy-Associated Antigens D015488 HTLV III LAV Antigens T Lymphotropic Virus Type III Antigens, Human C291812 HIV Antigens M0023851 N0000011455 Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (LAV) antigens. HIV-Associated Antigens C0019686 LAV Antigens AIDS Antigens HIV Antigens Lymphadenopathy Associated Antigens HTLV-III Antigens Viral Fusion Proteins [Chemical/Ingredient] C0042717 D014760 Viral Fusion Proteins Fusion Proteins, Viral Proteins, usually glycoproteins, found in the viral envelopes of a variety of viruses. They promote cell membrane fusion and thereby may function in the uptake of the virus by cells. C291813 Virus Fusion Proteins N0000011456 M0022730 11221 Viral Fusion Proteins Peptide Fragments [Chemical/Ingredient] Peptide Fragments Peptide Fragments M0016224 C291814 8027 Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. C0030935 D010446 N0000011457 Boronic Acids [Chemical/Ingredient] D001897 Boronic Acids C0006032 C291820 1707 Boronic Acids Inorganic or organic compounds that contain the basic structure RB(OH)2. M0002834 N0000011463 Tryptamines [Chemical/Ingredient] Decarboxylated monoamine derivatives of TRYPTOPHAN. Tryptamines Tryptamines Indolylethylamines D014363 C0041248 C291831 M0022087 10897 N0000011474 Hypothalmic Hormone Interactions [MoA] N0000019992 985094 C300377 Hypothalmic Hormone Interactions C2267109 Hypothalamic Hormone Receptor Agonists [MoA] 989569 Hypothalamic Hormone Receptor Agonists C300378 N0000019993 C2916835 Receptor Tyrosine Kinase Inhibitors [MoA] Receptor Tyrosine Kinase Inhibitors C2267115 987029 C300385 N0000020000 Tyrosine Kinase Inhibitors [MoA] 1028392 C2757011 C300386 Tyrosine Kinase Inhibitors N0000020001 Vascular Alterations [PE] 984378 N0000020002 Vascular Alterations C2267116 C300387 Vascular Growth Alteration [PE] C300388 Vascular Growth Alteration 985275 C2267117 N0000020003 Vascular Growth Decrease [PE] C2267119 N0000020005 Vascular Growth Decrease Angiogenesis Inhibition C300390 990782 HER Receptor Family Antagonists [MoA] EGFR Family Inhibitors EGFR Family Antagonists Epidermal Growth Factor Receptor Family Antagonists 990667 HER Inhibitors N0000020006 HER Receptor Family Antagonists Epidermal Growth Factor Receptor Family Inhibitors Human Epidermal Growth Factor Receptor Family Inhibitors C2916840 Human Epidermal Growth Factor Receptor Family Antagonists HER Receptor Family Inhibitors C300391 HER Family Inhibitors HER Antagonists HER Family Antagonists HER2/Neu/cerbB2 Antagonists [MoA] HER2/Neu/cerbB2 Antagonists HER2 Antagonists HER-2 Inhibitors C300393 HER2 Inhibitors HER2/Neu/cerbB2 Inhibitors 984590 C2916795 HER-2 Antagonists HER-2/Neu/cerbB2 Antagonists N0000020008 HER-2/Neu/cerbB2 Inhibitors Bcr-Abl Tyrosine Kinase Inhibitors [MoA] 984994 C300394 Bcr-Abl Tyrosine Kinase Inhibitor N0000020009 Bcr-Abl Tyrosine Kinase Inhibitors C2267122 HER1 Antagonists [MoA] HER1 Inhibitors HER-1 Antagonists HER1 Antagonists C300395 Epidermal Growth Factor Receptor Antagonists 989266 N0000020010 Epidermal Growth Factor Receptor Inhibitors EGFR Inhibitors HER-1 Inhibitors C2916831 EGFR Antagonists Cellular Growth Phase Reduction [PE] C2267126 N0000020013 986120 Cellular Growth Phase Reduction C300398 Ionotropic Glutamate Receptor Antagonists [MoA] 985979 C300399 Ionotropic Glutamate Receptor Antagonists C2916809 N0000020014 NMDA Receptor Antagonists [MoA] C2916808 NMDA Receptor Antagonists N0000020015 N-methyl-D-aspartate Receptor Antagonists 985849 C300400 Glucosyl Transferase Inhibitors [MoA] 988136 N0000020018 C2267130 C300403 Glucosyl Transferase Inhibitors Glucosylceramide Synthase Inhibitors [MoA] 989376 C300404 C2267131 Glucosylceramide Synthase Inhibitors N0000020019 Glycosphingolipid Synthesis Alteration [PE] Glycosphingolipid Synthesis Alteration C2267132 986153 C300405 N0000020020 Glycosphingolipid Synthesis Decrease [PE] 985980 C300407 Glycosphingolipid Synthesis Decrease C2267134 N0000020022 14-alpha Demethylase Inhibitors [MoA] C300411 C2267137 N0000020025 989952 14-alpha Demethylase Inhibitors Phosphodiesterase 5 Inhibitors [MoA] C2267138 Phosphodiesterase V Inhibitor N0000020026 985515 C300412 Phosphodiesterase V Inhibitors Phosphodiesterase 5 Inhibitors Polysaccharide Metabolism Alteration [PE] Polysaccharide Metabolism Alteration N0000020040 C300430 C2267149 986121 L-Calcium Channel Receptor Antagonists [MoA] L-Calcium Channel Receptor Antagonists C300455 989377 N0000020065 C2916833 Ubiquitin Ligase Inhibitors [MoA] C300474 C1661195 N0000020084 986156 Ubiquitin Ligase Inhibitors Viral Envelope Interactions [MoA] C2267190 989812 Viral Envelope Interactions N0000020089 C300479 INTERFERON ALFA-2A http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/103145s5060LBL.pdf Ingredient INTERFERON ALFA-2A C0021734 N0000020127 4022121 C15918 <VANDF_Record>50.6^183^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>183</VA_IEN> Active 5879 Interferon Alfa-2a MEGESTROL http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65b28775-ee59-88cf-e4d8-372c6c79ad14#nlm34084-4,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020264s017lbl.pdf C16868 Active MEGESTROL Megestrol N0000020211 <VANDF_Record>50.6^451^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>451</VA_IEN> C0025175 4022205 Ingredient 6703 ZALCITABINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s16lbl.pdf <VANDF_Record>50.6^2270^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2270</VA_IEN> ZALCITABINE Zalcitabine 3363 C21646 Active 4023282 N0000021287 C0012132 Ingredient ZOLPIDEM http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019908s029lbl.pdf Active 39993 N0000021601 C21714 <VANDF_Record>50.6^2769^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2769</VA_IEN> C0078839 Ingredient ZOLPIDEM zolpidem 4023596 VENLAFAXINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020151s056s057lbl.pdf C21404 C0078569 N0000021906 VENLAFAXINE 4023901 <VANDF_Record>50.6^3173^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3173</VA_IEN> 39786 venlafaxine Ingredient Active FLUVASTATIN http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020261s042,021192s016lbl.pdf 41127 Ingredient N0000021914 fluvastatin FLUVASTATIN C0082608 Active C14840 4023909 <VANDF_Record>50.6^3184^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3184</VA_IEN> STAVUDINE (dT4) N0000021950 <VANDF_Record>50.6^3225^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3225</VA_IEN> Ingredient 4023945 Inactive C1875783 C290406 693224 STAVUDINE (dT4) METFORMIN http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ed71d7ea-f5af-4406-8b0d-68e17cb1e61e&type=display Metformin Ingredient METFORMIN 4023979 6809 C0025598 N0000021984 Active C17000 <VANDF_Record>50.6^3277^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3277</VA_IEN> VINORELBINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20388S014lbl.pdf Active <VANDF_Record>50.6^3279^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3279</VA_IEN> N0000021986 VINORELBINE 4023981 C0078257 vinorelbine Ingredient 39541 C21450 GEMCITABINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020509s069lbl.pdf C0045093 N0000022036 GEMCITABINE Ingredient 4024031 gemcitabine C15022 12574 <VANDF_Record>50.6^3358^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3358</VA_IEN> Active TOPOTECAN http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020671s016s017lbl.pdf C21012 C0146224 Ingredient TOPOTECAN Topotecan Active 57308 N0000022037 <VANDF_Record>50.6^3360^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3360</VA_IEN> 4024032 ATORVASTATIN http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020702s056lbl.pdf atorvastatin Active <VANDF_Record>50.6^3382^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3382</VA_IEN> ATORVASTATIN Ingredient C11394 83367 N0000022046 4024041 C0286651 CEFEPIME http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050679s036lbl.pdf Ingredient C0055003 Active N0000022054 C12388 CEFEPIME 20481 4024049 <VANDF_Record>50.6^3392^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3392</VA_IEN> cefepime DELAVIRDINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/20705S8lbl.pdf Ingredient Active <VANDF_Record>50.6^3395^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3395</VA_IEN> C0288165 4024051 Delavirdine C13500 83816 DELAVIRDINE N0000022056 ROPIVACAINE C19622 35780 C0073571 ROPIVACAINE Ingredient <VANDF_Record>50.6^3403^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3403</VA_IEN> Active ropivacaine 4024055 N0000022060 PRAMIPEXOLE 746741 N0000022076 Active PRAMIPEXOLE Ingredient 4024071 Pramipexole C0074710 C19082 <VANDF_Record>50.6^3431^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3431</VA_IEN> <VANDF_Record>50.416^4691^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4691</VA_IEN> ROPINIROLE http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020658s018s020s021lbl.pdf Active Ingredient C19616 C0244821 <VANDF_Record>50.6^3446^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3446</VA_IEN> 4024081 N0000022086 72302 ropinirole ROPINIROLE CLOPIDOGREL http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=edae8df1-caf9-ff72-1304-5ae8b355f8e7&type=display clopidogrel C0070166 C12996 CLOPIDOGREL Ingredient <VANDF_Record>50.6^3467^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3467</VA_IEN> 4024096 32968 Active N0000022101 SILDENAFIL http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020895s036lbl.pdf SILDENAFIL Active sildenafil C19856 N0000022115 136411 <VANDF_Record>50.6^3484^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3484</VA_IEN> Ingredient C0529793 4024110 MONTELUKAST http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020829s060,020830s062,021409s037lbl.pdf MONTELUKAST N0000022122 montelukast C0298130 Ingredient <VANDF_Record>50.6^3503^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3503</VA_IEN> 4024117 C17436 88249 Active CERIVASTATIN http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/20740S19lbl.pdf 4024119 C0528023 <VANDF_Record>50.6^3505^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3505</VA_IEN> N0000022124 Ingredient CERIVASTATIN C12556 596723 Active ATAZANAVIR http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021567s026lbl.pdf 4024316 ATAZANAVIR 343047 Atazanavir Active Ingredient <VANDF_Record>50.6^3890^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3890</VA_IEN> <VANDF_Record>50.416^4656^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4656</VA_IEN> N0000022320 C1145759 C53848 GOLD <VANDF_Record>50.416^2241^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2241</VA_IEN> 4019622 N0000022608 C15176 4975 <VANDF_Record>50.6^323^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>323</VA_IEN> GOLD Ingredient Active C0018026 INTERFERON 5886 C15914 C0021747 Active <VANDF_Record>50.416^2410^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2410</VA_IEN> Ingredient 4019787 INTERFERON N0000022612 RABEPRAZOLE NA Rabeprazole sodium RABEPRAZOLE NA C19460 N0000022999 4021175 C0732569 <VANDF_Record>50.416^3847^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3847</VA_IEN> Ingredient Active 226868 ESZOPICLONE http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021476s012lbl.pdf 4024906 <VANDF_Record>50.6^4045^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4045</VA_IEN> Active 461016 N0000023088 UZX80K71OE <VANDF_Record>50.416^4212^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4212</VA_IEN> ESZOPICLONE Ingredient C1436328 C4837925188257 Eszopiclone TIPRANAVIR http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021814s011lbl.pdf tipranavir 4024917 TIPRANAVIR C0663733 C4837932838670 N0000023100 ZZT404XD09 <VANDF_Record>50.6^4059^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4059</VA_IEN> Ingredient Active <VANDF_Record>50.416^4224^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4224</VA_IEN> 190548 PREGABALIN http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=60185c88-ecfd-46f9-adb9-b97c6b00a553#nlm34084-4 <VANDF_Record>50.416^4231^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4231</VA_IEN> <VANDF_Record>50.6^4070^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4070</VA_IEN> pregabalin PREGABALIN C0657912 N0000023107 187832 Active 4024924 C4837938905643 55JG375S6M Ingredient COLCHICINE http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee1583ac-c308-4beb-b602-9ecac4977026#section-6 4017416 <VANDF_Record>50.6^3^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3</VA_IEN> C13128 Colchicine COLCHICINE SML2Y3J35T Active N0000145804 Ingredient <VANDF_Record>50.416^7^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>7</VA_IEN> 2683 C0009262 PROPYLTHIOURACIL http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/006188s021s022lbl.pdf 8794 4017432 <VANDF_Record>50.416^23^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>23</VA_IEN> C19284 Propylthiouracil Ingredient PROPYLTHIOURACIL C0033511 721M9407IY Active N0000145820 <VANDF_Record>50.6^12^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>12</VA_IEN> METHIMAZOLE http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=dc92f45f-8d27-4dcb-b72d-6b8b04c6f0ce&type=display Methimazole METHIMAZOLE 554Z48XN5E C0025644 6835 C17076 N0000145822 <VANDF_Record>50.416^25^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>25</VA_IEN> Active Ingredient <VANDF_Record>50.6^14^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>14</VA_IEN> 4017434 PENICILLIN G BENZATHINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050141s231lbl.pdf <VANDF_Record>50.416^30^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>30</VA_IEN> penicillin G benzathine RIT82F58GK 7982 Active C18320 C0030829 N0000145827 PENICILLIN G BENZATHINE Ingredient 4017439 TRIAMCINOLONE http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/012802s031lbl.pdf <VANDF_Record>50.416^192^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>192</VA_IEN> Triamcinolone C21066 1ZK20VI6TY Active 10759 N0000145980 <VANDF_Record>50.6^93^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>93</VA_IEN> 4017599 C0040864 TRIAMCINOLONE Ingredient HYDROXYUREA http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/016295s041s042lbl.pdf HYDROXYUREA C0020402 Ingredient <VANDF_Record>50.416^328^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>328</VA_IEN> hydroxyurea C15614 4017733 N0000146101 <VANDF_Record>50.6^129^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>129</VA_IEN> X6Q56QN5QC 5552 Active IOPAMIDOL Active <VANDF_Record>50.6^140^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>140</VA_IEN> 4017756 <VANDF_Record>50.416^351^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>351</VA_IEN> Iopamidol N0000146122 5966 C0022026 JR13W81H44 Ingredient C16008 IOPAMIDOL LEVODOPA http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017555s056s068s071lbl.pdf <VANDF_Record>50.416^385^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>385</VA_IEN> C0023570 C16452 N0000146151 4017790 <VANDF_Record>50.6^160^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>160</VA_IEN> Active 6375 LEVODOPA Levodopa Ingredient 46627O600J FLUCYTOSINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/017001s027lbl.pdf N0000146153 C0016278 Flucytosine FLUCYTOSINE <VANDF_Record>50.416^387^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>387</VA_IEN> Ingredient Active D83282DT06 4017792 <VANDF_Record>50.6^162^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>162</VA_IEN> C14750 4451 FLUOROURACIL http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/20985slr004_carac_lbl.pdf 4492 U3P01618RT Ingredient C0016360 C14794 N0000146166 <VANDF_Record>50.416^401^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>401</VA_IEN> FLUOROURACIL Fluorouracil <VANDF_Record>50.6^173^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>173</VA_IEN> Active 4017806 METRONIDAZOLE http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021806s003lbl.pdf Active 6922 N0000146194 <VANDF_Record>50.416^431^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>431</VA_IEN> Ingredient 4017836 METRONIDAZOLE 140QMO216E <VANDF_Record>50.6^200^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>200</VA_IEN> C0025872 Metronidazole C17246 PHENYTOIN http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008762s055,010151s042lbl.pdf Active 8183 6158TKW0C5 C18638 C0031507 <VANDF_Record>50.416^451^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>451</VA_IEN> N0000146211 <VANDF_Record>50.6^215^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>215</VA_IEN> 4017856 Ingredient Phenytoin PHENYTOIN INDOMETHACIN http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018332s032lbl.pdf 5781 4017890 XXE1CET956 C0021246 C15738 <VANDF_Record>50.6^239^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>239</VA_IEN> <VANDF_Record>50.416^485^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>485</VA_IEN> Active N0000146243 Ingredient INDOMETHACIN Indomethacin SULFASALAZINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/007073s124lbl.pdf 4017897 <VANDF_Record>50.416^492^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>492</VA_IEN> <VANDF_Record>50.6^248^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>248</VA_IEN> 9524 C0036078 3XC8GUZ6CB SULFASALAZINE Sulfasalazine N0000146249 Ingredient C20470 Active DEXAMETHASONE http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/11664slr062_decadron_lbl.pdf C13562 <VANDF_Record>50.416^517^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>517</VA_IEN> 7S5I7G3JQL N0000146273 DEXAMETHASONE Dexamethasone <VANDF_Record>50.6^270^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>270</VA_IEN> Active 3264 C0011777 Ingredient 4017922 PENICILLAMINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/19853s012,014lbl.pdf PENICILLAMINE <VANDF_Record>50.6^284^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>284</VA_IEN> Penicillamine GNN1DV99GX <VANDF_Record>50.416^535^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>535</VA_IEN> Ingredient 7975 4017940 N0000146290 C0030817 C18314 Active HYDROCORTISONE https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008697s032_33lbl.pdf Ingredient 4017941 N0000146291 C15494 <VANDF_Record>50.416^536^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>536</VA_IEN> 5492 Hydrocortisone HYDROCORTISONE C0020268 <VANDF_Record>50.6^286^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>286</VA_IEN> WI4X0X7BPJ Active ENALAPRIL MALEATE http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/018998s071lbl.pdf <VANDF_Record>50.416^549^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>549</VA_IEN> Active C14204 9O25354EPJ Ingredient N0000146304 ENALAPRIL MALEATE 4017954 203123 Enalapril Maleate C0700452 PREDNISOLONE http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/40323lbl.pdf PREDNISOLONE N0000146334 Ingredient prednisolone 9PHQ9Y1OLM <VANDF_Record>50.416^585^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>585</VA_IEN> Active 4017988 C0032950 8638 C19114 <VANDF_Record>50.6^318^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>318</VA_IEN> GOLD SODIUM THIOMALATE http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a29045b5-ba4f-407a-a0fd-3ef7e1ce64ee&type=display <VANDF_Record>50.416^592^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>592</VA_IEN> Ingredient 4981 C0018034 4017995 N0000146340 C15178 Gold Sodium Thiomalate Active GOLD SODIUM THIOMALATE AURANOFIN http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=05c34ddf-a0f7-4267-83f5-d02be3defc37&type=display 3H04W2810V 1227 Auranofin AURANOFIN <VANDF_Record>50.6^341^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>341</VA_IEN> C11424 N0000146358 Active <VANDF_Record>50.416^611^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>611</VA_IEN> Ingredient C0004320 4018014 AMIODARONE HYDROCHLORIDE http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018972s044lbl.pdf Active AMIODARONE HYDROCHLORIDE 976728SY6Z C0700442 Ingredient 203114 N0000146406 4018065 <VANDF_Record>50.416^662^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>662</VA_IEN> C11026 Amiodarone hydrochloride METHYLPREDNISOLONE 6902 Active C17198 METHYLPREDNISOLONE Ingredient 4018068 Methylprednisolone X4W7ZR7023 N0000146409 <VANDF_Record>50.6^394^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>394</VA_IEN> C0025815 <VANDF_Record>50.416^665^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>665</VA_IEN> METHYLPREDNISOLONE ACETATE http://www.accessdata.fda.gov/drugsatfda_docs/anda/98/40183_Methylprednisolone_Prntlbl.pdf Active 43502P7F0P C0600901 Ingredient METHYLPREDNISOLONE ACETATE 4018070 N0000146411 <VANDF_Record>50.416^667^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>667</VA_IEN> 155323 methylprednisolone acetate C17200 CYTARABINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021041s023lbl.pdf Ingredient 4018080 Active C13376 Cytarabine <VANDF_Record>50.6^402^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>402</VA_IEN> C0010711 N0000146419 04079A1RDZ CYTARABINE 3041 <VANDF_Record>50.416^677^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>677</VA_IEN> HALOPERIDOL http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=27cfe684-7d11-4f37-9c8b-b2bdd6b5348e#nlm34084-4 4018123 N0000146461 Haloperidol C0018546 HALOPERIDOL J6292F8L3D C15300 Ingredient Active 5093 <VANDF_Record>50.416^720^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>720</VA_IEN> <VANDF_Record>50.6^445^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>445</VA_IEN> CARMUSTINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017422s042lbl.pdf N0000146473 U68WG3173Y Active 4018136 <VANDF_Record>50.416^733^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>733</VA_IEN> Ingredient 2105 C12294 Carmustine <VANDF_Record>50.6^455^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>455</VA_IEN> CARMUSTINE C0007257 CISPLATIN http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018057s081lbl.pdf 2555 CISPLATIN Cisplatin 4018139 Q20Q21Q62J <VANDF_Record>50.416^736^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>736</VA_IEN> N0000146476 Ingredient C0008838 C12892 Active <VANDF_Record>50.6^458^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>458</VA_IEN> ETOPOSIDE http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e28c05f0-081f-406d-8bfb-9160a6908307&type=display <VANDF_Record>50.6^460^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>460</VA_IEN> N0000146478 C14476 Active ETOPOSIDE Etoposide Ingredient <VANDF_Record>50.416^738^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>738</VA_IEN> 6PLQ3CP4P3 C0015133 4018141 4179 METOLAZONE http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/19532s12lbl.pdf 4018161 N0000146498 Ingredient C17234 METOLAZONE Metolazone <VANDF_Record>50.6^481^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>481</VA_IEN> <VANDF_Record>50.416^758^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>758</VA_IEN> 6916 TZ7V40X7VX C0025854 Active TOBRAMYCIN http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf 10627 <VANDF_Record>50.416^1194^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>1194</VA_IEN> Tobramycin <VANDF_Record>50.6^914^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>914</VA_IEN> N0000146911 4018595 TOBRAMYCIN VZ8RRZ51VK Active C0040341 Ingredient C20940 FENTANYL 4018745 C14594 4337 UF599785JZ <VANDF_Record>50.416^1347^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>1347</VA_IEN> N0000147049 Active <VANDF_Record>50.6^1073^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>1073</VA_IEN> FENTANYL Ingredient Fentanyl C0015846 CYCLOSPORINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050715s028,050716s029lbl.pdf Cyclosporine N0000147064 83HN0GTJ6D C13348 <VANDF_Record>50.416^1363^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>1363</VA_IEN> 4018761 Ingredient C0010592 CYCLOSPORINE <VANDF_Record>50.6^1100^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>1100</VA_IEN> 3008 Active CHLORAMBUCIL http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf 4018769 <VANDF_Record>50.416^1371^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>1371</VA_IEN> C12646 C0008163 CHLORAMBUCIL 2346 Ingredient <VANDF_Record>50.6^1112^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>1112</VA_IEN> Active 18D0SL7309 Chlorambucil N0000147072 NITROFURANTOIN http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020064s019lbl.pdf Ingredient 7454 C0028156 N0000147151 <VANDF_Record>50.416^1452^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>1452</VA_IEN> C17710 Active <VANDF_Record>50.6^1217^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>1217</VA_IEN> 4018849 Nitrofurantoin 927AH8112L NITROFURANTOIN LEUPROLIDE ACETATE http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019943s032,020011s039lbl.pdf Active Leuprolide Acetate 203217 Ingredient 4018977 C16420 <VANDF_Record>50.416^1582^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>1582</VA_IEN> LEUPROLIDE ACETATE N0000147256 C0700596 37JNS02E7V SUCCIMER 4019174 SUCCIMER C0012384 Succimer 3446 <VANDF_Record>50.6^2227^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2227</VA_IEN> N0000147417 Active C20404 Ingredient DX1U2629QE <VANDF_Record>50.416^1783^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>1783</VA_IEN> DAPSONE http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021794s006lbl.pdf <VANDF_Record>50.416^1874^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>1874</VA_IEN> C0010980 N0000147467 3108 C13466 Active DAPSONE 8W5C518302 4019264 <VANDF_Record>50.6^1840^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>1840</VA_IEN> Dapsone Ingredient RIBAVIRIN http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020903s046,021546s002lbl.pdf 9344 <VANDF_Record>50.416^1910^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>1910</VA_IEN> N0000147496 C19534 Active 4019299 Ingredient 49717AWG6K RIBAVIRIN Ribavirin C0035525 <VANDF_Record>50.6^1909^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>1909</VA_IEN> CIPROFLOXACIN HYDROCHLORIDE http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019735s061lbl.pdf Ciprofloxacin Hydrochloride N0000147502 4BA73M5E37 81981 C12882 Ingredient C0282104 CIPROFLOXACIN HYDROCHLORIDE <VANDF_Record>50.416^1918^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>1918</VA_IEN> 4019306 Active CIPROFLOXACIN 2551 C0008809 <VANDF_Record>50.416^1919^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>1919</VA_IEN> 5E8K9I0O4U C12880 CIPROFLOXACIN <VANDF_Record>50.6^1919^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>1919</VA_IEN> Ciprofloxacin Ingredient 4019307 Active N0000147503 MISOPROSTOL http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019268s041lbl.pdf <VANDF_Record>50.6^1928^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>1928</VA_IEN> 42331 0E43V0BB57 N0000147506 Active C0085174 <VANDF_Record>50.416^1925^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>1925</VA_IEN> 4019313 C17370 Ingredient MISOPROSTOL Misoprostol LISINOPRIL http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019558s054lbl.pdf Active 29046 Ingredient N0000147537 <VANDF_Record>50.6^1990^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>1990</VA_IEN> E7199S1YWR 4019380 <VANDF_Record>50.416^1993^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>1993</VA_IEN> C16546 Lisinopril LISINOPRIL C0065374 OMEPRAZOLE http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s095,022056s011lbl.pdf Ingredient Omeprazole <VANDF_Record>50.6^2063^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2063</VA_IEN> C17900 N0000147569 4019439 Active KG60484QX9 C0028978 7646 <VANDF_Record>50.416^2053^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2053</VA_IEN> OMEPRAZOLE IFOSFAMIDE http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019763s016lbl.pdf Ifosfamide Active <VANDF_Record>50.6^2109^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2109</VA_IEN> <VANDF_Record>50.416^2090^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2090</VA_IEN> UM20QQM95Y Ingredient 5657 C0020823 C15684 N0000147596 4019476 IFOSFAMIDE CARBOPLATIN http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=806736d3-215a-4df5-8187-97f2161e5a53&type=display 4019478 BG3F62OND5 40048 C0079083 Ingredient <VANDF_Record>50.416^2092^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2092</VA_IEN> Carboplatin CARBOPLATIN <VANDF_Record>50.6^2112^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2112</VA_IEN> C12276 Active N0000147598 LOVASTATIN http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21316s010lbl.pdf N0000147602 Active 4019482 6472 C16638 9LHU78OQFD <VANDF_Record>50.6^2116^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2116</VA_IEN> LOVASTATIN Ingredient C0024027 Lovastatin <VANDF_Record>50.416^2096^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2096</VA_IEN> FLUCONAZOLE http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f694c617-3383-416c-91b6-b94fda371204&type=display Active FLUCONAZOLE C0016277 Fluconazole 4450 4019493 8VZV102JFY <VANDF_Record>50.6^2138^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2138</VA_IEN> C14748 <VANDF_Record>50.416^2107^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2107</VA_IEN> Ingredient N0000147613 MESALAMINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022301lbl.pdf <VANDF_Record>50.416^2108^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2108</VA_IEN> C0127615 <VANDF_Record>50.6^2139^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2139</VA_IEN> 4Q81I59GXC 4019494 Active N0000147614 MESALAMINE mesalamine 52582 C16968 Ingredient PROPOFOL Active <VANDF_Record>50.416^2114^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2114</VA_IEN> N0000147620 4019500 8782 YI7VU623SF C19244 C0033487 PROPOFOL Propofol <VANDF_Record>50.6^2145^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2145</VA_IEN> Ingredient ZIDOVUDINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019655s052,019910s039,020518s022lbl.pdf <VANDF_Record>50.6^2147^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2147</VA_IEN> C0043474 11413 C21656 Active ZIDOVUDINE Zidovudine Ingredient N0000147622 4019502 <VANDF_Record>50.416^2116^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2116</VA_IEN> 4B9XT59T7S NORFLOXACIN http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019384s060lbl.pdf Ingredient Active NORFLOXACIN N0F8P22L1P 7517 <VANDF_Record>50.6^2148^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2148</VA_IEN> C17744 N0000147623 4019503 <VANDF_Record>50.416^2117^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2117</VA_IEN> Norfloxacin C0028365 CAPSAICIN http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022395lbl.pdf 1992 Ingredient S07O44R1ZM C0006931 <VANDF_Record>50.6^2151^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2151</VA_IEN> CAPSAICIN Capsaicin <VANDF_Record>50.416^2120^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2120</VA_IEN> C12202 N0000147626 4019506 Active MITOXANTRONE HYDROCHLORIDE http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d0f0f1a-31af-40fa-9c64-e90891fa6ce4#nlm34084-4 C0700458 203129 4019527 U6USW86RD0 <VANDF_Record>50.416^2142^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2142</VA_IEN> Ingredient Mitoxantrone Hydrochloride Active N0000147641 MITOXANTRONE HYDROCHLORIDE C17378 RAMIPRIL http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019901s058lbl.pdf C0072973 Ramipril Active RAMIPRIL 35296 Ingredient <VANDF_Record>50.6^2235^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2235</VA_IEN> 4019562 C19482 L35JN3I7SJ N0000147662 <VANDF_Record>50.416^2177^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2177</VA_IEN> OLSALAZINE SODIUM http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019715s027lbl.pdf Active C17890 C0353940 Olsalazine sodium <VANDF_Record>50.416^2188^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2188</VA_IEN> 4019572 N0000147671 104123 OLSALAZINE SODIUM Y7JEW0XG7I Ingredient ALTRETAMINE http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8456a8db-a7f6-4bc0-86be-e9c8c374140b&type=display <VANDF_Record>50.416^2190^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2190</VA_IEN> ALTRETAMINE Altretamine C0019453 Active 4019574 N0000147673 Q8BIH59O7H <VANDF_Record>50.6^2249^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2249</VA_IEN> Ingredient 5296 C10894 AMANTADINE http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fc78c074-3ca8-4e29-9c18-8fab97558fc2&type=display N0000147697 AMANTADINE <VANDF_Record>50.416^2220^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2220</VA_IEN> Ingredient 620 4019601 BF4C9Z1J53 C10958 C0002403 <VANDF_Record>50.6^863^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>863</VA_IEN> Amantadine Active AMIODARONE AMIODARONE Active 4019606 N0000147701 Amiodarone <VANDF_Record>50.6^389^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>389</VA_IEN> <VANDF_Record>50.416^2225^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2225</VA_IEN> N3RQ532IUT 703 C11024 C0002598 Ingredient BETAXOLOL http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019507s008lbl.pdf <VANDF_Record>50.416^2252^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2252</VA_IEN> <VANDF_Record>50.6^903^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>903</VA_IEN> Ingredient BETAXOLOL C11712 Betaxolol 4019633 1520 C0005320 O0ZR1R6RZ2 N0000147726 Active BUPROPION http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022108s005s006lbl.pdf Ingredient 42347 C11932 C0085208 <VANDF_Record>50.6^2119^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2119</VA_IEN> Bupropion Active BUPROPION 4019645 N0000147738 01ZG3TPX31 <VANDF_Record>50.416^2264^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2264</VA_IEN> BUSPIRONE http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018731s051lbl.pdf <VANDF_Record>50.416^2265^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2265</VA_IEN> C11938 Buspirone <VANDF_Record>50.6^1165^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>1165</VA_IEN> BUSPIRONE Active C0006462 4019646 Ingredient 1827 TK65WKS8HL N0000147739 CLOMIPRAMINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019906s34lbl.pdf CLOMIPRAMINE Clomipramine C12982 NUV44L116D C0009010 2597 <VANDF_Record>50.416^2306^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2306</VA_IEN> Ingredient N0000147779 <VANDF_Record>50.6^2137^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2137</VA_IEN> 4019687 Active CYCLOBENZAPRINE <VANDF_Record>50.416^2318^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2318</VA_IEN> <VANDF_Record>50.6^295^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>295</VA_IEN> CYCLOBENZAPRINE Active 21949 69O5WQQ5TI C13328 Ingredient cyclobenzaprine 4019699 C0056732 N0000147791 CYPROHEPTADINE Active 3013 Ingredient 4019701 Cyproheptadine C13352 <VANDF_Record>50.6^276^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>276</VA_IEN> N0000147793 C0010620 CYPROHEPTADINE 2YHB6175DO <VANDF_Record>50.416^2320^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2320</VA_IEN> DEFEROXAMINE 3131 C0011145 Deferoxamine N0000147797 DEFEROXAMINE Ingredient <VANDF_Record>50.416^2324^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2324</VA_IEN> <VANDF_Record>50.6^1133^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>1133</VA_IEN> J06Y7MXW4D Active 4019705 C13486 DESIPRAMINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/014399s069lbl.pdf Active 3247 <VANDF_Record>50.6^924^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>924</VA_IEN> Ingredient DESIPRAMINE Desipramine C0011685 <VANDF_Record>50.416^2327^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2327</VA_IEN> TG537D343B 4019708 C13528 N0000147800 DILTIAZEM http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020092s017lbl.pdf Active <VANDF_Record>50.6^1169^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>1169</VA_IEN> C13816 DILTIAZEM Diltiazem <VANDF_Record>50.416^2341^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2341</VA_IEN> EE92BBP03H Ingredient N0000147814 C0012373 4019722 3443 DOXORUBICIN http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050718s033lbl.pdf 4019737 C14060 Active Ingredient DOXORUBICIN <VANDF_Record>50.6^428^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>428</VA_IEN> <VANDF_Record>50.416^2356^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2356</VA_IEN> C0013089 3639 N0000147829 80168379AG Doxorubicin ENALAPRIL N0000147835 <VANDF_Record>50.416^2363^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2363</VA_IEN> 3827 C0014025 <VANDF_Record>50.6^292^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>292</VA_IEN> ENALAPRIL Enalapril 4019744 Active C14202 69PN84IO1A Ingredient ETHAMBUTOL http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b2f95b0b-9de3-4c0b-a46e-a7eee6428b4b#nlm34084-4 8G167061QZ <VANDF_Record>50.416^2366^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2366</VA_IEN> 4110 N0000147838 Ethambutol C0014964 ETHAMBUTOL Ingredient 4019747 <VANDF_Record>50.6^260^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>260</VA_IEN> C14386 Active ETIDRONATE http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/017831s055lbl.pdf Ingredient ETIDRONATE Active N0000147844 C0086268 Etidronate <VANDF_Record>50.6^1269^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>1269</VA_IEN> 4019753 <VANDF_Record>50.416^2372^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2372</VA_IEN> 42682 C14464 FLECAINIDE http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display C14726 K94FTS1806 C0016229 4019757 FLECAINIDE <VANDF_Record>50.6^1175^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>1175</VA_IEN> Ingredient Flecainide <VANDF_Record>50.416^2377^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2377</VA_IEN> 4441 Active N0000147848 FLUOXETINE http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=59de2889-c3d3-4ebf-8826-13f30a3fa439#nlm34084-4 Ingredient FLUOXETINE Fluoxetine <VANDF_Record>50.416^2381^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2381</VA_IEN> Active 4493 <VANDF_Record>50.6^1996^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>1996</VA_IEN> 01K63SUP8D 4019761 N0000147852 C0016365 C14796 GANCICLOVIR http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/019661s030lbl.pdf P9G3CKZ4P5 4678 GANCICLOVIR N0000147855 <VANDF_Record>50.416^2384^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2384</VA_IEN> Ingredient 4019764 <VANDF_Record>50.6^2083^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2083</VA_IEN> Active Ganciclovir C14976 C0017066 LEUPROLIDE EFY6W0M8TG 4019800 LEUPROLIDE <VANDF_Record>50.6^1398^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>1398</VA_IEN> C0085272 Active C16418 N0000147889 Ingredient Leuprolide <VANDF_Record>50.416^2423^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2423</VA_IEN> 42375 MEFLOQUINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019591s026s028lbl.pdf <VANDF_Record>50.416^2434^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2434</VA_IEN> TML814419R 6694 N0000147900 Active MEFLOQUINE C0025153 Mefloquine 4019811 Ingredient <VANDF_Record>50.6^2143^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2143</VA_IEN> C16862 METHOTREXATE https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008085s066lbl.pdf N0000147916 6851 4019828 YL5FZ2Y5U1 Ingredient <VANDF_Record>50.6^254^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>254</VA_IEN> METHOTREXATE C17092 Active <VANDF_Record>50.416^2451^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2451</VA_IEN> Methotrexate C0025677 MITOXANTRONE Mitoxantrone C0026259 N0000147929 C17376 <VANDF_Record>50.6^2176^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2176</VA_IEN> BZ114NVM5P Ingredient Active <VANDF_Record>50.416^2465^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2465</VA_IEN> 4019842 7005 MITOXANTRONE NORTRIPTYLINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018013s58lbl.pdf <VANDF_Record>50.6^64^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>64</VA_IEN> NORTRIPTYLINE N0000147946 Active C0028420 C17750 Nortriptyline 7531 Ingredient BL03SY4LXB <VANDF_Record>50.416^2483^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2483</VA_IEN> 4019860 OLSALAZINE C17888 ULS5I8J03O olsalazine 32385 <VANDF_Record>50.416^2486^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2486</VA_IEN> OLSALAZINE 4019863 <VANDF_Record>50.6^2247^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2247</VA_IEN> Ingredient C0069454 N0000147949 Active PENICILLIN 70618 <VANDF_Record>50.416^2505^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2505</VA_IEN> N0000147965 Active 4019880 PENICILLIN <VANDF_Record>50.6^16^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>16</VA_IEN> Ingredient C0220892 Penicillin C18316 PENTAMIDINE http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e2ad9d3c-b6c3-4f70-87e0-722a8ff94ccb#nlm34084-4 PENTAMIDINE C0030863 Pentamidine C18340 N0000147966 Active 673LC5J4LQ 7994 <VANDF_Record>50.416^2506^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2506</VA_IEN> 4019881 Ingredient PERGOLIDE http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19385slr030,031,035_permax_lbl.pdf 24MJ822NZ9 <VANDF_Record>50.416^2508^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2508</VA_IEN> C18408 N0000147968 Active 8047 Ingredient PERGOLIDE C0031007 Pergolide 4019883 PROTRIPTYLINE http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=700abc58-9362-4ef5-9d7a-dd3c4d364d0a&type=display 8886 Protriptyline C19318 Ingredient <VANDF_Record>50.416^2543^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2543</VA_IEN> 4NDU154T12 <VANDF_Record>50.6^271^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>271</VA_IEN> 4019918 N0000148003 C0033743 PROTRIPTYLINE Active SELEGILINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021479s003s004lbl.pdf 4019929 9639 N0000148014 Ingredient <VANDF_Record>50.6^2121^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2121</VA_IEN> C0036579 C19766 SELEGILINE 2K1V7GP655 Selegiline Active <VANDF_Record>50.416^2554^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2554</VA_IEN> STREPTOMYCIN http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=abd1f64e-4283-4370-aae8-3666316aa36e&type=display C0038425 N0000148018 C20374 <VANDF_Record>50.6^40^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>40</VA_IEN> 10109 Ingredient <VANDF_Record>50.416^2558^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2558</VA_IEN> Streptomycin 4019933 STREPTOMYCIN Active Y45QSO73OB TAMOXIFEN http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=063fa789-4570-4715-c3bd-1bad0449fb26&type=display C20576 <VANDF_Record>50.416^2565^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2565</VA_IEN> 4019939 <VANDF_Record>50.6^772^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>772</VA_IEN> Ingredient N0000148024 10324 C0039286 094ZI81Y45 TAMOXIFEN Tamoxifen Active TOLMETIN http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a6c72634-4613-4d21-bc9a-09dad17eb137#nlm34084-4 N0000148037 <VANDF_Record>50.6^793^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>793</VA_IEN> 10636 C20990 TOLMETIN Tolmetin C0040377 Ingredient <VANDF_Record>50.416^2578^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2578</VA_IEN> 4019952 D8K2JPN18B Active TRIMIPRAMINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/016792s025lbl.pdf 10834 <VANDF_Record>50.6^384^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>384</VA_IEN> <VANDF_Record>50.416^2588^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2588</VA_IEN> TRIMIPRAMINE 6S082C9NDT C21180 Ingredient N0000148047 Active Trimipramine C0041056 4019962 ALDESLEUKIN http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103293s5130lbl.pdf Aldesleukin 4019994 Ingredient C9902 C0218986 <VANDF_Record>50.6^2716^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2716</VA_IEN> ALDESLEUKIN 70223 <VANDF_Record>50.416^2620^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2620</VA_IEN> N0000148066 Active DIDANOSINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020154s50,20155s39,20156s40,21183s16lbl.pdf 4020118 3364 N0000148104 K3GDH6OH08 <VANDF_Record>50.416^2753^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2753</VA_IEN> C0012133 Ingredient <VANDF_Record>50.6^2576^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2576</VA_IEN> DIDANOSINE C13724 Active Didanosine FLUDARABINE PHOSPHATE http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020038s033lbl.pdf 1X9VK9O1SC C0060483 <VANDF_Record>50.416^2814^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2814</VA_IEN> 4020177 25102 Ingredient FLUDARABINE PHOSPHATE Fludarabine phosphate C14754 N0000148119 Active SIMVASTATIN http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019766s083lbl.pdf SIMVASTATIN Simvastatin <VANDF_Record>50.416^3045^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3045</VA_IEN> C19902 Ingredient 4020400 36567 AGG2FN16EV C0074554 N0000148200 Active <VANDF_Record>50.6^2708^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2708</VA_IEN> TICLOPIDINE http://www.accessdata.fda.gov/drugsatfda_docs/anda/99/75161_Ticlopidine%20Hydrochloride_Prntlbl.pdf N0000148235 Active <VANDF_Record>50.6^2702^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2702</VA_IEN> 4020513 OM90ZUW7M1 10594 Ticlopidine TICLOPIDINE C0040207 Ingredient C20886 <VANDF_Record>50.416^3158^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3158</VA_IEN> FLUDARABINE fludarabine Ingredient FLUDARABINE C14752 4020528 N0000148244 <VANDF_Record>50.6^2271^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2271</VA_IEN> P2K93U8740 Active C0059985 <VANDF_Record>50.416^3173^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3173</VA_IEN> 24698 FLUTICASONE http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20549slr016,20548slr020,20121slr030_flonase_lbl.pdf 4020529 CUT2W21N7U C14834 Ingredient <VANDF_Record>50.416^3174^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3174</VA_IEN> C0082607 fluticasone FLUTICASONE Active <VANDF_Record>50.6^2706^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2706</VA_IEN> N0000148245 41126 FOSCARNET http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020068s017lbl.pdf N0000148246 33562 Foscarnet <VANDF_Record>50.6^2700^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2700</VA_IEN> Active 4020530 <VANDF_Record>50.416^3175^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3175</VA_IEN> C0070895 364P9RVW4X C14900 Ingredient FOSCARNET LOMEFLOXACIN http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/20013s015lbl.pdf C16602 28872 4020537 C0065162 Active <VANDF_Record>50.416^3183^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3183</VA_IEN> lomefloxacin <VANDF_Record>50.6^2698^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2698</VA_IEN> Ingredient LOMEFLOXACIN L6BR2WJD8V N0000148250 PRAVASTATIN http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019898s061lbl.pdf 4020548 Ingredient N0000148255 <VANDF_Record>50.6^2689^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2689</VA_IEN> C0085542 42463 <VANDF_Record>50.416^3194^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3194</VA_IEN> KXO2KT9N0G PRAVASTATIN Pravastatin C19096 Active ITRACONAZOLE http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020083s046lbl.pdf C16204 <VANDF_Record>50.416^3206^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3206</VA_IEN> <VANDF_Record>50.6^2786^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2786</VA_IEN> 304NUG5GF4 4020560 Ingredient 28031 Active C0064113 ITRACONAZOLE N0000148264 Itraconazole TENIPOSIDE http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020119s010s011lbl.pdf <VANDF_Record>50.6^2771^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2771</VA_IEN> <VANDF_Record>50.416^3220^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3220</VA_IEN> Ingredient N0000148273 4020571 957E6438QA TENIPOSIDE Active 10362 C0039512 Teniposide C20660 CLADRIBINE http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a2592a9b-bca6-4a5a-89c2-855a0634d5fe&type=display 4020629 N0000148293 <VANDF_Record>50.416^3278^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3278</VA_IEN> Active C0092801 44157 Cladribine <VANDF_Record>50.6^2787^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2787</VA_IEN> 47M74X9YT5 C12926 Ingredient CLADRIBINE PACLITAXEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf <VANDF_Record>50.6^2770^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2770</VA_IEN> Active N0000148314 P88XT4IS4D <VANDF_Record>50.416^3386^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3386</VA_IEN> Ingredient C0144576 Paclitaxel C18066 PACLITAXEL 4020736 56946 SUMATRIPTAN SUCCINATE http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fee7d073-0b99-48f2-7985-0d8cf970894b#nlm34084-4 C20530 C0206599 Ingredient N0000148323 J8BDZ68989 SUMATRIPTAN SUCCINATE <VANDF_Record>50.416^3445^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3445</VA_IEN> 67158 4020790 Sumatriptan Succinate Active AMLODIPINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019787s052lbl.pdf AMLODIPINE N0000148333 17767 Ingredient Amlodipine C11038 1J444QC288 C0051696 4020813 <VANDF_Record>50.6^2775^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2775</VA_IEN> <VANDF_Record>50.416^3469^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3469</VA_IEN> Active SOTALOL http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019865s020lbl.pdf <VANDF_Record>50.6^2782^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2782</VA_IEN> <VANDF_Record>50.416^3470^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3470</VA_IEN> Active N0000148334 SOTALOL A6D97U294I 4020814 9947 C0037707 Ingredient C20188 Sotalol PAROXETINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020031s058s066,020710s022s030lbl.pdf Ingredient C0070122 Paroxetine Active 41VRH5220H N0000148335 32937 <VANDF_Record>50.6^2778^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2778</VA_IEN> <VANDF_Record>50.416^3471^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3471</VA_IEN> C18174 4020815 PAROXETINE STAVUDINE (d4T) http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020412s038,020413s030lbl.pdf Stavudine <VANDF_Record>50.6^4241^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4241</VA_IEN> Active C20314 STAVUDINE (d4T) 59763 Ingredient 4020865 C0164662 BO9LE4QFZF <VANDF_Record>50.416^3522^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3522</VA_IEN> N0000148369 TACROLIMUS <VANDF_Record>50.416^3525^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3525</VA_IEN> Tacrolimus N0000148372 4020868 <VANDF_Record>50.6^3228^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3228</VA_IEN> Ingredient C20568 C0085149 42316 TACROLIMUS WM0HAQ4WNM Active LOSARTAN N0000148401 4020913 C16628 Ingredient C0126174 <VANDF_Record>50.416^3573^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3573</VA_IEN> <VANDF_Record>50.6^3285^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3285</VA_IEN> Losartan JMS50MPO89 52175 LOSARTAN Active LOSARTAN POTASSIUM http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020386s056lbl.pdf C0700492 Ingredient N0000148405 <VANDF_Record>50.416^3580^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3580</VA_IEN> 4020920 Losartan Potassium 203160 C16630 LOSARTAN POTASSIUM 3ST302B24A Active LANSOPRAZOLE http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=924c5a35-4804-4e14-a2fc-2b84d186d257&type=display lansoprazole Active 0K5C5T2QPG 4020922 LANSOPRAZOLE <VANDF_Record>50.6^3296^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3296</VA_IEN> C16354 Ingredient N0000148407 C0050940 17128 <VANDF_Record>50.416^3582^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3582</VA_IEN> IOPROMIDE iopromide C0063817 <VANDF_Record>50.6^3306^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3306</VA_IEN> 712BAC33MZ C16014 Active IOPROMIDE <VANDF_Record>50.416^3589^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3589</VA_IEN> N0000148411 4020929 Ingredient 27781 LAMIVUDINE Active <VANDF_Record>50.416^3600^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3600</VA_IEN> LAMIVUDINE N0000148418 Ingredient 4020938 <VANDF_Record>50.6^3315^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3315</VA_IEN> C16292 68244 C0209738 Lamivudine 2T8Q726O95 SAQUINAVIR http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021785s001,002,020828s019,020,020628s022,023lbl.pdf L3JE09KZ2F C0286738 N0000148419 Active SAQUINAVIR <VANDF_Record>50.416^3601^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3601</VA_IEN> C19734 <VANDF_Record>50.6^3316^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3316</VA_IEN> Ingredient 83395 4020939 Saquinavir ANASTROZOLE http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=03586c40-eb32-45c5-beb7-6762a6b78790&type=display C11178 84857 C0290883 N0000148427 Ingredient <VANDF_Record>50.416^3610^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3610</VA_IEN> <VANDF_Record>50.6^3323^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3323</VA_IEN> 4020948 anastrozole Active 2Z07MYW1AZ ANASTROZOLE BICALUTAMIDE http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020498s022lbl.pdf N0000148428 A0Z3NAU9DP 83008 C0285590 4020950 <VANDF_Record>50.6^3325^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3325</VA_IEN> Ingredient bicalutamide Active <VANDF_Record>50.416^3614^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3614</VA_IEN> BICALUTAMIDE C11726 RITONAVIR http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020659s055,022417s006lbl.pdf 85762 4020963 RITONAVIR N0000148436 <VANDF_Record>50.6^3349^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3349</VA_IEN> Active O3J8G9O825 C19590 C0292818 Ritonavir Ingredient <VANDF_Record>50.416^3629^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3629</VA_IEN> DOCETAXEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022234s000lbl.pdf Ingredient C13972 DOCETAXEL N0000148441 C0246415 15H5577CQD <VANDF_Record>50.6^3352^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3352</VA_IEN> Active <VANDF_Record>50.416^3634^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3634</VA_IEN> 4020968 docetaxel 72962 ZAFIRLUKAST http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020547s031lbl.pdf zafirlukast ZAFIRLUKAST N0000148457 Active 114970 <VANDF_Record>50.416^3654^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3654</VA_IEN> C21644 Ingredient C0378466 4020987 XZ629S5L50 <VANDF_Record>50.6^3373^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3373</VA_IEN> NEVIRAPINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020636s039_020933s030lbl.pdf Active <VANDF_Record>50.416^3658^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3658</VA_IEN> C0132326 99DK7FVK1H NEVIRAPINE N0000148461 4020991 C17650 <VANDF_Record>50.6^3377^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3377</VA_IEN> 53654 Nevirapine Ingredient LEVOFLOXACIN http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020634s062s064,020635s068s070,021721s029s031lbl.pdf C0282386 82122 N0000148474 Levofloxacin Ingredient LEVOFLOXACIN C16454 <VANDF_Record>50.6^3386^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3386</VA_IEN> 4021005 Active 6GNT3Y5LMF <VANDF_Record>50.416^3672^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3672</VA_IEN> TIZANIDINE C20930 C0146011 Active <VANDF_Record>50.6^3411^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3411</VA_IEN> Ingredient 57258 TIZANIDINE <VANDF_Record>50.416^3692^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3692</VA_IEN> 6AI06C00GW 4021025 tizanidine N0000148492 TOPIRAMATE http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020505s042,020844s036lbl.pdf 4021026 C0076829 TOPIRAMATE <VANDF_Record>50.6^3412^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3412</VA_IEN> C21010 Ingredient topiramate 0H73WJJ391 <VANDF_Record>50.416^3693^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3693</VA_IEN> N0000148493 38404 Active SUMATRIPTAN <VANDF_Record>50.416^3718^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3718</VA_IEN> 4021050 C20528 8R78F6L9VO 37418 Sumatriptan SUMATRIPTAN Active Ingredient N0000148514 C0075632 <VANDF_Record>50.6^2772^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2772</VA_IEN> ZOLMITRIPTAN http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Active 135775 <VANDF_Record>50.6^3485^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3485</VA_IEN> <VANDF_Record>50.416^3762^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3762</VA_IEN> C0528166 N0000148550 2FS66TH3YW 4021094 zolmitriptan Ingredient ZOLMITRIPTAN C21712 TOLCAPONE http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020697s013s015lbl.pdf <VANDF_Record>50.416^3763^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3763</VA_IEN> CIF6334OLY C0246330 N0000148551 tolcapone Active TOLCAPONE 4021095 <VANDF_Record>50.6^3486^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3486</VA_IEN> 72937 C20988 Ingredient CAPECITABINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020896s026lbl.pdf 6804DJ8Z9U <VANDF_Record>50.416^3767^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3767</VA_IEN> Ingredient C12188 Active capecitabine <VANDF_Record>50.6^3491^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3491</VA_IEN> N0000148555 194000 4021099 C0671970 CAPECITABINE RITUXIMAB http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563#nlm34084-4 rituximab N0000148560 Active Ingredient <VANDF_Record>50.416^3772^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3772</VA_IEN> 4021104 121191 <VANDF_Record>50.6^3496^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3496</VA_IEN> C19592 4F4X42SYQ6 RITUXIMAB C0393022 BASILIXIMAB Ingredient 196102 basiliximab C0676831 9927MT646M N0000148568 Active <VANDF_Record>50.416^3784^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3784</VA_IEN> <VANDF_Record>50.6^3509^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3509</VA_IEN> BASILIXIMAB C11516 4021113 INFLIXIMAB http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103772s5301lbl.pdf <VANDF_Record>50.6^3519^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3519</VA_IEN> 191831 INFLIXIMAB infliximab Ingredient B72HH48FLU C0666743 4021126 N0000148580 <VANDF_Record>50.416^3797^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3797</VA_IEN> C273255 Active LEFLUNOMIDE http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020905s022lbl.pdf G162GK9U4W Ingredient <VANDF_Record>50.416^3804^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3804</VA_IEN> 27169 <VANDF_Record>50.6^3527^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3527</VA_IEN> leflunomide N0000148586 LEFLUNOMIDE C16388 Active C0063041 4021132 EFAVIRENZ http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020972s040lbl.pdf 195085 C0674428 Active <VANDF_Record>50.6^3528^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3528</VA_IEN> efavirenz N0000148587 EFAVIRENZ JE6H2O27P8 <VANDF_Record>50.416^3805^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3805</VA_IEN> 4021133 C14148 Ingredient THALIDOMIDE http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021430s000,020785s031lbl.pdf Active C0039736 10432 4021134 4Z8R6ORS6L <VANDF_Record>50.416^3806^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3806</VA_IEN> THALIDOMIDE C20760 Thalidomide <VANDF_Record>50.6^3529^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3529</VA_IEN> N0000148588 Ingredient TRASTUZUMAB http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=492dbdb2-077e-4064-bff3-372d6af0a7a2#nlm34084-4 4021140 <VANDF_Record>50.416^3812^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3812</VA_IEN> 224905 C21052 C0728747 Ingredient TRASTUZUMAB Active trastuzumab P188ANX8CK N0000148593 <VANDF_Record>50.6^3536^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3536</VA_IEN> ROFECOXIB http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021052s026_021042s019lbl.pdf N0000148611 Active ROFECOXIB Ingredient 4021160 C0762662 0QTW8Z7MCR 232158 C19614 <VANDF_Record>50.416^3832^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3832</VA_IEN> <VANDF_Record>50.6^3572^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3572</VA_IEN> rofecoxib RABEPRAZOLE http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5d103551-978f-472a-9c62-51e6e4dea068&type=display 32828355LL C19456 <VANDF_Record>50.6^3588^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3588</VA_IEN> Active 114979 Ingredient N0000148623 C0378482 4021174 RABEPRAZOLE rabeprazole <VANDF_Record>50.416^3846^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3846</VA_IEN> SIROLIMUS http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3275b824-3f82-4151-2ab2-0036a9ba0acc&type=display <VANDF_Record>50.416^3848^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3848</VA_IEN> Active 35302 C0072980 N0000148624 Ingredient Sirolimus SIROLIMUS 4021176 W36ZG6FT64 <VANDF_Record>50.6^3589^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3589</VA_IEN> C19906 ZALEPLON http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020859s011lbl.pdf <VANDF_Record>50.6^3590^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3590</VA_IEN> C21652 N0000148625 S62U433RMH Ingredient C0251504 <VANDF_Record>50.416^3849^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3849</VA_IEN> Active 74667 zaleplon 4021177 ZALEPLON MOXIFLOXACIN http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021085s050s053,021277s046s050lbl.pdf <VANDF_Record>50.416^3857^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3857</VA_IEN> moxifloxacin MOXIFLOXACIN 139462 C17462 N0000148632 4021185 C0536495 Ingredient U188XYD42P Active <VANDF_Record>50.6^3597^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3597</VA_IEN> GATIFLOXACIN http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=14312de6-67d4-4de2-854c-ef764090dd83&type=display 228476 N0000148634 Active C0753645 gatifloxacin <VANDF_Record>50.6^3598^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3598</VA_IEN> C14990 GATIFLOXACIN <VANDF_Record>50.416^3859^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3859</VA_IEN> 4021187 Ingredient L4618BD7KJ EXEMESTANE http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020753s009s011s012lbl.pdf C0851344 <VANDF_Record>50.416^3863^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3863</VA_IEN> C14508 4021191 N0000148637 258494 exemestane Ingredient <VANDF_Record>50.6^3603^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3603</VA_IEN> Active EXEMESTANE NY22HMQ4BX ALOSETRON http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021107s014lbl.pdf <VANDF_Record>50.416^3866^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3866</VA_IEN> 13Z9HTH115 C10864 Ingredient 85248 C0291772 N0000148640 ALOSETRON 4021194 <VANDF_Record>50.6^3611^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3611</VA_IEN> alosetron Active BEXAROTENE http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021055s006lbl.pdf C11724 A61RXM4375 <VANDF_Record>50.416^3869^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3869</VA_IEN> Ingredient Active N0000148643 4021197 C0765273 <VANDF_Record>50.6^3620^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3620</VA_IEN> bexarotene BEXAROTENE 233272 PANTOPRAZOLE http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4b4edc09-bbfd-471f-ac16-6118937a6e7e#nlm34084-4 4021208 C0081876 D8TST4O562 PANTOPRAZOLE N0000148654 pantoprazole Ingredient <VANDF_Record>50.416^3880^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3880</VA_IEN> <VANDF_Record>50.6^3635^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3635</VA_IEN> 40790 Active C18102 CEVIMELINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020989s008lbl.pdf 4021212 C12614 cevimeline CEVIMELINE Ingredient K9V0CDQ56E <VANDF_Record>50.416^3884^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3884</VA_IEN> Active C0093437 <VANDF_Record>50.6^3638^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3638</VA_IEN> N0000148658 44281 LINEZOLID http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021130s022lbl.pdf ISQ9I6J12J C16518 Ingredient N0000148664 <VANDF_Record>50.416^3890^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3890</VA_IEN> C0663241 <VANDF_Record>50.6^3649^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3649</VA_IEN> 4021218 Active linezolid 190376 LINEZOLID RIVASTIGMINE http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fead084a-a376-4d57-bdf0-aa7ed3655505#nlm34084-4 Ingredient Active C19596 N0000148665 4021219 <VANDF_Record>50.6^3650^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3650</VA_IEN> 183379 RIVASTIGMINE <VANDF_Record>50.416^3891^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3891</VA_IEN> rivastigmine PKI06M3IW0 C0649350 ZONISAMIDE http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f94b2ba4-024f-4068-8759-da6c8d31c546#nlm34084-4 459384H98V N0000148668 <VANDF_Record>50.416^3896^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3896</VA_IEN> Active <VANDF_Record>50.6^3655^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3655</VA_IEN> 39998 C21720 Ingredient C0078844 ZONISAMIDE 4021224 zonisamide ZIPRASIDONE http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020825s038,020919s025,021483s005lbl.pdf C21710 4021249 C0380393 <VANDF_Record>50.416^3921^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3921</VA_IEN> ziprasidone 6UKA5VEJ6X ZIPRASIDONE Active 115698 N0000148690 <VANDF_Record>50.6^3688^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3688</VA_IEN> Ingredient PEGINTERFERON ALFA-2B http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103949s5217s5222lbl.pdf G8RGG88B68 Ingredient 253453 C0796545 <VANDF_Record>50.416^3928^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3928</VA_IEN> peginterferon alfa-2b PEGINTERFERON ALFA-2B C273259 4021256 Active N0000148697 IMATINIB http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021588s030s031lbl.pdf C0935989 4021257 Ingredient <VANDF_Record>50.6^3696^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3696</VA_IEN> BKJ8M8G5HI <VANDF_Record>50.416^3929^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3929</VA_IEN> IMATINIB Active N0000148698 C53876 imatinib 282388 VALGANCICLOVIR http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021304s008,022257s003lbl.pdf <VANDF_Record>50.416^3935^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3935</VA_IEN> VALGANCICLOVIR Ingredient N0000148704 <VANDF_Record>50.6^3707^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3707</VA_IEN> C31700 4021263 valganciclovir 275891 C0909381 Active GCU97FKN3R ALMOTRIPTAN http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021001s010s011lbl.pdf N0000148709 <VANDF_Record>50.416^3941^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3941</VA_IEN> Ingredient 279645 C0914729 4021269 <VANDF_Record>50.6^3711^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3711</VA_IEN> Active almotriptan 1O4XL5SN61 ALMOTRIPTAN C30948 TENOFOVIR http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021356s041lbl.pdf C0384228 Ingredient 4021279 <VANDF_Record>50.6^3724^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3724</VA_IEN> 99YXE507IL <VANDF_Record>50.416^3951^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3951</VA_IEN> C31664 N0000148716 117466 Active TENOFOVIR Tenofovir VALDECOXIB http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21341lbl.pdf valdecoxib <VANDF_Record>50.416^3956^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3956</VA_IEN> VALDECOXIB N0000148721 <VANDF_Record>50.6^3741^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3741</VA_IEN> Ingredient 4021284 Active 278567 C0913246 2919279Q3W C31696 VORICONAZOLE http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021266s035,021267s040,021630s026lbl.pdf 4021347 <VANDF_Record>50.416^4021^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4021</VA_IEN> C31720 JFU09I87TR N0000148767 C0393080 Ingredient <VANDF_Record>50.6^3813^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3813</VA_IEN> voriconazole Active VORICONAZOLE 121243 OXALIPLATIN http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/078810s000lbl.pdf OXALIPLATIN 32592 <VANDF_Record>50.416^4029^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4029</VA_IEN> C31520 oxaliplatin Ingredient 04ZR38536J 4021355 C0069717 Active N0000148774 <VANDF_Record>50.6^3821^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3821</VA_IEN> ELETRIPTAN http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021016s018lbl.pdf C31204 <VANDF_Record>50.6^3856^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3856</VA_IEN> 231049 eletriptan ELETRIPTAN C0759933 Ingredient 4021372 N0000148791 22QOO9B8KI <VANDF_Record>50.416^4046^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4046</VA_IEN> Active ENFUVIRTIDE http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021481s020lbl.pdf C0537439 ENFUVIRTIDE Ingredient C31208 19OWO1T3ZE Active N0000148793 139896 enfuvirtide <VANDF_Record>50.416^4049^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4049</VA_IEN> <VANDF_Record>50.6^3864^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3864</VA_IEN> 4021375 GEMIFLOXACIN http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021158s021lbl.pdf C0533545 Active <VANDF_Record>50.416^4062^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4062</VA_IEN> <VANDF_Record>50.6^3877^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3877</VA_IEN> 4021386 Ingredient C31304 N0000148804 OKR68Y0E4T 138099 GEMIFLOXACIN gemifloxacin APREPITANT Active 358255 APREPITANT aprepitant Ingredient C30984 4021391 C1176306 N0000148809 <VANDF_Record>50.6^3884^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3884</VA_IEN> 1NF15YR6UY <VANDF_Record>50.416^4067^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4067</VA_IEN> BORTEZOMIB http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021602s029s030lbl.pdf C31052 bortezomib 69G8BD63PP <VANDF_Record>50.6^3886^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3886</VA_IEN> 4021393 N0000148811 Active Ingredient 358258 BORTEZOMIB <VANDF_Record>50.416^4069^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4069</VA_IEN> C1176309 EMTRICITABINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021500s019lbl.pdf <VANDF_Record>50.416^4071^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4071</VA_IEN> N0000148813 Active C0909839 EMTRICITABINE G70B4ETF4S Ingredient 276237 <VANDF_Record>50.6^3888^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3888</VA_IEN> emtricitabine C53864 4021395 TRIPTORELIN http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020715s025,021288s022,022437s003lbl.pdf 38782 C0077275 <VANDF_Record>50.6^3894^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3894</VA_IEN> Ingredient 9081Y98W2V C53936 4021400 N0000148818 Active <VANDF_Record>50.416^4076^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4076</VA_IEN> Triptorelin TRIPTORELIN VARDENAFIL http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021400s013lbl.pdf Ingredient <VANDF_Record>50.6^3898^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3898</VA_IEN> C53944 UCE6F4125H <VANDF_Record>50.416^4080^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4080</VA_IEN> 306674 N0000148820 C0971579 4021404 VARDENAFIL vardenafil Active MIGLUSTAT http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021348s008lbl.pdf C53892 Active <VANDF_Record>50.6^3900^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3900</VA_IEN> 402316 C1321596 <VANDF_Record>50.416^4082^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4082</VA_IEN> Ingredient 4021406 Miglustat MIGLUSTAT ADN3S497AZ N0000148822 MEMANTINE http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=17b61eb2-2498-4d2e-9e1f-b0c2c21c9347#nlm34084-4,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021487s010s012s014,021627s008lbl.pdf Memantine 6719 Active W8O17SJF3T 4021409 MEMANTINE C0025242 Ingredient C53888 N0000148824 <VANDF_Record>50.416^4085^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4085</VA_IEN> <VANDF_Record>50.6^3913^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3913</VA_IEN> DAPTOMYCIN http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021572s038lbl.pdf 4021414 C53856 Daptomycin Active 22299 <VANDF_Record>50.6^3920^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3920</VA_IEN> Ingredient N0000148828 <VANDF_Record>50.416^4090^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4090</VA_IEN> NWQ5N31VKK DAPTOMYCIN C0057144 TADALAFIL http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ff61b237-be8e-461b-8114-78c52a8ad0ae#nlm34084-4 C273295 C1176316 <VANDF_Record>50.416^4091^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4091</VA_IEN> 358263 tadalafil Active Ingredient 4021415 TADALAFIL N0000148829 <VANDF_Record>50.6^3925^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3925</VA_IEN> 742SXX0ICT PEMETREXED http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021462s029s030s032lbl.pdf Ingredient C273299 04Q9AIZ7NO PEMETREXED pemetrexed 4021417 C0210657 68446 Active N0000148831 <VANDF_Record>50.416^4093^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4093</VA_IEN> <VANDF_Record>50.6^3927^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3927</VA_IEN> TINIDAZOLE http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021618s003lbl.pdf C0040263 TINIDAZOLE 10612 033KF7V46H 4021467 Ingredient C273398 Tinidazole Active N0000148851 <VANDF_Record>50.6^3970^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3970</VA_IEN> <VANDF_Record>50.416^4155^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4155</VA_IEN> ERLOTINIB http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf erlotinib J4T82NDH7E 4021511 <VANDF_Record>50.416^4203^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4203</VA_IEN> <VANDF_Record>50.6^4033^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4033</VA_IEN> C1135135 C273486 Ingredient 337525 Active N0000148872 ERLOTINIB Alkynes [Chemical/Ingredient] D000480 C0002078 Acetylenic Compounds Alkynes C7757209141385 507 Hydrocarbons with at least one triple bond in the linear portion, of the general formula Cn-H2n-2. Acetylenes N0000166367 Alkynes M0000724 Phenoxypropanolamines [Chemical/Ingredient] C7757556548667 N0000166515 Phenoxy-Propanolamines Compounds based on a propanolamine attached via an OXYGEN atom to a phenoxy ring. The side chain is one carbon longer than PHENYLETHYLAMINES. M0473241 Phenoxypropanolamines D050198 587150 C1563753 Phenoxypropanolamines Nitrophenols [Chemical/Ingredient] Nitrophenols N0000166599 C7757728016549 7473 M0014911 D009596 Nitrophenols C0028188 Organogold Compounds [Chemical/Ingredient] N0000166781 Organic compounds that contain GOLD as an integral part of the molecule. Some are used as ANTIRHEUMATIC AGENTS. The term chrysotherapy derives from an ancient Greek term for gold. D050607 C7758024259787 589356 M0476729 Organogold Compounds Organogold Compounds C1564425 Benzoxazines [Chemical/Ingredient] C0598594 N0000167044 Benzoxazines OXAZINES with a fused BENZENE ring. D048588 C7758506460737 154680 Benzoxazines M0461882 1-Deoxynojirimycin [Chemical/Ingredient] D017485 1-Deoxynojirimycin 43423 M0026526 C7758822898999 An alpha-glucosidase inhibitor with antiviral action. Derivatives of deoxynojirimycin may have anti-HIV activity. C0089267 3,4,5-Piperidinetriol, 2-(hydroxymethyl)-, (2R-(2alpha,3beta,4alpha,5beta))- N0000167204 1-Deoxynojirimycin Epothilones [Chemical/Ingredient] M0405146 A group of 16-member MACROLIDES which stabilize MICROTUBULES in a manner similar to PACLITAXEL. They were originally found in the myxobacterium Sorangium cellulosum, now renamed to Polyangium (MYXOCOCCALES). D034261 Epothilon Epothilones Epothilones 337764 C1136012 C7758211020115 N0000167392 Epothilone Macromolecular Substances [Chemical/Ingredient] N0000167471 Macromolecular Substances Macromolecular Substances C1449655 D046911 Compounds and molecular complexes that consist of very large numbers of atoms and are generally over 500 kDa in size. In biological systems macromolecular substances usually can be visualized using ELECTRON MICROSCOPY and are distinguished from ORGANELLES by the lack of a membrane structure. C7759277952086 M0455942 469962 Macromolecular Compounds and Complexes Imino Sugars [Chemical/Ingredient] Imino Sugars D050111 N0000168504 593639 Sugars in which the OXYGEN is replaced by a NITROGEN atom. This substitution prevents normal METABOLISM resulting in inhibition of GLYCOSIDASES and GLYCOSYLTRANSFERASES. M0472664 C7757306585892 Imino Sugars C1563733 Imino Pyranoses [Chemical/Ingredient] 586407 5-Imino-Pyranoses N0000168505 C7757307043772 M0472665 1,5-Imino Sugars 1-N-Imino Sugars Imino Pyranoses Six-carbon pyranose sugars in which the OXYGEN is replaced by a NITROGEN atom. D050112 C1563734 Imino Pyranoses Membrane Fusion Proteins [Chemical/Ingredient] N0000168691 C1564357 589182 M0476481 Membrane Fusion Proteins C7762026023419 Proteins that catalyze MEMBRANE FUSION. D050576 Membrane Fusion Proteins Vigabatrin [Chemical/Ingredient] C0048044 gamma-Vinyl-GABA M0328364 An analogue of GAMMA-AMINOBUTYRIC ACID. It is an irreversible inhibitor of 4-AMINOBUTYRATE TRANSAMINASE, the enzyme responsible for the catabolism of GAMMA-AMINOBUTYRIC ACID. (From Martindale The Extra Pharmacopoeia, 31st ed) 14851 gamma-Vinyl-gamma-Aminobutyric Acid Vigabatrin D020888 Vigabatrin C7757999946082 4-Amino-5-hexenoic Acid Vigabatrin N0000170228 Inflammation Mediators [Chemical/Ingredient] Inflammation Mediators C0243042 The endogenous compounds that mediate inflammation (AUTACOIDS) and related exogenous compounds including the synthetic prostaglandins (PROSTAGLANDINS, SYNTHETIC). Mediators of Inflammation 71683 N0000171017 M0028191 D018836 C7764415934706 Inflammation Mediators Autacoids [Chemical/Ingredient] M0019975 9832 C7764425293996 Autacoids C0037343 A chemically diverse group of substances produced by various tissues in the body that cause slow contraction of smooth muscle; they have other intense but varied pharmacologic activities. Slow-Reacting Substances D012898 N0000171025 Autacoids Pigments, Biological [Chemical/Ingredient] C7764620980040 Pigments, Biological D010860 N0000171195 587457 Any normal or abnormal coloring matter in PLANTS; ANIMALS or micro-organisms. Pigments, Biological C1571592 M0016854 pregabalin [Chemical/Ingredient] C080245 3-isobutyl GABA 187832 pregabalin pregabalin M0214473 C7765700397396 C0657912 pregabalin N0000171595 enfuvirtide [Chemical/Ingredient] C105196 N0000171600 M0274523 pentafuside C0537439 enfuvirtide C7765976926117 139896 enfuvirtide enfuvirtide tipranavir [Chemical/Ingredient] C7766023708879 C0663733 M0278998 C107201 tipranavir 190548 tipranavir tipranavir N0000171602 Headache Disorders, Primary [Disease/Finding] Conditions in which the primary symptom is HEADACHE and the headache cannot be attributed to any known causes. Headache Disorders, Primary D051270 N0000171629 1026706 Primary Headache Disorders Headache Disorders, Primary C7768697376063 C1565106 M0480011 Trigeminal Autonomic Cephalalgias [Disease/Finding] 986844 N0000171634 D051303 C1565172 M0480084 C7768704400419 Trigeminal Autonomic Cephalalgias Trigeminal Autonomic Cephalalgias Primary headache disorders that show symptoms caused by the activation of the AUTONOMIC NERVOUS SYSTEM of the TRIGEMINAL NERVE. These autonomic features include redness and tearing of the EYE, nasal congestion or discharge, facial SWEATING and other symptoms. Most subgroups show unilateral cranial PAIN. Renal Insufficiency [Disease/Finding] 1026620 D051437 C7769506319378 Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE. Renal Insufficiency C1565489 Kidney Insufficiency N0000171642 M0480487 Renal Insufficiency Renal Insufficiency, Chronic [Disease/Finding] 236425005 Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002) Chronic Kidney Insufficiency M0480472 1025359 N0000171643 C7769506596229 Renal Insufficiency, Chronic Renal Insufficiency, Chronic C0403447 Chronic Renal Insufficiency D051436 Kidney Insufficiency, Chronic Sexual Dysfunction, Physiological [Disease/Finding] Sex Disorders D012735 Sexual Disorders, Physiological C0237873 Sexual Dysfunction, Physiological Sexual Dysfunction, Physiological C7769454662813 N0000171659 Physiological disturbances in normal sexual performance in either the male or the female. 1027365 M0019736 Sexual Dysfunctions, Physiological Dyslipidemias [Disease/Finding] C0242339 M0010831 Dyslipidemias Dyslipidemia Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL. C7772221546872 D050171 370992007 Dyslipidemias N0000171679 1030190 ACTH-Secreting Pituitary Adenoma [Disease/Finding] ACTH-Secreting Pituitary Adenoma ACTH-Producing Pituitary Adenoma 254958004 D049913 ACTH-Secreting Pituitary Adenoma Pituitary Corticotropin-Secreting Adenoma M0470981 A pituitary adenoma which secretes ADRENOCORTICOTROPIN, leading to CUSHING DISEASE. Corticotroph Adenoma 1022338 N0000171690 Pituitary Adenoma, ACTH-Secreting C7767179526168 C1306214 SORAFENIB http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021923s012lbl.pdf 495881 Ingredient 9ZOQ3TZI87 C23260268461494 sorafenib <VANDF_Record>50.6^4098^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4098</VA_IEN> N0000171742 SORAFENIB Active 4025077 C1516119 <VANDF_Record>50.416^4259^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4259</VA_IEN> LENALIDOMIDE http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021880s023lbl.pdf C1144149 342369 LENALIDOMIDE N0000171749 <VANDF_Record>50.416^4271^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4271</VA_IEN> lenalidomide F0P408N6V4 C23260276570066 4025089 Active Ingredient <VANDF_Record>50.6^4111^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4111</VA_IEN> NELARABINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021877s001lbl.pdf <VANDF_Record>50.416^4275^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4275</VA_IEN> nelarabine Active 4025093 N0000171753 274771 Ingredient <VANDF_Record>50.6^4118^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4118</VA_IEN> NELARABINE C0907349 C23260280449330 RASAGILINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf 4025261 Active N0000171790 RASAGILINE rasagiline C0525678 Ingredient 003N66TS6T C23283822792840 <VANDF_Record>50.416^4319^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4319</VA_IEN> <VANDF_Record>50.6^4138^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4138</VA_IEN> 134748 VIGABATRIN http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020427s002lbl.pdf VIGABATRIN <VANDF_Record>50.6^4508^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4508</VA_IEN> Ingredient N0000171807 14851 <VANDF_Record>50.416^4338^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4338</VA_IEN> 4025280 C0048044 Active Vigabatrin C23283829651254 Platinum-containing Compounds [Chemical/Ingredient] C634435 N0000175073 Platinum-containing Compounds 991140 Nucleoside Synthesis Inhibitors [MoA] C2266855 N0000175074 C634436 987332 Nucleoside Synthesis Inhibitors Proteasome Inhibitors [MoA] C634437 N0000175075 988088 Proteasome Inhibitors Proteosome Inhibitors C2266856 Proteasome Inhibitor Protein Kinase Inhibitors [MoA] C634438 Protein Kinase Inhibitors 993161 N0000175076 C2757016 Chemical Classes for Pharmacologic Classification [Chemical/Ingredient] C634443 991135 N0000175081 Chemical Classes for Pharmacologic Classification Kinase Inhibitors [MoA] 1025684 Kinase Inhibitors N0000175082 C634444 C1152564 Polyunsaturated Alkamides [Chemical/Ingredient] D053284 Alkylamides, Polyunsaturated C25661221459710 N0000175092 Polyunsaturated Alkylamides C1720954 Polyunsaturated Alkamides Polyunsaturated Alkamides 658214 M0492305 Amides composed of unsaturated aliphatic FATTY ACIDS linked with AMINES by an amide bond. They are most prominent in ASTERACEAE; PIPERACEAE; and RUTACEAE; and also found in ARISTOLOCHIACEAE; BRASSICACEAE; CONVOLVULACEAE; EUPHORBIACEAE; MENISPERMACEAE; POACEAE; and SOLANACEAE. They are recognized by their pungent taste and for causing numbing and salivation. Alkamides, Polyunsaturated 2-Pyridinylmethylsulfinylbenzimidazoles [Chemical/Ingredient] C1721069 D053799 N0000175098 Benzimidazole Methylpyridine Sulfoxides 2-Pyridinylmethylsulfinylbenzimidazoles C25671927244663 M0496552 Compounds that contain benzimidazole joined to a 2-methylpyridine via a sulfoxide linkage. Several of the compounds in this class are ANTI-ULCER AGENTS that act by inhibiting the POTASSIUM HYDROGEN ATPASE found in the PROTON PUMP of GASTRIC PARIETAL CELLS. 2-Pyridinylmethylsulfinylbenzimidazoles 658403 Quinazolinones [Chemical/Ingredient] C25677206981334 Chemicals with two conjoined aromatic rings incorporating two nitrogen atoms and one of the carbons oxidized with a keto oxygen. D052999 C1720912 Quinazolinones N0000175104 657853 M0490629 Quinazolinones nelarabine [Chemical/Ingredient] M0359430 N0000175345 nelarabine C0907349 C104457 C25703953619244 2-amino-6-methoxypurine arabinoside 2-amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purine nelarabine nelarabine 274771 lenalidomide [Chemical/Ingredient] 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione M0479831 C25704408524826 342369 N0000175347 C467567 lenalidomide C1144149 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H- isoindol-2-yl)- IMiD3 cpd lenalidomide lenalidomide sorafenib [Chemical/Ingredient] 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate C471405 M0446095 sorafenib C25704431991775 sorafenib sorafenib 495881 N0000175349 C1516119 eszopiclone [Chemical/Ingredient] Eszopiclone C1436328 C515051 (+)-(5S)-6(chloropyridine-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)-pyrazin-5-yl-4-methyl-piperazine-1-carboxylate N0000175354 461016 eszopiclone eszopiclone C25705053602902 M0463158 Binding Activity [MoA] C2266866 Binding Activity N0000175355 C634738 990338 Cholinergic Interactions [MoA] C634751 Cholinergic Interactions C2266879 N0000175368 987379 Cholinergic Agonists [MoA] C634752 N0000175369 C2757066 Cholinergic Agonists 1033063 Tumor Necrosis Factor alpha Receptor Blocking Activity [MoA] C2267209 TNF-a Receptor Blocking Activity 988325 N0000175446 Tumor Necrosis Factor alpha Receptor Blocking Activity C30270 TNF-alpha Receptor Blocking Activity Corticosteroid Hormone Receptor Agonists [MoA] C634830 C2266939 Corticosteroid Hormone Receptor Agonists 988660 N0000175450 Tumor Necrosis Factor Receptor Blocking Activity [MoA] N0000175451 C634831 TNF Blocker TNF Receptor Blocking Activity Tumor Necrosis Factor Receptor Blocking Activity 984952 C2266940 Metal Chelating Activity [MoA] C634853 N0000175472 C1154714 Metal Chelating Activity 986481 Lipopeptides [Chemical/Ingredient] D055666 M0519359 Lipopeptides C2266975 N0000175508 819804 Lipopeptides C634901 Compounds consisting of a short peptide chain conjugated with an acyl chain. Decreased Immunologic Activity [PE] Decreased Immunologic Activity N0000175550 Immunologic Suppression Immunosuppression 989722 C1373218 Immune Suppression C634943 Immune System Suppression Increased Immunologic Activity [PE] Immunologic Stimulation C634944 C2267003 Immunostimulation Increased Immunologic Activity Immune Stimulation 990348 Immune System Stimulation N0000175551 Autonomic Nervous System Activity Alteration [PE] Autonomic Nervous System Activity Alteration N0000175642 990764 C635035 C2267060 Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient] C635127 Nonsteroidal Antiinflammatory Compounds Nonsteroidal Anti-inflammatory Compounds Non-steroidal Anti-inflammatory Compounds 991139 Non-steroidal Antiinflammatory Compounds N0000175721 Peripheral Nervous System Activity Alteration [PE] C635131 N0000175725 992027 Peripheral Nervous System Activity Alteration C2917266 Cholesterol Synthesis Inhibitors [MoA] C2917205 991925 N0000175919 Cholesterol Synthesis Inhibitors C635357 Coagulation Activity Alteration [PE] N0000175977 Coagulation Activity Alteration 991697 C635431 C2917139 Decreased Coagulation Activity [PE] Anti-coagulation Activity C2917212 Anticoagulation Activity N0000175978 1024413 Decreased Coagulation Activity C635432 Anticoagulation Anti-coagulation Increased Coagulation Activity [PE] Pro-coagulation Activity 992037 C2917275 C635433 Procoagulation Activity Increased Coagulation Activity N0000175979 Pro-coagulation Procoagulation DASATINIB http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021986s009s010lbl.pdf 4025488 <VANDF_Record>50.416^4401^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4401</VA_IEN> dasatinib <VANDF_Record>50.6^4184^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4184</VA_IEN> N0000176043 475342 C1455147 Ingredient RBZ1571X5H C50.416.4401 DASATINIB Active TELBIVUDINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022011S012,022154S009lbl.pdf 474128 C50.416.4431 2OC4HKD3SF <VANDF_Record>50.416^4431^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4431</VA_IEN> Ingredient TELBIVUDINE 4025782 telbivudine C1453933 N0000176071 <VANDF_Record>50.6^4213^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4213</VA_IEN> Active MYCOPHENOLATE 4025608 Ingredient C0883242 Active N0000176078 <VANDF_Record>50.416^4438^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4438</VA_IEN> 265323 <VANDF_Record>50.6^4198^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4198</VA_IEN> MYCOPHENOLATE C50.416.4438 MYCOPHENOLATE MARAVIROC http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022128s007lbl.pdf <VANDF_Record>50.6^4297^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4297</VA_IEN> 620216 N0000176115 C50.416.4476 MD6P741W8A C1667052 MARAVIROC 4026629 <VANDF_Record>50.416^4476^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4476</VA_IEN> Ingredient maraviroc Active IXABEPILONE http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022065s006lbl.pdf 4026737 C50.416.4480 C1135132 Ingredient N0000176119 IXABEPILONE ixabepilone Active <VANDF_Record>50.416^4480^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4480</VA_IEN> K27005NP0A <VANDF_Record>50.6^4306^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4306</VA_IEN> 337523 NILOTINIB http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022068s008s009lbl.pdf 4026964 F41401512X Active nilotinib 662281 N0000176124 C50.416.4485 NILOTINIB C1721377 <VANDF_Record>50.416^4485^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4485</VA_IEN> <VANDF_Record>50.6^4315^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4315</VA_IEN> Ingredient ETRAVIRINE http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022187s008lbl.pdf ETRAVIRINE N0000176133 etravirine 4027244 <VANDF_Record>50.416^4494^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4494</VA_IEN> 475969 0C50HW4FO1 C1456409 C50.416.4494 <VANDF_Record>50.6^4335^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4335</VA_IEN> Ingredient Active FOSAPREPITANT Ingredient 754762 <VANDF_Record>50.416^4496^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4496</VA_IEN> Active 4027246 6L8OF9XRDC <VANDF_Record>50.6^4340^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4340</VA_IEN> N0000176135 FOSAPREPITANT C50.416.4496 C2349941 FOSAPREPITANT DIMEGLUMINE <VANDF_Record>50.416^4497^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4497</VA_IEN> Active C50.416.4497 FOSAPREPITANT DIMEGLUMINE 754763 4027247 C2315887 N0000176136 Fosaprepitant dimeglumine D35FM8T64X Ingredient CERTOLIZUMAB 4027433 CERTOLIZUMAB Active Ingredient C50.416.4517 709271 <VANDF_Record>50.6^4367^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4367</VA_IEN> certolizumab pegol C1872109 N0000176156 <VANDF_Record>50.416^4517^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4517</VA_IEN> HISTRELIN http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021732s007s010s012lbl.pdf 50975 C50.6.4139 N0000176176 HISTRELIN C0121902 4025500 Ingredient histrelin <VANDF_Record>50.6^4139^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4139</VA_IEN> Active LEVOLEUCOVORIN http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020140s002lbl.pdf Active C2721771 877015 C50.416.4570 levoleucovorin Ingredient 4028507 N0000177954 <VANDF_Record>50.416^4570^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4570</VA_IEN> LEVOLEUCOVORIN <VANDF_Record>50.6^4439^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4439</VA_IEN> peginterferon alfa-2b [Chemical/Ingredient] pegylated interferon alfa-2b PEG INF alpha-2b C0796545 PEG-interferon alfa-2b PEG-IFNalpha-2b peginterferon alfa-2b PEG INF alfa-2b 253453 PEG-IFN alfa-2b polyethylene glycol-interferon alpha-2b pegylated interferon alpha-2b peginterferon alfa-2b N0000178331 C417083 polyethylene glycol-interferon alfa-2b C637785 peginterferon alpha-2b peginterferon alfa-2b PEG-interferon alpha-2b M0374956 PEG-IFN alpha-2b GOLIMUMAB http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125289s0038lbl.pdf <VANDF_Record>50.6^4460^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4460</VA_IEN> C2353893 <VANDF_Record>50.416^4583^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4583</VA_IEN> GOLIMUMAB Active 819300 Ingredient 4028717 N0000178413 golimumab C50.416.4583 Blood Pressure Alteration [PE] Blood Pressure Alteration C637932 C2917124 N0000178476 991626 Decreased Blood Pressure [PE] 991700 C2917141 C637933 N0000178477 Decreased Blood Pressure Antibodies, Monoclonal, Murine-Derived [Chemical/Ingredient] Murine-Derived Monoclonal Antibodies C2916903 991130 N0000178479 Antibodies, Monoclonal, Murine-Derived Antibodies obtained from a single clone of cells grown in mice or rats. C637952 Antibodies, Monoclonal, Murine-Derived D058846 M0544940 CERTOLIZUMAB PEGOL http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125160s111lbl.pdf Ingredient <VANDF_Record>50.416^4609^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4609</VA_IEN> 709271 certolizumab pegol C50.416.4609 C1872109 Active CERTOLIZUMAB PEGOL N0000178499 4028807 Azabicyclo Compounds [Chemical/Ingredient] N0000178749 CMSHM0499252 Bicyclic bridged compounds that contain a nitrogen which has three bonds. The nomenclature indicates the number of atoms in each path around the rings, such as [2.2.2] for three equal length paths. Some members are TROPANES and BETA LACTAMS. C1955840 Azabicyclo Compounds Azabicyclo Compounds 737880 M0499252 D053961 Human Immunodeficiency Virus Proteins [Chemical/Ingredient] D054298 C1955876 M0503879 733867 Human Immunodeficiency Virus Gene Products N0000178752 CMSHM0503879 Human Immunodeficiency Virus Proteins Human Immunodeficiency Virus Proteins Proteins synthesized by HUMAN IMMUNODEFICIENCY VIRUSES such as the HIV-1 and HIV-2. HIV Gene Products HIV Proteins env Gene Products, Human Immunodeficiency Virus [Chemical/Ingredient] env Gene Products, Human Immunodeficiency Virus CMSHM0503881 env Proteins, Human Immunodeficiency Virus Proteins encoded by the ENV GENE of the HUMAN IMMUNODEFICIENCY VIRUS. D054299 738284 N0000178753 env Gene Products, HIV M0503881 env Gene Products, Human Immunodeficiency Virus C1955877 envelope Proteins, Human Immunodeficiency Virus Isoindoles [Chemical/Ingredient] CMSHM0508166 Isoindoles D054833 N0000178808 742374 C1956073 M0508166 Benzopyrroles with the nitrogen at the number two carbon, in contrast to INDOLES which have the nitrogen adjacent to the six-membered ring. Isoindoles fludarabine monophosphate [Chemical/Ingredient] fludarabine phosphate C042382 fludarabine monophosphate M0125188 25102 fluoro-ara-AMP FaraAMP N0000179136 9 beta-D-arabinofuranosyl-2-fluoroadenine monophosphate Fludarabine phosphate CMSHM0125188 fludarabine monophosphate C0060483 F-ara-AMP Etidronate [Chemical/Ingredient] Hydroxyethanediphosphonate Ethanehydroxyphosphate N0000179310 1-Hydroxyethane-1,1-Diphosphonate D012968 Etidronate Etidronate M0020101 EHDP HEDP CMSHM0020101 1-Hydroxyethylidene-1,1-Bisphosphonate 1,1-hydroxyethylenediphosphonate C0086268 Etidronate 42682 Ethanehydroxydiphosphonate Sumatriptan Succinate [Chemical/Ingredient] C0206599 CMSHM0027393 67158 M0027393 N0000179363 Sumatriptan Succinate Sumatriptan Succinate Sumatriptan Succinate D018170 Penicillin [Chemical/Ingredient] C0220892 70618 Penicillin CMSHM0016153 D010406 N0000179370 Penicillin Penicillin M0016153 Ciprofloxacin Hydrochloride [Chemical/Ingredient] N0000179399 Ciprofloxacin Hydrochloride M0361510 CMSHM0361510 C0282104 D002939 81981 Ciprofloxacin Hydrochloride Ciprofloxacin Hydrochloride Levofloxacin [Chemical/Ingredient] N0000179456 Ofloxacin, (S)-Isomer C0282386 D015242 CMSHM0329513 Levofloxacin Levofloxacin Levofloxacin 82122 M0329513 rasagiline [Chemical/Ingredient] 134748 N0000179514 CMSHM0100095 rasagiline N-2-propynyl-1-indanamine C0525678 rasagiline C031967 M0100095 rasagiline methylprednisolone acetate [Chemical/Ingredient] C000873 N0000179565 C0600901 acetyl-methylprednisolone CMSHM0040839 methylprednisolone-21-acetate 155323 M0040839 methylprednisolone acetate methylprednisolone acetate methylprednisolone acetate Enalapril Maleate [Chemical/Ingredient] CMSHM0331398 N0000179593 203123 M0331398 Enalapril Maleate D004656 Enalapril Maleate Enalapril Maleate C0700452 Mitoxantrone Hydrochloride [Chemical/Ingredient] Mitoxantrone Hydrochloride Mitoxantrone Hydrochloride CMSHM0330040 C0700458 M0330040 N0000179596 203129 Mitoxantrone Hydrochloride D008942 Losartan Potassium [Chemical/Ingredient] 203160 Losartan Monopotassium Salt D019808 C0700492 Losartan Potassium N0000179615 CMSHM0351838 Losartan Potassium Losartan Potassium M0351838 Leuprolide Acetate [Chemical/Ingredient] M0329431 D016729 N0000179654 Leuprolide Acetate 203217 CMSHM0329431 Leuprolide Acetate C0700596 Leuprolide Acetate posaconazole [Chemical/Ingredient] http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b073b082-7b57-4423-8c06-,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022003s018s020,0205053s002s004,0205596s001s003lbl.pdf4fd4263d6f84&type=display C101425 posaconazole posaconazole 282446 CMSHM0265888 N0000179745 C0936148 M0265888 posaconazole ixabepilone [Chemical/Ingredient] ixabepilone M0473543 ixabepilone C430592 CMSHM0473543 N0000179767 337523 C1135132 ixabepilone telbivudine [Chemical/Ingredient] telbivudine M0469133 474128 telbivudine CMSHM0469133 C487779 C1453933 N0000179779 telbivudine beta-L-2'-deoxythymidine dasatinib [Chemical/Ingredient] M0470497 dasatinib CMSHM0470497 dasatinib C488369 C1455147 475342 dasatinib N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide N0000179780 etravirine [Chemical/Ingredient] N0000179781 etravirine 475969 CMSHM0420447 C1456409 etravirine etravirine M0420447 C451734 maraviroc [Chemical/Ingredient] C1667052 M0493371 620216 CMSHM0493371 maraviroc C502411 N0000179791 maraviroc maraviroc TOCILIZUMAB http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13#nlm34084-4 Active <VANDF_Record>50.416^4670^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4670</VA_IEN> C50.416^4670^ C1609165 Ingredient TOCILIZUMAB 4029705 612865 tocilizumab <VANDF_Record>50.6^4548^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4548</VA_IEN> N0000180629 Lipid Metabolism Disorders [Disease/Finding] 1023349 CMSHM0486903 D052439 M0486903 Lipid Metabolism Disorders C0154251 N0000181055 Pathological conditions resulting from abnormal anabolism or catabolism of lipids in the body. Lipid Metabolism Disorders Leukoencephalopathies [Disease/Finding] CMSHM0529130 N0000181110 1023470 Leukoencephalopathies Leukoencephalopathy D056784 Leukoencephalopathies M0529130 C0270612 Any of various diseases affecting the white matter of the central nervous system. White Matter Diseases Cardiovascular Infections [Disease/Finding] Infections, Cardiovascular Pathological conditions of the CARDIOVASCULAR SYSTEM caused by infections. N0000181166 D053821 M0496690 CMSHM0496690 1021827 Cardiovascular Infections Cardiovascular Infections C0596270 Hereditary Autoinflammatory Diseases [Disease/Finding] Hereditary Recurrent Fevers M0528303 1002196 C0751422 CMSHM0528303 D056660 Hereditary Autoinflammation Diseases N0000181174 Hereditary Autoinflammatory Diseases Hereditary Periodic Fever Syndromes Hereditary inflammation conditions, characterized by recurrent episodes of systemic inflammation. Common symptoms include recurrent fever, rash, arthritis, fatigue, and secondary AMYLOIDOSIS. Hereditary autoinflammatory diseases are associated with mutations in genes involved in regulation of normal inflammatory process and are not caused by AUTOANTIBODIES, or antigen specific T-LYMPHOCYTES. Hereditary Autoinflammatory Diseases Leprosy, Multibacillary [Disease/Finding] CMSHM0524817 A form of LEPROSY classified by the World Health Organization for the purpose of treatment, based on clinical manifestations and skin smear results. Patients with multibacillary leprosy have six or more lesions with or without positive skin smear results for the causative agent MYCOBACTERIUM LEPRAE. Multibacillary leprosy encompasses borderline lepromatous, midborderline, and lepromatous leprosy. 1021786 Leprosy, Multibacillary Multibacillary Leprosy N0000181226 D056006 Midborderline Lepromatous Borderline Lepromatous Leprosy, Multibacillary C1562585 M0524817 Female Urogenital Diseases [Disease/Finding] M0489295 C1720887 Pathological processes of the female URINARY TRACT and the reproductive system (GENITALIA, FEMALE). 1024696 D052776 Female Urogenital Diseases CMSHM0489295 Female Genitourinary Diseases N0000181236 Female Urogenital Diseases Neoplasms, Plasma Cell [Disease/Finding] CMSHM0502872 D054219 Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS. N0000181264 1005768 C1959632 M0502872 Neoplasms, Plasma Cell Neoplasms, Plasma Cell Plasma Cell Neoplasms Precursor Cell Lymphoblastic Leukemia-Lymphoma [Disease/Finding] M0502706 D054198 A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias. Precursor Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Lymphoid, Acute Lymphocytic Leukemia, Acute Leukemia, Lymphoblastic Leukemia, Lymphoblastic, Acute Lymphoblastic Lymphoma Lymphoma, Lymphoblastic Lymphoblastic Leukemia, Acute C1961102 Precursor Cell Lymphoblastic Leukemia-Lymphoma Lymphoblastic Leukemia N0000181267 Acute Lymphoid Leukemia CMSHM0502706 Leukemia, Lymphocytic, Acute 1024792 Euglenozoa Infections [Disease/Finding] N0000181296 C2717956 D056986 Euglenozoa Infections CMSHM0533725 1028488 Infections with the protozoa of the phylum EUGLENOZOA. M0533725 Euglenozoa Infections Proteostasis Deficiencies [Disease/Finding] C2718000 CMSHM0534903 D057165 Disorders caused by imbalances in the protein homeostasis network - synthesis, folding, and transport of proteins; post-translational modifications; and degradation or clearance of misfolded proteins. N0000181302 Proteostasis Deficiencies Proteostasis Deficiencies M0534903 1002154 Proteostasis Dysfunctions CABAZITAXEL http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201023lbl.pdf C2830183 <VANDF_Record>50.6^4570^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4570</VA_IEN> Ingredient CABAZITAXEL 996051 4030043 cabazitaxel N0000181529 <VANDF_Record>50.416^4693^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4693</VA_IEN> Active C50.416^4693^ Fibric Acids [Chemical/Ingredient] Fibric Acids Fibric Acids Methyl-2-Phenoxypropanoic Acid Derivatives C2936462 D058607 2-Phenoxy Isobutyric Acids CMSHM0543661 2-Phenoxy-2-Methylpropionic Acid Derivatives Compounds that either share the structure of fibric acid in their molecular arrangement or are considered variants of the fibric acid structure. Fibric Acid Derivatives M0543661 1029707 N0000182116 Isobutyric Acids [Chemical/Ingredient] 2-Methylpropionic Acids Isobutyric Acids C2936465 1023292 Dimethylacetic Acids N0000182117 CMSHM0543641 Isobutyric Acids D058610 M0543641 Aliphatic acids that contain four carbons in a branched-chain configuration. Thienopyridines [Chemical/Ingredient] Thienopyridines N0000182125 Thienopyridines D058924 Thienopyridine Derivatives Heterocyclic compounds that contain 4H,5H,6H,7H-thieno[2,3-c]pyridine as part of their structure. M0545395 1031667 CMSHM0545395 C2936588 TESAMORELIN http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022505s001s003lbl.pdf C50.416^4719^ TESAMORELIN N0000182253 <VANDF_Record>50.6^4599^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4599</VA_IEN> 1044584 tesamorelin C1876200 Active Ingredient 4030295 <VANDF_Record>50.416^4719^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4719</VA_IEN> ERIBULIN http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201532lbl.pdf C2350866 C50.6^4600^ 1045453 4030302 Active <VANDF_Record>50.6^4600^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4600</VA_IEN> eribulin ERIBULIN N0000182260 Ingredient IPILIMUMAB http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125377s0000lbl.pdf Ingredient 1094833 N0000182641 <VANDF_Record>50.416^4740^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4740</VA_IEN> Active <VANDF_Record>50.6^4623^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4623</VA_IEN> IPILIMUMAB ipilimumab C50.416^4740^ 4030653 VEMURAFENIB http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202429s000lbl.pdf CRIZOTINIB http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202570s003lbl.pdf CARFILZOMIB http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf TERIFLUNOMIDE http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202992s000lbl.pdf entity entity BFO 2 Reference: In all areas of empirical inquiry we encounter general terms of two sorts. First are general terms which refer to universals or types:animaltuberculosissurgical procedurediseaseSecond, are general terms used to refer to groups of entities which instantiate a given universal but do not correspond to the extension of any subuniversal of that universal because there is nothing intrinsic to the entities in question by virtue of which they – and only they – are counted as belonging to the given group. Examples are: animal purchased by the Emperortuberculosis diagnosed on a Wednesdaysurgical procedure performed on a patient from Stockholmperson identified as candidate for clinical trial #2056-555person who is signatory of Form 656-PPVpainting by Leonardo da VinciSuch terms, which represent what are called ‘specializations’ in [81 Entity An entity is anything that exists or has existed or will exist. (axiom label in BFO2 Reference: [001-001]) Entity doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example Werner Ceusters 'portions of reality' include 4 sorts, entities (as BFO construes them), universals, configurations, and relations. It is an open question as to whether entities as construed in BFO will at some point also include these other portions of reality. See, for example, 'How to track absolutely everything' at http://www.referent-tracking.com/_RTU/papers/CeustersICbookRevised.pdf Julius Caesar Verdi’s Requiem the Second World War your body mass index continuant continuant Continuant (forall (x) (if (Continuant x) (Entity x))) // axiom label in BFO2 CLIF: [008-002] (forall (x y) (if (and (Continuant x) (exists (t) (continuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [009-002] (forall (x) (if (Material Entity x) (exists (t) (and (TemporalRegion t) (existsAt x t))))) // axiom label in BFO2 CLIF: [011-002] (forall (x y) (if (and (Continuant x) (exists (t) (hasContinuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [126-001] A continuant is an entity that persists, endures, or continues to exist through time while maintaining its identity. (axiom label in BFO2 Reference: [008-002]) An entity that exists in full at any time in which it exists at all, persists through time while maintaining its identity and has no temporal parts. BFO 2 Reference: Continuant entities are entities which can be sliced to yield parts only along the spatial dimension, yielding for example the parts of your table which we call its legs, its top, its nails. ‘My desk stretches from the window to the door. It has spatial parts, and can be sliced (in space) in two. With respect to time, however, a thing is a continuant.’ [60, p. 240 Continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example, in an expansion involving bringing in some of Ceuster's other portions of reality, questions are raised as to whether universals are continuants if b is a continuant and if, for some t, c has_continuant_part b at t, then c is a continuant. (axiom label in BFO2 Reference: [126-001]) if b is a continuant and if, for some t, cis continuant_part of b at t, then c is a continuant. (axiom label in BFO2 Reference: [009-002]) if b is a material entity, then there is some temporal interval (referred to below as a one-dimensional temporal region) during which b exists. (axiom label in BFO2 Reference: [011-002]) occurrent (forall (x) (iff (Occurrent x) (and (Entity x) (exists (y) (temporalPartOf y x))))) // axiom label in BFO2 CLIF: [079-001] An entity that has temporal parts and that happens, unfolds or develops through time. BFO 2 Reference: every occurrent that is not a temporal or spatiotemporal region is s-dependent on some independent continuant that is not a spatial region Simons uses different terminology for relations of occurrents to regions: Denote the spatio-temporal location of a given occurrent e by 'spn[e]' and call this region its span. We may say an occurrent is at its span, in any larger region, and covers any smaller region. Now suppose we have fixed a frame of reference so that we can speak not merely of spatio-temporal but also of spatial regions (places) and temporal regions (times). The spread of an occurrent, (relative to a frame of reference) is the space it exactly occupies, and its spell is likewise the time it exactly occupies. We write 'spr[e]' and `spl[e]' respectively for the spread and spell of e, omitting mention of the frame. (forall (x) (if (Occurrent x) (exists (r) (and (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion x r))))) // axiom label in BFO2 CLIF: [108-001] An occurrent is an entity that unfolds itself in time or it is the instantaneous boundary of such an entity (for example a beginning or an ending) or it is a temporal or spatiotemporal region which such an entity occupies_temporal_region or occupies_spatiotemporal_region. (axiom label in BFO2 Reference: [077-002]) BFO 2 Reference: s-dependence obtains between every process and its participants in the sense that, as a matter of necessity, this process could not have existed unless these or those participants existed also. A process may have a succession of participants at different phases of its unfolding. Thus there may be different players on the field at different times during the course of a football game; but the process which is the entire game s-depends_on all of these players nonetheless. Some temporal parts of this process will s-depend_on on only some of the players. Occurrent occurrent Every occurrent occupies_spatiotemporal_region some spatiotemporal region. (axiom label in BFO2 Reference: [108-001]) Occurrent doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. An example would be the sum of a process and the process boundary of another process. b is an occurrent entity iff b is an entity that has temporal parts. (axiom label in BFO2 Reference: [079-001]) independent continuant IndependentContinuant (forall (x t) (if (and (IndependentContinuant x) (existsAt x t)) (exists (y) (and (Entity y) (specificallyDependsOnAt y x t))))) // axiom label in BFO2 CLIF: [018-002] (iff (IndependentContinuant a) (and (Continuant a) (not (exists (b t) (specificallyDependsOnAt a b t))))) // axiom label in BFO2 CLIF: [017-002] (forall (x t) (if (IndependentContinuant x) (exists (r) (and (SpatialRegion r) (locatedInAt x r t))))) // axiom label in BFO2 CLIF: [134-001] A continuant that is a bearer of quality and realizable entity entities, in which other entities inhere and which itself cannot inhere in anything. For any independent continuant b and any time t there is some spatial region r such that b is located_in r at t. (axiom label in BFO2 Reference: [134-001]) For every independent continuant b and time t during the region of time spanned by its life, there are entities which s-depends_on b during t. (axiom label in BFO2 Reference: [018-002]) a heart ic a chair a leg a molecule a spatial region an atom an orchestra. an organism b is an independent continuant = Def. b is a continuant which is such that there is no c and no t such that b s-depends_on c at t. (axiom label in BFO2 Reference: [017-002]) the bottom right portion of a human torso the interior of your mouth process Process (iff (Process a) (and (Occurrent a) (exists (b) (properTemporalPartOf b a)) (exists (c t) (and (MaterialEntity c) (specificallyDependsOnAt a c t))))) // axiom label in BFO2 CLIF: [083-003] An occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. BFO 2 Reference: The realm of occurrents is less pervasively marked by the presence of natural units than is the case in the realm of independent continuants. Thus there is here no counterpart of ‘object’. In BFO 1.0 ‘process’ served as such a counterpart. In BFO 2.0 ‘process’ is, rather, the occurrent counterpart of ‘material entity’. Those natural – as contrasted with engineered, which here means: deliberately executed – units which do exist in the realm of occurrents are typically either parasitic on the existence of natural units on the continuant side, or they are fiat in nature. Thus we can count lives; we can count football games; we can count chemical reactions performed in experiments or in chemical manufacturing. We cannot count the processes taking place, for instance, in an episode of insect mating behavior.Even where natural units are identifiable, for example cycles in a cyclical process such as the beating of a heart or an organism’s sleep/wake cycle, the processes in question form a sequence with no discontinuities (temporal gaps) of the sort that we find for instance where billiard balls or zebrafish or planets are separated by clear spatial gaps. Lives of organisms are process units, but they too unfold in a continuous series from other, prior processes such as fertilization, and they unfold in turn in continuous series of post-life processes such as post-mortem decay. Clear examples of boundaries of processes are almost always of the fiat sort (midnight, a time of death as declared in an operating theater or on a death certificate, the initiation of a state of war) a process of cell-division, \ a beating of the heart a process of meiosis a process of sleeping p is a process = Def. p is an occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. (axiom label in BFO2 Reference: [083-003]) process the course of a disease the flight of a bird the life of an organism your process of aging. disposition (forall (x) (if (Disposition x) (and (RealizableEntity x) (exists (y) (and (MaterialEntity y) (bearerOfAt x y t)))))) // axiom label in BFO2 CLIF: [062-002] BFO 2 Reference: Dispositions exist along a strength continuum. Weaker forms of disposition are realized in only a fraction of triggering cases. These forms occur in a significant number of cases of a similar type. Disposition (forall (x t) (if (and (RealizableEntity x) (existsAt x t)) (exists (y) (and (MaterialEntity y) (specificallyDepends x y t))))) // axiom label in BFO2 CLIF: [063-002] disposition If b is a realizable entity then for all t at which b exists, b s-depends_on some material entity at t. (axiom label in BFO2 Reference: [063-002]) an atom of element X has the disposition to decay to an atom of element Y b is a disposition means: b is a realizable entity & b’s bearer is some material entity & b is such that if it ceases to exist, then its bearer is physically changed, & b’s realization occurs when and because this bearer is in some special physical circumstances, & this realization occurs in virtue of the bearer’s physical make-up. (axiom label in BFO2 Reference: [062-002]) certain people have a predisposition to colon cancer children are innately disposed to categorize objects in certain ways. the cell wall is disposed to filter chemicals in endocytosis and exocytosis realizable entity (forall (x) (if (RealizableEntity x) (and (SpecificallyDependentContinuant x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (inheresIn x y)))))) // axiom label in BFO2 CLIF: [058-002] (forall (x t) (if (RealizableEntity x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (bearerOfAt y x t))))) // axiom label in BFO2 CLIF: [060-002] A specifically dependent continuant that inheres in continuant entities and are not exhibited in full at every time in which it inheres in an entity or group of entities. The exhibition or actualization of a realizable entity is a particular manifestation, functioning or process that occurs under certain circumstances. All realizable dependent continuants have independent continuants that are not spatial regions as their bearers. (axiom label in BFO2 Reference: [060-002]) RealizableEntity To say that b is a realizable entity is to say that b is a specifically dependent continuant that inheres in some independent continuant which is not a spatial region and is of a type instances of which are realized in processes of a correlated type. (axiom label in BFO2 Reference: [058-002]) realizable the disposition of this piece of metal to conduct electricity. the disposition of your blood to coagulate the function of your reproductive organs the role of being a doctor the role of this boundary to delineate where Utah and Colorado meet quality (forall (x) (if (Quality x) (SpecificallyDependentContinuant x))) // axiom label in BFO2 CLIF: [055-001] quality Quality (forall (x) (if (exists (t) (and (existsAt x t) (Quality x))) (forall (t_1) (if (existsAt x t_1) (Quality x))))) // axiom label in BFO2 CLIF: [105-001] If an entity is a quality at any time that it exists, then it is a quality at every time that it exists. (axiom label in BFO2 Reference: [105-001]) a quality is a specifically dependent continuant that, in contrast to roles and dispositions, does not require any further process in order to be realized. (axiom label in BFO2 Reference: [055-001]) the ambient temperature of this portion of air the color of a tomato the length of the circumference of your waist the mass of this piece of gold. the shape of your nose the shape of your nostril specifically dependent continuant (iff (SpecificallyDependentContinuant a) (and (Continuant a) (forall (t) (if (existsAt a t) (exists (b) (and (IndependentContinuant b) (not (SpatialRegion b)) (specificallyDependsOnAt a b t))))))) // axiom label in BFO2 CLIF: [050-003] SpecificallyDependentContinuant A continuant that inheres in or is borne by other entities. Every instance of A requires some specific instance of B which must always be the same. Reciprocal specifically dependent continuants: the function of this key to open this lock and the mutually dependent disposition of this lock: to be opened by this key Specifically dependent continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. We're not sure what else will develop here, but for example there are questions such as what are promises, obligation, etc. b is a specifically dependent continuant = Def. b is a continuant & there is some independent continuant c which is not a spatial region and which is such that b s-depends_on c at every time t during the course of b’s existence. (axiom label in BFO2 Reference: [050-003]) of one-sided specifically dependent continuants: the mass of this tomato of relational dependent continuants (multiple bearers): John’s love for Mary, the ownership relation between John and this statue, the relation of authority between John and his subordinates. sdc the disposition of this fish to decay the function of this heart: to pump blood the mutual dependence of proton donors and acceptors in chemical reactions [79 the mutual dependence of the role predator and the role prey as played by two organisms in a given interaction the pink color of a medium rare piece of grilled filet mignon at its center the role of being a doctor the shape of this hole. the smell of this portion of mozzarella role A realizable entity the manifestation of which brings about some result or end that is not essential to a continuant in virtue of the kind of thing that it is but that can be served or participated in by that kind of continuant in some kinds of natural, social or institutional contexts. Role role (forall (x) (if (Role x) (RealizableEntity x))) // axiom label in BFO2 CLIF: [061-001] BFO 2 Reference: One major family of examples of non-rigid universals involves roles, and ontologies developed for corresponding administrative purposes may consist entirely of representatives of entities of this sort. Thus ‘professor’, defined as follows,b instance_of professor at t =Def. there is some c, c instance_of professor role & c inheres_in b at t.denotes a non-rigid universal and so also do ‘nurse’, ‘student’, ‘colonel’, ‘taxpayer’, and so forth. (These terms are all, in the jargon of philosophy, phase sortals.) By using role terms in definitions, we can create a BFO conformant treatment of such entities drawing on the fact that, while an instance of professor may be simultaneously an instance of trade union member, no instance of the type professor role is also (at any time) an instance of the type trade union member role (any more than any instance of the type color is at any time an instance of the type length).If an ontology of employment positions should be defined in terms of roles following the above pattern, this enables the ontology to do justice to the fact that individuals instantiate the corresponding universals – professor, sergeant, nurse – only during certain phases in their lives. John’s role of husband to Mary is dependent on Mary’s role of wife to John, and both are dependent on the object aggregate comprising John and Mary as member parts joined together through the relational quality of being married. b is a role means: b is a realizable entity & b exists because there is some single bearer that is in some special physical, social, or institutional set of circumstances in which this bearer does not have to be& b is not such that, if it ceases to exist, then the physical make-up of the bearer is thereby changed. (axiom label in BFO2 Reference: [061-001]) the priest role the role of a boundary to demarcate two neighboring administrative territories the role of a building in serving as a military target the role of a stone in marking a property boundary the role of subject in a clinical trial the student role site (forall (x) (if (Site x) (ImmaterialEntity x))) // axiom label in BFO2 CLIF: [034-002] Manhattan Canyon) site Site a hole in the interior of a portion of cheese a rabbit hole an air traffic control region defined in the airspace above an airport b is a site means: b is a three-dimensional immaterial entity that is (partially or wholly) bounded by a material entity or it is a three-dimensional immaterial part thereof. (axiom label in BFO2 Reference: [034-002]) the Grand Canyon the Piazza San Marco the cockpit of an aircraft the hold of a ship the interior of a kangaroo pouch the interior of the trunk of your car the interior of your bedroom the interior of your office the interior of your refrigerator the lumen of your gut your left nostril (a fiat part – the opening – of your left nasal cavity) object object Object BFO 2 Reference: BFO rests on the presupposition that at multiple micro-, meso- and macroscopic scales reality exhibits certain stable, spatially separated or separable material units, combined or combinable into aggregates of various sorts (for example organisms into what are called ‘populations’). Such units play a central role in almost all domains of natural science from particle physics to cosmology. Many scientific laws govern the units in question, employing general terms (such as ‘molecule’ or ‘planet’) referring to the types and subtypes of units, and also to the types and subtypes of the processes through which such units develop and interact. The division of reality into such natural units is at the heart of biological science, as also is the fact that these units may form higher-level units (as cells form multicellular organisms) and that they may also form aggregates of units, for example as cells form portions of tissue and organs form families, herds, breeds, species, and so on. At the same time, the division of certain portions of reality into engineered units (manufactured artifacts) is the basis of modern industrial technology, which rests on the distributed mass production of engineered parts through division of labor and on their assembly into larger, compound units such as cars and laptops. The division of portions of reality into units is one starting point for the phenomenon of counting. BFO 2 Reference: Each object is such that there are entities of which we can assert unproblematically that they lie in its interior, and other entities of which we can assert unproblematically that they lie in its exterior. This may not be so for entities lying at or near the boundary between the interior and exterior. This means that two objects – for example the two cells depicted in Figure 3 – may be such that there are material entities crossing their boundaries which belong determinately to neither cell. Something similar obtains in certain cases of conjoined twins (see below). BFO 2 Reference: To say that b is causally unified means: b is a material entity which is such that its material parts are tied together in such a way that, in environments typical for entities of the type in question,if c, a continuant part of b that is in the interior of b at t, is larger than a certain threshold size (which will be determined differently from case to case, depending on factors such as porosity of external cover) and is moved in space to be at t at a location on the exterior of the spatial region that had been occupied by b at t, then either b’s other parts will be moved in coordinated fashion or b will be damaged (be affected, for example, by breakage or tearing) in the interval between t and t.causal changes in one part of b can have consequences for other parts of b without the mediation of any entity that lies on the exterior of b. Material entities with no proper material parts would satisfy these conditions trivially. Candidate examples of types of causal unity for material entities of more complex sorts are as follows (this is not intended to be an exhaustive list):CU1: Causal unity via physical coveringHere the parts in the interior of the unified entity are combined together causally through a common membrane or other physical covering\. The latter points outwards toward and may serve a protective function in relation to what lies on the exterior of the entity [13, 47 BFO 2 Reference: an object is a maximal causally unified material entity BFO 2 Reference: ‘objects’ are sometimes referred to as ‘grains’ [74 atom b is an object means: b is a material entity which manifests causal unity of one or other of the types CUn listed above & is of a type (a material universal) instances of which are maximal relative to this criterion of causal unity. (axiom label in BFO2 Reference: [024-001]) cell cells and organisms engineered artifacts grain of sand molecule organelle organism planet solid portions of matter star generically dependent continuant gdc (iff (GenericallyDependentContinuant a) (and (Continuant a) (exists (b t) (genericallyDependsOnAt a b t)))) // axiom label in BFO2 CLIF: [074-001] GenericallyDependentContinuant The entries in your database are patterns instantiated as quality instances in your hard drive. The database itself is an aggregate of such patterns. When you create the database you create a particular instance of the generically dependent continuant type database. Each entry in the database is an instance of the generically dependent continuant type IAO: information content entity. b is a generically dependent continuant = Def. b is a continuant that g-depends_on one or more other entities. (axiom label in BFO2 Reference: [074-001]) the pdf file on your laptop, the pdf file that is a copy thereof on my laptop the sequence of this protein molecule; the sequence that is a copy thereof in that protein molecule. material entity material (forall (x) (if (MaterialEntity x) (IndependentContinuant x))) // axiom label in BFO2 CLIF: [019-002] (forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt y x t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [020-002] (forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt x y t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [021-002] A material entity is an independent continuant that has some portion of matter as proper or improper continuant part. (axiom label in BFO2 Reference: [019-002]) BFO 2 Reference: Material entities (continuants) can preserve their identity even while gaining and losing material parts. Continuants are contrasted with occurrents, which unfold themselves in successive temporal parts or phases [60 BFO 2 Reference: Object, Fiat Object Part and Object Aggregate are not intended to be exhaustive of Material Entity. Users are invited to propose new subcategories of Material Entity. BFO 2 Reference: ‘Matter’ is intended to encompass both mass and energy (we will address the ontological treatment of portions of energy in a later version of BFO). A portion of matter is anything that includes elementary particles among its proper or improper parts: quarks and leptons, including electrons, as the smallest particles thus far discovered; baryons (including protons and neutrons) at a higher level of granularity; atoms and molecules at still higher levels, forming the cells, organs, organisms and other material entities studied by biologists, the portions of rock studied by geologists, the fossils studied by paleontologists, and so on.Material entities are three-dimensional entities (entities extended in three spatial dimensions), as contrasted with the processes in which they participate, which are four-dimensional entities (entities extended also along the dimension of time).According to the FMA, material entities may have immaterial entities as parts – including the entities identified below as sites; for example the interior (or ‘lumen’) of your small intestine is a part of your body. BFO 2.0 embodies a decision to follow the FMA here. Every entity which has a material entity as continuant part is a material entity. (axiom label in BFO2 Reference: [020-002]) MaterialEntity a flame a forest fire a human being a hurricane a photon a puff of smoke a sea wave a tornado an aggregate of human beings. an energy wave an epidemic every entity of which a material entity is continuant part is also a material entity. (axiom label in BFO2 Reference: [021-002]) the undetached arm of a human being immaterial entity immaterial BFO 2 Reference: Immaterial entities are divided into two subgroups:boundaries and sites, which bound, or are demarcated in relation, to material entities, and which can thus change location, shape and size and as their material hosts move or change shape or size (for example: your nasal passage; the hold of a ship; the boundary of Wales (which moves with the rotation of the Earth) [38, 7, 10 ImmaterialEntity disease of metabolism A disease that involving errors in metabolic processes of building or degradation of molecules. DOID:0014667 ICD10CM:E88.9 ICD9CM:277.9 MESH:D008659 NCI:C3235 SNOMEDCT_US_2016_03_01:154733004 SNOMEDCT_US_2016_03_01:190961002 SNOMEDCT_US_2016_03_01:267456000 SNOMEDCT_US_2016_03_01:30390004 SNOMEDCT_US_2016_03_01:75934005 UMLS_CUI:C0025517 disease_ontology metabolic disease carbohydrate metabolism disease An acquired metabolic disease that is characterized by abnormal carbohydrate metabolism. DOID:0050013 disease_ontology invasive aspergillosis An aspergillosis that is a serious fungal infection of the lung with pneumonia caused by Aspergillus, which spreads to other parts of the body through bloodstream in patients with acute leukemia and recipients of tissue transplants. Clinical symptoms include pulmonary nodules and hemorrhage. DOID:0050073 disease_ontology disease by infectious agent A disease that is the consequence of the presence of pathogenic microbial agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites, and aberrant proteins known as prions. DOID:0050117 DOID:10115 DOID:11078 DOID:1304 DOID:1321 DOID:2040 DOID:2288 DOID:3099 DOID:4120 DOID:4620 DOID:5256 DOID:945 DOID:95 DOID:9532 DOID:9696 ICD9CM:079.0 UMLS_CUI:C0001485 disease_ontology infectious disease sinusitis A paranasal sinus disease involving inflammation of the paranasal sinuses resulting from bacterial, fungal, viral infection, allergic or autoimmune issues. Symptoms can include fever, weakness, fatigue, cough and congestion. There may also be mucus drainage in the back of the throat, called postnasal drip. DOID:0050127 DOID:2052 DOID:9564 ICD10CM:J01 ICD10CM:J01.9 ICD10CM:J01.90 ICD9CM:461 ICD9CM:461.9 SNOMEDCT_US_2016_03_01:155498004 SNOMEDCT_US_2016_03_01:155501004 SNOMEDCT_US_2016_03_01:15805002 SNOMEDCT_US_2016_03_01:195649005 SNOMEDCT_US_2016_03_01:195653007 SNOMEDCT_US_2016_03_01:266378004 UMLS_CUI:C0149512 disease_ontology systemic mycosis A fungal infectious disease that results_in infection of internal organs and tissues located_in human body, has_material_basis_in Fungi, which enter the body via the respiratory tract, through the gut, paranasal sinuses or skin and spread through the bloodstream to multiple organs. DOID:0050136 disease_ontology sensory system disease A nervous system disease which is located in a part of the nervous system responsible for processing sensory information that consists of sensory receptors, neural pathways, and parts of the brain involved in sensory perception. Commonly recognized sensory systems are those for vision, hearing, somatic sensation (touch), taste and olfaction (smell). DOID:0050155 disease_ontology lower respiratory tract disease A respiratory system disease which involves the lower respiratory tract. DOID:0050161 ICD9CM:478.1 ICD9CM:478.19 SNOMEDCT_US_2016_03_01:195823002 SNOMEDCT_US_2016_03_01:266346007 UMLS_CUI:C0029581 disease_ontology monogenic disease A genetic disease that is the result of one or more abnormal alleles and may be dominant (a single copy of the abnormal allele is sufficient to give rise to the disease), semi-dominant, or recessive (requiring both copies of the gene to have an abnormal allele). DOID:0050177 disease_ontology primary bacterial infectious disease A bacterial infectious disease that results_in infection by bacteria as a result of their presence or activity within the normal, healthy host, and their intrinsic virulence is, in part, a necessary consequence of their need to reproduce and spread. DOID:0050338 disease_ontology commensal bacterial infectious disease A bacterial infectious disease that results_in infection by bacteria which are part of the normal human flora when one or more of the defense mechanisms designed to restrict them from the usually sterile internal tissues are breached by accident, by intent (surgery), or by an underlying metabolic or an infectious disorder. DOID:0050339 disease_ontology inflammatory bowel disease An intestinal disease characterized by inflammation located_in all parts of digestive tract. DOID:0050589 EFO:0003767 KEGG:05321 MESH:D015212 NCI:C3138 OMIM:PS266600 SNOMEDCT_US_2016_03_01:155759008 SNOMEDCT_US_2016_03_01:196974002 SNOMEDCT_US_2016_03_01:24526004 SNOMEDCT_US_2016_03_01:266516008 UMLS_CUI:C0021390 Xref MGI. OMIM mapping confirmed by DO. [SN]. disease_ontology respiratory system cancer An organ system cancer located_in the respiratory system that is characterized by uncontrolled cellular proliferation in the respiratory tract. DOID:0050615 disease_ontology female breast cancer 2011-06-15T02:48:20Z DOID:0050671 disease_ontology snadendla organ system cancer 2011-06-13T03:28:33Z A cancer that is classified based on the organ it starts in. DOID:0050686 disease_ontology snadendla MESH:D009371 cell type cancer 2011-06-13T03:28:50Z A cancer that is classified by the type of cell from which it is derived. DOID:0050687 disease_ontology snadendla autosomal recessive disease 2012-07-24T12:51:47Z An autosomal genetic disease that is characterized by the presence of two mutated copies of the gene, both of which must be present in order for the disease or trait to develop. DOID:0050737 disease_ontology lschriml autosomal genetic disease 2012-07-24T04:45:53Z A monogenic disease that is has material basis in a mutation in a single gene on one of the non-sex chromosomes. DOID:0050739 disease_ontology lschriml mature T-cell and NK-cell lymphoma 2012-09-18T01:56:52Z A non-Hodgkin lymphoma that has_material_basis_in mature T lymphocytes and natural killer cells. DOID:0050743 NK-T cell lymphoma disease_ontology lschriml mature T-cell and natural killer cell lymphoma secondary progressive multiple sclerosis 2013-11-07T11:22:49Z A multiple sclerosis that is characterised by a worsening of disability, rather than by relapses followed by recovery, which progressively worsens until a steady progression of disability replaces the cycles of attacks. DOID:0050783 MESH:D020528 SNOMEDCT_US_2016_03_01:425500002 SPMS Secondary-progressive MS UMLS_CUI:C0751965 disease_ontology lschriml endocardium disease 2014-02-12T01:53:42Z A heart disease that is located_in the innermost layer of tissue that lines the chambers of the heart. DOID:0050825 disease_ontology lschriml artery disease 2014-02-12T03:08:35Z A vascular disease that is located_in an artery. DOID:0050828 disease_ontology lschriml synucleinopathy 2014-08-14T03:29:17Z A neurodegenerative disease that is characterized by the abnormal accumulation of aggregates of alpha-synuclein protein in neurons, nerve fibres or glial cells. DOID:0050890 Synucleinopathies alpha Synucleinopathies disease_ontology lschriml large intestine adenocarcinoma 2014-10-13T15:00:10Z A large intestine cancer that has_material_basis_in epithelial cells of glandular origin. DOID:0050913 disease_ontology lschriml autoimmune disease of endocrine system A hypersensitivity reaction type II disease that is the abnormal functioning of the immune system resulting in production of antibodies or T cells against cells and/or tissues in the endocrine system. DOID:0060005 disease_ontology developmental disorder of mental health A disease of mental health that occur during a child's developmental period between birth and age 18 resulting in retarding of the child's psychological or physical development. DOID:0060037 disease_ontology specific developmental disorder A developmental disorder of mental health that categorizes specific learning disabilities and developmental disorders affecting coordination. DOID:0060038 disease_ontology sexual disorder A disease of mental health that involves the impairment in normal sexual functioning. DOID:0060043 disease_ontology hypersensitivity reaction disease An immune system disease that has material basis in abnormal immune responses. DOID:0060056 disease_ontology lymphoma A hematologic cancer that affects lymphocytes that reside in the lymphatic system and in blood-forming organs. DOID:0060058 DOID:1033 DOID:353 ICD10CM:C85.9 MESH:D008223 NCI:C3208 NCI:C7065 SNOMEDCT_US_2016_03_01:115244002 SNOMEDCT_US_2016_03_01:118600007 SNOMEDCT_US_2016_03_01:134218000 SNOMEDCT_US_2016_03_01:188676008 SNOMEDCT_US_2016_03_01:188694002 SNOMEDCT_US_2016_03_01:188695001 SNOMEDCT_US_2016_03_01:188704004 SNOMEDCT_US_2016_03_01:189959002 SNOMEDCT_US_2016_03_01:189965002 SNOMEDCT_US_2016_03_01:21964009 SNOMEDCT_US_2016_03_01:269627002 SNOMEDCT_US_2016_03_01:414628006 UMLS_CUI:C0024299 UMLS_CUI:C0598798 disease_ontology lymphoid cancer non-Hodgkin lymphoma A lymphoma that is characterized as any kind of lymphoma except Hodgkin's lymphoma. DOID:0060060 OMIM mapping confirmed by DO. [LS]. OMIM:605027 disease_ontology pre-malignant neoplasm 2011-05-11T12:18:41Z A disease of cellular proliferation that results in abnormal growths in the body, which do not invade or destroy the surrounding tissue but, given enough time, will transform into a cancer. DOID:0060071 disease_ontology lschriml benign neoplasm 2011-05-11T12:18:41Z A disease of cellular proliferation that results in abnormal growths in the body which lack the ability to metastasize. DOID:0060072 disease_ontology lschriml estrogen-receptor positive breast cancer 2011-06-08T12:23:02Z DOID:0060075 disease_ontology lschriml breast benign neoplasm 2011-06-08T01:02:29Z DOID:0060082 disease_ontology lschriml immune system cancer 2011-06-08T01:11:18Z An organ system cancer located_in the immune system that is characterized by uncontrolled cellular proliferation in organs of the immune system. DOID:0060083 disease_ontology lschriml cell type benign neoplasm 2011-07-14T11:59:48Z A benign neoplasm that is classified by the type of cell or tissue from which it is derived. DOID:0060084 disease_ontology lschriml organ system benign neoplasm 2011-07-14T12:12:23Z A benign neoplasm that is classified by the organ system from which it is arising from. DOID:0060085 disease_ontology lschriml thoracic benign neoplasm 2011-07-15T01:55:57Z An organ system benign neoplam that is located_in the thoracic cavity. DOID:0060097 disease_ontology lschriml musculoskeletal system cancer 2011-07-15T02:30:51Z An organ system cancer located_in the muscular and skeletal organs and characterized by uncontrolled cellular proliferation of the musculoskeletal organs. DOID:0060100 DOID:0060124 disease_ontology lschriml skeletal system cancer thoracic disease 2011-07-25T02:23:47Z A disease of anatomical entity that is located_in the thoracic cavity. DOID:0060118 disease_ontology lschriml pain agnosia 2011-08-22T12:04:56Z An agnosia that is a loss of the ability to perceive and process pain. DOID:0060145 analgesia disease_ontology lschriml acquired metabolic disease 2011-08-24T02:53:03Z A disease of metabolism that has _material_basis_in enzyme deficiency or accumulation of enzymes or toxins which interfere with normal function due to an endocrine organ disease, organ malfunction, inadequate intake, dietary deficiency, or malabsorption. DOID:0060158 disease_ontology lschriml pain disorder 2011-09-07T01:42:46Z A somatoform disorder that involves chronic pain in one or more areas, and is thought to be caused by psychological stress. DOID:0060164 disease_ontology lschriml colitis 2014-09-12T14:31:45Z An inflammatory bowel disease that involves inflammation located_in colon. DOID:0060180 EFO:0003872 ICD10CM:K52.9 MESH:D003092 NCI:C26723 OMIM:191390 SNOMEDCT:64226004 SNOMEDCT_US_2016_03_01:64226004 UMLS_CUI:C0009319 disease_ontology emitraka EAST syndrome A syndrome characterize by seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance. It has material basis in homozygous or compound heterozygous mutation in the KCNJ10 gene on chromosome 1q23. MESH:C557674 OMIM:612780 ORDO:199343 SeSAME syndrome UMLS_CUI:C2748572 epilepsy, ataxia, sensorineural deafness and tubulopathy seizures, sensorineural deafness, ataxia, mental retardation and electrolyte imbalance myeloid neoplasm A bone marrow cancer that is formed of any one of the bone marrow cells belonging to the granulocytic (neutrophil, eosinophil, basophil), monocytic/macrophage, erythroid, megakaryocytic and mast cell lineages. DOID:0070004 disease_ontology myeloma bone disease A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. DOID:0080001 DOID:1290 ICD10CM:M89.9 MESH:D001847 SNOMEDCT_US_2016_03_01:156814002 SNOMEDCT_US_2016_03_01:203524000 SNOMEDCT_US_2016_03_01:268126004 SNOMEDCT_US_2016_03_01:274145000 SNOMEDCT_US_2016_03_01:308147009 SNOMEDCT_US_2016_03_01:76069003 UMLS_CUI:C0005940 disease_ontology skeletal disease Cytomegalovirus retinitis CMV retinitis A retinitis that has_material_basis_in Cytomegalovirus. MESH:D017726 DOID:0080160 duodenum cancer A small intestine cancer that is located_in the beginning section of the small intestine. DOID:10021 DOID:6072 Duodenal cancer ICD10CM:C17.0 ICD9CM:152.0 MESH:D004379 NCI:C4803 NCI:C9328 SNOMEDCT_US_2016_03_01:154555009 SNOMEDCT_US_2016_03_01:254570009 SNOMEDCT_US_2016_03_01:269615000 SNOMEDCT_US_2016_03_01:363403002 UMLS_CUI:C0153426 UMLS_CUI:C0541912 cancer of duodenum disease_ontology duodenal neoplasm small intestine cancer An intestinal cancer that is located_in the small intestine. DOID:10154 ICD10CM:C17 ICD10CM:C17.9 ICD9CM:152.9 NCI:C7523 SNOMEDCT_US_2016_03_01:154555009 SNOMEDCT_US_2016_03_01:187755009 SNOMEDCT_US_2016_03_01:269615000 SNOMEDCT_US_2016_03_01:363509000 SNOMEDCT_US_2016_03_01:94048009 UMLS_CUI:C0153425 disease_ontology intestinal cancer A gastrointestinal system cancer that is located_in the intestine. DOID:10155 ICD10CM:C26.0 ICD9CM:159.0 MESH:D007414 NCI:C4572 SNOMEDCT_US_2016_03_01:187819006 SNOMEDCT_US_2016_03_01:190089002 SNOMEDCT_US_2016_03_01:363508008 SNOMEDCT_US_2016_03_01:93838000 UMLS_CUI:C0346627 disease_ontology malignant intestinal tumors malignant neoplasm of intestine heart conduction disease A cardiovascular system disease that involves the heart's electrical conduction system. DOID:10273 ICD9CM:426.6 SNOMEDCT_US_2016_03_01:195053008 SNOMEDCT_US_2016_03_01:195056000 UMLS_CUI:C0029630 disease_ontology heart rhythm disease prostate cancer A male reproductive organ cancer that is located_in the prostate. DOID:10283 DOID:514 ICD10CM:C61 ICD9CM:185 KEGG:05215 MESH:D011471 NCI:C3343 NCI:C7378 NGP - new growth of prostate OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959 ORDO:1331 SNOMEDCT_US_2016_03_01:126906006 SNOMEDCT_US_2016_03_01:363448003 SNOMEDCT_US_2016_03_01:399068003 SNOMEDCT_US_2016_03_01:93974005 UMLS_CUI:C0033578 UMLS_CUI:C0376358 Xref MGI. OMIM mapping confirmed by DO. [SN]. disease_ontology hereditary prostate cancer malignant tumor of the prostate prostate cancer, familial prostate neoplasm prostatic cancer prostatic neoplasm tumor of the prostate prostate carcinoma A prostate cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells. DOID:10286 EFO:0001663 KEGG:05215 NCI:C4863 SNOMEDCT_US_2016_03_01:154531004 SNOMEDCT_US_2016_03_01:254900004 SNOMEDCT_US_2016_03_01:363448003 UMLS_CUI:C0600139 cancer of prostate carcinoma OF PROSTATE carcinoma of prostate carcinoma of prostate (disorder) disease_ontology endocarditis A endocardium disease characterized by inflammation of the endocardium of the heart chambers and valves. DOID:10314 DOID:14058 ICD10CM:I33.9 ICD9CM:421.9 MESH:D004696 NCI:C34582 NCI:C35432 SNOMEDCT_US_2016_03_01:194935007 SNOMEDCT_US_2016_03_01:56819008 SNOMEDCT_US_2016_03_01:91357005 UMLS_CUI:C0014118 UMLS_CUI:C0375268 disease_ontology lymphoblastic leukemia A leukemia that has_material_basis_in lymphoblasts (immature white blood cells). DOID:1037 ICD10CM:C91 ICD10CM:C91.9 ICD10CM:C91.90 ICD9CM:204 ICD9CM:204.9 MESH:D007945 NCI:C7539 SNOMEDCT_US_2016_03_01:154587007 SNOMEDCT_US_2016_03_01:188725004 SNOMEDCT_US_2016_03_01:188731001 SNOMEDCT_US_2016_03_01:190033006 SNOMEDCT_US_2016_03_01:269631008 SNOMEDCT_US_2016_03_01:32280000 SNOMEDCT_US_2016_03_01:93170002 UMLS_CUI:C0023448 disease_ontology bacterial infectious disease A disease by infectious agent that results_in infection, has_material_basis_in Bacteria. DOID:104 ICD10CM:A49 ICD10CM:A49.9 MESH:D001424 NCI:C2890 SNOMEDCT_US_2016_03_01:154318005 SNOMEDCT_US_2016_03_01:186470002 SNOMEDCT_US_2016_03_01:187347000 SNOMEDCT_US_2016_03_01:266182006 SNOMEDCT_US_2016_03_01:266187000 SNOMEDCT_US_2016_03_01:301811001 SNOMEDCT_US_2016_03_01:87628006 UMLS_CUI:C0004623 disease_ontology MESH:D016905 MESH:D016908 chronic lymphocytic leukemia A lymphoblastic leukemia characterized by over production of B-cells and their accumulation in bone marrow and blood. B-cell chronic lymphocytic leukemia B-cell chronic lymphoid leukemia CLL DOID:1040 EFO:0000095 ICD10CM:C91.1 ICD10CM:C91.10 ICD9CM:204.1 MESH:D015451 NCI:C3163 OMIM:109543 OMIM:151400 OMIM:609630 OMIM:612557 OMIM:612558 OMIM:612559 ORDO:67038 SNOMEDCT_US_2016_03_01:154589005 SNOMEDCT_US_2016_03_01:277473004 SNOMEDCT_US_2016_03_01:51092000 SNOMEDCT_US_2016_03_01:92814006 UMLS_CUI:C0023434 Xref MGI. chronic lymphatic leukemia disease_ontology lymphoplasmacytic leukemia lymphoid leukemia DOID:10747 ICD9CM:204.2 SNOMEDCT_US_2016_03_01:154590001 SNOMEDCT_US_2016_03_01:188726003 SNOMEDCT_US_2016_03_01:190035004 SNOMEDCT_US_2016_03_01:33560006 SNOMEDCT_US_2016_03_01:95274002 UMLS_CUI:C0152271 disease_ontology subacute lymphoid leukemia hypertension An artery disease characterized by chronic elevated blood pressure in the arteries. DOID:10763 EFO:0000537 HTN High blood pressure (& [essential hypertension]) ICD10CM:I10 ICD10CM:I10-I15 ICD9CM:401-405.99 ICD9CM:997.91 MESH:D006973 NCI:C3117 SNOMEDCT_US_2016_03_01:155295004 SNOMEDCT_US_2016_03_01:155302005 SNOMEDCT_US_2016_03_01:194756002 SNOMEDCT_US_2016_03_01:194757006 SNOMEDCT_US_2016_03_01:194760004 SNOMEDCT_US_2016_03_01:194794002 SNOMEDCT_US_2016_03_01:195537001 SNOMEDCT_US_2016_03_01:266287006 SNOMEDCT_US_2016_03_01:38341003 UMLS_CUI:C0020538 disease_ontology hyperpiesia hypertensive disease vascular hypertensive disorder gastric ulcer DOID:10807 DOID:10808 DOID:10809 DOID:12047 DOID:12057 DOID:12068 DOID:12069 DOID:12806 DOID:13124 DOID:13125 DOID:241 DOID:242 ICD10CM:K25 ICD9CM:531 MESH:D013276 NCI:C3388 SNOMEDCT_US_2016_03_01:155681009 SNOMEDCT_US_2016_03_01:155690002 SNOMEDCT_US_2016_03_01:196627009 SNOMEDCT_US_2016_03_01:196642007 SNOMEDCT_US_2016_03_01:196649003 SNOMEDCT_US_2016_03_01:196650003 SNOMEDCT_US_2016_03_01:266436006 SNOMEDCT_US_2016_03_01:397825006 SNOMEDCT_US_2016_03_01:6034002 UMLS_CUI:C0038358 acute gastric ulcer with haemorrhage and perforation acute gastric ulcer with hemorrhage AND obstruction (disorder) acute gastric ulcer with hemorrhage AND perforation acute gastric ulcer with hemorrhage AND perforation (disorder) acute gastric ulcer with hemorrhage AND perforation [dup] (disorder) acute gastric ulcer with hemorrhage AND with perforation but without obstruction acute gastric ulcer with hemorrhage AND with perforation but without obstruction (disorder) acute gastric ulcer with hemorrhage and obstruction acute gastric ulcer with hemorrhage and perforation acute gastric ulcer with hemorrhage and perforation, with obstruction acute gastric ulcer with hemorrhage and perforation, without mention of obstruction acute gastric ulcer with hemorrhage, with obstruction acute gastric ulcer with hemorrhage, with perforation AND with obstruction (disorder) acute gastric ulcer with perforation acute gastric ulcer with perforation AND obstruction acute gastric ulcer with perforation AND obstruction (disorder) acute gastric ulcer with perforation, with obstruction acute gastric ulcer without hemorrhage and without perforation acute gastric ulcer without hemorrhage, without perforation AND without obstruction acute gastric ulcer without hemorrhage, without perforation AND without obstruction (disorder) acute gastric ulcer without mention of hemorrhage or perforation, without mention of obstruction bleeding acute gastric ulcer chronic gastric ulcer without hemorrhage AND without perforation chronic gastric ulcer without hemorrhage AND without perforation but with obstruction chronic gastric ulcer without hemorrhage AND without perforation but with obstruction (disorder) chronic gastric ulcer without mention of hemorrhage or perforation, with obstruction disease_ontology sickle cell anemia DOID:10923 DOID:12924 DOID:13024 Hb SC disease Hb-S/Hb-C disease Hb-SS disease without crisis Hemoglobin S disease without crisis (disorder) ICD10CM:D57 ICD10CM:D57.1 ICD10CM:D57.2 ICD10CM:D57.20 ICD9CM:282.6 ICD9CM:282.60 ICD9CM:282.63 MESH:D000755 MESH:D006450 NCI:C34383 NCI:C34676 OMIM mapping confirmed by DO. [LS]. OMIM:603903 SNOMEDCT_US_2016_03_01:127040003 SNOMEDCT_US_2016_03_01:154798006 SNOMEDCT_US_2016_03_01:191194009 SNOMEDCT_US_2016_03_01:191195005 SNOMEDCT_US_2016_03_01:191199004 SNOMEDCT_US_2016_03_01:276267006 SNOMEDCT_US_2016_03_01:35434009 SNOMEDCT_US_2016_03_01:417357006 SNOMEDCT_US_2016_03_01:80046004 Sickle-cell/Hb-C disease without crisis UMLS_CUI:C0002895 UMLS_CUI:C0019034 disease_ontology drepanocytosis hemoglobin SC disease obsessive-compulsive disorder An anxiety disorder that involves unwanted and repeated thoughts, feelings, ideas, sensations (obsessions), or behaviors that make them feel driven to do something (compulsions). Anancastic neurosis DOID:10933 ICD10CM:F42 ICD9CM:300.3 MESH:D009771 NCI:C88411 SNOMEDCT_US_2016_03_01:191736004 SNOMEDCT_US_2016_03_01:191739006 SNOMEDCT_US_2016_03_01:192406007 SNOMEDCT_US_2016_03_01:192411009 SNOMEDCT_US_2016_03_01:71478004 UMLS_CUI:C0028768 disease_ontology obsessive compulsive disorder sarcoma A cell type cancer that has_material_basis_in abnormally proliferating cells derives_from embryonic mesoderm. DOID:1115 DOID:3936 ICD10CM:C49 ICD9CM:171 ICD9CM:171.9 SNOMEDCT_US_2016_03_01:187985009 SNOMEDCT_US_2016_03_01:93765001 UMLS_CUI:C0153519 connective and soft tissue neoplasm disease_ontology tumor of soft tissue and skeleton pneumocystosis An opportunistic mycosis that is located_in lungs, but can also occur in eyes, ears, skin, thyroid, pituitary, palate, parathyroid, esophagus, pleura, heart, liver, spleen, small intestine, adrenals, kidneys, bone marrow, and lymph nodes, has_material_basis_in Pneumocystis jirovecii that effects interstitial and alveolar tissues and has_symptom nonproductive cough, has_symptom shortness of breath, and has_symptom fever. DOID:11339 ICD10CM:B59 ICD9CM:136.3 MESH:D011020 NCI:C3334 Pneumocystis carinii pneumonia Pneumocystis jirovecii pneumonia Pneumocystis pneumonia Pneumocystosis Pneumocystosis pneumonia SNOMEDCT_US_2016_03_01:155557008 SNOMEDCT_US_2016_03_01:415125002 SNOMEDCT_US_2016_03_01:57541005 SNOMEDCT_US_2016_03_01:88860002 UMLS_CUI:C1535939 disease_ontology pulmonary pneumocystosis (disorder) heart disease A cardiovascular system disease that involves the heart. DOID:114 ICD10CM:I51.9 ICD9CM:429.9 MESH:D006331 NCI:C3079 SNOMEDCT_US_2016_03_01:155263000 SNOMEDCT_US_2016_03_01:194707003 SNOMEDCT_US_2016_03_01:195152001 SNOMEDCT_US_2016_03_01:266275004 SNOMEDCT_US_2016_03_01:266311004 SNOMEDCT_US_2016_03_01:56265001 UMLS_CUI:C0018799 disease_ontology bronchial disease A lower respiratory tract disease that affects the airways leading into the lungs, which is caused due to inflammation of the bronchi and bronchioles, infection, or blockage. Bronchospasm DOID:1175 DOID:1176 DOID:12322 MESH:D001982 SNOMEDCT_US_2016_03_01:41427001 UMLS_CUI:C0006261 disease_ontology esophagitis